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ABSTRACT 
Catalyzed and Uncatalyzed Modifications of Nucleosides, Synthesis of Hippadine, and 
Deuterated 1,2,3-Triazoles 
by  
Hari K. Akula 
Advisor: Prof. Mahesh K. Lakshman 
The C4 amide carbonyl of O-t-butyldimethylsilyl-protected thymidine, 2’-deoxyuridine, and 3’-
azidothymidine (AZT) was activated by reaction with (benzotriazol-1-yloxy)tris(dimethylamino) 
phosphonium hexafluorophosphate (BOP) and 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) in 
THF as solvent.  This led to the formation of corresponding O4-(benzotriazol-1-yl) derivatives, 
which are reactive intermediates.  Substitution at the C4 position was then carried out by 
reactions with alkyl and aryl amines, and thiols.  Typically, reactions were conducted as a two-
step, one-pot transformation, and also as a one-step conversion.  After examining the reactions, 
the formation of 1-(4-pyrimidinyl)-1H-benzotriazole-3-oxide derivatives from the pyrimidine 
nucleosides was identified.  However, these too underwent conversion to the desired products.  
C4 modified pyrimidine nucleosides were desilylated using standard conditions.  Desilylated 3’-
azido derivatives obtained from AZT were also converted to the 3’-amino derivatives by 
catalytic reduction.  All products were evaluated for their abilities to inhibit cancer cell 
proliferation and for antiviral activities.  Some compounds displayed moderate inhibitory activity 
against proliferation of murine leukemia (L1210), human cervix carcinoma (HeLa), and human 
T-lymphocytic (CEM) cell lines.  Many were seen to be active against HIV-1 and HIV-2, and 
! v!
one was active against herpes simplex virus-1 (HSV-1).  Evaluations of the structures and 
activities indicated that the methyl group at the C5 position is important for biological activity.  
Chemoselective N-arylation of 8-vinyladenine nucleosides can be carried out with the 
Pd(OAc)2/Xantphos/Cs2CO3 combination.  All the other ligands such as DPEPhos, DPPF, and 
BIPHEP in combination with Pd(OAc)2, and the complex Pd-118 resulted in Heck arylation, 
exclusively.  Both aryl iodides and bromides can be used under these conditions.  Generally, all 
reactions resulted in N-arylated products in good yields, along with small amounts of Heck-like 
products and C,N-diarylated products.  However, the Heck-like products were observed mostly 
in the reactions of aryl iodides.  The results from the Pd-catalyzed N-arylation reactions of deoxy 
and ribonucleosides were very similar, but a higher catalyst loading and temperature for 
reactions of the ribonucleoside was required.  A modular, one-pot approach was utilized for the 
synthesis of diaryl products via sequential C–C reaction and C–N arylation.  The generality of 
chemoselective arylation of simple substrates was tested by exposing p-aminostyrene under N-
arylation and Heck-arylation conditions.   The results indicated that in this case as well, the 
Pd/Xantphos/Cs2CO3 combination was effective for chemoselective N-arylation and the 
Pd/DPEPhos/Cs2CO3 combination was effective for chemoselective Heck-arylation.  
In order to synthesize nucleosides adducts produced by a cis ring-opening of benzo[a]pyrene diol 
epoxide 1, diastereoselective synthesis of (±)-10β-amino-7β,8α,9β-trihydroxy-7,8,9,10-
tetrahydrobenzo[a]pyrene was carried out in nine steps from (±)-7β,8α-dibenzoyloxy-7,8,9,10-
tetrahydrobenzo[a]pyrene.  The (±)-7β,8α-dibenzoyloxy-7,8-dihydrobenzo[a]pyrene was 
converted to the diol epoxide and then reacted with lithium chloride and acetic anhydride to give 
a peracyl trans chloro triol with a chloride at the benzylic position.  Displacement of chloride by 
azide, followed by deacylation, and reduction of the azide afforded the requisite amino triol.  
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B[a]P-deoxyadenosine adducts were synthesized by the reaction of this amino triol with a 6-
fluoropurine 2’-deoxyriboside derivative.  The two adducts obtained from this reaction were 
separated by preparative TLC and the chirality in each was assigned by comparing their circular 
dichroism data with the literature.  The 2-fluoro-2’-deoxyinosine derivative required for the 
synthesis of B[a]P-deoxyguanosine adducts, was synthesized by a modified approach utilizing a 
C6 modification protocol for guanosine nucleosides via the amide activation by BOP.  However, 
the reaction of 2-fluoro-2’-deoxyinosine derivative with the amino triol was unsuccessful.  
Hence, the hydrochloride salt of amino triol was prepared and then reacted with 2-fluoro-2’-
deoxyinosine derivative.  This reaction yielded two B[a]P-deoxyguanosine adducts, which were 
separated by preparative TLC and the chirality in each was assigned by comparing their circular 
dichroism data with literature.  However, careful NMR analysis of B[a]P-dA and dG adducts 
indicated that the products were not the anticipated cis ring-opened nucleoside adducts as 
previously reported, but the data were more consistent with trans ring-opened B[a]P DE1-
nucleoside adducts.  This information suggested that the amino triol synthesized had the 
undesired trans stereochemistry at the C9 and C10 positions.  This was further confirmed by 
careful evaluation of chemical shift and coupling constant data of synthesized azido triol with 
known data of trans and cis ring-opened azido triols. 
By utilizing PPh3/I2 mediated amidation reaction as a key step, a simple approach was developed 
for the synthesis of hippadine via anhydrolycorinone.  N-(Piperonoyl)indoline was synthesized 
by reacting piperonylic acid and indoline in the presence of PPh3/I2  and iPr2NEt. The 
combination of polymer-supported PPh3/I2 in place of PPh3/I2 was also very effective under these 
conditions, and both combinations gave comparable yields of N-(piperonoyl)indoline.  However, 
in CDCl3, the 1H NMR data of the amide obtained was missing one aromatic resonance.  The 
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structure of amide obtained via these amidation reactions was further confirmed by obtaining 1H 
NMR in C6D6 at 70 °C and COSY data.  The amide was then cyclized using PhI(OTFA)2 and 
BF3!Et2O to give anhydrolycorinone that was finally oxidized by DDQ to give hippadine in an 
overall yield of 13%, over three steps.  
Deuteration at the C-5 position of the 1,2,3-triazole structure was carried out efficiently during 
the triazole-forming step by using a copper-catalyzed azide−alkyne cycloaddition (CuAAC) 
reaction.  Reactions of alkynes and azides were conducted in a biphasic medium of CH2Cl2/ D2O, 
using the CuSO4 and Na ascorbate.  The mild reaction conditions allow the applicability of this 
method to relatively high complex substrates, such as nucleosides.  Generally, good yields and 
high levels of deuterium incorporation were observed in all cases.  Using appropriately 
deuterated precursors, partially to fully deuterated triazoles were also assembled under the same 
conditions.  The competition of deuteration vs protonation in the CuAAC reaction was evaluated 
by conducting a reaction of phenyl azide with 4-ethynyltoluene with equimolar H2O and D2O.   
Higher hydrogen atom incorporation in the triazole products was observed as compared to 
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FACILE MODIFICATION AT THE C-4 POSITION OF 
PYRIMIDINE NUCLEOSIDES 
[1.1] INTRODUCTION 
Pyrimidine-based modified nucleosides are prominent because of their applications in 
biochemistry, biotechnology, and also in medicine.1  A large group of FDA approved antiviral 
agents are in fact pyrimidine-based modified nucleosides.  Some examples are shown in Figure 1.  
 
Figure 1. Some clinically used modified pyrimidine nucleoside antiviral agents 
Among these unnatural nucleosides, C-4 modified pyrimidine nucleosides are notable due to 
their antiviral and anticancer activities.2-4  For example, 5-methoxymethyl-2’-deoxycytidine 
(MMdCyd, 1) is highly active against HSV-1 (Figure 2).  However, the activity is lost in the 
presence of cytidine or deoxycytidine deaminases, due to the loss of C-4 amino group.  
Tetrahydrodeoxyuridine (H4dU, 2), a potent inhibitor of deoxycytidine deaminase is often used 
in combination with MMdCyd (1) in order to retain activity of compound 1.  To avoid the usage 
of H4dU (2), Zoghaib et al. developed C-4 modified analogues of MMdCyd (3a–d, Figure 2).  
They found these analogues to be resistant to deamination by cytidine and deoxycytidine 
deaminases and were also active against HSV-1, more potently than the parent compound 
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Figure 2. 5-Methoxymethyl-2’-deoxycytidine (1), tetrahydro-2’deoxyuridine (2), and C-4 
modified analogues of 5-methoxymethyl-2’-deoxycytidine (3a–d)  
Apart from their medicinal properties, various C-4 modified pyrimidine nucleosides are also 
very useful in investigating processes such as mutagenesis and carcinogenesis.5,6  Hence, it is 
important to develop strategies for simple syntheses of C-4 modified nucleosides. One 
commonly used approach for modification at the C-4 position of pyrimidine nucleosides entails 
an addition-elimination process on a stable electrophilic nucleoside derivative.  In this approach, 
the amide functionality in the pyrimidine nucleoside is activated by an appropriate reagent and a 
leaving group (LG) is installed at the C-4 position (Scheme 1).  The presence of a leaving group 
at the C-4 position makes the nucleoside electrophilic and upon exposure to various nucleophiles, 
produces C-4 modified pyrimidine nucleoside derivatives. 
Scheme 1. C-4 Modification via an electrophilic pyrimidine nucleoside derivative  
 
Thus far, a number of electrophilic pyrimidine nucleoside derivatives have been developed 
and one of the first is a 4-thiopyrimidine nucleoside derivative. The 4-thiopyrimidine nucleoside 



























3a, R = Methyl 
3b, R = Ethyl
3c, R = Propyl





















nucleosides 4a–c with P2S5 in a pyridine-water mixture, under reflux conditions (Scheme 2).7  A 
recent report by Felczak et al. showed that Lawesson’s reagent can also be used for this 
thionation.8   
Scheme 2. Synthesis of 4-thiopyrimidine nucleosides 5a–c from pyrimidine nucleoside 
derivatives 4a–c  
 
Typically, benzoyl protection of the free hydroxyl groups on the pyrimidine nucleosides is 
preferred prior to the thionation with P2S5, as it was observed that acetyl groups tend to 
hydrolyze under the conditions. However, in some cases benzoyl esters were also observed to 
hydrolyze upon extended reaction times.4  C-4 modification by using 4-thio pyrimidine 
nucleosides often requires harsh conditions and special equipment. For example, compound 6 
was prepared by heating 5a with 45% methylamine in ethanol solution in a sealed tube at 100 °C 
(Scheme 3). Similarly, compound 7 was prepared by heating a solution of 5a in ethanol with β–












a, R = CH3, R' = H
b, R = H, R' = OBz

















































Based on the aforementioned drawbacks, Fox et al. modified 4-thiopyrimidine nucleoside 
derivatives 5a–b to their corresponding 4-methythio derivatives 8a–b.4,9,10  Compounds 8a–b 
were prepared by initial deacylation of compounds 5a–b, followed by treatment of the resultant 
product with MeI in 1N NaOH solution (Scheme 4).9  They observed that 4-methylthio 
derivatives 8a, 8b were superior to their precursors 5a, 5b, and underwent displacement 
reactions with different nucleophiles under milder conditions.4 They also observed that 4-
methylthiouridine (8b) was more reactive than 4-methylthiothymidine (8a) towards displacement 
reactions, when amino acids were used as nucleophiles.  However, the stability of 4-methylthio 
derivatives is highly pH dependent and they are prone to hydrolysis even under mildly acidic 
conditions.4  
Scheme 4. Synthesis of 4-methylthio derivatives 8a–b from their corresponding 4-thio 
derivatives 5a–b 
 
Saladino et al. developed a different strategy for the C-4 modification of pyrimidine 
nucleosides by oxidizing 4-thiopyrimidine nucleosides 9a–b with dimethyldioxirane (DMDO) in 
presence of various nucleophiles (Scheme 5).11-13  Various aliphatic and aromatic amines, and 
alcohols were used to test the scope of this reaction and good yields were observed in all the 
reactions. 
Scheme 5. C-4 modification of pyrimidine nucleosides by oxidation of 4-thiopyrimidine 








5a, R = CH3, R' = H













8a, R = CH3, R' = H
8b, R = H, R' = OH
1. 1N NaOH, 
    EtOH, 1 h
2. MeI,1N NaOH
    0.5 h
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Žemlička et al. hypothesized that 4-chloropyrimidine nucleosides could function as excellent 
electrophilic derivatives for C-4 modification. 4-Chloropyrimidine nucleoside derivatives were 
synthesized by treating various thymidine and uridine nucleoside derivatives with SOCl2 and a 
catalytic amount of DMF (Scheme 6).14,15  The combination of SOCl2 and DMF generates a 
reactive species dimethylchloromethyleneammonium chloride.  This reagent reacts with the 
amido group of the pyrimidine nucleoside and generates the corresponding 4-chloro derivative.  
On the basis of the Appel reaction, Santacroce et al. developed milder reaction conditions for the 
synthesis of 4-chloropyrimidine nucleosides by using the PPh3/CCl4 combination (Scheme 
6).16,17  However, 4-chloropyrimidine nucleosides were found to be very unstable and are swiftly 
used for further transformation upon synthesis.18       
Scheme 6. Synthesis of a 4-chloropyrimidine nucleoside derivative and subsequent 
transformation to O4-ethylpyrimidine nucleoside derivative 
 
In one such approach reported by Matsuda et al. the 4-chloropyrimidine nucleoside 
derivative was generated in situ and immediately treated with NaOEt. This resulted in the 
formation of the corresponding O4-ethylpyrimidine nucleoside derivative and this compound was 
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10, R = CH3, R' = H
11, R = H, R' = OAc
R" = alkyl or

























the observation that O4-alkylpyrimidine nucleoside derivatives are relatively stable but are 
susceptible to addition-elimination reactions with various nucleophiles.20 
Scheme 7. Synthesis of 4-(3-nitro-1,2,4-triazol-1-yl)pyrimidine nucleoside derivative 
 
4-(1,2,4-Triazol-1-yl)pyrimidine nucleoside derivatives are an important class of compounds, 
which are widely used for C-4 modification due to a good balance between their stability and 
reactivity.21,22 For example, 4-(3-nitro-1,2,4-triazol-1-yl)pyrimidine nucleoside 14b was 
synthesized by reacting uridine 13b with 1-(mesitylene-2-sulphonyl)-3-nitro-1,2,4-triazole in 
pyridine, where diphenyl phosphate ((PhO)2P(O)OH) was used as a catalyst (Scheme 7).21  
Intermediate 14b upon exposure to various nucleophiles led to successful modification at C-4 
position.  However, thymidine equivalent 14a cannot be prepared under the conditions used for 
uridine derivative 13b.23,24  An expedient synthesis for the compound 14b was reported, where 
uridine derivative 13b was reacted with readily available diphenyl phosphoryl chloride 
((PhO)2POCl) and 3-nitro-1,2,4-triazole.22   
Similarly to the synthesis of 3-nitro-1,2,4-triazolyl pyrimidine derivatives,  the 1,2,4-triazolyl 
derivatives also shown remarkable stability and reactivity towards various nucleophiles.22  C-4 
triazole derivative 15b can be prepared from the uridine 13b by either reacting with O-
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oxide (Scheme 8).22  The reagent tri(1H-1,2,4-triazol-1-yl)phosphine oxide was generated in situ 
by reacting POCl3 with 1,2,4-triazole in presence of Et3N.  On the contrary, compound 15b can 
also be prepared from 14b by reacting it with 1,2,4-triazole and Et3N in CH3CN (Scheme 8).22 
Scheme 8. Synthesis of 4-(1,2,4-triazol-1-yl) pyrimidine nucleoside derivative from uridine 
derivative 13b or 3-nitro-1,2,4-triazolyl derivative 14b 
 
Although the 3-nitro-1,2,4-triazol-1-yl nucleoside derivative 14b is more reactive than the 
1,2,4-triazolyl derivative 15b, the latter analogues are more commonly used because of their ease 
in synthesis and relative stability.22 For example, compounds 16a and 16b are easily transformed 
to their corresponding 1,2,4-triazolyl derivatives 17a and 17b by reaction with p-chlorophenyl 



























































purification, the products thus obtained were treated with 2-cyanoethanol  to give their 
corresponding nucleotides 17a and 17b.  Here, the 3’-OH group of the pyrimidine nucleosides 
16a and 16b were concurrently phosphorylated while the amide functionality was activated to 
give the 1,2,4-triazolyl derivatives. This approach enables the easy access for the site–specific 
modification of pyrimidine bases in oligoribonucleotides.25,26 
In their studies, Reese et al. observed that 4-tetrazolyl pyrimidine nucleoside derivatives can 
also act as excellent electrophilic nucleoside derivatives for accomplishing C-4 modification.23,24  
C-4 tetrazole derivative 18 was prepared by reacting uridine derivative 13b with tetrazole, 
diphenyl phosphate ((PhO)2P(O)OH) and p-toluenesulfonyl chloride, in pyridine at room 
temperature for 1.5 days (Scheme 10).  C-4 tetrazole derivative 18 was stable, isolable, and 
underwent nucleophillic displacement with various nucleophiles. 
Scheme 10. Synthesis of 4-tetrazol-1-ylpyrimidine nucleoside derivative 18  
 
In an independent work, Sung et al. observed that phosphorylation of the 3’-OH group of 
uridine derivative 16b with p-chlorophenyl phosphoryl ditetrazolide (19) in pyridine followed by 
treatment with 2-cyanoethanol, yielded compound 20, where a concomitant installation of a 
tetrazole unit took place at the C-4 position of 16b (Scheme 11).27   
Scheme 11. Concomitant introduction of a tetrazole group at C-4 position during the 
































Although, the 4-triazolyl and 4-tetrazolyl pyrimidine nucleoside derivatives are excellent 
electrophilic nucleosides that undergo nucleophilic displacement with various nucleophiles under 
mild conditions, their synthesis is inconvenient.  The reagents are often generated in situ, are 
highly moisture sensitive, and in some cases, long reaction times are required.22-27  Focusing on 
this issue, Matsuda et al. designed an alternate electrophilic nucleoside, 3-Methyl-1-imidazolium 
intermediates 21a and 21b, which were synthesized by reacting 1-methylimidazole with POCl3 
in CH3CN at 0 °C, followed by the addition of pyrimidine nucleoside 4a or 4b (Scheme 12).28  
These intermediates 21a and 21b when exposed to diverse nucleophiles underwent displacement 
readily and resulted in the corresponding C-4 modified pyrimidine nucleosides in good yields.  







































Scheme 12. Synthesis of 3-methyl-1-imidazolium intermediates 21a and 21b from the reaction 
of 1-methylimidazole and POCl3 with pyrimidine nucleosides 4a and 4b 
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succeeds only as a one-pot reaction, since the intermediates 21a and 21b are highly labile, and 
therefore, cannot be isolated.28 
Bischofberger has developed a different class of electrophilic nucleoside derivatives with the 
synthesis of pyrimidine 4-aryl sulfonates.29  Typically, 2,4,6-triisopropylphenyl  and 2-
mesitylenyl groups were used as the aryl substituents.  The O4-triisopropylphenyl sulfonate 
derivatives 23a and 23b were synthesized by reacting silyl protected pyrimidine nucleosides 22a 
and 22b with NaH in THF, followed by the addition of 2,4,6-triisopropylphenylsulfonyl chloride 
(Scheme 13).  Compounds 23a and 23b could also be prepared by treating the nucleosides 22a 
and 22b with Et3N and DMAP in CH2Cl2, followed by the addition of 2,4,6-
triisopropylphenylsulfonyl chloride.  However in the later case, the yields of the products 23a 
and 23b are low.  In a similar manner, O4-mesitylene sulfonate derivatives 24a and 24b were 
also prepared under the same conditions utilized for the synthesis of compounds 23a and 23b 
(Scheme 13).  Nevertheless, the products 24a and 24b degraded upon storage and have to be 



































a, R = CH3, R' = H




Owing to their greater stability, O4-triisopropylphenyl sulfonate derivatives are most 
commonly used for the C-4 modification of pyrimidine nucleosides.  In addition to the utilities of 
O4-aryl sulfonate derivatives in nucleophilic displacement reactions, we30 and others31 showed 
that these substrates can also be successfully applied to the C–C bond-forming reactions by 
palladium-catalyzed cross-coupling chemistry (Scheme 14).   
Scheme 14. Pd-catalyzed C–C bond forming reactions with O4-aryl sulfonate derivatives of 
pyrimidine nucleosides  
 
Similarly to O4-triisopropylphenyl and O4-mesitylene sulfonate pyrimidine nucleoside 






















































least in one case, we observed that the rate of degradation of O4-toluene sulfonate derivative is 
much slower than the corresponding O4-mesitylene sulfonate derivative.30  To improve the yield 
of substitution reactions, C-4 modification reactions with O4-toluene sulfonate derivatives are 
often carried out in one-pot, by subjecting pyrimidine O4-toluene sulfonate derivatives to 
nucleophilic displacement reactions with nucleophiles immediately, upon their formation 
(Scheme 15).32 
In one case, pyrimidine O4-toluene sulfonate derivatives 29a and 29b were converted to their 
corresponding quaternary ammonium salts 30a and 30b as reactive electrophilic pyrimidine 
nucleoside derivatives (Scheme 16).33  However, these salts were also not isolated but were 
subjected to nucleophilic displacement reaction with aq. NH3 to give the corresponding cytidine 
derivatives.   
Scheme 16. One-pot conversion of pyrimidine O4-toluene sulfonate derivatives 29a and 29b to 
their corresponding quaternary ammonium salts 30a and 30b 
 
Apart from the aforementioned electrophilic pyrimidine nucleoside derivatives, O4-
trimethylsilyl pyrimidine nucleoside derivatives are also used for C-4 modification.34  These 
derivatives can be easily prepared by the silylation of acyl-protected or free pyrimidine 
nucleosides.  However, their usage is limited because of their inability to react with a wide 














28a, R = CH3 
28b, R = H
TsCl, Et3N
R R
30a, R = CH3, n = 1
30b, R = H, n = 2












29a, R = CH3
29b, R = H
R' = 4-ClBz
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Direct alkylation or arylation of pyrimidine nucleosides is an auxiliary strategy to the 
addition-elimination approach for the C-4 modification of pyrimidine nucleosides.  For example, 
acyl protected thymidine derivatives 4a and 13a were converted to their O4-alkyl derivatives 31a 
and 31b, by Ag2CO3 catalyzed reaction of 4a and 13a with various alkyl chlorides (R’Cl) in 
toluene (Equation 1 in Scheme 17).  Similarly, 2’-deoxycytidine (32) could be N-arylated to give 
the compound 33, by copper catalyzed reaction of the compound 32 with 4-tolylboronic acid and 
TMEDA in DMSO at 60 °C over 16 h (Equation 2 in Scheme 17).35  However, only one example 
was shown and the yield was modest.  Kane et al. developed a method for the N4-monoalkylation 
of 2’-deoxycytidine (32).36  This approach involves the formation of the amidine intermediate 34, 
by reacting 32 with N,N-dimethylformamide dimethyl acetal in DMF at 40 °C for 1 h.  The crude 
mixture containing the compound 34 was then treated with NaBH4 for 2 h, to give the product 35 
(Equation 3 in Scheme 17).  However, this approach is not highly appreciated since it requires 
the use of a strong reducing agent and also due to commercial unavailability of N,N-
dialkylformamide dimethyl acetal derivatives. 
Although C-4 modification of pyrimidine nucleosides via addition-elimination is 
straightforward as compared to direct alkylation or arylation approaches, there are some 
drawbacks in terms of the stability and reactivity of electrophilic nucleoside derivatives that are 
reported so far and the harsh conditions required for the nucleophilic displacement reactions.  
Hence, we decided to develop a one-pot strategy for the C-4 modification of pyrimidine 
nucleosides via a new class of electrophilic pyrimidine nucleoside derivatives, which would be 
readily reactive towards nucleophilic displacement reactions with various nucleophiles. 
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DMSO, 60 °C, 16 h
46%
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[1.2] RESULTS AND DISCUSSION 
[1.2.1] Optimization and Substrate Scope 
The premise of developing a new electrophilic pyrimidine nucleoside depends upon our 
recent success in developing the methodology for C-6 modification of purine nucleosides.37-45  In 
this strategy, the amide group of protected or unprotected purine nucleoside dervatives 36a–f 
was activated by (benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 
(BOP), a known peptide coupling agent in the presence of a suitable base (Scheme 18).  This 
activation leads to the formation of a O6-(benzotriazol-1-yl) purine nucleoside derivatives 37a–f, 
which are stable and reactive. These derivatives upon exposure to various nucleophiles lead to 
the C-6 modified purine nucleosides under mild conditions. 
Scheme 18. C-6 Modification of purine nucleosides through the formation of O6-(benzotriazol-1-
yl) purine nucleoside derivatives 37a–f 
 
During the course of our initial report on the synthesis and reactivity of O6-(benzotriazol-1-
yl) inosine derivatives (37a–d),37 a similar methodology was also reported for the direct 






























Nu = NR2R3, SR3, OR3
R2 = alkyl or H,










a, R = R1 = H, X = H
b, R = H, R1 = TBDMS, X = H 
c, R = OR1, R1 = H, X = H
d, R = OR1, R1 = TBDMS, X = H
e, R = R1 = H, X = NH2
f, R = OR1, R1 = TBDMS, X = NH2
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Ever since our initial reports on the C-6 modified purine nucleosides, the amide activation with 
BOP has seen light in various applications in the recent past.47-52  Since several pyrimidine 
nucleosides like thymidine and uridine possess an amide linkage.  Thus, we postulated that the 
corresponding O4-(benzotriazol-1-yl) derivatives can be synthesized by the activation of amide 
linkage with BOP and a suitable base.  By exposing the O4-(benzotriazol-1-yl) derivative to 
displacement reactions with various nucleophiles,  C-4 modification can be achieved. 
To test our hypothesis, we started our initial experiments by reacting thymidine (38) with 
BOP and DBU in THF (entry 1 in Table 1).  After 3 h, complete conversion of 38 to the O4-
(benzotriazol-1-yl) derivative 39 was observed. However, during isolation by silica gel 
chromatography, compound 39 decomposed. Hence, we decided to expose the O4-(benzotriazol-
1-yl) derivative 39, upon its formation, to morpholine prior to isolation (entry 2).  The C-4 
modified product 41 was observed to form in 12 h in ca. 58% yield.  However, purification by 
silica gel chromatography was not very successful due to the high polarity of 41, it co-eluted 
along with several other unknown polar impurities.  
Table 1. Optimization of conditions for the C-4 modification via activation of thymidine with 
BOP and basea 
 
Entry Substrate Conditions Product: yieldb 
1 38 BOP, DBU, THF, 3 h 39: decompc 








38: R = H








39: R = H










41: R = H
42: R = TBDMS
Conditions Nucleophile
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3 22a BOP, DBU, THF, 0.5 h 40: decompd 
4f 22a BOP, DBU, THF, 0.5 h, then morpholine, 2 h 42: 76% 
5g 22a BOP, Cs2CO3, THF, 24 h 40: inch 
6 22a BOP, DBU, DME, 2 h 40: inch 
7f 22a BOP, DBU, MeCN, 0.5 h, then morpholine, 2 
h 
42: 73% 
8g, f 22a BOP, Cs2CO3, MeCN, 0.5 h, then morpholine, 
2 h 
42: 94% 
9i 22a BOP, DBU, morpholine, THF, 20 min 42: 90% 
10g,i 22a BOP, Cs2CO3, morpholine, MeCN, 24 h 42: incj 
a Reactions were conducted at room temperature with 0.424 M solutions of 38 or 22a (except 
when noted otherwise), BOP (2 equiv.), base (2 equiv.) in anhydrous solvent.  b Where reported, 
yield of isolated and purified product.  c Product was not isolated due to decomposition over 
silica.  d Morpholine (4 equiv.) was added to the reaction mixture, after complete conversion of 
38 to 39.  e Product isolation was difficult as it co-elutes with morpholine, HMPA and other 
impurities.  f Morpholine (4 equiv.) was added to the reaction mixture, after complete conversion 
of 22a to 40.  g Reactions were conducted with 0.1325 M solution of 22a.  h Product was not 
isolated due to incomplete reaction (As assessed by TLC, ca. 50% conversion of the starting 
material was observed).  i After stirring a mixture of 22a, BOP (2 equiv.), and base (2 equiv.) in 
the appropriate solvent for 5 min, morpholine (4 equiv.) was added to the reaction mixture.  j 
Product was not isolated due to incomplete reaction (As assessed by TLC, ca. 10% conversion of 
the starting material was observed).   
 
To decrease polarity of the final product and increase ease of purification, we decided to test 
silyl protected-thymidine derivative 22a under the conditions used in entry 1 (entry 3).  The O4-
(benzotriazol-1-yl) derivative 40 was formed within a short reaction time of 0.5 h.  However, an 
attempt to isolate the product by silica gel chromatography lead to decomposition of majority of 
product 40 to its parent compound 22a, and 40 was isolated as a mixture along with 22a.  Several 
other attempts to isolate 40 were made using neutral and basic alumina, but hydrolysis was 
observed in all cases.  Silyl protection of the free hydroxyl groups in 38 did not provide any 
additional stability to the O4-(benzotriazol-1-yl) derivative 40.  As a result, we decided to not 
isolate O4-(benzotriazol-1-yl) derivative 40, but proceed towards C-4 modification by subjecting 
40 to nucleophilic displacement with morpholine upon its formation (entry 4).  After the 
formation of compound 40, the desired product 42 was formed within 2 h.  Product 42 was 
isolated in a good 76% yield, without any problems in the purification.  Surprisingly, changing 
! 19!
the base from DBU to Cs2CO3 did not yield 40.  To improve the solubility of the base, the same 
reaction was conducted at higher dilution (entry 5).  This reaction seemed to progress really fast 
within the first 0.5 h and about 70% conversion observed at that stage. To our surprise, upon 
further extending the reaction time to 24 h, only 50% conversion of 22a was observed.  It is 
possible that product 40 hydrolyzed to the starting material (22a) over a prolonged reaction time, 
under these conditions.  Substituting THF with DME as solvent to the conditions in entry 4, did 
not provide any improvement, and only 50% conversion of the starting material 22a was 
observed after 2 h (entry 6).  However, switching from THF to acetonitrile did in fact yield the 
O4-(benzotriazol-1-yl) derivative 40 within 0.5 h (entry 7).  Subsequent addition of morpholine 
to the reaction mixture lead to the formation of the product 42 in 2 h, in a good 73% yield, 
comparable to that in entry 4.  Interchanging DBU with Cs2CO3 to the conditions in entry 7 
increased the yield of 42 to 94% (entry 8).  However, this reaction proceeds only at higher 
dilution and requires vigorous stirring.  To further improve the conditions of the reaction, we 
decided to perform a one-step reaction for the formation of product 42 i.e., addition of the 
nucleophile to the reaction mixture along with BOP and base, rather than adding nucleophile 
after the formation of intermediate 40.  We believe that the availability of the nucleophile within 
the reaction medium allows the O4-(benzotriazol-1-yl) derivative 40  to react immediately with 
the nucleophile upon its formation, without any competing processes.  As expected, the reaction 
proceeded to form product 42 within a short 20 min, in an excellent 90% yield (entry 9).  
Surprisingly, the one-step reaction with Cs2CO3 as a base and acetonitrile as solvent, did not 
even proceed to the formation of intermediate 40, and only 10% conversion of the starting 
material 22a was observed even after 24 h (entry 10).      
! 20!
Having optimized conditions for C-4 modification, the scope was investigated with substrates 
and nucleophiles. Silyl-protected 2’-deoxyuridine 43 and 3’-azido-2’,3’-dideoxythymidine 
(AZT) 47 were chosen along with the thymidine derivative 22a for this purpose, and various 
amines and thiols were used as nucleophiles (Table 2).  The one-pot, two-step method and the 
one-step method with BOP, DBU in THF were chosen as standard conditions.  Typically, in a 
one-pot, two-step method, the nucleoside was reacted with 2 equiv. each of BOP and DBU in 
THF to form the corresponding benzotriazol-1-yl derivative.  Then the nucleophile was added to 
the reaction mixture from step 1 and the reaction was allowed to proceed until the benzotriazol-
1-yl derivative completely consumed to the product.  Conditions used in step 2 were subject to 
the nucleophile used and will be discussed later in more detail.  In the one-step method, the 
nucleoside was reacted with BOP (2 equiv.) and DBU, along with the nucleophile in a suitable 
solvent. 
Table 2. Generality of the two-step, one-pot and one-step reactions for the C-4 modification of 
pyrimidine nucleosidesa 
 
Entry Substrate Nucleophile 



























22a: R = CH3, R1 = OR2
43: R = H, R1 = OR2
47: R = CH3, R1 = N3
45a-j: R = CH3, R1 = OR2
46a-e: R = H, R1 = OR2











THF, rt, 0.5 h
40: R = CH3, R1 = OR2
44: R = H, R1 = OR2
48: R = CH3, R1 = N3
R2 = TBDMS









THF, rt, 1 h 
3 43 PhCH2NH2 rt, 2 h 46a: 78% 
BOP, DBU, 
THF, rt, 30 
min 
46a: 92% 




THF, rt, 1 h 45c: 93%
e 
5 22a Et2NH rt, 2 h 45d: 78% 
BOP, DBU, 
THF, rt, 1 h 45d: 98% 
6 47 Et2NH rt, 1 h 49a: 57% rt, 1 h 49a: 80% 
7 22a 
 
rt, 2 h 45e: 75% 
BOP, DBU, 





rt, 2 h 46b: 71% 
BOP, DBU, 





rt, 2 h 49b: 53% rt, 1 h 49b: 80% 
10 22a 
 
rt, 2 h 45f: 75% BOP, DBU, THF, rt, 1 h 45f: 92% 
11 43 
 
rt, 2 h 46c: 75% 
BOP, DBU, 





rt, 1.5 h 49c: 63% rt, 40 min 49c: 90% 
13 43 
 
rt, 2 h 46d: 76% 
BOP, DBU, 


























reflux, 12 h 
46e: 69%h 




DME, rt, 3 h 45h: 76%
h 
18 22a PhCH2SH 
Cs2CO3, 
DME, 4 h 45i: 70%
g BOP, DBU, DME, rt, 3 h 45i: 82%
h 
19 22a MeSNa DMSO, 50 °C, 2 h  45j: 49%
i not done NAj 
a Reactions were conducted at 0.424 M concentration using 0.212 mmol of 22a, 0.219 mmol of 
43, and 0.262 mmol of 47.  b BOP (2 equiv.), DBU (2 equiv.) in anhydrous THF were used to 
form the corresponding O4-(benzotriazol-1-yl) derivatives and then nucleophile (4 equiv.) was 














nucleophile (4 equiv.) were reacted in an appropriate solvent.  d Yields are of isolated and 
purified products.  e The following amine solutions were used: 2 M MeNH2 in THF and 40 wt% 
Me2NH in H2O.  f Yield was based on recovery of the compound 22a, the reaction was 
incomplete (ca. 7% of 22a was reisolated).  g After the formation of benzotriazolyl derivative, 
solvent was evaporated.  Then nucleophile (2 equiv.), and base (2 equiv.) in an appropriate 
solvent (2 mL) were used.  h DBU (4 equiv.), nucleophile (2 equiv.), and appropriate solvent (2 
mL) were used.  i After the formation of O4-(benzotriazol-1-yl) derivative, solvent was 
evaporated.  Then NaSMe (2 equiv.) was used in dry DMSO.  j A one-step approach was not 
attempted in this case.  
 
Various 1° and 2° aliphatic amines were used as nucleophiles in both the one-pot, two-step 
and the one-step methods.  In the case of one-pot, two-step method, after formation of 
benzotriazol-1-yl derivative in step 1, 4 equiv. of the nucleophile was added and reaction was 
conducted until the completion.  All the reactions were completed within 0.5–2 h range and the 
yields were in 71–84% range with substrates 22a and 43(Table 2).  Yields were moderate (53–
63%) in the case of the AZT derivative 47 (Table 2).  The one-step reactions with aliphatic 
amines were conducted by reacting the nucleoside with 2 equiv. each of BOP, DBU, and 4 equiv. 
of the amine.  These reactions were very rapid and excellent yields (89–98%) were observed in 
all reactions.  Surprisingly, the reaction of MeNH2 with thymidine derivative 22a did not go to 
completion after 45 min, and 7% of 22a was reisolated (entry 1 in Table 2).  Prolonging the 
reaction to 16 h, did not improve the outcome.  We then queried if aromatic amines can also be 
used as nucleophiles under these conditions.  We chose p-toluidine and initially tested the one-
pot, two-step reaction conditions.  This was performed by adding p-toluidine (2 equiv.) and 
iPr2NEt (2 equiv.) as the base, to the reaction mixture after formation of O4-(benzotriazol-1-yl) 
derivative 40 in step 1 and heating the reaction mixture at 50 °C.  However, this did not lead to 
formation of the desired product 45g.  Hence, we decided to modify the conditions in the step 2.  
On the basis of our previous observations, nucleophilic displacement reactions of O6-
(benzotriazol-1-yl) purine nucleosides with p-toluidine and iPr2NEt, requires a polar solvent like 
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EtOH.37  Hence, we conducted a reaction under similar conditions; by evaporating the solvent 
after step 1, addition of 2 mL of EtOH, followed by the addition of p-toluidine (2 equiv.) and 
iPr2NEt (2 equiv.).  Heating the resultant reaction mixture at 50 °C for 16 h gave the desired 
product 45g in 62% yield (entry 15).  The one-pot reaction was conducted by refluxing 
thymidine derivative 22a with BOP (2 equiv.), DBU (4 equiv.) and p-toluidine (2 equiv) in 
CH3CN for 12 h (entry 15).  Desired product 45g was isolated in 67% yield.  Similarly, product 
46e was synthesized from 2’-deoxyuridine derivative 43 in both the one-pot, two-step, and the 
one-step methods in yields of 64% and 69% (entry 16).  The one-step method seems to be 
superior to the one-pot, two-step method when aliphatic amines are used as nucleophiles, in 
terms of both reaction times and yield, especially in the case of AZT derivative 47.  Only a slight 
advantage was observed in the one-step method with p-toluidine was used as nucleophile.     
Next, we wanted to test if thiols would be as good nucleophiles as amines under the standard 
conditions.  However, reaction of O4-(benzotriazol-1-yl) derivative 40 with 2 equiv. each of 
EtSH and Cs2CO3 in THF was slow and produced the desired product 45h along with multiple 
byproducts.  Reactions of thiols with O6-(benzotriazol-1-yl) purine nucleosides are typically 
conducted by using Cs2CO3 as base and DME as solvent.37,42  Hence, after the formation of O4-
(benzotriazol-1-yl) derivative 40  in step 1 from thymidine derivative 22a, the solvent was 
evaporated, 2 mL of DME was added, followed by the addition of 2 equiv. each of EtSH and 
Cs2CO3 (entry 17).  After 3.5 h, the product 45h was isolated in 68% yield.  For the one-step 
method, the reaction conditions were slightly modified from the standard conditions. The 
reaction of 22a was conducted with BOP (2 equiv.), DBU (4 equiv.) and EtSH (2 equiv.) in 
DME as solvent at room temperature (entry 17).  This reaction yielded the product 45h in 3 h in 
76% yield.  The N4-thiobenzyl product 45i was also synthesized in the above manner via the one-
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pot, two-step and the one-step methods in 70% and 82% yield, respectively (entry 18).  However, 
the reaction with MeSNa under the one-pot, two-step reaction conditions used in entry 13, didn’t 
yield product 45j, due to insolubility of MeSNa in DME.  A similar result was also observed 
when the reaction was conducted in THF as solvent.  Hence, to improve the solubility of MeSNa, 
we decided to conduct step 2 reactions in various polar solvents like CH3CN, DMF, DMSO, and 
EtOH.  Reactions of O4-(benzotriazol-1-yl) derivative 40 with 2 equiv. of MeSNa in CH3CN or 
in DMF at 50 °C, did not reach completion.  When the same reaction was conducted in DMSO at 
50 °C over 2 h, the product 45j was isolated in a moderate 49% yield along with two other minor 
byproducts (entry 19).  After comparing the polarity of the byproducts with 40 by TLC and 
careful evaluation by 1H NMR and mass spectrometry, the two byproducts were identified as 
compounds 50 and 51 (Figure 3). Trace amounts of the compounds 50 and 51 were also 
observed to form in the reactions conducted in CH3CN and DMF as solvents.  However, no 
attempt was made to isolate the byproducts in these cases. The yield of the product 45j did not 
improve even after increasing the amount of MeSNa from 2 equiv. to 4 equiv. in a reaction 
conducted with DMSO as solvent.  In the reaction conducted at room temperature with EtOH as 
solvent, a new product 52 (Figure 3) was formed exclusively in 12 h in 73% yield.  It is possible 
that 52 can form either by displacing BtO– from the O4-(benzotriazol-1-yl) intermediate 40 or 
MeS– from 45j by EtOH.  It is well known that 4-methylthiopyrimidine nucleoside derivatives 
like 45j are good electrophilic nucleosides and easily undergo addition-elimination reactions 
with nucleophiles.4,9,10  A one-step approach for the synthesis of the compound 45j was not 
attempted.  One other important observation that was made during the isolation of the N4-
alkylthio derivatives 45h–j is that they decompose on silica. Particularly, compound 45j 
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decomposes faster than the compounds 45h and 45i.  This issue was resolved by neutralizing the 
silica gel with 5% Et3N in hexanes prior to loading the crude material.  
 
Figure 3. Unusual products furnished during the reaction of O4-(benzotriazol-1-yl) derivative 40 
with NaSMe 
Intrigued with the formation of the byproducts 50 and 51, we then focused on investigating 
the source of their formation.  The N-oxide 50 could arise by the rearrangement of the isomeric 
O4-(benzotriazol-1-yl) derivative 40.  Reese et al. observed a similar case previously during their 
studies on activating the amide linkage in 3’,5’-di-O-acetylthymidine (13a) with 1-hydroxy-1H-
benzotriazole, 2-chlorophenyl phosphorodichloridate, and Et3N.53  The corresponding O4-
(benzotriazol-1-yl) derivative that resulted from this reaction was isolated.  This compound upon 
heating with 1-methylimidazole in dry pyridine at 50 °C underwent rearrangement to give the 
corresponding N-oxide derivative.  Compound 51 could have originated by either deoxygenation 
of the N-oxide 50 or the O4-(benzotriazol-1-yl) derivative 40.  In our recent studies, we have 
shown that diboron reagents B2(OH)4 and (pinB)2 can easily deoxygenate 1-hydroxy-1H-
benzotriazoles and O6-(benzotriazol-1-yl)purine nucleosides.54,55  It is possible that the peptide 
coupling agent BOP may contain P(III) reagents as contaminants.  These species could result the 
formation of the benzotriazolide derivative 51 by deoxygenating either of 50 or 40.  Hence, to 































DBU and BOP from two different sources (Chem-Impex and Aldrich), and the products formed 
in those reactions were examined (Table 3). 
Table 3. Analysis of the products formed with BOP from two different sourcesa 
 
BOP Supplierb DBU Time %Yield
c  
40 50 51 Recovered 22a 
Chem-Impex  
(99.7% pure) 
2 equiv.  0.5 h 33.3 % 17.6 % 0.8 % 14.1 % 
2 equiv. 24 h 14.5%d 31.6 % 9.9%d – 
Aldrich 
(97% pure) 
2 equiv. 0.5 h 58.6 % 23.5 % – – 
2 equiv. 24 h 21.7 %d 46.1 % 3.5 %d – 
4 equiv. 24 h – 8.4 % 25.9 % – 
a Reactions were conducted with 0.212 mmol of 22a, BOP (2 equiv.), DBU in THF (0.5 mL).  b 
Purities are as stated by the suppliers.  c Yields are of isolated and purified products.  d 
Compounds 40 and 51 were isolated as a mixture to avoid decomposition of 40 to 22a.  The 
yields were calculated based on relative ratios of H-1’ of 40 and 51 in the 1H NMR. 
 
In the reactions conducted, within 0.5 h, the reaction with BOP from Aldrich showed better 
results, producing ca. 60% of the O4-(benzotriazol-1-yl) derivative 40.  Although, the N-oxide 
derivative 50 was also formed in both reactions in ca. 20% yields, the reduced product 51 was 
observed only in the reaction with BOP from Chem-Impex.  When the same reactions were 
conducted over 24 h, a significant increase in the amounts of the N-oxide derivative 50 and 
reduced product 51 was observed.  However, the amount of the reduced product 51 formed in the 
reaction with BOP from Chem-Impex was relatively high (ca. 10% compared to 3.5% with the 
Aldrich sample).  In order to study the role of DBU in these reactions, we conducted a reaction 





































22a 40 50 51
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derivative 40 was completely consumed, the amount of the reduced product 51 increased to ca. 
26%, and only 8% of the N-oxide product 50 was isolated.  Several studies have shown that 
DBU can act as a good nucleophile, and this usually leads to a caprolactam by ring opening.56  
Since it is known that the N-oxide type derivative of uridine can also undergo displacement 
reactions with nucleophiles,53 it is plausible that DBU could displace the BtO– by reacting with 
the compounds 40 and/or 50.  The BtO– group thus displaced could undergo deoxygenation with 
the P(III) contaminants from the BOP reagent to form the benzotriazolide (Bt–).  Bt– could then 
react with any of the electrophilic nucleosides generated in the reaction (40 and/or 50 or even the 
compounds generated from DBU reacting with 40 and 50) to form compound 51.  This 
hypothesis is in congruence with our recent proposal for the mechanism of the deoxygenation of 
O6-(benzotriazol-1-yl)purine nucleosides.55  Despite the presence of P(III) contaminants in BOP, 
compounds with azide functionality were unaffected during the course of the reaction.  
After analysis of the formation of side products 50 and 51, we conducted another reaction for 
the structural confirmation of these two compounds by using the conditions used for the 
deoxygenation of 1-hydroxy-1H-benzotriazoles.54 This was done by reacting N-oxide 50 with 
B2(OH)4 in CH3CN at 60 °C for 2 h (Figure 4).  This resulted in compound 51 as the product 































Figure 4. Deoxygenation of the N-oxide derivative 50 to compound 51 with B2(OH)4. Partial 1H 
NMR of the compounds 50 (in black) and 51 (in blue). Benzotriazolyl resonances are indicated 
by an asterick. 
[1.2.2] Mechanistic Studies 
 We next focused on investigating the mechanistic pathways for the formation of the O4-
(benzotriazol-1-yl) derivative 40 and the N-oxide derivative 50.  There are 3 plausible pathways 





on to BOP, after undergoing deprotonation with DBU.  Pathway a involves the formation of a 
phosphonium intermediate 53, where as in pathways b and c, the O4-(benzotriazol-1-yl) 
derivative 40 is directly produced by displacing HMPA from BOP with attack of the amide 
oxygen either at the N1 atom of the benzotriazolyl moiety via a SN2 process or at the N3 atom of 
benzotriazolyl moiety via a SN2’-like process.  Phosphonium intermediate 53 can react either 
with BtO– to form the compounds 40 and 50 or it can directly react with the nucleophile to give 
the C-4 modified product.   
Unlike in the case of pyrimidine nucleosides, formation of N-oxide derivatives was not 
observed with purine nucleosides.  However, formation of phosphonium intermediate was 
clearly evident by 31P{1H} NMR experiments.37,42  Although, the N-oxide derivative 50 was 
formed as a minor byproduct in the case of pyrimidine nucleosides, it is observed that the O4-
(benzotriazol-1-yl) derivative 40 eventually transforms to the compound 50 over a period of time 
(Table 3).  However, the direct formation of the compound 50 cannot be ruled out.  Hence, to 
probe these mechanistic pathways, we conducted several 31P{1H} experiments.  In the first 
experiment, the 31P{1H} NMR spectrum of BOP (d = 43.8 ppm, PF6– d = –144.5 ppm) was 
recorded in CD3CN at room temperature (Figure 5).  No new resonances were observed upon 
exposing this BOP solution to the compound 22a.  However, immediately upon addition of DBU 
to the mixture, a new resonance corresponding to HMPA  (d = 23.5 ppm) was observed.  Over a 
period of time, the amount of BOP decreased, while the amount of HMPA formation increased.  
Despite the support from this experiment for pathways b and c, the formation of a short-lived 
phosphonium species 53 cannot be excluded.  To evaluate if a short-lived species could be 
detected at a lower temperature, we conducted the same 31P{1H} NMR experiment at –25 °C.  
Again, no new resonances could correspond to phosphonium species 53 were observed.  
! 30!
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Figure 5. 31P{1H} NMR studies recorded in CD3CN to observe the reaction between BOP, 22a, 
and DBU  
 The rapid formation of HMPA upon the addition of DBU to a mixture of compound 22a and 
BOP in CD3CN could also result via the direct nucleophilic attack by DBU on BOP. Similarly, in 
the one-step approach, the presence of nucleophile in the reaction medium could also lead to the 
formation of HMPA by the reaction of the nucleophile with BOP.  To further investigate these, 
we performed three more experiments in CD3CN at room temperature (i) with BOP and DBU 
(Panel A, Figure 6), (ii) with BOP and pyrrolidine (Panel B, Figure 6), (iii) with BOP, DBU and 





Figure 6. 31P{1H} NMR studies: Panel A shows the time course of the reaction between BOP 
and DBU, Panel B shows the time course of the reaction between BOP and pyrrolidine, and 
Panel C shows the time course of the reaction between BOP, DBU, and pyrrolidine. 
In the reaction of BOP with DBU, a trace amount of HMPA was observed after 1 h, and it 
slowly increased over a period of 24 h (Panel A, Figure 6).  In the reactions of BOP with 
pyrrolidine and the combination of DBU and pyrrolidine, relatively more HMPA was observed 
after 1 h, compared to the reaction of BOP with DBU (Panels B and C, Figure 6).  The amount of 
HMPA increased over a 24 h time period in the latter cases as well.  However, the amount of 
HMPA generated in these three conditions was relatively low when compared to the reaction of 
BOP and DBU in the presence of the nucleoside 22a.  The reaction of BOP, DBU, and the 
nucleoside 22a in CH3CN is typically faster (0.5 h).  On the basis of all these experiments, it 
appears that the formation of the compounds 40 and 50 can indeed proceed via pathways b 
and/or c.  But results are in contrast to those from the reactions of purine nucleosides, where 
clear evidence for the formation of phosphonium intermediates was observed.37,42     
[1.2.3] Biological Studies 
The C-4 modified pyrimidine nucleosides were desilylated using standard reaction conditions 
i.e., n-Bu4NF in THF at room temperature, KF in MeOH at 80 oC, and 
tris(dimethylamino)sulfonium difluorotrimethylsilicate (TASF) in MeCN from 0 oC to room 
temperature (Figure 7).  Desilylation of compound 45h with KF in MeOH at 80 oC in 12 h, 
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resulted in O4-methylthymidine (54i) in a low 28% yield.  This further demonstrates the 
reactivity of N4-alkylthiopyrimidine nucleosides.  Hence, compound 45h was desilylated with n-
Bu4NF in THF at room temperature and the desired compound 54g was isolated in a good 70% 
yield.  Similarly, the labile 45j was desilylated under mild conditions using TASF in MeCN, to 

































































































































































Method A (Using n-Bu4NF/THF)
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Figure 7. Compounds synthesized with reaction times, yields using desilylation conditions. 
Method A.  n-Bu4NF, THF, rt; Method B: KF, MeOH, 80 oC; Method C: TASF, MeCN, 0 oC to rt. 
Studies have shown that the presence of an amino group at the 3’-position of several 
pyrimidine nucleosides led to compounds with anticancer properties.57-60  We wondered, if 
reduction of the 3’-azido group of the C-4 modified AZT analogues to their corresponding 3’-
amino derivatives, would lead to potential anti-cancer agents.  Hence, 3’-azido pyrimidine 
nucleoside analogues 56a–d were reduced with 5% palladium on charcoal and H2 gas, in MeOH 
as a solvent, at room temperature, to the corresponding 3’-amino pyrimidine nucleoside 
analogues 57a–d in excellent yields (Scheme 20). 
Scheme 20. Azide reduction of C-4 modified AZT analogues to their corresponding amines 
 
Once all the desired compounds were obtained, they were sent to our collaborators at Rega 
institute for medical research in Belgium in order to evaluate the biological activities. All the 
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57a: 99%    57b: 97%   57c: 99%   57d: 96%
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inhibition of proliferation of murine leukemia (L1210), human cervix carcinoma (HeLa), and 
human T-lymphocytic (CEM) cell lines (Figure 8).  The C-4 modified thymidine derivatives 41, 
54a, c, d, f–h showed moderate activity in these assays.  Interestingly, the corresponding C-4 
modified 2’-deoxyuridine derivatives 33, 55a, b, d did not show any activity.  This implies that 
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 5.4 ± 2.0 µMb
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a IC50 = 50% Inhibitory concentration or compound concentration required to 
inhibit tumor cell proliferation by 50%. b EC50 = 50% effective concentration or 
compound concentration required to inhibit virus replication by 50%.   
Figure 8.  Compounds that displayed biological activities 
The antiviral activity of the compounds was also studied by testing against various viruses: 
(a) cytomegalo (CMV), varicella-zoster (VZV), herpes simplex-1 (HSV-1), herpes simplex-2 
(HSV-2), vaccinia, and vesicular stomatitis (VSV) in human embryonic lung (HEL) cells, (b) 
VSV, coxsackie, and respiratory syncytial viruses in human cervix carcinoma (HeLa) cells, (c) 
parainfluenza-3, reo, sindbis, coxsackie B-4, and punta toro viruses in green monkey kidney 
(VERO) cells, (d) feline corona and feline herpes in feline kidney (CRFK) cells, and (e) 
influenza A H1N1, influenza B H3N2, and influenza B in canine kidney (MDCK) cells.  Except 
for the 3’-azido pyrimidine analogues 56a–d, none of the other compounds showed any antiviral 
activity.  The 3’-azido group is necessary for the compounds to exhibit antiviral properties.  The 
diethylamino derivative 56a and the piperidinyl derivative 56c showed comparable activity 
against HIV-1 and HIV-2.  Surprisingly, decreasing ring size from piperidinyl to pyrrolidinyl in 
compound 56b decreased the activity (Figure 8).  Most notably, incorporating an oxygen atom in 
the six-membered ring as in the morpholinyl derivative 56d, increased activity by ten fold.  
Surprisingly, the byproduct O4-methylthymidine (54i) obtained from the desilylation of 45h, 
showed inhibition against HSV-1 Kos strain (EC50 = 5.4 ± 2.0 µM), while the minimum 
cytotoxic concentration required to cause a microscopically detectable alteration of normal cell 
morphology was >100 µM (Figure 8).  Interestingly, 54i did not inhibit HSV-2 and an acyclovir-





We established a simple and easy method for the C-4 modification of pyrimidine nucleosides 
using BOP and DBU.  Various amines and thiols were used as nucleophiles.  This method 
involves the formation of O4-(benzotriazol-1-yl)pyrimidine nucleosides derivative as 
intermediates by the activation of the amide linkage with BOP and DBU.  A one-pot, two-step 
and a one-step approach were studied with various amines and thiols.  In most of the cases, the 
one-step approach was superior to the one-pot, two-step method.  Our approach is tolerant of a 
3’-azido group in the nucleoside.  The O4-(benzotriazol-1-yl)pyrimidine nucleoside transforms 
into an isomeric N-oxide derivative over extended reaction times, and the 4-(benzotriazol-1-
yl)pyrimidine nucleoside derivatives are generated possibly by reduction of the N-oxide with PIII 
species in BOP.  Deoxygenation of the N-oxide derivative with B2(OH)4 lead to the 
corresponding (benzotriazol-1-yl)pyrimidine nucleoside confirming the product structure.  
Spectroscopic studies further confirmed that these compounds were indeed as anticipated.  
Mechanism of the reaction was investigated by 31P{1H} NMR experiments.  All products were 
desilylated and the 3’-azido compounds were reduced to the corresponding 3’-amines.  
Anticancer activity of the resultant compounds was assessed using L1210, HeLa, and CEM cell 
lines, where some C-4 thymidine derivatives showed moderate activity.  Out of all the 
compounds, 3’-azido pyrimidine nucleosides displayed activity against HIV-1 and HIV-2 and 
O4-methylthymidine (54i) showed anti-HSV-1 activity.  In conclusion, this method provides a 





[1.4] EXPERIMENTAL SECTION 
General Experimental Considerations.  Reactions were conducted in screw-cap glass vials 
with Teflon-lined caps.  Thin-layer chromatography was performed on 200 µm aluminum-foil-
backed silica gel plates.  Column chromatography was performed using 200–300 mesh silica gel.  
In some cases the silica gel column had to be flushed twice with 5% Et3N in hexanes before 
loading the crude material in order to deactivate silica gel (see details under the compound 
headings).  THF was distilled from LiAlH4 and then from Na prior to use.  CH3CN and 1,2-
dimethoxyethane (DME) were distilled from CaH2.  All other reagents were used as received 
from commercial suppliers.  1H NMR spectra were obtained at 500 MHz and are referenced to 
the residual protonated solvent resonance.  13C NMR spectra were obtained at 125 MHz and are 
referenced to the solvent resonance.  Chemical shifts (d) are reported in parts per million (ppm) 
and coupling constants (J) are in hertz (Hz).  Standard abbreviations are used to designate 
resonance multiplicities. 
General procedure for the C-4 modification of pyrimidine nucleosides 22a, 43, and 47 
(One-pot, two-step Method) 
 
Step 1 of two-step procedure (synthesis of 40, 44, and 48) 










22a: R = CH3, R1 = OR2
43: R = H, R1 = OR2
47: R = CH3, R1 = N3
45a-j: R = CH3, R1 = OR2
46a-e: R = H, R1 = OR2











THF, rt, 0.5 h
40: R = CH3, R1 = OR2
44: R = H, R1 = OR2
48: R = CH3, R1 = N3
R2 = TBDMS









To a 0.424 M solution of the nucleoside derivative (22a: 0.212 mmol, 43: 0.219 mmol, and 47: 
0.262 mmol) in THF, BOP (2 equiv.) and DBU (2 equiv.) were added, and the mixture was 
stirred at room temperature for 30 min. 
Step 2 for aliphatic amines (synthesis of 42, 45a–f, 46a–d, 49a–d) 
To the reaction mixture from step 1, the appropriate amine (4 equiv.) was added and the reaction 
mixture was stirred at room temperature until consumption of the corresponding benzotriazolyl 
intermediate (40, 44 or 48) occurred.  The mixture was diluted with EtOAc (25 mL) and washed 
with deionized water (3 x 50 mL) followed by brine (15 mL).  The organic layer was dried over 
anhydrous Na2SO4, filtered, and evaporated under reduced pressure.  The crude material was 
purified by chromatography on a silica gel column using a suitable eluting solvent (see 
individual compound headings below). 
1-(3,5-Di-O-(t-butyldimethylsilyl)-2-deoxy-β-D-ribofuranosyl)-4-(morpholin-4-yl)-5-methyl-
2(1H)-pyrimidinone (42) 
Chromatography on a silica gel column by sequential elution with 50% 
EtOAc in hexanes and EtOAc gave compound 42 (86.9 mg, 76%) as a 
sticky, white solid.  Rf (SiO2/EtOAc) = 0.32.  1H NMR (500 MHz, acetone-
d6): δ 7.66 (s, 1H, H-6), 6.29 (t, J = 6.7 Hz, 1H, H-1’), 4.50 (dt, J = 2.8, 5.8 
Hz, 1H, H-3’), 3.96 (app q, Japp ~ 3.2 Hz, 1H, H-4’), 3.90 (dd, J = 3.7, 11.3 Hz, 1H, H-5’), 3.86 
(dd, J = 3.6, 11.4 Hz, 1H, H-5’), 3.70–3.66 (m, 4H, morpholinyl-CH2), 3.65–3.61 (m, 4H, 
morpholinyl-CH2), 2.30 (ddd, J = 2.9, 5.9, 13.3 Hz, 1H, H-2’), 2.15 (m, 4H, Me, and H-2’), 0.92 
and 0.91 (2s, 18H, t-Bu), 0.13 and 0.12 (2s, 6H, SiMe), 0.11 and 0.10 (2s, 6H, SiMe).  13C NMR 












26.1, 18.9, 18.5, 18.0, –4.5, –4.7, –5.3.  HRMS (ESI/TOF) m/z calculated for C26H49N3O5Si2Na 
[M + Na]+: 562.3103, found 562.3107.  
3’,5’-Di-O-(t-butyldimethylsilyl)-N,5-dimethyl-2’-deoxycytidine (45a) 
Chromatography on a silica gel column by sequential elution with EtOAc 
and 1% MeOH in EtOAc, gave compound 45a (85.8 mg, 84%) as a white 
solid.  Rf (SiO2/EtOAc) = 0.17.  1H NMR (500 MHz, CDCl3): δ 7.49 (s, 1H, 
H-6), 6.38 (t, J = 6.5 Hz, 1H, H-1’), 5.25 (br s, 1H, NH), 4.36 (dt, J = 3.3, 
6.4 Hz, 1H, H-3’), 3.90–3.87 (m, 2H, H-4’ and H-5’), 3.77–3.74 (m, 1H, H-5’), 3.06 (d, J = 4.7 
Hz, 3H, NMe), 2.39 (ddd, J = 3.7, 6.1, 13.3 Hz, 1H, H-2’), 1.97 (dt, J = 6.6, 13.3 Hz, 1H, H-2’), 
1.88 (s, 3H, Me), 0.92 and 0.88 (2s, 18H, t-Bu), 0.10 and 0.09 (2s, 6H, SiMe), 0.06 and 0.05 (2s, 
6H, SiMe).  13C NMR (125 MHz, CDCl3): δ 163.8, 156.4, 136.5, 102.1, 87.6, 85.7, 71.9, 62.9, 
42.1, 28.4, 26.1, 25.9, 18.5, 18.1, 13.3, –4.5, –4.7, –5.2, –5.3.  HRMS (ESI/TOF) m/z calculated 
for C23H45N3O4Si2Na [M + Na]+: 506.2841, found 506.2844.  
N-Benzyl-3’,5’-di-O-(t-butyldimethylsilyl)-5-methyl-2’-deoxycytidine (45b) 
Chromatography on a silica gel column by elution with 50% EtOAc in 
hexanes gave compound 45b (85.7 mg, 72%) as a white solid.  Rf 
(SiO2/50% EtOAc in hexanes) = 0.24.  1H NMR (500 MHz, acetone-d6): δ 
7.54 (s, 1H, H-6), 7.36 (d, J = 7.5 Hz, 2H, Ar-H), 7.28 (t, J = 7.5 Hz, 2H, 
Ar-H), 7.21 (t, J = 7.3 Hz, 1H, Ar-H), 7.06–6.98 (m, 1H, NH), 6.35 (dd, J = 6.0, 7.7 Hz, 1H, H-
1’), 4.70–4.68 (m, 2H, NCH2), 4.50 (dt, J = 2.8, 5.7 Hz, 1H, H-3’), 3.92 (app q, Japp ~ 3.1 Hz, 1H, 
H-4’), 3.90–3.84 (m, 2H, H-5’), 2.24 (ddd, J = 2.7, 5.8, 13.1 Hz, 1H, H-2’), 2.08–2.04 (m, 1H, 






















SiMe).  13C NMR (125 MHz, acetone-d6): δ 164.1, 156.1, 140.6, 137.9, 128.9, 128.6, 127.5, 
102.6, 88.3, 86.1, 73.6, 64.0, 44.6, 42.0, 26.4, 26.2, 18.9, 18.6, 13.6, –4.4, –4.6, –5.1, –5.2.  
HRMS (ESI/TOF) m/z calculated for C29H49N3O4Si2Na [M + Na]+: 582.3154, found 582.3156.  
3’,5’-Di-O-(t-butyldimethylsilyl)-N,N,5-trimethyl-2’-deoxycytidine (45c) 
Chromatography on a silica gel column by sequential elution with 50% 
EtOAc in hexanes and EtOAc gave compound 45c (79.9 mg, 76%) as a 
viscous, colorless liquid.  Rf (SiO2/EtOAc) = 0.35.  1H NMR (500 MHz, 
CDCl3): δ 7.48 (s, 1H, H-6), 6.34 (t, J = 6.4 Hz, 1H, H-1’), 4.35 (dt, J = 3.3, 
6.4 Hz, 1H, H-3’), 3.90-3.86 (m, 2H, H-4’ and H-5’), 3.75 (dd, J = 2.5, 11.1 Hz, 1H, H-5’), 3.13 
(s, 6H, NMe2), 2.37 (ddd, J = 3.8, 5.9, 13.3 Hz, 1H, H-2’), 2.13 (s, 3H, Me), 1.95 (dt, J = 6.6, 
13.3 Hz, 1H, H-2’), 0.91 and 0.87 (2s, 18H, t-Bu), 0.10 and 0.09 (2s, 6H, SiMe), 0.05 and 0.04 
(2s, 6H, SiMe).  HRMS (ESI/TOF) m/z calculated for C24H47N3O4Si2Na [M + Na]+: 520.2997, 
found 520.2974.  The 1H NMR spectrum matches to that of the authentic material.61  
3’,5’-Di-O-(t-butyldimethylsilyl)-N,N-diethyl-5-methyl-2’-deoxycytidine (45d) 
Chromatography on a silica gel column by sequential elution with 25% 
EtOAc in hexanes and 50% EtOAc in hexanes gave compound 45d (86.9 
mg, 78%) as a viscous, colorless liquid.  Rf (SiO2/50% EtOAc in hexanes) 
= 0.24.  1H NMR (500 MHz, CDCl3): δ 7.43 (s, 1H, H-6), 6.35 (t, J = 6.5 
Hz, 1H, H-1’), 4.37 (dt, J = 3.2, 6.3 Hz, 1H, H-3’), 3.90–3.86 (m, 2H, H-4’ and H-5’), 3.76 (dd, 
J = 2.0, 11.2 Hz, 1H, H-5’), 3.60–3.52 (m, 4H, NCH2), 2.38 (ddd, J = 3.8, 5.7, 13.2 Hz, 1H, H-
2’), 2.13 (s, 3H, Me), 1.99 (dt, J = 6.7, 13.3 Hz, 1H, H-2’), 1.20 (t, J = 7.0 Hz, 6H, Me), 0.92 and 






















CDCl3): δ 164.5, 155.4, 140.7, 102.2, 87.7, 85.8, 71.9, 62.9, 43.8, 42.2, 26.2, 26.0, 19.0, 18.6, 
18.2, 14.0, –4.3, –4.7, –5.1, –5.2.  HRMS (ESI/TOF) m/z calculated for C26H52N3O4Si2 [M + 
H]+: 526.3491, found 526.3499.  
1-(3,5-Di-O-(t-butyldimethylsilyl)-2-deoxy-β-D-ribofuranosyl)-5-methyl-4-(pyrrolidin-1-yl)-
2(1H)-pyrimidinone (45e)  
Chromatography on a silica gel column by sequential elution with 40% 
EtOAc in hexanes and 75% EtOAc in hexanes gave compound 45e (83.5 
mg, 75%) as a viscous, colorless liquid.  Rf (SiO2/EtOAc) = 0.48.  1H NMR 
(500 MHz, CDCl3): δ 7.38 (s, 1H, H-6), 6.26 (t, J = 6.5 Hz, 1H, H-1’), 4.33 
(dt, J = 3.1, 6.1 Hz, 1H, H-3’), 3.86 (app q, Japp ~ 2.9 Hz, 1H, H-4’), 3.82 (dd, J = 2.8, 11.3 Hz, 
1H, H-5’), 3.73–3.71 (m, 5H, H-5’ and N(CH2)2), 2.27 (ddd, J = 3.5, 6.0, 13.3 Hz, 1H, H-2’), 
2.16 (s, 3H, Me), 1.95 (dt, J = 6.7, 13.4 Hz, 1H, H-2’), 1.92–1.84 (m, 4H, CH2), 0.89 and 0.84 
(2s, 18H, t-Bu), 0.07 and 0.06 (2s, 6H, SiMe), 0.03 (s, 6H, SiMe).  13C NMR (125 MHz, 
acetone-d6): δ 163.4, 155.1, 140.1, 102.6, 88.2, 85.9, 73.6, 64.0, 49.7, 41.9, 26.3, 26.2, 25.9 (br), 
18.9, 18.6, 18.2, –4.5, –4.6, –5.2, –5.3.  HRMS (ESI/TOF) m/z calculated for C26H49N3O4Si2Na 
[M + Na]+: 546.3154, found 546.3159. 
1-(3,5-Di-O-(t-butyldimethylsilyl)-2-deoxy-β-D-ribofuranosyl)-5-methyl-4-(piperidin-1-yl)-
2(1H)-pyrimidinone (45f) 
Chromatography on a silica gel column by sequential elution with 25% EtOAc in hexanes and 
50% EtOAc in hexanes gave compound 45f (85.8 mg, 75%) as a viscous, colorless liquid.  Rf 
(SiO2/50% EtOAc in hexanes) = 0.28.  1H NMR (500 MHz, CDCl3): δ 7.53 (s, 1H, H-6), 6.35 (t, 











3.75 (dd, J = 1.8, 10.7 Hz, 1H, H-5’), 3.55–3.50 (br m, 4H, NCH2), 2.39 
(ddd, J = 3.9, 6.1, 13.3 Hz, 1H, H-2’), 2.06 (s, 3H, Me), 1.99 (dt, J = 6.6, 
13.3 Hz, 1H, H-2’), 1.69-1.58 (br m, 6H, (CH2)3), 0.92 and 0.88 (2s, 18H, t-
Bu), 0.10 and 0.09 (2s, 6H, SiMe), 0.06 and 0.05 (2s, 6H, SiMe).  13C NMR 
(125 MHz, CDCl3): δ 166.8, 155.6, 140.8, 103.4, 87.6, 85.8, 71.7, 62.8, 48.4, 42.1, 26.2, 26.1, 
25.9, 24.6, 18.5, 18.2, 18.1, –4.4, –4.8, –5.2, –5.3.  HRMS (ESI/TOF) m/z calculated for 
C27H51N3O4Si2Na [M + Na]+: 560.3310, found 560.3315.  
N-benzyl-3’,5’-Di-O-(t-butyldimethylsilyl)-2’-deoxycytidine (46a) 
Chromatography on a silica gel column by sequential elution with 25% 
EtOAc in hexanes and 60% EtOAc in hexanes gave compound 46a (93.6 
mg, 78%) as a viscous, colorless liquid.  Rf (SiO2/50% EtOAc in hexanes) 
= 0.20.  1H NMR (500 MHz, acetone-d6): δ 7.83 (d, J = 7.5 Hz, 1H, H-6), 
7.36 (d, J = 7.2 Hz, 2H, Ar-H), 7.31 (t, J = 7.5 Hz, 2H, Ar-H), 7.24 (t, J = 7.2 Hz, 1H, Ar-H), 
7.18–7.17 (br t, J = 6.0 Hz, 1H, NH), 6.30 (t, J = 6.3 Hz, 1H, H-1’), 5.83 (d, J = 7.5 Hz, 1H, H-5), 
4.63–4.60 (m, 2H, NCH2), 4.52 (dt, J = 3.7, 6.0 Hz, 1H, H-3’), 3.92–3.89 (m, 2H, H-4’ and H-5’), 
3.87–3.84 (m, 1H, H-2’), 2.30 (ddd, J = 4.2, 6.1, 13.2 Hz, 1H, H-2’), 2.11 (dt, J = 6.5, 13.1 Hz, 
1H, H-2’), 0.94 and 0.92 (2s, 18H, t-Bu), 0.13 (s, 12H, SiMe).  13C NMR (125 MHz, acetone-d6): 
δ 164.7, 156.4, 140.5, 140.0, 129.1, 128.6, 127.7, 95.5, 88.0, 86.2, 72.5, 63.4, 44.6, 42.2, 26.3, 
26.2, 18.9, 18.5, –4.4, –4.6, –5.2, –5.3.  HRMS (ESI/TOF) m/z calculated for C28H47N3O4Si2Na 






















 Chromatography on a silica gel column by sequential elution with 50% 
EtOAc in hexanes and EtOAc, gave compound 46b (79.7 mg, 71%) as a 
white solid.  Rf (SiO2/EtOAc) = 0.23.  1H NMR (500 MHz, CDCl3): δ 7.94 
(d, J = 7.6 Hz, 1H, H-6), 6.30 (t, J = 5.7 Hz, 1H, H-1’), 5.60 (d, J = 7.6 Hz, 
1H, H-5), 4.36 (app q, Japp ~ 5.7 Hz, 1H, H-3’), 3.91 (dd, J = 2.4, 11.3 Hz, 1H, H-5’), 3.86 (dt, J 
= 2.4, 4.9 Hz, 1H, H-4’), 3.75 (dd, J = 2.2, 11.3 Hz, 1H, H-5’), 3.66 (t, J = 6.8 Hz, 2H, NCHH), 
3.38 (t, J = 6.8 Hz, 2H, NCHH), 2.40 (dt, J = 6.4, 13.1 Hz, 1H, H-2’), 2.11–2.06 (m, 1H, H-2’), 
2.04–1.97 (m, 2H, CH2), 1.96–1.87 (m, 2H, CH2), 0.92 and 0.86 (2s, 18H, t-Bu), 0.10 and 0.09 
(2s, 6H, SiMe), 0.04 and 0.03 (2s, 6H, SiMe).  13C NMR (125 MHz, acetone-d6): δ 162.3, 155.7, 
141.2, 93.0, 88.2, 86.3, 72.8, 63.6, 47.3, 42.3, 26.4, 26.2, 25.3, 18.9, 18.6, –4.4, –4.6, –5.2, –5.3.  
HRMS (ESI/TOF) m/z calculated for C25H47N3O4Si2Na [M + Na]+: 532.2997, found 532.2994. 
1-(3,5-Di-O-(t-butyldimethylsilyl)-2-deoxy-β-D-ribofuranosyl)-4-(piperidin-1-yl)-2(1H)-
pyrimidinone (46c) 
Chromatography on a silica gel column by sequential elution with 30% 
EtOAc in hexanes and 60% EtOAc in hexanes, gave compound 46c (86.4 
mg, 75%) as a white solid.  Rf (SiO2/100% EtOAc) = 0.57.  1H NMR (500 
MHz, acetone-d6): δ 7.91 (d, J = 7.8 Hz, 1H, H-6), 6.30 (t, J = 6.4 Hz, 1H, 
H-1’), 6.28 (d, J = 7.8 Hz, 1H, H-5), 4.52 (dt, J = 3.2, 6.1 Hz, 1H, H-3’), 3.94–3.88 (m, 3H, H-4’ 
and H-5’), 3.85 (dd, J = 2.9, 11.2 Hz, 1H, H-5’), 3.81–3.49 (br m, 4H, NCH2), 2.30 (ddd, J = 3.9, 
6.0, 13.2 Hz, 1H, H-2’), 2.21 (dt, J = 6.5, 13.2 Hz, 1H, H-2’), 1.71–1.64 (m, 2H, CH2), 1.59–1.51 
(br m, 4H, CH2), 0.93 and 0.91 (2s, 18H, t-Bu), 0.13 (s, 6H, SiMe), 0.12 and 0.11 (2s, 6H, SiMe).  


















45.2 (br), 42.2, 26.6 (br), 26.3, 26.1, 25.1, 18.9, 18.5, –4.5, –4.6, –5.2, –5.3.  HRMS (ESI/TOF) 
m/z calculated for C26H49N3O4Si2Na [M + Na]+: 546.3154, found 546.3159.  
 1-(3,5-Di-O-(t-butyldimethylsilyl)-2-deoxy-β-D-ribofuranosyl)-4-(morpholin-4-yl)-2(1H)-
pyrimidinone (46d) 
Chromatography on a silica gel column by sequential elution with 50% 
EtOAc in hexanes followed by EtOAc, gave compound 46d (87.5 mg, 
76%) as a colorless liquid.  Rf (SiO2/EtOAc) = 0.48.  1H NMR (500 MHz, 
acetone-d6): δ 7.93 (d, J = 7.8 Hz, 1H, H-6), 6.27 (t, J = 6.3 Hz, 1H, H-1’), 
6.01 (d, J = 7.8 Hz, 1H, H-5), 4.51 (dt, J = 3.5, 5.7 Hz, 1H, H-3’), 3.93–3.89 (m, 2H, H-4’ and 
H-5’), 3.85 (dd, J = 2.4, 10.8 Hz, 1H, H-5’), 3.66 (br s, 8H, O(CH2)2 and N(CH2)2), 2.31 (ddd, J 
= 4.1, 6.0, 13.2 Hz, 1H, H-2’), 2.18 (dt, J = 6.5, 13.1 Hz, 1H, H-2’), 0.94 and 0.92 (2s, 18H, t-
Bu), 0.13 and 0.12 (2s, 12H, SiMe).  13C NMR (125 MHz, CDCl3): δ 164.0, 155.3, 142.1, 91.2, 
88.3, 86.4, 72.8, 67.1, 63.6, 45.2 (br), 42.4, 26.4, 26.2, 18.9, 18.6, –4.4, –4.6, –5.3.  HRMS 
(ESI/TOF) m/z calculated for C25H47N3O5Si2Na [M + Na]+: 548.2946, found 548.2950.  
3’-Azido-5’-O-(t-butyldimethylsilyl)-N,N-diethyl-5-methyl-2’,3’-dideoxycytidine (49a) 
Chromatography on a silica gel column by sequential elution with 25% 
EtOAc in hexanes and 75% EtOAc in hexanes gave compound 49a (65.4 
mg, 57%) as colorless, viscous liquid.  Rf (SiO2/EtOAc) = 0.35.  1H NMR 
(500 MHz, acetone-d6): δ 7.52 (s, 1H, H-6), 6.18 (t, J = 6.5 Hz, 1H, H-1’), 
4.43 (dt, J = 3.8, 7.3 Hz, 1H, H-3’), 4.00–3.94 (m, 2H, H-4’ and H-5’), 3.92 
(dd, J = 3.4, 11.1 Hz, 1H, H-5’), 3.58 (q, J = 7.0 Hz, 4H, NCH2), 2.43 (ddd, J = 4.6, 6.1, 13.6 Hz, 





















0.94 (s, 9H, t-Bu), 0.15 (s, 6H, SiMe).  13C NMR (125 MHz, acetone-d6): δ 165.0, 155.2, 141.6, 
102.7, 86.1, 85.2, 64.0, 62.1, 44.2, 38.6, 26.3, 18.9, 18.8, 14.0, –5.2, –5.3.  HRMS (ESI/TOF) 
m/z calculated for C20H36N6O3SiNa [M + Na]+: 459.2510, found 459.2519.  
1-(3-Azido-5-O-(t-butyldimethylsilyl)-2,3-dideoxy-β-D-ribofuranosyl)-5-methyl-4-
(pyrrolidin-1-yl)-2(1H)-pyrimidinone (49b) 
Chromatography on a silica gel column using EtOAc gave compound 49b 
(60.4 mg, 53%) as a viscous, colorless liquid.  Rf (SiO2/EtOAc) = 0.27.  1H 
NMR (500 MHz, acetone-d6): δ 7.43 (s, 1H, H-6), 6.19 (t, J = 6.6 Hz, 1H, 
H-1’), 4.42 (dt, J = 3.8, 7.4 Hz, 1H, H-3’), 3.97–3.90 (m, 3H, H-  4’, H-5’, 
and H-5’), 3.73–3.63 (br m, 4H, NCH2), 2.39 (ddd, J  = 4.4, 6.3, 13.6 Hz, 1H, H-2’),  2.30 (dt, J 
= 6.9, 13.7 Hz, 1H, H-2’), 2.20 (d, J = 0.9 Hz, 3H, Me), 1.93-1.85 (m, 4H, CH2), 0.94  (s, 9H, t-
Bu), 0.15 (s, 6H, SiMe).  13C NMR (125 MHz, acetone-d6): δ 163.6, 154.9, 140.2, 102.7, 85.9, 
85.0, 64.1, 62.1, 49.8, 38.5, 26.3, 25.9 (br), 18.9, 18.2, –5.2, –5.3.  HRMS (ESI/TOF) m/z 
calculated for C20H34N6O3SiNa [M + Na]+: 457.2354, found 457.2365.  
 1-(3-Azido-5-O-(t-butyldimethylsilyl)-2,3-dideoxy-β-D-ribofuranosyl)-5-methyl-4-
(piperidin-1-yl)-2(1H)-pyrimidinone (49c) 
Chromatography on a silica gel column by sequential elution with 50% 
EtOAc in hexanes and EtOAc gave compound 49c (74.1 mg, 63%) as a 
colorless, viscous liquid.  Rf (SiO2/EtOAc) = 0.55.  1H NMR (500 MHz, 
acetone-d6):  δ 7.57 (d, J = 0.7 Hz, 1H, H-6), 6.16 (t, J = 6.5 Hz, 1H, H-1’), 
4.43 (dt, J = 4.1, 7.2 Hz, 1H, H-3’), 4.00–3.95 (m, 2H, H-4’ and H-5’), 3.92 (dd, J = 3.3, 11.2 Hz, 




















= 6.9, 13.7 Hz, 1H, H-2’), 2.10 (d, J = 0.7 Hz, 3H, Me), 1.70–1.64 (m, 2H, CH2), 1.64–1.58 (m, 
4H, CH2), 0.94 (s, 9H, t-Bu), 0.15 (s, 6H, SiMe).  13C NMR (125 MHz, acetone-d6): δ 167.4, 
155.1, 141.9, 103.6, 86.2, 85.2, 64.0, 62.0, 48.8, 38.7, 26.7, 26.3, 25.3, 18.9, 18.0, –5.2, –5.3.  
HRMS (ESI/TOF) m/z calculated for C21H36N6O3SiNa [M + Na]+: 471.2510, found 471.2506. 
1-(3-Azido-5-O-(t-butyldimethylsilyl)-2,3-dideoxy-β-D-ribofuranosyl)-5-methyl-4-
(morpholin-4-yl)-2(1H)-pyrimidinone (49d) 
Chromatography on a silica gel column by sequential elution with 50% 
EtOAc in hexanes and EtOAc, gave compound 49d (67.3 mg, 57%) as a 
colorless liquid.  Rf (SiO2/EtOAc) =  0.27.  1H NMR (500 MHz, acetone-
d6): δ 7.62 (s, 1H, H-6), 6.15 (t, J = 6.4 Hz, 1H, H-1’), 4.43 (dt, J = 4.3, 7.1 
Hz, 1H, H-3’), 4.01 (app q, Japp ~ 3.7 Hz, 1H, H-4’), 3.97 (dd, J = 3.5, 11.3 Hz, 1H, H-5’), 3.93 
(dd, J = 3.4, 11.3 Hz, 1H, H-5), 3.73–3.65 (m, 4H, morpholinyl–CH2), 3.62–3.52 (m, 4H, 
morpholinyl–CH2), 2.47 (ddd, J = 4.5, 6.3, 13.7 Hz, 1H, H-2’), 2.34 (dt, J = 6.9,  13.7 Hz, 1H, 
H-2’), 2.11 (s, 3H, Me), 0.94 (s, 9H, t-Bu), 0.15 (s, 6H, SiMe).  13C NMR (125 MHz, acetone-
d6): δ 167.5, 155.0, 142.3, 103.5, 86.4, 85.4, 67.3, 64.0, 62.0, 48.4, 38.7, 26.3, 18.9, 17.8, –5.2.  
HRMS (ESI/TOF) m/z calculated for C20H34N6O4SiNa [M + Na]+: 473.2303, found 473.2302.  
Step 2 for p-toluidine (synthesis of 45g and 46e) 
The reaction mixture from step 1 was evaporated on a rotary evaporator and dried under high 
vacuum for 10 min.  The residual material was dissolved in EtOH (2 mL), p-toluidine (2 equiv.) 
and iPr2NEt (2 equiv.) were added, and the mixture was stirred at 50 °C for 16 h.  The reaction 
mixture was cooled then diluted with EtOAc (25 mL), washed with deionized water (3 x 50 mL), 












under reduced pressure.  The crude material was purified by chromatography on a silica gel 
column using a suitable eluting solvent (see individual compound headings below). 
3’,5’-Di-O-(t-butyldimethylsilyl)-5-methyl-N-(p-tolyl)-2’-deoxycytidine (45g) 
Chromatography on a silica gel column by sequential elution with 
15% EtOAc in hexanes and 40% EtOAc in hexanes, gave compound 
45g (73.6 mg, 62%) as a light-brown solid.  Rf (SiO2/25% EtOAc in 
hexanes) = 0.14.  1H NMR (500 MHz, CDCl3): δ 7.54 (br s, 3H, H-6, 
Ar-H), 7.36 (d, J = 8.1 Hz, 2H, Ar-H), 6.67–6.40 (m, 1H, NH), 6.34 (t, J = 6.4 Hz, 1H, H-1’),  
4.37 (dt, J = 3.3, 6.3 Hz, 1H, H-3’), 3.92–3.89 (m, 2H, H-4’ and H-5’), 3.77 (dd, J = 2.3, 11.2 
Hz, 1H,  H-5’), 2.42 (br s, 1H, H-2’), 2.33 (s, 3H, ArMe), 2.03–1.98 (m, 4H, H-2’, Me), 0.93 and 
0.89 (2s, 18H, t-Bu), 0.12 and 0.11 (2s, 6H, SiMe), 0.07 and 0.06 (2s, 6H, SiMe).  13C NMR 
(125 MHz, CDCl3): δ 161.2, 155.6, 137.9, 135.8, 134.1, 129.6, 121.9, 102.2, 87.7, 86.0, 71.8, 
62.9, 42.1, 26.1, 25.9, 21.0, 18.6, 18.2, 13.8, –4.4, –4.7, –5.2.  HRMS (ESI/TOF) m/z calculated 
for C29H50N3O4Si2 [M + H]+: 560.3334, found 560.3311.  
3’,5’-Di-O-(t-butyldimethylsilyl)-N-(p-tolyl)-2’-deoxycytidine (46e) 
Chromatography on a silica gel column by sequential elution with 
20% EtOAc in hexanes and 40% EtOAc in hexanes gave compound 
46e (74.1 mg, 64%), as a light-brown solid.  Rf (SiO2/50% EtOAc in 
hexanes) = 0.24.  1H NMR (500 MHz, CDCl3): δ 8.46–8.08 (br, 1H, 
NH), 8.19 (d, J = 7.4 Hz, 1H, H-6), 7.52–7.22 (br m, 2H, Ar-H), 7.22–
7.11 (m, 2H, Ar-H), 6.32–6.27 (m, 1H, H-1’), 5.88 (d, J = 7.4 Hz, 1H, H–5), 4.41–4.34 (m, 1H, 





















2’), 2.34 (s, 3H, ArMe), 2.16-2.08 (m, H-2), 0.90 and 0.88 (2s, 18H, t-Bu), 0.09 (s, 6H, SiMe), 
0.06 (s, 6H, SiMe).  13C NMR (125 MHz, CDCl3): δ 163.9 (br), 155.8 (br), 141.7 (br), 135.3 (br), 
130.0, 124.1 (br), 92.1 (br), 87.5, 86.2, 70.4, 62.1, 42.3, 26.1, 25.9, 21.1, 18.5, 18.1, –4.4, –4.8, –
5.3, –5.4.  HRMS (ESI/TOF) m/z calculated for C28H48N3O4Si2 [M + H]+: 546.3178, found 
546.3173. 
Step 2 for thiols (synthesis of 45h and 45i) 
The reaction mixture from step 1 was evaporated on a rotary evaporator and dried under high 
vacuum for 10 min.  The residual material was dissolved in dry DME (2 mL), the appropriate 
thiol (0.425 mmol, 2 equiv.) and Cs2CO3 (138.1 mg, 0.425 mmol, 2 equiv.) were added, and the 
mixture was stirred at room temperature until consumption of 40 occurred.  The reaction mixture 
was then diluted with EtOAc (25 mL), washed with deionized water (3 x 50 mL), and brine (15 
mL).  The organic layer was dried over anhydrous Na2SO4, filtered, and evaporated under 
reduced pressure.  The crude material was purified by chromatography on a neutralized silica gel 
column using a suitable eluting solvent (see individual compound headings below and the 
General Experimental Considerations). 
3’,5’-Di-O-(t-butyldimethylsilyl)-S4-ethyl-4-thiothymidine (45h) 
Chromatography on a neutralized silica gel column by sequential elution 
with 5% EtOAc in hexanes and 10% EtOAc in hexanes gave compound 
45h (74.4 mg, 68%) as a white solid.  Rf (SiO2/50% EtOAc in hexanes) = 
0.75.  1H NMR (500 MHz, acetone-d6): δ 7.73 (d, J = 0.4 Hz, 1H, H-6), 
6.20 (t, J = 6.6 Hz, 1H, H-1’), 4.52 (dt, J = 2.9, 5.8 Hz, 1H, H-3’), 4.02 (app q, Japp ~ 3.1 Hz, 1H, 












7.4 Hz, 2H, SCH2) 2.43 (ddd, J = 3.0, 5.9, 13.3 Hz, 1H, H-2’), 2.15 (ddd, J = 6.1, 7.2, 13.3 Hz, 
1H, H-2’), 1.99 (d, J = 0.6 Hz, 3H, Me), 1.31 (t, J = 7.3 Hz, 3H, Me), 0.93 and 0.92 (2s, 18H, t-
Bu), 0.14 (2s, 6H, SiMe), 0.13 (2s, 6H, SiMe).  13C NMR (125 MHz, acetone-d6): δ 177.6, 153.5, 
138.4, 111.2, 88.9, 87.3, 73.3, 63.7, 42.5, 26.3, 26.2, 24.3, 18.9, 18.5, 14.5, 14.3, –4.5, –4.7, –5.3.  
HRMS (ESI/TOF) m/z calculated for C24H46N2O4SSi2Na [M + Na]+: 537.2609, found 537.2611. 
3’,5’-Di-O-(t-butyldimethylsilyl)-S4-benzyl-4-thiothymidine (45i) 
Chromatography on a neutralized silica gel column by sequential elution 
with 5% EtOAc in hexanes, 7% EtOAc in hexanes, and 10% EtOAc in 
hexanes gave compound 45i (85.6 mg, 70%) as a white solid.  Rf 
(SiO2/25% EtOAc in hexanes) = 0.57.  1H NMR (500 MHz, acetone- d6): δ 
7.77 (s, 1H, H-6), 7.46 (d, J = 7.2 Hz, 2H, Ar-H), 7.31 (t, J = 7.4 Hz, 2H, Ar-H), 7.25 (t, J  = 7.3 
Hz, 1H, Ar-H), 6.23 (t, J = 6.6 Hz, 1H, H-1’), 4.53 (dt, J = 2.9, 5.8 Hz, 1H, H-3’), 4.45 (s, 2H, -
SCH2), 4.03 (app q, Japp ~ 3.2 Hz, 1H, H-4’), 3.94 (dd, J = 3.6, 11.4 Hz, 1H, H-5’), 3.89 (dd, J = 
3.3, 11.4 Hz, 1H, H-5’), 2.45 (ddd, J = 3.1, 5.9, 13.3 Hz, 1H, H-2’), 2.17 (ddd, J = 6.2, 7.1, 13.3  
Hz, 1H, H-2’), 1.99 (s, 3H, Me), 0.93 (2s, 18H, t-Bu), 0.14 (2s, 12H, SiMe).  13C NMR (125 
MHz, acetone-d6): δ 177.1, 153.5, 138.9, 138.3, 130.1, 129.3, 128.0, 111.1, 89.1, 87.5, 73.4, 
63.8, 42.5, 34.1, 26.3, 26.2, 18.9, 18.5, 14.3, –4.4, –4.6, –5.2.  HRMS (ESI/TOF) m/z calculated 
for C29H48N2O4SSi2Na [M + Na]+: 599.2766, found 599.2764.  
Step 2 for NaSMe (synthesis of 45j) 
The reaction mixture from step 1 was evaporated on a rotary evaporator and dried under high 
vacuum for 10 min.  The residual material was dissolved in dry DMSO (1 mL) and NaSMe (29.7 












then diluted with EtOAc (25 mL), washed with deionized water (3 x 50 mL), and brine (15 mL).  
The organic layer was dried over anhydrous Na2SO4, filtered, and evaporated under reduced 
pressure.  The crude material was purified on a neutralized silica gel column by sequential 
elution with 10% EtOAc in hexanes, 15% EtOAc in hexanes, 20% EtOAc in hexanes, and 50% 
EtOAc in hexanes to give: 51 (6.5 mg, 5%) as an off-white solid, 45j (52.4 mg, 49%) as a 
colorless, viscous oil, and 50 (15.4 mg, 12%) as an off-white solid. 
3’,5’-Di-O-(t-butyldimethylsilyl)-S4-methyl-4-thiothymidine (45j) 
Rf (SiO2/50% EtOAc in hexanes) = 0.67.  1H NMR (500 MHz, CDCl3): δ 
7.67 (s, 1H, H-6), 6.27 (t, J = 6.3 Hz, 1H, H-1’), 4.36 (dt, J = 3.6, 6.4 Hz, 
1H, H-3’), 3.96 (app q, Japp ~ 3.0 Hz, 1H, H-4’), 3.91 (dd, J = 2.6, 11.4 Hz, 
1H, H-5’), 3.77 (dd, J = 2.5, 11.4 Hz, 1H, H-5’), 2.56 (s, 3H, SMe), 2.51 
(ddd, J = 4.0, 6.2, 13.4 Hz, 1H, H-2’), 2.04-1.99 (m, 4H, H-2’, Me), 0.91 and 0.89 (2s, 18H, t-
Bu), 0.11 and 0.10 (2s, 6H, SiMe), 0.07 and 0.06 (2s, 6H, SiMe).  13C NMR (125 MHz, CDCl3): 
δ 178.4, 154.0, 136.9, 111.7, 88.2, 86.8, 71.6, 62.7, 42.5, 26.1, 26.0, 18.6, 18.2, 14.5,  13.3, –4.3, 
–4.7, –5.2.  HRMS (ESI/TOF) m/z calculated for C23H45N2O4SSi2 [M + H]+: 501.2633, found 
501.2631.  
1-(3,5-Di-O-(t-butyldimethylsilyl)-2-deoxy-β-D-ribofuranosyl)-5-methyl-4-(3-oxido-1H-
benzotriazol-1-yl)- 2(1H)-pyrimidinone (50) 
Rf (SiO2/50% EtOAc in hexanes) = 0.32.  1H NMR (500 MHz, CDCl3): δ 8.88 (d, J = 8.6 Hz, 1H, 
Ar-H), 8.19 (s, 1H, H-6), 8.02 (d, J = 8.4 Hz, 1H, Ar-H), 7.75 (t, J = 7.8 Hz, 1H, Ar-H), 7.55 (t, J 
= 7.7 Hz, 1H, Ar-H), 6.30 (t, J = 6.3 Hz, 1H, H-1’), 4.40 (dt, J = 3.1, 6.1 Hz, 1H, H-3’), 4.07 












1H, H-5’), 2.64 (ddd, J = 3.6, 6.1, 13.5 Hz, 1H, H-2’), 2.50 (s, 3H, Me), 
2.09 (dt, J = 6.5, 13.3 Hz, 1H, H-2’), 0.91 and 0.90 (2s, 18H, t-Bu), 0.12 
and 0.11 (2s, 6H, SiMe), 0.09 and 0.08 (2s, 6H, SiMe).  13C NMR (125 
MHz, CDCl3): δ 158.5, 154.0, 146.0, 133.9, 132.5, 131.9, 126.8, 118.6, 
115.3, 105.3, 89.0, 87.9, 72.0, 62.9, 42.8, 26.1, 25.9, 18.6, 18.4, 18.2, –4.3, –4.7, –5.2.  HRMS 
(ESI/TOF) m/z calculated for C28H46N5O5Si2 [M + H]+: 588.3032, found 588.3032.  
4-(1H-Benzotriazol-1-yl)-1-(3,5-di-O-(t-butyldimethylsilyl)-2-deoxy-β-D-ribofuranosyl)-5-
methyl-2(1H)-pyrimidinone (51) 
Rf (SiO2/20% EtOAc in hexanes) = 0.50.  1H NMR (500 MHz, CDCl3): δ 
8.16 (s, 1H, H-6), 8.07 (d, J = 8.4 Hz, 1H, Ar-H), 7.52 (t, J = 7.5 Hz, 1H, 
Ar-H), 7.44–7.40 (m, 2H, Ar-H), 6.19 (t, J = 6.2 Hz, 1H, H-1’), 4.38 (dt, J 
= 3.4, 6.3 Hz, 1H, H-3’), 4.00 (app q, Japp ~ 2.9 Hz, 1H, H-4’), 3.96 (dd,  J 
= 2.2, 11.5 Hz, 1H, H-5’), 3.80 (dd, J = 2.0, 11.5 Hz, 1H, H-5’), 2.51 (ddd, J = 4.1, 6.0, 13.4 Hz, 
1H, H-2’), 2.28 (s, 3H, Me), 2.02 (dt, J = 6.4, 13.2 Hz, 1H, H-2’), 0.96 and 0.88 (2s, 18H, t-Bu), 
0.16 and 0.14 (2s, 6H, SiMe), 0.07 (s, 6H, SiMe).  13C NMR (125 MHz, CDCl3): δ 169.1, 154.0, 
144.1, 143.8, 129.1, 128.9, 125.0, 120.8, 108.9, 100.7, 88.6, 87.6, 71.6, 62.7, 42.7, 26.2, 26.0, 
18.7, 18.2, 12.2, –4.3, –4.7, –5.1.  HRMS (ESI/TOF) m/z calculated for C28H46N5O5Si2 [M + 
H]+: 588.3032, found 588.3018. 
General procedure for the C-4 modification of pyrimidine nucleosides 22a, 43, and 47 


























Procedure for aliphatic amines (synthesis of 42, 45a–f, 46a–d, 49a–d) 
To a 0.424 M solution of the nucleoside derivative (22a: 0.212 mmol, 43: 0.219 mmol, 47: 0.262 
mmol) in THF, BOP (2 equiv.) and DBU (2 equiv.) were added, and the mixture was stirred at 
room temperature for 5 min.  Then an appropriate amine (4 equiv.) was added to the mixture and 
the stirring was continued at room temperature until the consumption of the starting material was 
observed.  The mixture was then diluted with EtOAc (25 mL), washed with deionized water (3 x 
50 mL), and brine (15 mL).  The organic layer was dried over anhydrous Na2SO4, filtered, and 
evaporated under reduced pressure.  The crude material was purified by chromatography on a 
silica gel column using a suitable eluting solvent (see individual compound headings above).   
3’,5’-Di-O-(t-butyldimethylsilyl)-N,5-dimethyl-2’-deoxycytidine (45a) 
Chromatography on a silica gel column by sequential elution with EtOAc and 1% MeOH in 
EtOAc gave compound 45a (92.6 mg, 90%) as a white solid, and the starting material 22a (7 mg, 
7%). 
Procedure for reaction with p-toluidine (synthesis of 45g and 46e) 
To a solution of the nucleoside derivative (22a: 0.212 mmol, 43: 0.219 mmol) in dry CH3CN (2 
mL), BOP (2 equiv.) and DBU (4 equiv.) were added, and the mixture was stirred at room 









22a: R = CH3, R1 = OR2
43: R = H, R1 = OR2
47: R = CH3, R1 = N3
45a-j: R = CH3, R1 = OR2
46a-e: R = H, R1 = OR2













50 °C for 16 h.  The mixture was then diluted with EtOAc (25 mL), washed with deionized water 
(3 x 50 mL), and brine (15 mL).  The organic layer was dried over anhydrous Na2SO4, filtered, 
and evaporated under reduced pressure.  The crude material was purified by chromatography on 
a silica gel column using a suitable eluting solvent (see individual compound headings above). 
Procedure for reactions with thiols (synthesis of 45i–j) 
To a solution of nucleoside derivative 22a (100 mg, 0.212 mmol, 1 equiv.) in dry DME (2 mL), 
BOP (188 mg, 0.425 mmol, 2 mol equiv) and DBU (127 µL, 0.850 mmol, 4 mol equiv) were 
added, and the mixture was stirred at room temperature for 5 min.  Then an appropriate thiol 
(0.425 mmol, 2 equiv.) was added to the mixture and the stirring was continued at room 
temperature for 3 h.  The reaction mixture was then diluted with EtOAc (25 mL), washed with 
deionized water (3 x 50 mL), and brine (15 mL).  The organic layer was dried over anhydrous 
Na2SO4, filtered, and evaporated under reduced pressure.  The crude material was purified by 
chromatography on a neutralized silica gel column using a suitable eluting solvent (see 
individual compound headings above).   
Undesired 3’,5’-di-O-(t-butyldimethylsilyl)-O4-ethylthymidine (52) obtained in a reaction 
with NaSMe 
 
To a solution of the nucleoside derivative 22a (100 mg, 0.212 mmol, 1 equiv.) in THF (0.5 mL), 





















    rt, 12 h, 73%
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added, and the mixture was stirred at room temperature for 30 min.  The mixture was evaporated 
on a rotary evaporator and dried under high vacuum for 10 min.  The residual material was then 
dissolved in dry EtOH (1 mL), NaSMe (59.4 mg, 0.848 mmol, 4 equiv.) was added, and the 
mixture was stirred at room temperature for 12 h.  The mixture was evaporated and the crude 
material was loaded onto a silica gel column.  Sequential elution with 15% hexanes in EtOAc 
and 30% hexanes in EtOAc gave compound 52 (77.5 mg, 73%) as a colorless, viscous liquid.  Rf 
(SiO2/50% EtOAc in hexanes) = 0.68.  1H NMR (500 MHz, CDCl3): δ 7.69 (s, 1H, H-6), 6.32 (t, 
J = 6.4 Hz, 1H, H-1’), 4.42 (t, J = 7.1 Hz, 2H, OCH2), 4.35 (dt, J = 3.3, 6.3 Hz, 1H, H-3’), 3.91 
(app q, Japp ~ 2.8 Hz, 1H, H-4’), 3.88 (dd, J = 2.6, 11.3 Hz, 1H, H-5’), 3.74 (dd, J = 2.5, 11.3 Hz, 
1H, H-5’), 2.42 (ddd, J = 3.7, 6.1, 13.3 Hz, 1H, H-2’), 1.97 (dt, J = 6.6, 13.3 Hz, 1H, H-2’), 1.90 
(s, 3H, Me), 1.33 (q, J = 7.1 Hz, 3H, Me), 0.89 and 0.86 (2s, 18H, t-Bu), 0.09 and 0.08 (2s, 6H, 
SiMe), 0.04 and 0.03 (2s, 6H, SiMe).  13C NMR (125 MHz, CDCl3): δ 170.5, 156.1, 139.4, 104.5, 
88.0, 86.4, 71.8, 63.3, 62.8, 42.4, 26.0, 25.9, 18.5, 18.2, 14.4, 12.5, –4.4, –4.7, –5.2.  HRMS 
(ESI/TOF) m/z calculated for C24H46N2O5Si2Na [M + Na]+: 521.2837, found 521.2858. 







































22a 40 50 51
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To a solution of 22a (100.0 mg, 0.212 mmol, 1 equiv.) in dry THF (0.5 mL), BOP (188.0 mg, 
0.424 mmol, 2 equiv.) and DBU were added, and the mixture was stirred at room temperature for 
a certain period of time. 
Reactions with BOP from Chem-Impex 
Conditions 1.  DBU (64 µL, 0.424 mmol, 2 equiv.) was used.  The reaction mixture was stirred 
for 0.5 h and then evaporated.  Chromatography through a plug of neutralized silica gel by initial 
elution with 15% EtOAc in hexanes gave compound 51 (1.0 mg, 1%) as a white solid.  
Subsequent elution with 25% EtOAc in hexanes gave a mixture of compounds 40 (39.1 mg, 
31%) and 22a (14.1 mg, 14%) as a white, sticky solid.  Further elution with 50% EtOAc in 
hexanes gave compound 50 (21.9 mg, 18%) as a white solid.  Yields of 40 and 22a were 
calculated on the basis of the integration in the 1H NMR spectrum of the mixture. 
Conditions 2. DBU (64 µL, 0.424 mmol, 2 equiv.) was used.  The reaction mixture was stirred 
for 24 h and then evaporated.  Chromatography through a plug of neutralized silica gel by initial 
elution with 30% EtOAc in hexanes gave a mixture of compounds 51 (12.0 mg, 10%) and 40 
(39.1 mg, 31%) as a white solid.  Subsequent elution with 50% EtOAc in hexanes gave 
compound 50 (39.4 mg, 32%) as a white solid.  Yields of 51 and 40 were calculated on the basis 
of the integration in the 1H NMR spectrum of the mixture. 
Reactions with BOP from Sigma-Aldrich 
Conditions 1. DBU (64 µL, 0.424 mmol, 2 equiv.) was used.  The reaction mixture was stirred 
for 0.5 h and then evaporated.  Chromatography through a plug of neutralized silica gel by initial 
elution with 30% EtOAc in hexanes gave compound 40 (73.0 mg, 59%) as a white solid.  
! 56!
Subsequent elution with 50% EtOAc in hexanes gave compound 50 (29.3 mg, 23%) as a white 
solid.  
O4-(1H-Benzotriazol-1-yl)-3’,5’-di-O-(t-butyldimethylsilyl)thymidine (40) 
Rf (SiO2/20% EtOAc in hexanes) = 0.50.  1H NMR (500 MHz, CDCl3): δ 
8.16 (s, 1H, H-6), 8.07 (d, J = 8.4 Hz, 1H, Ar-H), 7.52 (t, J = 7.5 Hz, 1H, 
Ar-H), 7.44–7.40 (m, 2H, Ar-H), 6.19 (t, J = 6.2 Hz, 1H, H-1’), 4.38 (dt, 
J = 3.4, 6.3 Hz, 1H, H-3’), 4.00 (app q, Japp ~ 2.9 Hz, 1H, H-4’), 3.96 (dd, 
J = 2.2, 11.5 Hz, 1H, H-5’), 3.80 (dd, J = 2.0, 11.5 Hz, 1H, H-5’), 2.51 
(ddd, J = 4.1, 6.0, 13.4 Hz, 1H, H-2’), 2.28 (s, 3H, Me), 2.02 (dt, J = 6.4, 13.2 Hz, 1H, H-2’), 
0.96 and 0.88 (2s, 18H, t-Bu), 0.16 and 0.14 (2s, 6H, SiMe), 0.07 (s, 6H, SiMe).  13C NMR (125 
MHz, CDCl3): δ 169.1, 154.0, 144.1, 143.8, 129.1, 128.9, 125.0, 120.8, 108.9, 100.7, 88.6, 87.6, 
71.6, 62.7, 42.7, 26.2, 26.0, 18.7, 18.2, 12.2, –4.3, –4.7, –5.1.  HRMS (ESI/TOF) m/z calculated 
for C28H46N5O5Si2 [M + H]+: 588.3032, found 588.3018. 
Conditions 2.  DBU (64 µL, 0.424 mmol, 2 equiv.) was used.  The reaction mixture was stirred 
for 24 h and then evaporated.  Chromatography through a plug of neutralized silica gel by initial 
elution with 30% EtOAc in hexanes gave a mixture of compounds 51 (4.2 mg, 3%) and 40 (27.0 
mg, 22%) as a white solid.  Subsequent elution with 50% EtOAc in hexanes gave compound 50 
(57.4 mg, 46%) as a white solid.  Yields of 51 and 40 were calculated on the basis of the 
integration in 1H NMR spectrum of the mixture. 
Conditions 3. DBU (127 µL, 0.424 mmol, 4 equiv.) was used.  The reaction was stirred for 24 h 
and then evaporated.  Chromatography through a plug of neutralized silica gel by initial elution 













Subsequent elution with 50% EtOAc in hexanes gave compound 50 (10.5 mg, 8%) as a white 
solid. 
Procedure for the deoxygenation of 50 to 51 with B2(OH)4 
 
To a solution of N-oxide 50 (20 mg, 0.034 mmol, 1 mol equiv) in dry MeCN (0.2 mL) B2(OH)4 
(3.7 mg, 0.041 mmol, 1.2 equiv.) was added, and the mixture was stirred at 60 oC for 2 h.  The 
mixture was then evaporated and the crude material was purified on a silica gel column eluted 
with 30% EtOAc in hexanes to give compound 51 (18.8 mg, 97%) as a white solid. 
Procedure for desilylation reactions 
 
Method A (with nBu4NF/THF for synthesis of 41, 54a–h, 55a–d, 56a–d) 
To a 0.115 M solution of the appropriate nucleoside (1 equiv.) in dry THF, nBu4NF (1 M 
solution in THF, 2.4 equiv.) was added, and the mixture was stirred at room temperature for 20 



































6, 8a, 41, 54a-h: R = CH3, R1 = OH
33, 55a-d: R = H, R1 = OH









42, 45a-j: R = CH3, R1 = OTBDMS
46a-e: R = H, R1 = OTBDMS
49a-d: R = CH3, R1 = N3
F
! 58!
short silica gel column using a suitable eluting solvent (see individual compound headings 
below) 
1-(2-Deoxy-β-D-ribofuranosyl)-5-methyl-4-(morpholin-4-yl)-2(1H)-pyrimidinone (41) 
Chromatography on a silica gel column by sequential elution with EtOAc and 
10% MeOH in EtOAc gave compound 41 (83.4 mg, 96%) as a white solid.  Rf 
(SiO2/10% MeOH in EtOAc) = 0.18.  1H NMR (500 MHz, CD3OD): δ 7.98 (s, 
1H, H-6), 6.26 (t, J = 6.4 Hz, 1H, H-1’), 4.41 (dt, J = 3.7, 6.4 Hz, 1H, H-3’), 
3.96 (app q, Japp ~ 3.5 Hz, 1H, H-4’), 3.85 (dd, J = 3.1, 12.1 Hz, 1H, H-5’), 3.78–3.75 (m, 5H, 
morpholinyl–CH2 and H-5’), 3.72–3.70 (m, 4H, morpholinyl–CH2), 2.39 (ddd, J = 4.0, 6.1, 13.5 
Hz, 1H, H-2’), 2.21–2.14 (m, 4H, Me and H-2’).  13C NMR (125 MHz, CD3OD): δ 167.4, 157.5, 
143.6, 105.8, 88.9, 87.6, 71.8, 67.8, 62.6, 48.8, 42.1, 17.9.  HRMS (ESI/TOF) m/z calculated for 
C14H21N3O5Na [M + Na]+: 334.1373, found 334.1366. 
N-Benzyl-5-methyl-2’-deoxycytidine (54a) 
Chromatography on a silica gel column by sequential elution with EtOAc and 
10% MeOH in EtOAc gave compound 54a (54.2 mg, 92%) as a white solid.  Rf 
(SiO2/10% MeOH in EtOAc) = 0.24.  1H NMR (500 MHz, CD3OD): δ 7.82 (s, 
1H, H-6), 7.35 (d, J = 7.1 Hz, 2H, Ar-H), 7.31 (t, J = 7.5 Hz, 2H, Ar-H), 7.23 (t, 
J = 7.2 Hz, 1H, Ar-H), 6.30 (t, J = 6.5 Hz, 1H, H-1’), 4.71 (s, 2H, CH2), 4.40 (dt, J = 3.3, 6.4 Hz, 
1H, H-3’), 3.94 (app q, Japp ~ 3.4 Hz, 1H, H-4’), 3.84 (dd, J = 3.1, 12.1 Hz, 1H, H-5’), 3.76 (dd, 
J = 3.8, 12.1 Hz, 1H, H-5’), 2.34 (ddd, J = 3.8, 5.9, 13.5 Hz, 1H, H-2’), 2.17 (dt, J = 6.7, 13.5 Hz, 






















128.6, 128.0, 104.9, 88.7, 87.3, 72.0, 62.8, 45.1, 41.9, 13.2.  HRMS (ESI/TOF) m/z calculated 
for C17H21N3O4Na [M + Na]+: 354.1424, found 354.1440. 
N,N,5-Trimethyl-2’-deoxycytidine (54b) 
Chromatography on a silica gel column by sequential elution with EtOAc and 
20% MeOH in EtOAc gave compound 54b (51.5 mg, 96%) as an off-white 
solid.  Rf (SiO2/10% MeOH in EtOAc) = 0.10.  1H NMR (500 MHz, CD3OD): δ 
7.81 (s, 1H, H-6), 6.23 (t, J = 6.5 Hz, 1H, H-1’), 4.38 (dt, J = 3.4, 6.5 Hz, 1H, 
H-3’), 3.92 (app q, Japp ~ 3.5 Hz, 1H, H-4’), 3.81 (dd, J = 3.2, 12.0 Hz, 1H, H-5’), 3.73 (dd, J = 
3.7, 12.0 Hz, 1H, H-5’), 3.21 (s, 6H, NMe2), 2.32 (ddd, J = 3.8, 6.1, 13.5 Hz, 1H, H-2’), 2.25 (s, 
3H, Me), 2.15 (dt, J = 6.7, 13.5 Hz, 1H, H-2’).  13C NMR (125 MHz, CD3OD): δ 166.9, 157.4, 
142.3, 105.2, 88.8, 87.3, 71.9, 62.7, 41.9, 40.6, 18.7.  HRMS (ESI/TOF) m/z calculated for 
C12H19N3O4Na [M + Na]+: 292.1268, found 292.1272. 
N,N-Diethyl-5-methyl-2’-deoxycytidine (54c) 
Chromatography on a silica gel column by sequential elution with EtOAc and 
10% MeOH in EtOAc gave compound 54c (81.1 mg, 96%) as a white solid.  Rf 
(SiO2/10% MeOH in EtOAc) = 0.20.  1H NMR (500 MHz, CD3OD): δ 7.83 (s, 
1H, H-6), 6.26 (t, J = 6.5 Hz, 1H, H-1’), 4.41 (dt, J = 3.4, 6.5 Hz, 1H, H-3’), 
3.95 (app q, Japp ~ 3.5 Hz, 1H, H-4’), 3.84 (dd, J = 3.1, 12.0 Hz, 1H, H-5’), 3.76 (dd, J = 3.7, 
12.0 Hz, 1H, H-5’), 3.66 (q, J = 7.0 Hz, 4H, NCH2), 2.35 (ddd, J = 3.8, 6.1, 13.5 Hz, 1H, H-2’), 
2.25 (s, 3H, Me), 2.19 (dt, J = 6.7, 13.5 Hz, 1H, H-2’), 1.26 (t, J = 7.0 Hz, 6H, Me).  13C NMR 
(125 MHz, CD3OD): δ 165.1, 157.4, 142.6, 104.8, 88.8, 87.3, 71.9, 62.7, 45.0, 41.9, 18.7, 14.1.  























Chromatography on a silica gel column by sequential elution with EtOAc and 
20% MeOH in EtOAc gave compound 54d (54.6 mg, 97%) as an off-white 
solid.  Rf (SiO2/10% MeOH in EtOAc) = 0.12. 1H NMR (500 MHz, CD3OD): δ 
7.75 (s, 1H, H-6), 6.24 (t, J = 6.6 Hz, 1H, H-1’), 4.38 (dt, J = 3.4, 6.5 Hz, 1H, 
H-3’), 3.91 (app q, Japp ~ 3.4 Hz, 1H, H-4’), 3.81 (dd, J = 3.1, 12.0 Hz, 1H, H-5’), 3.78-3.72 (m, 
5H, H-5’ and NCH2), 2.30 (ddd, J = 3.8, 6.1, 13.5 Hz, 1H, H-2’), 2.25 (s, 3H, Me), 2.17–2.12 (m, 
1H, H-2’), 1.93 (br s, 4H, (CH2)2).  13C NMR (125 MHz, CD3OD): δ 163.9, 157.6, 141.2, 105.2, 
88.7, 87.2, 72.0, 62.8, 50.6, 41.9, 26.1, 18.1.  HRMS (ESI/TOF) m/z calculated for 
C14H21N3O4Na [M + Na]+: 318.1424, found 318.1403. 
1-(2-Deoxy-β-D-ribofuranosyl)-5-methyl-4-(piperidin-1-yl)-2(1H)-pyrimidinone (54e) 
Chromatography on a silica gel column by sequential elution with EtOAc and 
10% MeOH in EtOAc, gave compound 54e (53.9 mg, 94%) as a white solid.  Rf 
(SiO2/10% MeOH in EtOAc) = 0.20.  1H NMR (500 MHz, CD3OD): δ 7.90 (s, 
1H, H-6), 6.26 (t, J = 6.5 Hz, 1H, H-1’), 4.41 (dt, J = 3.5, 6.6 Hz, 1H, H-3’), 
3.95 (app q, Japp ~ 3.5 Hz, 1H, H-4’), 3.85 (dd, J = 3.2, 12.1 Hz, 1H, H-5’), 3.76 
(dd, J = 3.7, 12.1 Hz, 1H, H-5’), 3.68–3.64 (m, 4H, NCH2), 2.37 (ddd, J = 3.9, 6.1, 13.5 Hz, 1H, 
H-2’), 2.21–2.15 (m, 4H, Me and H-2’), 1.77–1.72 (m, 2H, CH2), 1.71–1.66 (m, 4H, CH2).  13C 
NMR (125 MHz, CD3OD): δ 167.2, 153.8, 143.1, 105.9, 88.9, 87.4, 71.9, 62.7, 49.4, 42.0, 27.3, 






















Chromatography on a silica gel column by sequential elution with EtOAc 
and 10% MeOH in EtOAc gave compound 54f (83.2 mg, 94%) as an off-
white solid.  Rf (SiO2/10% MeOH in EtOAc) = 0.30.  1H NMR (500 MHz, 
CD3OD): δ 7.90 (s, 1H, H-6), 7.52 (d, J = 8.3 Hz, 2H, Ar-H), 7.12 (d, J = 
8.2 Hz, 2H, Ar-H), 6.26 (t, J = 6.5 Hz, 1H, H-1’), 4.38 (dt, J = 3.4, 6.6 Hz, 
1H, H-3’), 3.93 (app q, Japp ~ 3.5 Hz, 1H, H-4’), 3.83 (dd, J = 3.2, 12.1 Hz, 1H, H-5’), 3.74 (dd, 
J = 3.8, 12.1 Hz, 1H, H-5’), 2.34 (ddd, J = 3.9, 6.1, 13.5 Hz, 1H, H-2’), 2.30 (s, 3H, Me), 2.19 
(dt, J = 6.7, 13.5 Hz, 1H, H-2’), 2.08 (s, 3H, Me).  13C NMR (125 MHz, CD3OD): δ 163.5, 158.3, 
139.8, 136.9, 135.6, 130.0, 124.5, 105.5, 88.8, 87.5, 71.9, 62.7, 42.0, 21.0, 13.6.  HRMS 
(ESI/TOF) m/z calculated for C17H22N3O4 [M + H]+: 332.1605, found 332.1604. 
S4-Ethyl-4-thiothymidine (54g) 
Chromatography on a neutralized silica gel column by sequential elution with 
EtOAc and 5% MeOH in EtOAc gave compound 54g (58.7 mg, 70%) as a 
white solid.  Rf (SiO2/10% MeOH in EtOAc) = 0.36.  1H NMR (500 MHz, 
CD3OD): δ 8.09 (s, 1H, H-6), 6.20 (t, J = 6.2 Hz, 1H, H-1’), 4.38 (dt, J = 3.6, 
6.6 Hz, 1H, H-3’), 3.98 (app q, Japp ~ 3.5 Hz, 1H, H-4’), 3.85 (dd, J = 2.9, 12.2 
Hz, 1H, H-5’), 3.75 (dd, J = 3.6, 12.2 Hz, 1H, H-5’), 3.20 (q, J = 7.4 Hz, 2H, SCH2), 2.46 (ddd, J 
= 4.5, 6.0, 13.6 Hz, 1H, H-2’), 2.16 (dt, J = 6.6, 13.4 Hz, 1H, H-2’), 2.04 (s, 3H, Me), 1.35 (t, J = 
7.4 Hz, 3H, Me).  13C NMR (125 MHz, CD3OD): δ 179.9, 156.0, 139.4, 114.2, 89.3, 88.3, 71.5, 
62.4, 42.4, 25.1, 14.5, 14.2.  HRMS (ESI/TOF) m/z calculated for C12H18N2O4SNa [M + Na]+: 























Chromatography on neutralized silica gel column by sequential elution with 
EtOAc and 5% MeOH in EtOAc, gave compound 54h (95.7 mg, 79%) as a 
white solid.  Rf (SiO2/10% MeOH in EtOAc) = 0.37.  1H NMR (500 MHz, 
CD3OD): δ 8.13 (s, 1H, H-6), 7.42 (d, J = 7.9 Hz, 2H, Ar-H), 7.30 (t, J = 7.3 Hz, 
2H, Ar-H), 7.24 (t, J = 7.1 Hz, 1H, Ar-H), 6.22 (t, J = 6.2 Hz, 1H, H-1’), 4.47 (s, 2H, SCH2), 
4.38 (dt, J = 4.0, 5.7 Hz, 1H, H-3’), 3.98 (app q, Japp ~ 3.5 Hz, 1H, H-4’), 3.85 (dd, J = 3.0, 12.2 
Hz, 1H, H-5’), 3.75 (dd, J = 3.7, 12.2 Hz, 1H, H-5’), 2.48 (ddd, J = 4.4, 6.2, 13.6 Hz, 1H, H-2’), 
2.18 (dt, J = 6.6, 13.4 Hz, 1H, H-2’), 2.04 (s, 3H, Me).  13C NMR (125 MHz, CD3OD): δ 179.1, 
155.9, 139.8, 138.3, 130.3, 129.6, 128.4, 113.9, 89.2, 88.3, 71.5, 62.3, 42.4, 34.7, 14.1.  HRMS 
(ESI/TOF) m/z calculated for C17H20N2O4SNa [M + Na]+: 371.1036, found 371.1035. 
N-Benzyl-2’-deoxycytidine (55a) 
Chromatography on a silica gel column by sequential elution with EtOAc and 
10% MeOH in EtOAc gave compound 55a (53.6 mg, 92%) as a white solid.  Rf 
(SiO2/10% MeOH in EtOAc) = 0.24.  1H NMR (500 MHz, CD3OD): δ 7.91 (d, 
J = 7.5 Hz, 1H, H-6), 7.34–7.28 (m, 4H, Ar-H), 7.25–7.22 (m, 1H, Ar-H), 6.27 
(t, J = 6.5 Hz, 1H, H-1’), 5.90 (d, J = 7.5 Hz, 1H, H-5), 4.59–4.56 (m, 2H, 
NCH2), 4.36 (dt, J = 3.3, 6.4 Hz, 1H, H-3’), 3.93 (app q, Japp ~ 3.6 Hz, 1H, H-4’), 3.78 (dd, J = 
3.3, 12.0 Hz, 1H, H-5’), 3.72 (dd, J = 3.9, 12.0 Hz, 1H, H-5’), 2.34 (ddd, J = 3.7, 6.1, 13.5 Hz, 
1H, H-2’), 2.13 (dt, J = 6.7, 13.5 Hz, 1H, H-2’).  13C NMR (125 MHz, CD3OD): δ 165.4, 158.7, 
141.3, 139.7, 129.5, 128.8, 128.3, 96.9, 88.8, 87.5, 72.1, 62.8, 45.2, 41.9.  HRMS (ESI/TOF) m/z 






















Chromatography on a silica gel column by sequential elution with EtOAc and 
10% MeOH in EtOAc gave compound 55b (72.1 mg, 87%) as a white solid.  Rf 
(SiO2/20% MeOH in EtOAc) = 0.22.  1H NMR (500 MHz, CD3OD): δ 8.01 (d, 
J = 7.6 Hz, 1H, H-6), 6.26 (t, J = 6.5 Hz, 1H, H-1’), 5.96 (d, J = 7.7 Hz, 1H, H-
5), 4.36 (dt, J = 3.3, 6.4 Hz, 1H, H-3’), 3.93 (app q, Japp ~ 3.5 Hz, 1H, H-4’), 3.79 (dd, J = 3.2, 
12.0 Hz, 1H, H-5’), 3.72 (dd, J = 3.8, 12.0 Hz, 1H, H-5’), 3.56 (t, J = 6.8 Hz, 2H, NCHH), 3.46 
(t, J = 6.8 Hz, 2H, NCHH), 2.35 (ddd, J = 4.0, 5.9, 13.5 Hz, 1H, H-2’), 2.03 (dt, J = 6.6, 13.4 Hz, 
1H, H-2’), 2.03 (quint, J = 6.7 Hz, 2H, CH2), 1.95 (quint, J = 6.7 Hz, 2H, CH2).  13C NMR (125 
MHz, CD3OD): δ 162.8, 158.0, 142.0, 95.0, 88.8, 87.5, 72.0, 62.8, 48.2, 48.1, 42.1, 26.5, 25.7.  
HRMS (ESI/TOF) m/z calculated for C13H19N3O4Na [M + Na]+: 304.1268, found 304.1272. 
1-(2-Deoxy-β-D-ribofuranosyl)-4-(piperidin-1-yl)-2(1H)-pyrimidinone (55c) 
Chromatography on a silica gel column by sequential elution with EtOAc and 
10% MeOH in EtOAc gave compound 55c (52.1 mg, 90%) as a white solid.  Rf 
(SiO2/20% MeOH in EtOAc) = 0.17.  1H NMR (500 MHz, CD3OD): δ 8.00 (d, 
J = 7.9 Hz, 1H, H-6), 6.24 (t, J = 6.5 Hz, 1H, H-1’), 6.21 (d, J = 7.9 Hz, 1H, H-
5), 4.36 (dt, J = 3.4, 6.5 Hz, 1H, H-3’), 3.93 (app q, Japp ~ 3.5 Hz, 1H, H-4’), 3.89–3.69 (m, 2H, 
NCHH), 3.79 (dd, J = 3.3, 12.0 Hz, 1H, H-5’), 3.72 (dd, J = 3.7, 12.1 Hz, 1H, H-5’), 3.67–3.55 
(m, 2H, NCHH), 2.35 (ddd, J = 3.8, 6.1, 13.5 Hz, 1H, H-2’), 2.35 (dt, J = 6.7, 13.5 Hz, 1H, H-2’), 
1.76–1.69 (m, 2H, CH2), 1.65–1.57 (m, 4H, CH2).  13C NMR (125 MHz, CD3OD): δ 163.8, 
158.3 (br), 142.5, 93.6, 88.8, 87.5, 72.1, 62.8, 47.8 (br), 47.8 (br), 42.0, 27.0 (br), 25.5.  HRMS 



















Chromatography on a silica gel column by sequential elution with EtOAc 
followed by 15% MeOH in EtOAc gave compound 55d (54.2 mg, 93%) as a 
white solid.  Rf (SiO2/10% MeOH in EtOAc) = 0.12.  1H NMR (500 MHz, 
CD3OD): δ 8.08 (d, J = 7.8 Hz, 1H, H-6), 6.24 (t, J = 6.4 Hz, 1H, H-1’), 6.20 (d, 
J = 7.8 Hz, 1H, H-5), 4.36 (dt, J = 3.4, 6.4 Hz, 1H, H-3’), 3.94 (app q, Japp ~ 3.5 Hz, 1H, H-4’), 
3.79 (dd, J = 3.3, 12.0 Hz, 1H, H-5’), 3.74–3.55 (m, 9H, H-5’ and morpholinyl–CH2), 2.37 (ddd, 
J = 3.9, 6.1, 13.5 Hz, 1H, H-2’), 2.14 (dt, J = 6.7, 13.4 Hz, 1H, H-2’).  13C NMR (125 MHz, 
CD3OD): δ 164.5, 158.1, 143.0, 93.3, 88.9, 87.7, 72.0, 67.5, 62.7, 46.6 (br), 45.1 (br), 42.1.  
HRMS (ESI/TOF) m/z calculated for C13H19N3O5Na [M + Na]+: 320.1217, found 320.1213. 
3’-Azido-N,N-diethyl-5-methyl-2’,3’-dideoxycytidine (56a) 
Chromatography on a silica gel column by sequential elution with EtOAc and 
10% MeOH in EtOAc gave compound 56a (71.0 mg, 96%) as an off-white 
solid.  Rf (SiO2/10% MeOH in EtOAc) = 0.59.  1H NMR (500 MHz, CD3OD): δ 
7.80 (s, 1H, H-6), 6.13 (t, J = 6.2 Hz, 1H, H-1’), 4.32 (app q, Japp ~ 6.1 Hz, 1H, 
H-3’), 3.92 (dt, J = 3.2, 4.9 Hz, 1H, H-4’), 3.86 (dd, J = 3.1, 12.2 Hz, 1H, H-5’), 3.75 (dd, J = 3.2, 
12.2 Hz, 1H, H-5’), 3.63 (q, J = 7.0 Hz, 4H, NCH2), 2.44 (dt, J = 6.4, 13.2 Hz, 1H, H-2’), 2.36 
(dt, J = 6.7, 13.5 Hz, 1H, H-2’), 2.22 (s, 3H, Me), 1.23 (t, J = 7.0 Hz, 6H, Me).  13C NMR (125 
MHz, CD3OD): δ 165.2, 157.3, 142.5, 104.8, 87.0, 86.2, 62.3, 61.4, 45.0, 39.0, 18.7, 14.1. 























Chromatography on a silica gel column by sequential elution with EtOAc and 
10% MeOH in EtOAc gave compound 56b (71.5 mg, 97%) as an off-white 
solid.  Rf (SiO2/10% MeOH in EtOAc) = 0.20. 1H NMR (500 MHz, CD3OD): δ 
7.75 (s, 1H, H-6), 6.13 (t, J = 6.2 Hz, 1H, H-1’), 4.32 (app q, Japp ~ 6.0 Hz, 1H, 
H-3’), 3.91 (app q, Japp ~ 3.9 Hz, 1H, H-4’), 3.85 (dd, J = 3.1, 12.2 Hz, 1H, H-5’), 3.76–3.66 (m, 
5H, H-5’ and NCH2), 2.41 (dt, J = 6.3, 13.1 Hz, 1H, H-2’), 2.36 (dt, J = 6.7, 13.5 Hz, 1H, H-2’), 
2.24 (s, 3H, Me), 1.92 (br s, 4H, CH2).  13C NMR (125 MHz, CD3OD): δ 163.2, 157.4, 141.0, 
105.2, 86.9, 86.1, 62.4, 61.5, 50.6 (br), 38.9, 26.2 (br), 18.1.  HRMS (ESI/TOF) m/z calculated 
for C14H21N6O3 [M + H]+: 321.1670, found 321.1663. 
1-(3-Azido-2,3-dideoxy-β-D-ribofuranosyl)-5-methyl-4-(piperidin-1-yl)-2(1H)-pyrimidinone 
(56c) 
Chromatography on a silica gel column by sequential elution with EtOAc and 
10% MeOH in EtOAc gave compound 56c (122.1 mg, 99%) as an off-white 
solid.  Rf (SiO2/10% MeOH in EtOAc) = 0.60.  1H NMR (500 MHz, CD3OD): δ 
7.87 (s, 1H, H-6), 6.13 (t, J = 6.1 Hz, 1H, H-1’), 4.32 (app q, Japp ~ 6.1 Hz, 1H, 
H-3’), 3.93 (dt, J = 2.8, 5.3 Hz, 1H, H-4’), 3.86 (dd, J = 3.0, 12.2 Hz, 1H, H-5’), 3.75 (dd, J = 3.2, 
12.2 Hz, 1H, H-5’), 3.66–3.60 (m, 4H, NCH2), 2.45 (dt, J = 6.4, 13.2 Hz, 1H, H-2’), 2.35 (dt, J = 
6.7, 13.5 Hz, 1H, H-2’), 2.15 (s, 3H, Me), 1.75–1.68 (m, 2H, CH2), 1.68–1.61(m, 4H, CH2).  13C 
NMR (125 MHz, CD3OD): δ 167.2, 157.5, 142.9, 105.9, 87.1, 86.3, 62.3, 61.3, 49.4, 39.1, 27.3, 























Chromatography on a silica gel column by sequential elution with EtOAc and 
10% MeOH in EtOAc gave compound 56d (73.2 mg, 98%) as a white solid.  Rf 
(SiO2/10% MeOH in EtOAc) = 0.23.  1H NMR (500 MHz, CD3OD): δ 7.96 (s, 
1H, H-6), 6.13 (t, J = 6.0 Hz, 1H, H-1’), 4.32 (app q, Japp ~ 6.2 Hz, 1H, H-3’), 
3.94 (dt, J = 2.9, 5.4 Hz, 1H, H-4’), 3.87 (dd, J = 3.1, 12.2 Hz, 1H, H-5’), 3.77-3.73 (m, 5H, H-5’, 
and morpholinyl–CH2), 3.71–3.68 (m, 4H, morpholinyl–CH2), 2.47 (dt, J = 6.5, 13.3 Hz, 1H, H-
2’), 2.37 (dt, J = 6.6, 13.5 Hz, 1H, H-2’), 2.15 (s, 3H, Me).  13C NMR (125 MHz, CD3OD): δ 
167.0, 156.9, 143.6, 105.8, 87.3, 86.4, 67.8, 62.1, 61.1, 48.9, 39.1, 17.9.  HRMS (ESI/TOF) m/z 
calculated for C14H20N6O4Na [M + Na]+: 359.1438, found 359.1434.  
Method B (with KF for synthesis of 6 and 33) 
To a 0.096 M solution of the appropriate nucleoside (1 equiv.) in dry MeOH, KF (4 equiv.) was 
added, and the mixture was stirred at 80 oC for 12 h.  The mixture was evaporated and the crude 
material was purified through a short silica gel column by elution with suitable solvent system 
(see individual compound headings below). 
N,5-Dimethyl-2’-deoxycytidine (6) 
Chromatography on a silica gel column by sequential elution with EtOAc and 
20% MeOH in EtOAc gave compound 6 (35.4 mg, 89%) as a white solid.  Rf 
(SiO2/20% MeOH in EtOAc) = 0.16.  1H NMR (500 MHz, CD3OD): δ 7.73 (s, 
1H, H-6), 6.28 (t, J = 6.6 Hz, 1H, H-1’), 4.37 (dt, J = 3.4, 6.5 Hz, 1H, H-3’), 






















12.1 Hz, 1H, H-5’), 2.94 (s, 3H, NMe), 2.30 (ddd, J = 3.7, 6.1, 13.5 Hz, 1H, H-2’), 2.13 (dt, J = 
6.7, 13.5 Hz, 1H, H-2’), 1.93 (s, 3H, Me).  13C NMR (125 MHz, CD3OD): δ 165.4, 158.6, 138.3, 
105.0, 88.7, 87.2, 72.0, 62.8, 41.9, 28.3, 13.1.  HRMS (ESI/TOF) m/z calculated for 
C11H17N3O4Na [M + Na]+: 278.1111, found 278.1123. 
N-(p-Tolyl)-2’-deoxycytidine (33) 
Chromatography on a silica gel column by sequential elution with EtOAc 
and 10% MeOH in EtOAc gave compound 33 (42.9 mg, 87%) as a white 
solid.  Rf (SiO2/10% MeOH in EtOAc) = 0.40.  1H NMR (500 MHz, 
CD3OD): δ 8.05 (d, J = 7.5 Hz, 1H, H-6), 7.60 (br s, 2H, Ar-H), 7.14 (d, J 
= 7.3 Hz, 2H, Ar-H), 6.27 (t, J = 6.5 Hz, 1H, H-1’), 6.03 (d, J = 7.5 Hz, 1H, H-5), 4.37 (dt, J = 
3.4, 6.5 Hz, 1H, H-3’), 3.95 (app q, Japp ~ 3.6 Hz, 1H, H-4’), 3.80 (dd, J = 3.3, 12.0 Hz, 1H, H-
5’), 3.73 (dd, J = 3.9, 12.1 Hz, 1H, H-5’), 2.39 (ddd, J = 3.8, 6.1, 13.6 Hz, 1H, H-2’), 2.31 (s, 3H, 
Me), 2.16 (dt, J = 6.7, 13.5 Hz, 1H, H-2’).  1H NMR (500 MHz, DMSO-d6): δ 9.62 (br s, 1H, 
NH), 7.93 (d, J = 7.5 Hz, 1H, H-6), 7.63 (br s, 2H, Ar–H), 7.13 (d, J = 8.2 Hz, 2H, Ar–H), 6.17 (t, 
J = 6.6 Hz, 1H, H-1’), 5.97 (d, J = 7.4 Hz, 1H, H-5), 5.22 (d, J = 4.2 Hz, 1H, OH), 4.99 (t, J = 
5.2 Hz, 1H, OH), 4.24–4.18 (m, 1H, H-3’), 3.79 (app q, Japp ~ 3.5 Hz, 1H, H-4’), 3.62–3.51 (m, 
2H, H-5’ and H-5’), 2.26 (s, 3H, Me), 2.16 (ddd, J = 3.3, 5.8, 13.2 Hz, 1H, H-2’), 1.97 (dt, J = 
6.6, 13.3 Hz, 1H, H-2’).  HRMS (ESI/TOF) m/z calculated for C16H20N3O4 [M + H]+: 318.1448, 
found 318.1443.  The 1H NMR spectrum matches to that of the authentic material.35  
O4-Methylthymidine (54i) 
Chromatography on a silica gel column by sequential elution with EtOAc and 10% MeOH in 











0.37.  1H NMR (500 MHz, CD3OD): δ 8.13 (s, 1H, H-6), 6.24 (t, J = 6.4 Hz, 1H, 
H-1’), 4.38 (dt, J = 3.8, 6.3 Hz, 1H, H-3’), 3.97–3.94 (m, 4H, H-4’ and OCH3), 
3.84 (dd, J = 3.1, 12.1 Hz, 1H, H-5’), 3.75 (dd, J = 3.7, 12.1 Hz, 1H, H-5’), 2.41 
(ddd, J = 4.1, 6.2, 13.6 Hz, 1H, H-2’), 2.15 (dt, J = 6.6, 13.4 Hz, 1H, H-2’), 1.97 
(s, 3H, Me).  13C NMR (125 MHz, CD3OD): δ 172.5, 158.2, 142.0, 106.6, 89.1, 87.9, 71.7, 62.5, 
55.1, 42.2, 12.1.  HRMS (ESI/TOF) m/z calculated for C11H16N2O5Na [M + Na]+: 279.0951, 
found 279.0948. 
Method C (with TASF for synthesis of 8a) 
S4-Methyl-4-thiothymidine (8a) 
To a solution of the compound 45j (50 mg, 0.099 mmol, 1 equiv.) in 1 mL dry 
MeCN at 0 °C, a solution of TASF (412.5 mg, 0.499 mmol, 5 equiv.) in 0.33 
mL dry MeCN was added dropwise and stirred at 0 °C for 1 h. Then the 
reaction mixture was allowed to stir at room temperature for 16 h.  The crude 
material after desilylation was quickly filtered through a short silica plug plug using 10% MeOH 
in EtOAc.  The filtrate was evaporated and washed with EtOAc followed by 2% MeOH in 
EtOAc to obtain compound 8a (18.3 mg, 68%) as a white solid.  Rf (SiO2/10% MeOH in EtOAc) 
= 0.49.  1H NMR (500 MHz, CD3OD): δ 8.10 (s, 1H, H-6), 6.21 (t, J = 6.2 Hz, 1H, H-1’), 4.39 
(dt, J = 4.1, 6.1 Hz, 1H, H-3’), 3.99 (app q, Japp ~ 3.5 Hz, 1H, H-4’), 3.85 (dd, J = 3.0, 12.1 Hz, 
1H, H-5’), 3.76 (dd, J = 3.7, 12.1 Hz, 1H, H-5’), 2.54 (s, 3H, SCH3), 2.46 (ddd, J = 4.4, 6.1, 13.6 
Hz, 1H, H-2’), 2.17 (dt, J = 6.6, 13.4 Hz, 1H, H-2’), 2.10 (s, 3H, Me).  13C NMR (125 MHz, 
CD3OD): δ 180.3, 156.0, 139.2, 114.1, 89.3, 88.2, 71.6, 62.4, 42.4, 14.1, 13.0.  HRMS 





















General procedure for reduction of 3’-azido nucleosides To amines (synthesis of 57a–d) 
 
To a solution of the AZT derivative (0.131 mmol, 1equiv.) in dry MeOH (0.6 mL) in a 4 mL vial, 
5% Pd/C (27.5 mg) was added.  The reaction vial was placed in a two-necked flask to which a 
hydrogen balloon was attached via a gas inlet adapter with a Teflon stopcock at one neck and the 
other neck was stoppered with a rubber septum. The flask was connected to a vacuum line via a 
needle inserted through the septum.  The flask was degassed and filled with H2 gas via the 
balloon, and this process was repeated three times.  Finally, the reaction was allowed to proceed 
for 1 h at room temperature under a balloon filled with hydrogen gas.  The reaction mixture was 
filtered through a short plug of Celite and the residue was washed with methanol.  The filtrate 
was evaporated under reduced pressure and washed with EtOAc followed by 5% MeOH in 
EtOAc.  The resulting solid was dried under high vacuum.  All the products are very polar 
materials. 
3’-Amino-N,N-diethyl-5-methyl-2’,3’-dideoxycytidine (57a) 
Compound 57a (38.4 mg, 99%) was obtained as a light-yellow solid.  Rf 
(SiO2/MeOH) = 0.34.  1H NMR (500 MHz, CD3OD): δ 7.90 (s, 1H, H-6), 6.12 
(t, J = 5.4 Hz, 1H, H-1’), 3.89 (dd, J = 2.4, 12.2 Hz, 1H, H-5’), 3.79 (dd, J = 3.2, 
12.2 Hz, 1H, H-5’), 3.72 (dt, J = 3.2, 6.7 Hz, 1H, H-4’), 3.62 (q, J = 7.0 Hz, 4H, 
































7.0 Hz, 6H, Me).  13C NMR (125 MHz, CD3OD): δ 165.2, 157.4, 142.7, 104.4, 88.8, 86.7, 61.8, 
51.0, 45.0, 42.7, 18.2, 14.1.  HRMS (ESI/TOF) m/z calculated for C14H25N4O3 [M + H]+: 
297.1921, found 297.1916. 
1-(3-Amino-2,3-dideoxy-β-D-ribofuranosyl)-5-methyl-4-(piperidin-1-yl)-2(1H)-
pyrimidinone (57b) 
Compound 57b (37.5 mg, 97%) was obtained as a light-yellow solid.  Rf 
(SiO2/MeOH) = 0.23.  1H NMR (500 MHz, CD3OD): δ 7.84 (s, 1H, H-6), 6.12 
(t, J = 5.5 Hz, 1H, H-1’), 3.89 (dd, J = 2.6, 12.2 Hz, 1H, H-5’), 3.80–3.69 (m, 
6H, H-4’, H-5’, and NCH2), 3.49 (app q, Japp ~ 7.4 Hz, 1H, H-3’), 2.28–2.20 (m, 
5H, H-2’, H-2’, and Me), 1.96-1.90 (m, 4H, CH2).  13C NMR (125 MHz, CD3OD): δ 164.0, 
157.5, 141.2, 104.8, 88.8, 86.6, 61.9, 51.1, 50.5, 42.6, 26.2, 18.1.  HRMS (ESI/TOF) m/z 
calculated for C14H22N4O3Na [M + Na]+: 317.1584, found 317.1598.  
1-(3-Amino-2,3-dideoxy-β-D-ribofuranosyl)-5-methyl-4-(pyrrolidin-1-yl)-2(1H)-
pyrimidinone (57c) 
Compound 57c (39.9 mg, 99%) was obtained as a white solid.  Rf (SiO2/MeOH)  
= 0.31.  1H NMR (500 MHz, CD3OD): δ 7.98 (s, 1H, H-6), 6.12 (t, J = 5.3 Hz, 
1H, H-1’), 3.90 (dd, J = 2.6, 12.3 Hz, 1H, H-5’), 3.80 (dd, J = 3.3, 12.3 Hz, 1H, 
H-5’), 3.72 (dt, J = 3.2, 6.7 Hz, 1H, H-4’), 3.65–3.58 (m, 4H, NCH2), 3.49 (app 
q, Japp ~ 7.5 Hz, 1H, H-3’), 2.27–2.22 (m, 2H, H-2’ and H-2’), 2.14 (s, 3H, Me), 1.74–1.68 (m, 
2H, CH2), 1.68-1.61(m, 4H, CH2).  13C NMR (125 MHz, CD3OD): δ 167.3, 157.6, 143.1, 105.5, 
88.9, 86.8, 61.7, 50.9, 49.4, 42.7, 27.3, 25.5, 18.2.  HRMS (ESI/TOF) m/z calculated for 






















Compound 57d (39 mg, 96%) was obtained as a light-yellow solid.  Rf 
(SiO2/MeOH) = 0.17.  1H NMR (500 MHz, CD3OD): δ 8.07 (s, 1H, H-6), 6.11 
(t, J = 5.2 Hz, 1H, H-1’), 3.91 (dd, J = 2.3,  12.3 Hz, 1H, H-5’), 3.80 (dd, J = 
3.2, 12.3 Hz, 1H, H-5’), 3.76–3.71 (m, 5H, H-4’, morpholinyl-CH2), 3.70–3.65 
(m, 4H, morpholinyl-CH2), 3.49 (app q, Japp ~ 7.5 Hz, 1H, H-3’), 2.31-2.21 (m, 
2H, H-2’ and H-2’), 2.14 (s, 3H, Me).  13C NMR (125 MHz, CD3OD): δ 167.4, 157.4, 143.6, 
105.4, 89.0, 87.0, 67.8, 61.6, 50.8, 48.7, 42.7, 17.9. HRMS (ESI/TOF) m/z calculated for 
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PALLADIUM CATALYZED CHEMOSELECTIVE ARYLATION 
OF 8-VINYLPURINE NUCLEOSIDES 
[2.1] INTRODUCTION 
Palladium-catalyzed carbon–nitrogen (C–N) bond-forming reactions have become an 
important area in the field of organic synthesis.1-6  This is because, palladium-catalyzed cross-
coupling reactions allow access not only to small molecules but also to larger dendrimers,7 
oligoanilines,8 and biologically important nucleoside analogues.9   Typically, a palladium-
catalyzed C–N bond-forming reaction occurs between an aryl halide or aryl sulfonate and an 
amine, in the presence of palladium catalyst, ligand, base and a suitable solvent (Scheme 1). 
Scheme 1. C–N cross-coupling reaction catalyzed by palladium-ligand complex 
 
    Before the exploration of palladium catalysis, the first C–N cross-coupling reaction was 
reported with copper.10  In this method, anthranilic acid was reacted with bromobenzene or p-
bromonitrobenzene in the presence of K2CO3 and a catalytic amount of copper, at an elevated 
X
X = I, Br, Cl







R, R' = H, alkyl or 
            aryl
Scheme 2. Copper catalyzed C–N cross-coupling reactions  
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temperature in nitrobenzene (Scheme 2, eq. 1).  A similar reaction was also reported between 
benzamide and bromobenzene under the same conditions (Scheme 2, eq. 2).  Typically, these 
reactions require high temperatures, long reaction times and, in some cases, stoichiometric 
amounts of copper.   
The limitations of copper-mediated C–N bond-forming reactions invoked exploration of new 
methods and that resulted in palladium catalysis.  Migita et al. reported the first Pd-catalyzed C–
N bond-forming reaction between aryl bromides and a N-stannyl amide.11  These reactions were 
catalyzed by bis(tri-O-tolylphosphine)palladium(II)chloride ([(o-tolyl)3P]2PdCl2) in toluene at 
100 oC over 3 h (Scheme 3).  Modest to good yields (16–81%) were obtained with a wide variety 
of substituted aryl bromides.  However, this strategy is not devoid of limitations, such as i) 
unreactivity of aryl chlorides and iodides under the reaction conditions, and ii) necessity for toxic 
tin substrates and production of new tin derivatives in the reaction. 
Scheme 3. Palladium-catalyzed cross-coupling reactions between aryl bromides and a N-stannyl 
amide 
 
Intrigued with the successful aryl amination protocol of Migita et al., Hartwig et al. 
investigated the mechanistic processes involved in the Pd-catalyzed C–N bond-forming 
reactions.12  In their studies, they found that when tin amides 1a and 1b were individually reacted 
with [(o-tolyl)3P]2PdCl2 in toluene at 90–110 oC, new phosphine and amine bound complexes 2a 
and 2b were formed in 50–60% yields (Scheme 4).  The complexes 2a and 2b showed catalytic 
activity comparable to that of [(o-tolyl)3P]2PdCl2.  On the other hand, the Pd(0) species ([(o-
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16–81%
! 80!
complexes 2a and 2b.  This led to the belief that a Pd(0) species is generated in the reaction and 
is responsible for the C–N bond formation.  On the basis of their findings, Hartwig et al. 
proposed a plausible mechanism for Pd-catalyzed C–N bond-forming reactions between aryl 
bromides and tin amides (Scheme 4).12  In this mechanism, Pd(0) species 3, generated from a 
Pd(II) complex, undergoes oxidative addition with the aryl bromide to give either monomeric 
intermediate 4a or dimeric form 4b.  X-ray and solution molecular weight analysis clearly 
supported the formation of dimeric form 4b.12  However, stoichiometric and kinetic studies 
indicated that the ligand dissociates from the dimeric aryl halide complex 4b to form the three 
coordinated monomeric species 4a, in order to undergo transmetalation with tin amide to give 
complex 5.13,14  Reductive elimination of intermediate 5 then yields the aryl amine and Pd(0) 









1a, R = Me
1b, R = Et
[(o-tolyl)3P][NHR2]PdCl2
2a, R = Me




















While Hartwig et al. were investigating the mechanistic aspects of Pd-catalyzed C–N bond-
forming reactions, Buchwald et al. focused on improving the reaction conditions for the Pd-
catalyzed C–N reactions.15    They were able to conduct reactions with lowered catalyst loadings 
and expanded the scope of the reaction by generating various tin amides in situ from (N,N-
diethylamino)tributyltin via transamination reactions.  Moderate to high yields (55–88%) were 
obtained with various electron-rich, -poor and -neutral aryl bromides.  Nevertheless, there were 
certain aspects that still need to be addressed, such as, toxicity issues related to tin derivatives, 
poor reactivity of aryl iodides and reactivity confined to only secondary amines and primary 
anilines.15  
Addressing the issue related to the necessity of tin amide derivatives, Buchwald et al.16 and 
Hartwig et al.17 independently reported tin-free Pd-catalyzed C–N bond-forming reactions by 
using free amine and a strong base.  In Buchwald’s protocol, reactions between aryl bromides 
and amines were conducted with either [(o-tolyl)3P]2PdCl2 or Pd(dba)2/(o-tolyl)3P in 
combination with sodium tert-butoxide (NaOtBu) in toluene, at elevated temperature (Scheme 5).  
Similar conditions were employed in Hartwig’s protocol except that [(o-tolyl)3P]2Pd or [(o-
tolyl)3P]2PdCl2 were used as the catalyst and lithium hexamethyldisilazide (LiHMDS) was used 
as the base.  On the basis of their observations, a plausible mechanism was proposed (Scheme 5).  
In this mechanism, Pd(0) species (L-Pd, 3) undergoes oxidative addition with the aryl bromide to 
give the intermediate 4, in a similar fashion to that shown in Scheme 4.  The amine then 
coordinates to the intermediate 4 to give the Pd-amine complex 6.  The base (either NaOtBu or 
LiHMDS) then abstracts a proton from the complex 6, leading to the intermediate 7.  Reductive 





Although the tin-free protocols do produce good yields with various aryl bromides and 
amines, reactions with primary amines such as butylamine and hexylamine produced lower 
yields.17  Significant amounts of reduction products of aryl bromides were also observed in these 
reactions.  This is because of the competing β-hydride elimination from the Pd-amine complex 7 
leading to imines and arenes (Scheme 5).  Reactions conducted with aryl iodides and primary 
amines in the presence of the Pd(dba)2/(o-tolyl)3P combination and NaOtBu in dioxane at 100 oC 
also produced similar results.18  Even though ortho substitution on the aryl iodides did suppress 
β-hydride elimination to some extent and produced decent yields of aryl amine products, this 
strategy still warrants an alternate solution to suppress β-hydride elimination.  Typically, 
bidentate phosphine ligands were utilized in transition metal complexes to inhibit β-hydride 
elimination.19  However, Hartwig’s results indicated that Pd-catalyzed C–N bond-forming 
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sterically bulky monophosphine ligand such as (o-tolyl)3P was commonly used in these reactions.  
Since, bidentate phosphine ligands under Pd-catalyzed C–N bond-forming reaction conditions do 
not result in three-coordinate monophosphine species, their use was discouraged.  Despite the 
negative feedback from the initial experiments on the C–N coupling reactions with bidentate 
phosphine ligands, Buchwald et al., experimented with various bis(phosphine) ligands.19  
Eventually, promising results were obtained when a combination of Pd2(dba)3/(±)-2,2′-
bis(diphenylphosphino)-1,1′-binaphthalene (BINAP) and NaOtBu were utilized for the reactions 
of aryl bromides with amines in toluene at 80 oC.19  The Pd2(dba)3/BINAP combination showed 
high efficiency with various aryl bromides and amines.  Comparative studies on reaction rates, 
yields, and suppression of reduction products with various ligands in a reaction of n-hexylamine 
with 1-bromo-3,5-dimethylbenzene (8), clearly indicated that BINAP was superior to (o-tolyl)3P,  
and other bidentate phosphine ligands (Scheme 6).  Although, 1,1′-ferrocenediyl-
Scheme 6. Effects of ligands in palladium-catalyzed C–N bond-forming reaction of n-
hexylamine with 5-bromo-3,5-dimethylbenzene (8) 
 
Ligand Time Conversion  Yield   Ratio of 9/10 
BINAP 2 h 100% 88%  39/1 
(o-tolyl)3P 22 h 88% 35%  1.5/1 
DPPF 3 h 100% –  13.2/1 
!
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bis(diphenylphosphine) (DPPF) showed faster conversion rate compared to (o-tolyl)3P, 
significant amount of reduction product 10 was also observed.  Other bidentate phosphine 
ligands such as 1,2-bis(diphenylphosphino)ethane (DPPE), 1,3-bis(diphenylphosphino)propane 
(DPPP), 1,4-bis(diphenylphosphino)butane (DPPB) were less reactive and showed 2–18% 
conversion of 8, over a period of 3–6 h (data not shown).      
Later Hartwig et al. also showed that using a chelating ligand based catalyst such as 
(DPPF)PdCl2 in the place of Pd(dba)2/(o-tolyl)3P in aryl amination reactions restricted the β-
hydride elimination process (Scheme 7).20,21 Reactions of both aryl iodides and aryl bromides 
with primary alkyl and aryl amines resulted in high yields (80–96%).  These results are clearly 
superior to those reactions conducted with similar substrates using (o-tolyl)3P based Pd catalysts.  
The suppression of β-hydride elimination with DPPF, which is smaller in size as compared to (o-
tolyl)3P, indicates that the chelation is more important than the steric bulk of the ligands.     
Scheme 7. (DPPF)PdCl2 catalyzed C–N bond-forming reactions of aryl halides with primary 
alkyl and aryl amines 
 
From the time success with Pd-catalyzed aryl amination reactions of aryl halides with alkyl 
and aryl amines has been realized, N-arylation of imines,22,23 azoles,22 imides,24 amides,24 
carbamates,24 sulfonamides,24 sulfoximines25-27 have all been achieved with some modifications 
to the reaction conditions.  These modifications involve i) use of milder bases such as Cs2CO3 
and K3PO4,23,24,28 ii) reactions with aryl triflates23,26,29 and unreactive aryl chlorides.28  One 
important feature of the reactions with aryl chlorides is that some of the reactions could be 
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ligands such as BINAP or DPPF successfully led to aryl amination reactions, the overall 
mechanism was unknown.  Hatwig et al. conducted various experiments with aryl bromides and 
amines using the catalysts Pd(BINAP)2 (11a) and Pd(DPPF)2 (11b).30  Their results were 
consistent with the previously proposed mechanism for aryl amination reactions, which involves 
oxidative addition of an aryl bromide, generation of an amine ligated Pd complex, followed by 
reductive elimination from the palladium amido complex to give the product (Schemes 4 and 5).  
However, kinetic studies indicated that ligand dissociation from 11a to Pd(BINAP) (12a) was the 
rate-limiting step and the resultant complex 12a undergoes oxidative addition with the aryl 
bromide.  This led to the proposal of a new catalytic cycle for the Pd-catalyzed C–N bond 
forming reactions where catalysts 11a and 11b are part of the catalytic cycle (Scheme 8).  
Scheme 8. Catalytic cycle for the C–N bond forming reactions catalyzed by Pd(BINAP)2 or 
Pd(DPPF)2, as proposed by Hartwig et al.   
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Dissociation of catalyst 11 is followed by the oxidative addition of aryl bromide to the Pd 
complex 12, the resultant aryl halide complex 13 reacts with the amine (HNR1R2) and the base 
(NaOR) to give Pd-amido complex 14.  Intermediate 14 then undergoes C–N bond formation to 
give the three-coordinated amine-ligated Pd complex 15.  Dissociation of the intermediate 15 
then results the aryl amine.   
However, results from the kinetic studies by Buchwald et al. in collaboration with 
Blackmond et al. on aryl amination catalyzed by Pd2(dba)3/BINAP combination or 11a, were in 
contradiction with the results of Hartwig et al.31  In their studies, they observed that Pd complex 
12a generated from either Pd2(dba)3/BINAP combination or pure 12a, initially coordinates to the 
amine forming three-coordinated Pd complex 16 rather than undergoing oxidative addition 
(Scheme 9).  The rate-limiting oxidative addition is observed to occur much faster with the 
intermediate 16 rather than 12a.  Thus the resultant aryl amine Pd complex 17 reacts with the 






that the when Pd2(dba)3/(±)-BINAP combination was used in the reaction, the amine activates 
Pd2(dba)3 by forming [Pd(BINAP)(amine)].   
The contradictions in the mechanisms of (±)-BINAP ligated Pd-catalyzed aryl amination 
reactions proposed by Hartwig et al. and Buchwald et al. led to reassessment of the mechanism.  
This was carried out by a collaborative effort of Hartwig, Buchwald, and Blackmond.  After 
careful evaluation of the identity of the Pd(0) species and the rates of reactions of aryl halides 
with amines in the aryl amination reactions, a new mechanism was proposed (Scheme 10).31  In 
this mechanism, active catalyst 12a is initially generated from 11a, with 11a being out of the 
catalytic cycle.  Unlike in the case of the catalytic cycle proposed by Buchwald et al., 12a 
undergoes oxidative addition with the aryl bromide to give aryl palladium complex 13a.  Then, 






elimination from 14a results in the aryl amine product.  Due to the extensive mechanistic studies 
and the improvements to aryl amination reactions by Buchwald and Hartwig, Pd-catalyzed C–N 
bond forming reactions have been named as Buchwald-Hartwig amination reactions.    
On this premise, we were interested in investigating the applicability of Pd-catalyzed C–N 
bond-forming reactions to nucleosides.  This chemistry is of importance because several C-6, C-
8, and C-2 modified purine nucleosides has therapeutic value, and have also been used in 
structural, biochemical, and biological studies.  For example, nucleoside analogues 19a–d act as 
modulators of adenosine receptors, 20 exhibited anti-malarial properties, and 21 inhibits DNA 





methyl-6-phenylimidazolo[4,5-b]pyridine covalently bind to DNA and cause mutations, which 
may lead to cancer.  Thus, nucleoside adducts 22 and 23 have been used to study the structural 
and biochemical processes that lead to carcinogenesis (Figure 1).36,37   
Typically, the amine modified purine nucleosides were synthesized by displacing halogens 
from the C-2, C-6 or C-8 position of the purine nucleosides via an SNAr pathway or by conjugate 
addition-elimination pathway.  However, these reactions are typically limited to aliphatic amines 
and electron-rich aryl amines.38  This limits availability of compounds such as 19d, 21–23, 
where the nucleoside is bonded to an aromatic amine.  Hence, it was important to investigate Pd-
catalyzed aryl amination reactions of nucleosides in order to access aryl amine modified purine 
nucleosides.   
Buchwald et al. had reported a protocol for the synthesis of aminopyridines using Pd-
catalyzed C–N bond-forming reactions.39  In this approach, halopyridines were coupled with 
alkyl and aryl amines by using a combination of Pd catalysts (Pd2(dba)3 or Pd(OAc)2) and 
chelating phosphine ligands (DPPP or (±)-BINAP), with NaOtBu as the base (Scheme 11).  It 
was known from previous studies that pyridine inhibits Pd/(o-tolyl)3P catalyzed arylamination 
reactions via the formation of bis-pyridyl complexes by displacing phosphine ligands from 
critical reaction intermediates.39,40  This new protocol showcased that the chelating ligands DPPP 
or (±)-BINAP enable Pd-catalyzed synthesis of aminopyridines by preventing the formation bis-
Scheme 11. Pd-catalyzed synthesis of aminopyridines from halopyridines and amines in the 
presence of chelating ligands 
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pyridyl complexes that are detrimental to reactivity. 
On the basis of Buchwald’s synthesis of aminopyridines, and due to structural features of 4-
bromo and 2-bromopyridines within 6-bromopurine nucleoside 18, Lakshman et al. were 
interested in studying reaction of 6-bromopurine nucleoside 18 with aryl amines, under Pd-
catalyzed C–N bond-forming conditions (Figure 2).  This strategy would allow facile access to 
C-6 modified adenine nucleoside derivatives.  However, there are some important 
considerations: i) nucleoside 18 contains 
multiple heteroatoms and can potentially lead 
to ligand exchange with metal complexes and 
inhibit the reaction, despite the use of 
chelating ligands,  ii) unlike the 
bromopyridines, nucleosides are more labile 
in nature and can easily undergo 
deglycosylation.  
Initially, the conditions for Pd-catalyzed aryl amination reaction of 18 with p-toluidine were 
carefully evaluated.  The combination of Pd2(dba)3 and 2-(dicyclohexylphosphino)-2′-(N,N-
dimethylamino)-1,1′-biphenyl (DavePhos) with K3PO4 as the base, in 1,2-DME as solvent, at 80 
oC, was found to be optimal (Table 1).41,42  Moderate to good yields (52–72%) were obtained for 
the C-6 amine-modified purine nucleosides 24a–f.  Use of strong bases such as NaOtBu resulted 
in low yields of the products due to the formation of byproducts.  Notably, the reaction between 
18 and p-toluidine conducted in the absence of the catalyst and ligand, resulted in no product.  
This result ruled out the possibility for formation of products 24a–f via a SNAr pathway.41 
!
Figure 2. Structural similarities between a 6-




Table 1. Palladium-catalyzed C–N bond-forming reactions between 6-bromopurine nucleoside 
(18) with various aryl amines  
 




















Later, Koomen et al. reported Pd-catalyzed amination of 6-chloropurine ribonucleoside 25 
with alkyl and aryl amines using Pd2(dba)3/(±)-BINAP combination with either Cs2CO3 or 
KOtBu.43  However, only reaction with simple aliphatic amines resulted in good yields and the 
reactions with sterically hindered aliphatic amines and aromatic amines resulted in either low 
yields or no products.43  This led Lakshman and co-workers to evaluate the reactivity of 6-chloro 
and 6-bromo purine nucleosides with sterically hindered aliphatic amines of polycyclic aromatic 
hydrocarbons (PAHs).  This strategy, if effective, would allow easy access to several PAH-
nucleoside adducts.  PAHs are health hazards and are common pollutants present in air, water 
and soil.44  PAHs undergo metabolic activation and form diol epoxides.  These diol epoxides are 






































covalent DNA modification.44  These DNA lesions can lead to mutations and tumorigenesis.44-46  
Hence, it is important to have access to PAH-nucleoside adducts for studies directed towards 
understanding the structural, functional, and biological factors influenced by nucleoside 
modification within DNA.  Hence, the hypothesis was tested by initially reacting 6-bromo and 6-
chloropurine nucleosides 18 and 25 respectively, with a relatively simpler benzo[a]pyrene 
derivative (±)-26.47  Use of Pd(OAc)2/(±)-BINAP/Cs2CO3 in toluene at 80 oC, resulted a 
diastereomeric pair of B[a]P-dA adducts 27a, b (eq. 1, Scheme 12).  Surprisingly, the reaction 
times of 6-chloropurine nucleoside 25 and 6-bromopurine nucleoside 18 were comparable (5.5 
and 5 h respectively).  However, the yield with 6-chloropurine nucleoside 25 was higher as 
compared to that from 6-bromopurine nucleoside 18 (90% vs 80%).  This clearly shows that 6-
chloropurine nucleoside 25 is at least as effective as 6-bromopurine nucleoside 18 in Pd-
catalyzed aryl amination reactions.  Next, the conditions were applied to the synthesis of B[a]P-
dA adducts 29a, b by reacting 6-chloropurine nucleoside 25  with benzoyl-protected B[a]P 
Scheme 12. Synthesis of B[a]P-nucleoside adducts 27a,b and 29a,b via Pd-catalysis 
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amino triol (±)-28.  This reaction was complete within 4 h and yielded products 29a, b in 71% 
yield (eq. 2, Scheme 12).  One important feature of this strategy is that, despite the possibility of 
β-hydride elimination, no attrition of chirality was observed in either of the products.47  This may 
be attributable to the bis coordinating (±)-BINAP ligand used in these reactions.   
With this success, we48-50 and others51 reported synthesis of several other PAH-nucleoside 
adducts by coupling PAH amine donors with electrophilic halo nucleosides using Pd-catalysis.  
Some of the examples of PAH–nucleoside adducts with PAHs bonded at C-2 (in the case of 2’-
deoxyguanosine), and C-6 (in the case of 2’-deoxyadenosine) positions of purine nucleosides are 
shown in Figure 3.  
 
Figure 3. PAH-nucleoside adducts accessed by palladium catalysis 
 Next, Lakshman et al. decided to evaluate the reactivity of aromatic amines with 6-chloro- 
and bromo ribo- and 2’-deoxyribonucleosides.  Hence, ribose and 2’-deoxyribonucleosides, 18, 
and 25, as well as 30 and 31 were considered as model substrates.  After evaluating several 
conditions, Pd(OAc)2/Xantphos with Cs2CO3 as the base in toluene, at 100 oC, proved to be the 
best conditions for aryl amination reactions of 18, 25, 30, and 31.  These reactions were 
generally very fast and were complete within 1–1.5 h, in very high yields (86–99%).  An 
example is shown in Scheme 13, where 6-bromo and 6-chloro purine nucleosides 18, 25, 30, and 
31 were reacted with silylated 2’-deoxyadenosine (dA) and adenosine (A) analogues 32a, b 


























respectively. These dimers were known to form in vitro by DNA cross-linking processes 
mediated by nitrous acid.52  Since these processes can lead to deleterious biological changes, 
synthetic access to dimers 33a and 33b will enable to study the physiological transformations. 
Scheme 13. Pd-catalyzed aryl amination reactions of 6-halonucleosides 18, 25, 30, and 31 with 
2’-deoxyadenosine and adenosine derivatives 32a,b 
    !
      Lakshman et al. also reported the synthesis of C6-azolyl purine nucleosides by use of Pd-
catalyzed C–N bond-forming reactions.53  In this strategy, 6-chloropurine nucleoside 25 and 6-
bromopurine nucleosides 18, 30 were coupled with various heteroaryl amines by use of 
Pd(OAc)2/Xantphos as the catalyst combination, Cs2CO3 as the base in toluene or 1,4-dioxane, at 
100 oC (Scheme 14).53  Interestingly, the ligands that were commonly used for Pd-catalyzed aryl 
amination reactions such as Davephos and (±)-BINAP were not effective under these conditions 
and only xantphos produced high yields.  This could be due to a combination of factors, such as 
i) the large bite-angle of Xantphos allowing the formation of stable complexes and also 
enhancing reductive elimination, ii) the apical oxygen atom in Xantphos stabilizing intermediates 
in the cis-trans isomerization of oxidative-addition complexes.  Both 6-chloropurine nucleoside 
25 and 6-bromopurine nucleosides 18 and 30 were effective substrates under these conditions.  
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resulted in higher yields.  However, reactions of benzimidazole, carbazole, and 1,2,4-triazole in 
1,4-dioxane were clearly superior to those in toluene.53   
Scheme 14. Synthesis of C6-azolylpurine nucleoside analogues via Pd-catalyzed coupling of 
halonucleosides 18, 25, and 30 with heteroaryl amines 
 
From the previous reports, it was known that arene aryl sulfonates could also be used for Pd-
catalyzed aryl amination reactions.54,55  However, there were no reports on the utility of O6-aryl 
sulfonate derivatives of nucleosides in Pd-catalyzed C–N coupling reactions.  Lakshman et al. 
investigated the reactivity of nucleosides with a sulfonate group at the C6 position of purine 
nucleosides.56  However, the stability of O6-aryl sulfonate nucleoside derivatives under Pd-
catalyzed aryl amination reaction conditions is a matter of concern.  Therefore, several O6-aryl 
sulfonate derivatives of 2’-deoxyguanosine were tested in reactions with p-toluidine, in the 
presence of different Pd catalyst and ligand combinations.  It was observed that the O6-tosyl 
derivative of 2’-deoxyguanosine 36 was most stable and produced better yields under these 
conditions compared to the sterically bulky mesylate or 2,4,6-triisopropylphenyl analogues of 36.  
The reactions required a combination of Pd(OAc)2/Davephos/K3PO4 with 1,4-dioxane/t-BuOH 
mixture as solvent, at 110 oC (Scheme 15).  The reactions were, in general, fast (1–1.5 h) and 
gave products in moderate to high yields (55–98%).56  In the search of designing new ligands, 
Lakshman et al. recently reported the synthesis of ligand 38, which is isomeric to DavePhos.57  
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O6-tosyl derivative of 2’-deoxyguanosine 36 (Scheme 15).57  Studies on reaction times and 
product yields showed that ligand 38 was comparable to DavePhos.  However, in some cases, 
ligand 38 was clearly superior to DavePhos.  Pd(OAc)2/ligand 38 combination was also very 
effective in C–C bond-forming reactions and were much superior to the Pd(OAc)2/DavePhos 
combination.  Notably, some of the reactions were also carried out at room temperature by using 
the Pd(OAc)2/ligand 38 combination.57 
Scheme 15. C–N coupling reactions of aryl amines with a O6-tosyl nucleoside derivative 
catalyzed by a Pd(OAc)2/biarylphosphine ligand combination   
 
Although Pd-catalyzed aryl amination reaction of electrophilic halonucleosides with aryl 
amines is an effective method for the synthesis of N6-aryl purine nucleosides, an easy and 
alternative route would involve Pd-catalyzed coupling of aryl halides with nucleosides 
containing an amine functionality (Figure 4).  Typically, synthesis of 6-bromo purine nucleoside 
18 and its chloro analogue 25 was carried out from 2’-deoxyadenosine in 2 and 3 steps, 
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aryl halides with amino group of nucleosides would be cost-effective and a less labor-intensive 
approach to access N6-aryl purine nucleosides.      
 
Figure 4. Alternative route to the synthesis of N6-aryl purine nucleosides  
In this regard, Sigurdsson and Hopkins et al. reported the first Pd-catalyzed C–N bond-
forming reaction on nucleosides.59  They successfully synthesized a dG-dG dimer by coupling 
protected 2’-deoxyguanosine and protected 2-bromo-2’-deoxyinosine derivatives through the use 
of the Pd(OAc)2/R-(+)-BINAP/NaOtBu combination in toluene, at 80 oC.  Later, De Riccardis 
and Johnson et al. reported the synthesis of N6-aryl purine nucleosides by Pd-catalyzed aryl 
amination reaction of 2’-deoxyadenosine derivative 32a with various aryl bromides and triflates, 
using the Pd(OAc)2/(±)-BINAP/Cs2CO3 combination in toluene, at 80 oC (Scheme 16).60  
Although, high yields (84–88%) were obtained in these reactions, this method is applicable to 
only aryl bromides and triflates that contain a nitro group at the ortho position.  The presence of 
electron-withdrawing groups such as nitro group activates aryl bromides and triflates increases 
the rate of oxidative addition in Pd-catalyzed coupling reactions.  Interestingly, at least in one 
case, a N6,N6-diarylated nucleoside (40) was formed as the major product, when equivalent 
amounts of 1-(2-nitronaphthyl)triflate and 32a were coupled.  Hence, to suppress the diarylation, 
these reaction were conducted with excess 32a as compared to the aryl bromides and triflates.60 
  Scheme 16. N6-arylation of 32a with aryl bromides and triflates under Pd-catalyzed C–N 




















In an extension of their work, De Riccardis and Johnson et al. utilized Pd-catalyzed aryl 
amination reactions of 32a to synthesize cross-linked purine nucleosides 33a and 43.61  This was 
achieved by reacting bromo nucleosides 18 and 42 with 32a under the conditions used for N6-
arylation of 32a (Scheme 17).  However, the yields for the products 33a and 43 were very low 
(21% and 24% respectively).  Modifying reaction conditions did not improve the yields.  
Replacing the 6-bromo purine nucleoside 18 with its iodo analogue 41, increased the yield of the 
product 33a to 53% (Scheme 17).61  In order to improve the yield of 43, the iodo analogue of 42 
was needed.  However, attempts towards the synthesis of iodo analogue of 42 failed.  Later, 
Hopkins and Sigurdsson et al. reported an improved synthesis of 43 by using the same substrates 
as De Riccardis and Johnson, i.e., 32a and 42.62  However, the Pd2(dba)3/R-(+)-BINAP/tBuONa 
combination was used in toluene, at 80 oC.  These conditions lead to the product 43 in relatively 
better yield (44%), despite use of a stronger base tBuONa, which was known to be detrimental to 








































Scheme 17. Synthesis of cross-linked purine nuclesoides 33a and 43 by Pd-catalyzed C–N 
coupling reactions 
 
The limitations of using only activated aryl bromides and triflates in N6-arylation of 32a,60 
and the low product yields in the case of cross-linked purine nucleoside synthesis,61 caused 
Lakshman et al. to reevaluate the Pd-catalyzed transformation of 2’-deoxyadenosine derivative 
32a.  Initial attempts at the arylation of 32a with bromo PAHs using the Pd(OAc)2/(±)-
BINAP/Cs2CO3 combination in toluene, at 100 oC, had been shown to be inadequate in 
applicability.48  In our previous reports on Pd-catalyzed aryl amination reactions of 6-
halonucleosides with aryl and heteroaryl amines, it was observed that a Pd catalyst/Xantphos 
combination was very effective as compared to other Pd catalyst /ligand combinations.53  In this 
context, we wanted to investigate how effective Pd catalyst/Xantphos combinations would be as 
compared to other catalytic systems.  Hence, we evaluated the coupling of aryl bromides with 
32a by screening different combinations of Pd catalysts with Xantphos and other ligands.63  In 
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in toluene, at 90 oC (Scheme 18).  Then, the scope of the reaction was tested by reacting 32a with 
several aryl bromides under the optimized conditions.  Both electron-deficient and electron-rich 
aryl bromides reacted well under the conditions.  However, product yields in the latter case were 
slightly lower as compared to the former.  Bromonaphthalenes reacted very slowly with 32a (27–
48 h).  Surprisingly, the reaction times for electron-deficient aryl bromides especially in the case 
of 4-formyl bromobenzene and 4-acetyl bromobenzene were also longer (24 h).  However, the 
yields, in general, were very high in most cases.  Later, we turned our focus to improve the yield 
of the cross-linked purine nucleoside 33a.  For this, we conducted the reaction of 32a with 6-
bromopurine nucleoside 18 and its chloro analogue 25 in the presence of the 
Pd(OAc)2/Xantphos/Cs2CO3 combination in toluene, at 100 oC.  This resulted in the dA-dA 
dimer 32a in relatively high 65–77% yields compared to the previous reports (Scheme 13).64 
Scheme 18. Pd-Xantphos catalyzed N6-arylation of 32a 
!
Recently, Lakshman et al. reported a study on Heck arylation chemistry of 8-vinyladenine 
nucleosides 45 and 46.65  For this coupling, Pd(OAc)2/P(o-tol)3/Et3N combination in DMF at 100 
oC proved to be the most effective among all conditions that were tested.  A wide array of aryl 
iodides and aryl bromides were successfully reacted at the β-position of 8-vinyladenine 
nucleosides 45 and 46 (Scheme 19).  These reactions lead to the trans-alkenes as the major 
products.  However, in some cases, where electron-rich aryl halides were used, the product 



























(57–92%) were obtained in all cases.  Attempts at utilizing aryl chlorides for the Heck arylation 
were successful with minor modifications to the optimized conditions.  However, it was limited 
to only activated aryl halides.65 
Scheme 19. Chemoselective Heck-arylation of 8-vinlyadenine nucleoside derivatives 45 and 46 
 
Typically, in Heck arylation reactions, a new C–C bond is formed by reacting aryl/vinyl 
halides or triflates with alkenes that contain an electron-withdrawing group in the presence of Pd 
catalyst and a base, in a suitable solvent.66,67  Pd(OAc)2 is the most commonly used Pd source, 
where as P(PPh3)3 and P(o-tol)3 are the commonly used ligands for Heck arylation reactions.  The 
mechanism of Heck coupling reactions involves 4 main steps in the catalytic cycle.  They are 
oxidative addition, syn-insertion, syn β-hydride elimination, and reductive elimination.   The 
general mechanistic pathway proposed by Heck for reactions catalyzed by Pd(OAc)2 and 
monophosphine ligand (L) combination is shown in Scheme 20.66,68  In this mechanism, initially 
Pd(0) species 50 was generated by the reduction of Pd(OAc)2 by the phosphine ligand L.  Then, 
50 undergo oxidative addition with aryl/vinyl halide or triflate to give trans-aryl palladium 
complex 51.  This is followed by the dissociation of a phosphine ligand L from 51 to give three 
co-ordinated palladium species 52, that then co-ordinates to the alkene.  The resultant species 53 
undergoes syn insertion to the alkene to give alkyl palladium species 54.  Internal C–C bond 
rotation in 54 allows the β-hydrogen to align syn to the palladium atom, and this facilitates a syn 
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alkene dissociates from 56 to give the free alkene 49 and a hydridopalladium complex 57.  
Reductive elimination from 57 via action of a base then regenerates the catalytic species 50.    
Scheme 20. Proposed mechanistic pathway for Heck-arylation reactions catalyzed by Pd(OAc)2 
and monophosphine ligand (L) combination 
 
On the basis of the mechanisms proposed for Pd-catalyzed C–N bond-forming reactions and 
Heck C–C arylations, it is evident that both processes are catalyzed by a Pd(0) species, generated 
in situ, and involve a phosphine ligand, a base and an aryl halide.  This implies that under Pd-
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functionalities such as 45 and 46, C–N arylation could potentially take place.  However, in our 
analysis, Heck arylation reactions of 45 and 46 with aryl halides resulted only in C–C products 
47 and 48.  Practically, no C–N arylated products were observed.  As mentioned earlier, we have 
reported that Pd-Xantphos combinations are very effective for N6-arylation of the exocyclic 
amino group of 2’-deoxyadenosine derivative 32a (Scheme 18).63 All these results intrigued us 
and led us to evaluate the chemoselective N6-arylation of 8-vinyladenine nucleosides 45 and 46 
by Pd-catalysis (Scheme 21).  In particular, we wanted to investigate how important ligand 
structure was for these reactions.  
   Scheme 21. Chemoselective N6-arylation of 8-vinlyadenine nucleoside derivatives 45 and 46 to 
be evaluated 
 
Recently, it was reported that 8-vinyl-2′-deoxyadenosine (8vdA, 60) exhibited fluorescent 
properties and its quantum yield is comparable to that of 2-aminopurine nucleoside 61, one of the 
most commonly used fluorophores (Figure 5).69  Similarly, 8vdA analogue 62 also showed 
strong fluorescence in non-polar solvents (Figure 5).70  On the other hand, 8vdA-10, a 10-mer 
stem–tetraloop RNA in which 60 was incorporated, inhibits ricin toxin A-chain (RTA).71  On the 
basis of the biological and fluorescent properties of 60 and its analogues, N6-modification of 60, 
in principle, can lead to potential fluorophores and biologically active compounds.  Pd-catalyzed 
chemoselective N6-arylation of 8-vinyladenine nucleosides 45 and 46 provides an excellent route 
to access such modified 8-vinyladenine nucleosides (58 and 59). 
 Pd catalyst 
ligand
base 
















45, R' = H
46, R' = OR
NH2
Ar X












 Pd catalyst 
ligand
base 
solvent, T  °C
R = TBDMS
47, R' = H
48, R' = OR
58, R' = H
59, R' = OR
! 104!
!































[2.2] RESULTS AND DISCUSSION 
In order to evaluate conditions for chemoselective N6-arylation, we needed access to 3’,5’-
silyl protected 8-vinyl-2’-deoxyadenosine 45.  The synthesis of 45 has previously been reported 
starting from 3’,5’-silyl-protected 2’-deoxyadenosine 32a, in two steps.65,72  Hence, following 
the reported procedure, compound 45 was synthesized by lithiation at the C-8 position of 
nucleoside 32a with lithium diisopropyl amide (LDA) followed by iodination with iodine in 
anhydrous THF (Scheme 22).  This gave the 8-iodo-2’-deoxyadenosine nucleoside 63 in 80% 
yield.  Stille coupling of 8-iodo nucleoside 63 with tributyl vinyltin in the presence of Pd(PPh3)4  
in anhydrous THF, at 90 oC, gave the desired product 45 in 80% yield (Scheme 22).   
Scheme 22. Synthesis of 8-vinly-2’-deoxyadenosineadenosine derivative 45 from 3’,5’-disilyl 2’-
deoxyadenosine 32a 
 
With compound 45 in hand, we began to evaluate conditions for selective N6-arylation of 45.  
For this, we choose six ligands i.e., Xantphos, bis[(2-diphenylphosphino)phenyl] ether 
(DPEPhos), (±)-BINAP, 2,2'-Bis(diphenylphosphino)-1,1'-biphenyl (BIPHEP), and DPPF 
(Figure 6).  Xantphos, (±)-BINAP and DPPF were chosen because it was already proven that 
they are effective in aryl amination reactions of alkyl, and aromatic amines with aryl halides and 
also in reactions involving nucleosides.  DPEPhos and BIPHEP were chosen due to their 
structural similarities to Xantphos and (±)-BINAP, respectively.  The reactions were conducted 






































Figure 6. Ligands and one Pd catalyst tested for the reactions 
Due to our success with the Pd/Xantphos combination for aryl amination reactions of 
nucleosides, we initially conducted a reaction of 45 with 1.5 equiv. of PhI in the presence of 10 
mol% Pd(OAc)2/20 mol% Xantphos/1.5 equiv. of Cs2CO3 combination in toluene, at 100 oC.  
This reaction was complete within 5 h and the desired N6-arylated product 58a was isolated in a 
65% yield (entry 1, Table 2).  However, some C,N-diarylated product 64a (18%) and Heck-like 
product 47a (7%) were also observed in this reaction.  Reducing the Xantphos stoichiometry to 
10 mol% did not influence the outcome of the reaction (entry 2, Table 2).  However, replacing 
the base Cs2CO3 with K3PO4 effected the chemoselectivity of the reaction, resulting in the Heck-
like product 47a as the major isomer (75%) and the N6-arylated product 58a (10%) and C,N-
diarylated product 64a (5%), as the minor byproducts (entry 3, Table 2).  Use of the combination 
of 10 mol% Pd(OAc)2/20 mol% DPEphos/1.5 molar equiv. of Cs2CO3 resulted exclusively in the 
Heck-like product 47a in a 75% yield (entry 4, Table 2).  This is quite interesting, since 
DPEPhos is structural very similar to Xantphos, except that DPEPhos is more flexible as 
compared to Xantphos.  Reducing the ligand stoichiometry to 10 mol% or changing the base to 
K3PO4, from the conditions in entry 4 did not effect the product formed or the yield (entries 5 


























replaced with the bidentate (±)-BINAP, with a slight selectivity for Heck-like reaction (entry 7, 
Table 2).  Surprisingly, use of Pd(OAc)2/BIPHEP/1.5 molar equiv. of Cs2CO3 resulted 
exclusively in the Heck-like product 47a (entries 8 and 9, Table 2).  Similarly, DPPF also gave 
the Heck-like product 47a, exclusively (entries 10 and 11, Table 2).  In general, 1:1 and 1:2 
Pd/ligand combinations resulted in closely similar outcome and the ligands DPEPhos, BIPHEP 
and DPPF showed selectivity for Heck-like reactions, resulting in product 47a, in comparable 
yields (74–80%).  Remarkbly, substituting Pd(OAc)2 with Pd2(dba)3, from the conditions in entry 
1, resulted in the N6-arylated product 58a (30%), C,N-diarylated product 64a (15%), and Heck-
like product 47a (40%), with complete loss of selectivity (entry 12, Table 2).  Next, in an attempt 
to reduce the amount of diarylated product 64a formation, we conducted the reactions with 1.3 
equiv. of PhI at 75 oC (entry 13, Table 2).  This significantly reduced the amount of the 
diarylation product and also increased the yield of the N6-arylation product.  Under conditions 
similar to entry 13, 1.3 equiv. of PhBr was reacted with 45, resulting in products 58a (78%) and 
64a (5%) (entry 14, Table 2).  However, a higher catalyst loading and temperature were required 
for this reaction, but no formation of the Heck-like product 47a was observed.  Lowering the 
temperature and reducing the ligand stoichiometry in entry 3, successfully led to the formation of 
Heck-like product 47a, with little effect on the yield (compare entry 3 to entries 15 and 16 in 
Table 2).  Lastly, with preformed complex Pd-118, Heck-like product 47a (82%) was isolated 
exclusively (entry 17, Table 2).  This result was comparable to the results observed in the 
reactions conducted with Pd(OAc)2/DPPF combination (entries 11 vs 17, Table 2).       
Table 2. Conditions evaluated for C–N bond-forming reactions of protected 8-vinyl-2’-
deoxyadenosine derivative 45a 
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1 Pd(OAc)2 (10) 
Xantphos 
(20) Cs2CO3 5 h, 100 
oC 65% 7% 18% 
2 Pd(OAc)2 (10) 
Xantphos 
(10) Cs2CO3 5 h, 100 
oC 67% 7% 17% 
3 Pd(OAc)2 (10) 
Xantphos 
(20) K3PO4 18 h, 100 
oC 10% 75% 5% 
4 Pd(OAc)2 (10) 
DPEPhos 
(20) Cs2CO3 18 h, 100 
oC  75%  
5 Pd(OAc)2 (10) 
DPEPhos 
(10) Cs2CO3 18 h, 100 
oC  74%  
6 Pd(OAc)2 (10) 
DPEPhos 
(20) K3PO4 18 h, 100 
oC  76%  
7 Pd(OAc)2 (10) 
BINAP 
(20) Cs2CO3 18 h, 100 
oC 15% 25% 5% 
8 Pd(OAc)2 (10) 
BIPHEP 
(20) Cs2CO3 18 h, 100 
oC  74%  
9 Pd(OAc)2 (10) 
BIPHEP 
(10) Cs2CO3 18 h, 100 
oC  79%  
10 Pd(OAc)2 (10) 
DPPF 
(20) K3PO4 18 h, 100 
oC  78%  
11 Pd(OAc)2 (10) 
DPPF 
(10) Cs2CO3 18 h, 100 
oC  80%  
12 Pd2(dba)3 (10) 
Xantphos 
(20) Cs2CO3 18 h, 100 
oC 30% 40% 15% 
13c Pd(OAc)2 (10) 
Xantphos 
(10) Cs2CO3 5 h, 75 
oC 75% 5% 5% 
14d Pd(OAc)2 (15) 
Xantphos 
(15) Cs2CO3 12 h, 85 
oC 78%  5% 
15 Pd(OAc)2 (10) 
Xantphos 
(20) K3PO4 18 h, 75 
oC 5% 77% 10% 
16 Pd(OAc)2 (10) 
Xantphos 
(10) K3PO4 18 h, 75 
oC 5% 76% 9% 
17 Pd-118 (10) None Cs2CO3 18 h, 75 
oC  82%  
a Reactions were conducted at a 0.1 M concentration of the nucleoside in PhMe (1 mL), 
Ph–I
 Pd catalyst 
ligand
base 










































using 0.1 mmol of 45, 1.5 equiv. of PhI, and 1.5 equiv. of base.  b Yields are of isolated 
and purified products.  c Reactions was conducted 1.3 equiv. of PhI, and 1.5 equiv. of base.  
d Reactions was conducted 1.3 equiv. of PhBr, and 1.5 equiv. of base. 
 
Next, we wanted to evaluate the scope of the Pd-catalyzed chemoselective N6-arylation of 8-
vinyl-2’-deoxyadenosine derivative 45 by using the combination of Pd(OAc)2/Xantphos/Cs2CO3 
with various aryl bromides and aryl iodides.  The results are shown in Table 3.  All reactions 
were selective towards N6-arylation of 45 and good yields (70–80%) were observed for the N-
aryl products 58b–e in all cases.  Small amounts of diaryl products 64b–e (3–7%) were also 
observed in all cases.  However, the Heck-like products 47b–e were observed mostly with aryl 
iodides.  Reactions with aryl bromides required higher temperature.  As compared to aryl 
bromides, aryl iodides are more reactive in Pd-catalysis.  Hence, this could be the reason why the 
reactions with aryl bromides require higher temperature.  Both electron-rich and electron-
deficient aryl halides were reactive under these conditions.  However, aryl halides that are 
activated for cross-coupling i.e., 4-iodo and 4-bromoacetophenone resulted in relatively higher 
yields (entries 3 and 4, Table 3).  Sterically hindered 2-iodotoluene also effectively reacted under 
these conditions (entry 5, Table 3). Reactions with 4-iodoanisole and 4-bromoanisole were also 
successful, however, product isolation was not easy in these cases.  
Table 3. Pd-catalyzed aryl amination reactions of 8-vinyl-2’-deoxyadenosine derivative 45 with 
aryl iodides and bromidesa 
 
Entry Ar-X Conditionsb N-Aryl Heck-like C,N-Diaryl 
Ar–X
 Pd catalyst 
ligand
base 










































Productc Productc Productc 
1 
 
A 58b: 71% 47b: 7% 64b: 4% 
2 
 
B 58b: 70% 47b: trace 64b: 3% 
3 
 
A 58c: 77% 47c: 6% 64c: 7% 
4 
 
B 58c: 80% 47c: trace 64c: 4% 
5 
 
A 58d: 72% 47d: 6% 64d: 5% 
a Reactions were conducted at a 0.1 M concentration of the nucleoside in PhMe (1 mL), using 
0.1 mmol of 45.  b Conditions A: Reaction was conducted with 10 mol% of Pd(OAc)2, 10 mol% 
of Xantphos, 1.3 equiv. of aryl iodide, 1.5 equiv. of Cs2CO3, in PhMe, 85 °C, 12 h. Conditions 
B: Reaction was conducted with 15 mol% of Pd(OAc)2, 15 mol% of Xantphos, 1.3 equiv. of aryl 
bromide, 1.5 equiv. of Cs2CO3, in PhMe, 85 °C, 12 h.  c  Yields are of isolated and purified 
products.  
 
From Table 3, it is apparent that the reactions of 8-vinyl-2’-deoxyadenosine 45 with aryl 
iodides and bromides were, in fact, chemoselective giving primarily N-arylation.  We then 
queried if the ribose analogue of 45 would also undergo comparable chemoselective N-arylation 
under the same conditions used for 45.  For this, we needed 8-vinyladenosine 46.  Hence, the 
synthesis of 46 was carried out as shown in Scheme 23, following previous reports.65  8-Iodo 
purine riboside 65 was synthesized by lithiation-iodonation of 32b, following the same 
procedure used for the synthesis of 8-iodo-2’-deoxyriboside 63.  In this reaction, compound 65 
was isolated in a good 69% yield.  Suzuki coupling of 65 with potassium vinyl tetrafluoborate in 
the presence of the Pd(PPh3)4/Cs2CO3 combination in toluene, at 90 oC gave the required product 
46 in 74% yield (Scheme 23).  















With the availability of 8-vinlyadenosine derivative 46, we tested the conditions for the 
chemoselectivity N-arylation of 46, by using the combination of 10 mol% Pd(OAc)2/10 mol% 
Xantphos/1.5 molar equiv. of Cs2CO3/1.3 molar equiv. of PhI, at 85 oC.  However, these 
reactions were less successful under these conditions and required higher catalyst load and 
temperature.  The reactions with aryl iodides were conducted using 15 mol% Pd(OAc)2/15 mol% 
Xantphos at 100 oC, and the reactions with aryl bromides were conducted with 20 mol% 
Pd(OAc)2/20 mol% Xantphos at 100 oC.  In both cases, 1.5 equiv. of Cs2CO3 and 1.3 equiv. of 
the aryl halide were used.  The results from these reactions are shown in Table 4.  In general, 
good yields (68–79%) yields were obtained for the N-arylated products 59a–e.  Diaryl products 
66a–e were formed in all cases, but only in small amounts (1–7%).  As observed in the case of 8-
vinyl-2’-deoxyadenosine 45, the Heck-like products 48a–e were more likely to form with aryl 
iodides.  Also, 4-iodo and 4-bromoacetophenone resulted in relatively high yields of the N-
arylated product 59c.  Overall, the results from the reactions of 8-vinlyadenosine derivative 46 
under the optimal conditions were comparable to that of 8-vinyl-2’-deoxyadenosine 45.  
Table 4. Pd-catalyzed aryl amination reactions of 8-vinyladenosine derivative 46 with aryl 
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A 59a: 71% 48a: 3% 66a: 7% 
2 
 
B 59a: 74% 48a: trace 66a: 6% 
3 
 
A 59b: 70% 48b: 7% 66b: 5% 
4 
 
B 59b: 69% 48b: 2% 66b: 2% 
5 
 
A 59c: 78% 48c: 5% 66c: – d 
6 
 
B 59c: 79% 48c: trace 66c: – d 
7 
 
A 59d: 71% 48d: 7% 66d: 4% 
8e 
 
A 59e: 68% 48e: 4% 66e: 3% 
a Reactions were conducted at a 0.1 M concentration of the nucleoside in PhMe (0.8 mL), using 
0.08 mmol of 46.  b Conditions A: Reaction was conducted with 15 mol% of Pd(OAc)2, 15 
mol% of Xantphos, 1.3 equiv. of aryl iodide, 1.5 equiv. of Cs2CO3, in PhMe, 100 °C, 12 h. 
Conditions B: Reaction was conducted with 20 mol% of Pd(OAc)2, 20 mol% of Xantphos, 1.3 
equiv. of aryl bromide, 1.5 equiv. of Cs2CO3, in PhMe, 100 °C, 12 h.  c Yields are of isolated and 
purified products.  d Product formation was not observed.  e Reaction time was 24 h.   
 
We next intended to query a sequential diarylation of 8-vinyl-2’-deoxyadenosine 45 and its 
ribose analogue 46 in a one-pot operation, by modulating the catalytic conditions.  In principle, 
this can be achieved in two ways.  In one approach N-arylation is carried out first, then followed 
by a C–C reaction.  Complimentary to this approach, C–C reaction followed by N-arylation 
could also result diarylated products (Scheme 24). 
Scheme 24. Possible approaches for the sequential diarylation of 8-vinyladenine nucleosides 45 


















We initially attempted sequential diarylation of 45 by Pd-catalyzed C–N bond-formation 
with 4-iodotoluene using Pd(OAc)2/Xantphos/1.5 equiv. of Cs2CO3 combination followed by C–
C bond-forming reaction with PhI using Pd(OAc)2/DPEphos/1.5 equiv. of Cs2CO3 combination.  
The diaryl product formation was clearly observed.  However, due to formation of byproducts in 
the N-arylation step, isolation of the final product was very difficult.  Hence, the complimentary 
approach, i.e., C–C bond-formation followed by C–N bond-formation was used to carry out the 
diarylation of nucleosides 45 and 46 (Table 5).  The combination of Pd(OAc)2/DPEPhos/1.5 
molar equiv. of Cs2CO3 was used for the C–C bond-forming reactions and 
Pd(OAc)2/Xantphos/1.5 equiv. of Cs2CO3 was used for C–N bond-forming reactions.  For both 
steps 1.3 equiv. of aryl iodides were used and the reactions were conducted sequentially in a 
single pot.  Three C,N-diarylated compounds 64f, g and 66f were synthesized via this approach.  
Moderate yields (35–42%) were obtained over two steps but a proof of principle was clearly 
obtained.  However, when we tried to synthesize C,N-diarylated compound 64h via this approach, 
it was unsuccessful.  Although the C–C bond-forming reaction of 45 with 4-iodoacetophenone 
was successful, the resulting Heck-like product 47c did not undergo N-arylation with PhI.  















































45, R = TBDMS, R' = H
46, R = TBDMS, R' = OR
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Since, the acetyl group is in direct conjugation with the amino group in 47c (Figure 7), this could 
potentially deactivate the amino group and, thus, inhibit the C–N bond-forming reaction.  In 
principle, 64h can be synthesized by C–N bond-forming reaction with PhI followed by a C–C 
bond-forming reaction with 4-iodoacetophenone. 
Table 5. One-pot sequential C–C followed by C–N arylation of 8-vinlyadenine nucleoside 




























C 66f: 35% 
a Reactions were conducted at a 0.1 M concentration of the nucleoside in PhMe, using 0.1 mmol 
of 45 and 0.08 mmol of 46.  b Conditions A: Reaction was conducted with 10 mol% of 
Pd(OAc)2, 10 mol% of DPEPhos, 1.3 equiv. of aryl iodide, 1.5 equiv. of Cs2CO3, in PhMe, 
100 °C, 12 h.  Conditions B: Reaction was conducted with 10 mol% of Pd(OAc)2, 10 mol% of 
Xantphos, 1.3 equiv. of aryl iodide, 1.5 equiv. of Cs2CO3, in PhMe, 100 °C, 12 h.  Conditions 
C: Reaction was conducted with 20 mol% of Pd(OAc)2, 20 mol% of Xantphos, 1.3 equiv. of aryl 
iodide, 1.5 equiv. of Cs2CO3, in PhMe, 100 °C, 12 h.  c Yields are of isolated and purified 
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Figure 7. Flow of electrons in the conjugated system 47c 
Finally, we wanted to investigate if simple substrates that contain both amino and vinyl 
groups, such as p-aminostyrene can be chemoselectively arylated under the conditions developed.  
Hence, we conducted a reaction of p-aminostyrene and 1.3 equiv. of PhI by using the 
combination of  Pd(OAc)2/Xantphos/Cs2CO3 in toluene, at 80 oC.  Although, N-aryl product 67 
was observed to form in this reaction, the C,N-diaryl product 68 was isolated as the major 
product, and the reaction was incomplete.  Conducting a reaction with 1.3 molar equiv. of p-
aminostyrene and 1.0 equiv. of PhI under the same conditions went to completion and reduced 
the diarylation.  From this reaction, the N-aryl product 67 was isolated in 62% yield as the major 
product, along with C,N-diaryl product 68 in 17% yield (Scheme 25).  Similarly, when a reaction 
was conducted with 1.3 equiv. of p-aminostyrene and 1.0 equiv. of PhI by using 
Pd(OAc)2/DPEPhos/Cs2CO3 combination in toluene, at 80 oC, primarily the Heck-like product 











Scheme 25. Pd-catalyzed chemoselective arylation of p-aminostyrene 
!
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(1%) was also isolated in this reaction.  The results from Scheme 25 clearly indicates that 
Pd(OAc)2/Xantphos and Pd(OAc)2/DPEPhos combinations are highly selective for N-arylation 
and Heck arylation, respectively even in simple substrates.  Further, these combinations can be 





In summary, we have demonstrated that the Pd(OAc)2/Xantphos combination with Cs2CO3 as 
the base is an effective catalytic system for chemoselective N-arylation of 8-vinyladenine 
nucleosides 45 and 46.  All the other catalytic systems with Pd(OAc)2 in combination of ligands 
such as DPEPhos, DPPF, BIPHEP,  as well as Pd-118 resulted in Heck arylation, exclusively.  
Various aryl iodides and bromides were tested under these conditions.  In general, all reactions 
resulted N-arylated products in good yields.  Small amounts of Heck-like products and C,N-
diarylated products were also isolated in these reactions.  However, the Heck-like products were 
observed mostly in the reactions of aryl iodides.  This could be due to higher reactivity of aryl 
iodides in Pd-catalysis.  The results from the Pd-catalyzed N-arylation reactions of deoxy and 
ribonucleosides, 45 and 46, respectively, were very similar.  However, ribonucleoside 46 
required a higher catalyst loading and temperature.  Further, by modulating the chemoselective 
catalytic conditions, diaryl products 64g,h and 66f were also synthesized in a one-pot, via 
sequential C–C reaction and C–N arylation.  To test the generality of chemoselective arylation of 
simple substrates, p-aminostyrene was exposed to N-arylation and Heck-arylation conditions 
identified here.   The results indicated that in this case as well, the Pd/Xantphos combination was 
effective for chemoselective N-arylation, whereas the Pd/DPEPhos combination was effective 
for chemoselective Heck-arylation of this simple substrate as well.  As observed in the case of 





[2.4] EXPERIMENTAL SECTION 
General Experimental Considerations.  Reactions were conducted in screw-cap glass vials 
with Teflon-lined caps.  Thin-layer chromatography was performed on 200 µm aluminum-foil-
backed silica gel plates.  Column chromatography was performed using 200–300 mesh silica gel.  
THF and PhMe were distilled from LiAlH4 and then from Na prior to use.  All other reagents 
were used as received from commercial suppliers.  1H NMR spectra were obtained at 500 MHz 
and are referenced to the residual protonated solvent resonance.  13C NMR spectra were obtained 
at 125 MHz and are referenced to the solvent resonance.  Chemical shifts (d) are reported in parts 
per million (ppm) and coupling constants (J) are in hertz (Hz).  Standard abbreviations are used 
to designate resonance multiplicities. 
3’,5’-Bis-O-(tert-butyldimethylsilyl)-8-iodo-2’-deoxyadenosine (63)72,73 
 
Into a clean, dry, 250 mL three-neck round-bottomed flask equipped with a stirring bar was 
placed 32a (3.79 g, 7.90 mmol, 1 equiv.) in dry THF (76 mL).  The solution was cooled down to 
–70 oC and LDA (19.8 mL, 39.5 mmol, 5 equiv.) was added dropwise to the stirring mixture.  
The mixture was stirred at –70 oC for 1 h.  Then a solution of I2 (4.00 g, 15.8 mmol, 2 equiv.) in 
THF (38 mL) was added to the reaction mixture dropwise, maintaining the temperature at –70 oC.  
The reaction mixture was brought to 0 oC and stirred for 1 more hour.  The mixture was diluted 























Et2O (3 x 50 mL).  The combined organic layers were washed with brine (20 mL), dried over 
anhydrous Na2SO4, filtered, and evaporated to dryness under reduced pressure.  The crude 
product was chromatographed on a short silica gel column using CH2Cl2 followed by 5% MeOH 
in CH2Cl2.  The product 63 (3.83 g, 80% yield) was obtained as a light-brown solid.  1H NMR 
(500 MHz, CDCl3): δ 8.21 (s, 1H, Ar-H), 6.24 (t, J = 6.7 Hz, 1H, H-1’), 5.46 (br s, 2H, NH2), 
4.87 (dt, J = 3.7, 5.9 Hz, 1H, H-3’), 3.98–3.90 (m, 2H, H-4’, H-5’), 3.73–3.66 (m, 2H, H-5’, H-
2’), 2.23 (ddd, J = 4.1, 6.8, 13.1 Hz, 1H, H-2’’), 0.94 and 0.83 (2s, 18H, t-Bu), 0.15 (s, 6H, 
SiMe), 0.01 and –0.05 (2s, 6H, SiMe). 
8-Ethenyl-3’,5’-bis-O-(tert-butyldimethylsilyl)-2’-deoxyadenosine (45)65 
 
Into a clean, dry, 100 mL round-bottomed flask containing a stirring bar and with an attached 
condenser, was placed 63 (3.20 g, 5.28 mmol, 1 equiv.) in dry THF (54 mL).  Then tri(n-
butyl)tin (3.10 mL, 10.6 mmol, 2 equiv.) and Pd(PPh3)4 (0.610 g, 0.528 mmol, 0.1 equiv.) were 
added to the solution, and the resulting mixture was stirred at 90 oC for 24 h.  After cooling to 
room temperature, the reaction mixture was diluted with EtOAc (30 mL) and washed with water 
(15 mL).  The aqueous layer was back extracted with EtOAc (3 x 15 mL).  The combined 
organic layers were washed with brine (20 mL), dried over anhydrous Na2SO4, filtered, and 
evaporated to dryness under reduced pressure.  The crude product was chromatographed on a 
silica gel column using CH2Cl2 followed by 5% acetone in CH2Cl2.  The product 45 (2.14 g, 80% 
yield) was obtained as a white solid.  1H NMR (500 MHz, CDCl3): δ 8.28 (s, 1H, Ar-H), 7.03 (dd, 























5.67 (d, J = 11.1 Hz, 1H, =CHcis), 5.56 (s, 2H, NH2), 4.77 (dt, J = 3.3, 6.4 Hz, 1H, H-3’), 3.91–
3.88 (m, 2H, H-4’, H-5’), 3.72 (dd, J = 3.6, 10.7 Hz, 1H, H-5’), 3.23 (dt, J = 3.7, 6.5, 13.1 Hz, 
1H, H-2’), 2.22 (ddd, J = 3.7, 6.5, 13.1 Hz, 1H, H-2’’), 0.93 and 0.86 (2s, 18H, t-Bu), 0.13 (s, 6H, 
SiMe), 0.03 and 0.00 (2s, 6H, SiMe). 
General procedure for the N-arylation of 8-ethenyl-3’,5’-bis-O-(tert-butyldime-thylsilyl)-2’-
deoxyadenosine (45) 
 
With aryl iodides 
In a clean, dry, 8 mL vial equipped with a stirring bar were placed Pd(OAc)2 (2.2 mg, 1.0 
µmol) and Xantphos (5.7 mg, 1.0 µmol) in dry PhMe (1 mL), and the mixture was stirred for 2 
min.  Then 45 (50 mg, 0.10 mmol), Cs2CO3 (48.4 mg, 0.15 mmol) and the aryl iodide (1.3 
equiv.) were added to the mixture.  The reaction mixture was flushed with nitrogen gas, sealed 
with a Teflon-lined cap, and placed in a sand bath that was maintained at 85 oC.  Reactions were 
monitored by TLC and upon consumption of the starting material, the reaction mixtures were 
diluted with EtOAc (20 mL) and washed with water (3 x 10 mL), brine (10 mL), dried over 
anhydrous Na2SO4, filtered, and evaporated to dryness under reduced pressure.  The crude 
reaction products were purified by column chromatography and then by preparative TLC using 
appropriate solvents (see the individual compound headings below).  

























In a clean, dry, 8 mL vial equipped with a stirring bar were placed Pd(OAc)2 (3.3 mg, 1.5 
µmol) and Xantphos (8.6 mg, 1.5 µmol) in dry PhMe (1 mL), and the mixture was stirred for 2 
min.  Then 45 (50 mg, 0.10 mmol), Cs2CO3 (48.4 mg, 0.15 mmol) and the aryl bromide (1.3 
equiv.) were added to the mixture.  The reaction mixture was flushed with nitrogen gas, sealed 
with a Teflon-lined cap, and placed in a sand bath that was maintained at 85 oC.  Reactions were 
monitored by TLC and upon consumption of the starting material, the reaction mixtures were 
diluted with EtOAc (20 mL) and washed with water (3 x 10 mL), brine (10 mL), dried over 
anhydrous Na2SO4, filtered, and evaporated to dryness under reduced pressure.  The crude 
reaction products were purified by column chromatography and then by preparative TLC using 
appropriate solvents (see the individual reactions below).  
N-Arylation of 8-ethenyl-3’,5’-bis-O-(tert-butyldimethylsilyl)-2’-deoxyadenosi-ne (45) with 
PhI 
The reaction was carried out with Pd(OAc)2 (2.2 mg, 1.0 µmol, 0.1 equiv.), Xantphos (5.7 mg, 
1.0 µmol, 0.1 equiv.), 45 (50 mg, 0.10 mmol, 1 equiv.), Cs2CO3 (48.4 mg, 0.15 mmol, 1.5 
equiv.) and PhI (15.0 µL, 0.13 mmol, 1.3 equiv.) in dry PhMe (1 mL) at 75 oC for 6 h.  
Purification of the crude material by chromatography on a silica gel column (200–300 mesh) 
with 5–10% EtOAc in hexanes gave compound 64a (3.2 mg, 5% yield) as a brown, viscous 
liquid and compound 58a (43.1 mg, 75% yield) as a pale-yellow, viscous liquid.  Subsequent 




 Rf (SiO2/10% EtOAc in hexanes) = 0.13. 1H NMR (500 MHz, CDCl3): 
δ 8.45 (s, 1H, Ar-H), 7.81 (d, J = 7.8 Hz, 2H, Ar-H), 7.64 (br s, 1H, 
NH), 7.38 (t, J = 7.7 Hz, 2H, Ar-H), 7.11–7.03 (m, 2H, Ar-H, =CH), 
6.51 (d, J = 17.2 Hz, 1H, =CHtrans), 6.44 (t, J = 6.8 Hz, 1H, H-1’), 5.71 
(d, J = 11.1 Hz, 1H, =CHcis), 4.79 (dt, J = 3.3, 6.4 Hz, 1H, H-3’), 3.97–3.90 (m, 2H, H-4’, H-5’), 
3.73 (dd, J = 3.7, 10.8 Hz, 1H, H-5’’), 3.38 (dt, J = 6.7, 13.4 Hz, 1H, H-2’), 2.25 (ddd, J = 3.6, 
6.5, 13.1 Hz, 1H, H-2’’), 0.94, and 0.86 (2s, 18H, t-Bu), 0.14 (s, 6H, SiMe), 0.03 and 0.00 (2s, 
6H, SiMe).  13C NMR (125 MHz, CDCl3): δ 152.4, 151.9, 150.5, 149.7, 139.0, 129.3, 124.5, 
124.1, 123.6, 120.4, 120.3, 87.7, 83.9, 72.1, 62.6, 38.9, 26.1, 26.0, 18.6, 18.3, –4.4, –4.5, –5.3.  
HRMS (ESI/TOF) m/z calculated for C30H48N5O3Si2 [M + H]+: 582.3290, found 582.3281. 
3’,5’-Bis-O-(tert-butyldimethylsilyl)-8-[(E)-2-phenylethenyl]-2’-deoxyadenosine (47a)65 
1H NMR (500 MHz, CDCl3): δ 8.27 (s, 1H, Ar-H), 7.82 (d, J = 15.9 Hz, 
1H, =CHtrans), 7.60 (d, J = 7.5 Hz, 2H, Ar-H), 7.41 (t, J = 7.4 Hz, 2H, 
Ar-H), 7.36 (t, J = 7.2 Hz, 1H, Ar-H), 7.23 (d, J = 17.2 Hz, 1H, 
=CHtrans), 6.43 (t, J = 6.6 Hz, 1H, H-1’), 5.53 (br s, 2H, NH2), 4.84 (dt, 
J = 3.5, 6.3 Hz, 1H, H-3’), 3.98 (app q, Japp ~ 4.9 Hz, 1H, H-4’), 3.88 (dd, J = 6.2, 10.8 Hz, 1H, 
H-5’), 3.72 (dd, J = 4.8, 10.8 Hz, 1H, H-5’’), 3.60 (dt, J = 6.5, 13.1 Hz, 1H, H-2’), 2.26 (ddd, J = 
4.5, 6.8, 13.0 Hz, 1H, H-2’’), 0.94 and 0.82 (2s, 18H, t-Bu), 0.15 (2s, 6H, SiMe), 0.00 and –0.05 




















Rf (SiO2/10% EtOAc in hexanes) = 0.33.  1H NMR (500 MHz, CDCl3): 
δ 8.44 (s, 1H, Ar-H), 7.88 (d, J = 15.9 Hz, 1H, =CHtrans), 7.84 (d, J = 
7.7 Hz, 2H, Ar-H), 7.76 (br s, 1H, NH), 7.62 (d, J = 7.3 Hz, 2H, Ar-H), 
7.45–7.34 (m, 5H, Ar-H), 7.26 (d, J = 15.9 Hz, 1H, =CHtrans), 7.11 (t, J 
= 7.4 Hz, 1H, Ar-H), 6.46 (t, J = 6.7 Hz, 1H, H-1’), 4.85 (dt, J = 3.9, 5.9 Hz, 1H, H-3’), 4.00 
(app q, Japp ~ 4.9 Hz, 1H, H-4’), 3.90 (dd, J = 6.2, 10.8 Hz, 1H, H-5’), 3.74 (dd, J = 4.7, 10.8 Hz, 
1H, H-5’’), 3.66 (dt, J = 6.5, 13.1 Hz, 1H, H-2’), 2.29 (ddd, J = 4.3, 6.7, 13.1 Hz, 1H, H-2’’), 
0.95 and 0.82 (2s, 18H, t-Bu), 0.16, 0.00, and –0.04 (4s, 12H, SiMe).  13C NMR (125 MHz, 
CDCl3): δ 152.0, 151.7, 150.5, 150.2, 139.1, 138.3, 136.0, 129.5, 129.2, 129.1, 127.7, 123.4, 
120.9, 120.2, 114.2, 87.7, 84.3, 72.6, 63.0, 37.9, 26.1, 26.0, 18.6, 18.3, –4.4, –4.5, –5.2, –5.3.  
HRMS (ESI/TOF) m/z calculated for C36H52N5O3Si2 [M + H]+: 658.3603, found 658.3607. 
N-Arylation of 8-ethenyl-3’,5’-bis-O-(tert-butyldimethylsilyl)-2’-deoxyadenosine (45) with 
PhBr 
The reaction was carried out with Pd(OAc)2 (3.3 mg, 1.5 µmol, 0.15 equiv.), Xantphos (8.6 mg, 
1.5 µmol, 0.15 equiv.), 45 (50 mg, 0.10 mmol, 1 equiv.), Cs2CO3 (48.4 mg, 0.15 mmol, 1.5 
equiv.), and PhBr (13.5 µL, 0.13 mmol, 1.3 equiv.) in dry PhMe (1 mL), at 85 oC for 12 h.  
Purification of the crude material by chromatography on a silica gel column (200–300 mesh) 
with 5–10% EtOAc in hexanes gave compound 64a (3.5 mg, 5% yield) as a brown, viscous 
liquid and compound 58a (45.0 mg, 78% yield) as a pale-yellow, viscous liquid.  











The reaction was carried out with Pd(OAc)2 (2.2 mg, 1.0 µmol, 0.1 equiv.), Xantphos (5.7 mg, 
1.0 µmol, 0.1 equiv.), 45 (50 mg, 0.10 mmol, 1 equiv.), Cs2CO3 (48.4 mg, 0.15 mmol, 1.5 
equiv.), and 4-iodotoluene (28.1 mg, 0.13 mmol, 1.3 equiv.) in dry PhMe (1 mL), at 85 oC for 12 
h.  Purification of the crude material by chromatography on a silica gel column (200–300 mesh) 
with 7–15% EtOAc in hexanes gave compounds 64b and 58b as a mixture.  Subsequent elution 
with 30% EtOAc in hexanes gave compound 47b (4.1 mg, 7% yield) as a pale-yellow solid.  
Purification of the mixture of 64b and 58b by preparative TLC (1 mm, 20 x 20 cm SiO2 plate 
eluted with 15% EtOAc in hexanes) gave compound 64b (2.6 mg, 4% yield) as a pale-yellow, 
viscous liquid and compound 58b (41.7 mg, 71% yield) as a pale-yellow, viscous liquid.  
3’,5’-Bis-O-(tert-butyldimethylsilyl)-N6-(4-tolyl)-8-ethenyl-2’deoxyadenosine (58b) 
Rf (SiO2/10% EtOAc in hexanes) = 0.13.  1H NMR (500 MHz, CDCl3): 
δ 8.42 (s, 1H, Ar-H), 7.71–7.60 (m, 3H, Ar-H, NH), 7.19 (d, J = 7.8 Hz, 
2H, Ar-H), 7.06 (dd, J = 11.1, 17.2 Hz, 1H, =CH), 6.49 (d, J = 17.2 Hz, 
1H, =CHtrans), 6.44 (t, J = 6.9 Hz, 1H, H-1’), 5.70 (d, J = 11.1 Hz, 1H, 
=CHcis), 4.80–4.76 (m, 1H, H-3’), 3.99-3.89 (m, 2H, H-4’, H-5’), 3.73 
(dd, J = 3.3, 10.6 Hz, 1H, H-5’’), 3.38–3.34 (m, 1H, H-2’), 2.40–2.20 (m, 4H, Me, H-2’’), 0.93 
and 0.86 (2s, 18H, t-Bu), 0.13 (s, 6H, SiMe), 0.03 and 0.00 (2s, 6H, SiMe).  HRMS (ESI/TOF) 
m/z calculated for C31H50N5O3Si2 [M + H]+: 596.3447, found 596.3445. 
3’,5’-Bis-O-(tert-butyldimethylsilyl)-8-[(E)-2-(4-tolyl)ethenyl]-2’-deoxyadenosine (47b)65 
1H NMR (500 MHz, CDCl3): δ 8.26 (s, 1H, Ar-H), 7.80 (d, J = 15.8 Hz, 1H, =CHtrans), 7.50 (d, J 
= 7.9 Hz, 2H, Ar-H), 7.21 (d, J = 7.9 Hz, 2H, Ar-H), 7.17 (d, J = 15.8 Hz, 1H, =CHtrans), 6.42 (t, 











~ 4.8 Hz, 1H, H-4’), 3.89 (dd, J = 6.2, 10.8 Hz, 1H, H-5’), 3.72 (dd, J 
= 4.8, 10.8 Hz, 1H, H-5’’), 3.61 (dt, J = 6.5, 13.1 Hz, 1H, H-2’), 2.39 
(s, 3H, Me), 2.25 (ddd, J = 4.7, 6.8, 12.8 Hz, 1H, H-2’’), 0.94 and 0.82 
(2s, 18H, t-Bu), 0.15, 0.14, 0.00, and –0.05 (4s, 12H, SiMe). 
3’,5’-Bis-O-(tert-butyldimethylsilyl)-N6-(4-tolyl)-8-[(E)-2-(4-tolyl)ethenyl]-2’-deoxyadenosi-
ne (64b) 
Rf (SiO2/20% EtOAc in hexanes) = 0.55.  1H NMR (500 MHz, 
CDCl3): δ 8.41 (s, 1H, Ar-H), 7.83 (d, J = 15.6 Hz, 1H, =CHtrans), 
7.70–7.64 (m, 2H, Ar-H, NH), 7.51 (d, J = 8.0 Hz, 2H, Ar-H), 7.24–
7.17 (m, 5H, Ar-H, =CHtrans), 6.45 (t, J = 6.6 Hz, 1H, H-1’), 4.84 (dt, J 
= 3.2, 5.7 Hz, 1H, H-3’), 4.00 (app q, Japp ~ 4.6 Hz, 1H, H-4’), 3.90 
(dd, J = 6.3, 10.7 Hz, 1H, H-5’), 3.73 (dd, J = 4.7, 10.8 Hz, 1H, H-5’’), 3.65 (dt, J = 6.5, 13.1 Hz, 
1H, H-2’), 2.40 (s, 3H, Me), 2.35 (s, 3H, Me), 2.27 (ddd, J = 4.3, 6.5, 12.8 Hz, 1H, H-2’’), 0.95 
and 0.82 (2s, 18H, t-Bu), 0.16 (s, 6H, SiMe), 0.00 and –0.04 (2s, 6H, SiMe).  HRMS (ESI/TOF) 
m/z calculated for C38H56N5O3Si2 [M + H]+: 686.3916, found 686.3911. 
N-Arylation of 8-ethenyl-3’,5’-bis-O-(tert-butyldimethylsilyl)-2’-deoxyadenosine (45) with 
4-bromotoluene 
The reaction was carried out with Pd(OAc)2 (3.3 mg, 1.5 µmol, 0.15 equiv.), Xantphos (8.6 mg, 
1.5 µmol, 0.15 equiv.), 45 (50 mg, 0.10 mmol, 1 equiv.), Cs2CO3 (48.4 mg, 0.15 mmol, 1.5 
equiv.), and 4-bromotoluene (15.8 µL, 0.13 mmol, 1.3 equiv.) in dry PhMe (1 mL), at 85 oC for 
12 h.  Purification of the crude material by chromatography on a silica gel column (200–300 





















purification of the mixture of 64b and 58b by preparative TLC (1 mm, 20 x 20 cm SiO2 plate 
eluted with 10% EtOAc in hexanes) gave compound 64b (1.9 mg, 3% yield) as a pale-yellow, 
viscous liquid and compound 58b (41.3 mg, 70% yield) as a pale-yellow, viscous liquid. 
N-Arylation of 8-ethenyl-3’,5’-bis-O-(tert-butyldimethylsilyl)-2’-deoxyadenosine (45) with 
4-iodoacetophenone 
The reaction was carried out with Pd(OAc)2 (2.2 mg, 1.0 µmol, 0.1 equiv.), Xantphos (5.7 mg, 
1.0 µmol, 0.1 equiv.), 45 (50 mg, 0.10 mmol, 1 equiv.), Cs2CO3 (48.4 mg, 0.15 mmol, 1.5 
equiv.) and 4-iodoacetophenone (31.7 mg, 0.13 mmol, 1.3 equiv.) in dry PhMe (1 mL) at 85 oC 
for 12 h.  Purification of the crude material by chromatography on a silica gel column (200–300 
mesh) with 30% EtOAc in hexanes gave compounds 58c and 64c as a mixture.  Subsequent 
elution with 60% EtOAc in hexanes gave compound 47c (3.9 mg, 6% yield) as a pale-yellow 
solid.  Purification of the mixture of 64c and 58c by preparative TLC (1 mm, 20 x 20 cm SiO2 
plate eluted with 30% EtOAc in hexanes) gave compound 58c (47.6 mg, 77% yield) as a pale-
yellow solid and compound 64c (5.2 mg, 7% yield) as a pale-yellow solid.  
3’,5’-Bis-O-(tert-butyldimethylsilyl)-N6-(4-acetylphenyl)-8-ethenyl-2’-deoxyadenosine (58c) 
 Rf (SiO2/50% EtOAc in hexanes) = 0.61.  1H NMR (500 MHz, CDCl3): 
δ 8.51 (s, 1H, Ar-H), 8.15 (br s, 1H, NH), 8.01–7.97 (m, 4H, Ar-H), 
7.07 (dd, J = 11.1, 17.2 Hz, 1H, =CH), 6.51 (d, J = 17.1 Hz, 1H, 
=CHtrans), 6.44 (t, J = 6.9 Hz, 1H, H-1’), 5.74 (d, J = 11.0 Hz, 1H, 
=CHcis), 4.80 (dt, J = 3.3, 6.4 Hz, 1H, H-3’), 3.96 (app q, Japp ~ 4.1 Hz, 
1H, H-4’), 3.91 (dd, J = 4.9, 11.0 Hz, 1H, H-5’), 3.73 (dd, J = 3.8, 11.0 Hz, 1H, H-5’’), 3.36 (dt, 











and 0.85 (2s, 18H, t-Bu), 0.14 (s, 6H, SiMe), 0.03 and 0.01 (2s, 6H, SiMe).  13C NMR (125 MHz, 
CDCl3): δ 197.1, 152.1, 151.2, 150.8, 150.2, 143.8, 131.9, 130.1, 124.7, 124.3, 120.7, 119.0, 87.7, 
84.0, 72.0, 62.6, 38.9, 26.6, 26.1, 26.0, 18.6, 18.3, –4.4, –4.5, –5.3.  HRMS (ESI/TOF) m/z 
calculated for C32H49N5O4Si2Na [M + Na]+: 646.3215, found 646.3226. 
3’,5’-Bis-O-(tert-butyldimethylsilyl)-8-[(E)-2-(4-acetylphenyl)ethenyl]-2’-deoxyadenosine 
(47c)65 
1H NMR (500 MHz, CDCl3): δ 8.29 (s, 1H, Ar-H), 7.99 (d, J = 8.1 Hz, 
2H, Ar-H), 7.86 (d, J = 15.8 Hz, 1H, =CHtrans), 7.68 (d, J = 8.1 Hz, 2H, 
Ar-H), 7.34 (d, J = 15.8 Hz, 1H, =CHtrans), 6.43 (t, J = 6.5 Hz, 1H, H-
1’), 5.52 (s, 2H, NH2), 4.85 (app q, Japp ~ 4.6 Hz, 1H, H-3’), 3.99 (app 
q, Japp ~ 4.7 Hz, 1H, H-4’), 3.87 (dd, J = 6.0, 10.9 Hz, 1H, H-5’), 3.71 (dd, J = 4.7, 10.9 Hz, 1H, 
H-5’’), 3.64 (dt, J = 6.4, 13.1 Hz, 1H, H-2’), 2.63 (s, 3H, Me), 2.29 (ddd, J = 4.7, 6.7, 13.0 Hz, 
1H, H-2’’), 0.95 and 0.81 (2s, 18H, t-Bu), 0.16, –0.01, and –0.06 (3s, 12H, SiMe). 
3’,5’-Bis-O-(tert-butyldimethylsilyl)-N6-(4-acetylphenyl)-8-[(E)-2-(4-acetylphenyl)ethenyl]-
2’-deoxyadenosine (64c) 
 Rf (SiO2/50% EtOAc in hexanes) = 0.46.  1H NMR (500 MHz, 
CDCl3): δ 8.52 (s, 1H, Ar-H), 8.02–7.99 (m, 7H, Ar-H, NH), 7.92 (d, J 
= 15.9 Hz, 1H, =CHtrans), 7.70 (d, J = 8.2 Hz, 2H, Ar-H), 7.38 (d, J = 
15.9 Hz, 1H, =CHtrans), 6.45 (t, J = 6.5 Hz, 1H, H-1’), 4.88 (app q, Japp 
~ 5.0 Hz, 1H, H-3’), 4.01 (app q, Japp ~ 4.8 Hz, 1H, H-4’), 3.89 (dd, J 
= 5.8, 10.9 Hz, 1H, H-5’), 3.73–3.67 (m, 2H, H-5’’, H-2’), 2.64 (s, 3H, Me), 2.60 (s, 3H, Me), 





















0.02 and –0.07 (2s, 6H, SiMe).  13C NMR (125 MHz, CDCl3): δ 197.5, 197.1, 152.1, 151.2, 
150.8, 150.2, 143.7, 140.2, 137.6, 137.2, 131.9, 130.1, 129.2, 127.8, 121.4, 118.9, 116.4, 87.8, 
84.5, 72.4, 62.9, 37.9, 26.9, 26.6, 26.1, 26.0, 18.6, 18.3, –4.4, –4.5, –5.2, –5.3.  HRMS 
(ESI/TOF) m/z calculated for C40H56N5O5Si2 [M + H]+: 742.3814, found 742.3834. 
N-Arylation of 8-ethenyl-3’,5’-bis-O-(tert-butyldimethylsilyl)-2’-deoxyadenosine (45) with 
4-bromoacetophenone 
The reaction was carried out with Pd(OAc)2 (3.3 mg, 1.5 µmol, 0.15 equiv.), Xantphos (8.6 mg, 
1.5 µmol, 0.15 equiv.), 45 (50 mg, 0.10 mmol, 1 equiv.), Cs2CO3 (48.4 mg, 0.15 mmol, 1.5 
equiv.) and 4-bromotoluene (15.8 µL, 0.13 mmol, 1.3 equiv.) in dry PhMe (1 mL) at 85 oC for 12 
h.  Purification of the crude material by chromatography on a silica gel column (200–300 mesh) 
with 30% EtOAc in hexanes gave compounds 58c and 64c as a mixture.  Further purification of 
the mixture of 64c and 58c by preparative TLC (1 mm, 20 x 20 cm SiO2 plate eluted with 30% 
EtOAc in hexanes) gave compound 58c (49.2 mg, 80% yield) as a yellow solid and compound 
64c (2.8 mg, 4% yield) as a pale-yellow solid. 
N-Arylation of 8-ethenyl-3’,5’-bis-O-(tert-butyldimethylsilyl)-2’-deoxyadenosine (45) with 
2-iodotoluene 
The reaction was carried out with Pd(OAc)2 (2.2 mg, 1.0 µmol, 0.1 equiv.), Xantphos (5.7 mg, 
1.0 µmol, 0.1 equiv.), 45 (50 mg, 0.10 mmol, 1 equiv.), Cs2CO3 (48.4 mg, 0.15 mmol, 1.5 
equiv.), and 2-iodotoluene (16.4 µL, 0.13 mmol, 1.3 equiv.) in dry PhMe (1 mL), at 85 oC for 12 
h.  Purification of the crude material by chromatography on a silica gel column (200–300 mesh) 
with 10–20% EtOAc in hexanes gave compounds 64d and 58d as a mixture.  Subsequent elution 
with 40% EtOAc in hexanes gave the compound 47d (3.6 mg, 6% yield) as a white solid.  
! 129!
Purification of the mixture of 64d and 58d by preparative TLC (1 mm, 20 x 20 cm SiO2 plate 
eluted with 20% EtOAc in hexanes) gave compound 64d (3.3 mg, 5% yield) as a yellow viscous 
liquid and compound 58d (42.6 mg, 72% yield) as a yellow viscous liquid. 
 3’,5’-Bis-O-(tert-butyldimethylsilyl)-N6-(2-tolyl)-8-ethenyl-2’-deoxyadenosine (58d) 
Rf (SiO2/20% EtOAc in hexanes) = 0.34.  1H NMR (500 MHz, CDCl3): 
δ 8.38 (s, 1H, Ar-H), 7.94 (d, J = 7.9 Hz, 1H, Ar-H), 7.51 (br s, 1H, 
NH), 7.29–7.25 (m, 2H, Ar-H), 7.18 (t, J = 7.9 Hz, 1H, Ar-H), 7.06 (dd, 
J = 11.1, 17.2 Hz, 1H, =CH), 6.52 (d, J = 17.2 Hz, 1H, =CHtrans), 6.44 (t, 
J = 6.9 Hz, 1H, H-1’), 5.71 (d, J = 11.2 Hz, 1H, =CHcis), 4.79 (dt, J = 
3.2, 6.4 Hz, 1H, H-3’), 3.96-3.89 (m, 2H, H-4’, H-5’), 3.73 (dd, J = 3.6, 10.7 Hz, 1H, H-5’’), 
3.37 (dt, J = 6.8, 13.4 Hz, 1H, H-2’), 2.37 (s, 3H, Me), 2.25 (ddd, J = 3.6, 6.5, 13.1 Hz, 1H, H-
2’’), 0.93 and 0.86 (2s, 18H, t-Bu), 0.13 (s, 6H, SiMe), 0.03 and 0.00 (2s, 6H, SiMe).  13C NMR 
(125 MHz, CDCl3): δ 152.6, 152.5, 150.5, 149.5, 136.6, 130.9 (2s), 126.9, 125.2, 124.5, 124.0, 
123.9, 120.4, 87.6, 83.9, 72.0, 62.6, 38.8, 26.1, 26.0, 18.6, 18.3, 18.2, –4.4, –4.5, –5.3.  HRMS 
(ESI/TOF) m/z calculated for C31H50N5O3Si2 [M + H]+: 596.3447, found 596.3461.     
3’,5’-Bis-O-(tert-butyldimethylsilyl)-8-[(E)-2-(2-tolyl)ethenyl]-2’-deoxyadenosine (47d)65 
1H NMR (500 MHz, CDCl3): δ 8.27 (s, 1H, Ar-H), 8.08 (d, J = 15.7 Hz, 
1H, =CHtrans), 7.65 (d, J = 7.1 Hz, 1H, Ar-H), 7.29–7.24 (m, 2H, Ar-H), 
7.23–7.20 (m, 1H, Ar-H), 7.13 (d, J = 15.7 Hz, 1H, =CHtrans), 6.42 (t, J 




















(app q, Japp ~ 4.8 Hz, 1H, H-4’), 3.87 (dd, J = 6.2, 10.8 Hz, 1H, H-5’), 3.71 (dd, J = 4.8, 10.8 Hz, 
1H, H-5’’), 3.62 (dt, J = 6.5, 13.1 Hz, 1H, H-2’), 2.50 (s, 3H, Me), 2.25 (ddd, J = 4.4, 6.6, 13.0 
Hz, 1H, H-2’’), 0.93 and 0.82 (2s, 18H, t-Bu), 0.14, –0.01, and –0.06 (3s, 12H, SiMe). 
3’,5’-Bis-O-(tert-butyldimethylsilyl)-N6-(2-tolyl)-8-[(E)-2-(2-tolyl)ethenyl]-2’-deoxyadenosi-
ne (64d) 
Rf (SiO2/20% EtOAc in hexanes) = 0.54.  1H NMR (500 MHz, CDCl3): 
δ 8.37 (s, 1H, Ar-H), 8.12 (d, J = 15.8 Hz, 1H, =CHtrans), 7.96 (d, J = 
7.9 Hz, 1H, Ar-H), 7.67 (d, J = 6.6 Hz, 1H, Ar-H), 7.45 (br s, 1H, NH), 
7.30–7.23 (m, 5H, Ar-H), 7.16 (d, J = 15.8 Hz, 1H, =CHtrans), 7.12 (t, J 
= 7.6 Hz, 1H, Ar-H), 6.45 (t, J = 6.6 Hz, 1H, H-1’), 4.84 (dt, J = 3.7, 
5.9 Hz, 1H, H-3’), 3.99 (app q, Japp ~ 4.9 Hz, 1H, H-4’), 3.89 (dd, J = 6.3, 10.9 Hz, 1H, H-5’), 
3.72 (dd, J = 4.8, 10.8 Hz, 1H, H-5’’), 3.67 (dt, J = 6.5, 13.2 Hz, 1H, H-2’), 2.52 (s, 3H, Me), 
2.41 (s, 3H, Me), 2.27 (ddd, J = 4.1, 6.7, 13.2 Hz, 1H, H-2’’), 0.94 and 0.82 (2s, 18H, t-Bu), 0.15 
(s, 6H, SiMe), 0.00 and –0.05 (2s, 6H, SiMe).  13C NMR (125 MHz, CDCl3): δ 152.5, 152.2, 
150.7, 150.3, 137.3, 136.6, 136.1, 135.1, 131.0, 129.3, 129.1, 127.7, 126.9, 126.5, 126.0, 125.2, 
124.0, 120.9, 115.3, 87.7, 84.3, 72.6, 63.0, 37.8, 26.1, 20.2, 18.6, 18.4, 18.3, –4.4, –4.5, –5.2, –





































To a clean, dry, 250 mL three-neck round-bottomed flask, a solid addition tube containing I2 
(0.48 g, 1.88 mmol, 2 equiv.) was connected to one-neck.  A solution of 32b (0.45 g, 0.94 mmol, 
1 equiv.) in dry THF (14 mL) was introduced into the flask, and the solution was cooled to –70 
oC.  LDA (2.34 mL, 4.69 mmol, 5 equiv.) was added dropwise to the stirring mixture.  The 
mixture was stirred at –70 oC for 1 h, brought to 0 oC, and I2 was added to the reaction mixture 
by twisting the addition tube.  The mixture was stirred for 1 more hour.  The reaction mixture 
was diluted with Et2O (30 mL) and washed with water (20 mL).  The aqueous layer was back 
extracted with Et2O (3 x 20 mL).  The combined organic layers were washed with brine (10 mL), 
dried over anhydrous Na2SO4, filtered, and evaporated to dryness under reduced pressure.  The 
crude product was chromatographed on a short silica gel column using CH2Cl2 followed by 5% 
MeOH in CH2Cl2.  The product 65 (0.392 mg, 69% yield) was obtained as a light-brown solid.  
1H NMR (500 MHz, CDCl3): δ 8.21 (s, 1H, Ar-H), 5.86 (d, J = 5.9 Hz, 1H, H-1’), 5.64 (br s, 2H, 
NH2), 5.56 (dd, J = 4.4, 5.8 Hz, 1H, H-2’), 4.57 (dd, J = 2.1, 4.2 Hz, 1H, H-3’), 4.11–4.04 (m, 
2H, H-5’, H-5”), 3.71 (app q, Japp ~ 7.4 Hz, 1H, H-4’), 0.92, 0.84 and 0.80 (3s, 27H, t-Bu), 0.16 




Into a clean, dry, 50 mL round-bottomed flask containing a stirring bar and with an 
condenser, was placed 65 (1.65 g, 2.24 mmol, 1 equiv.) in a 9:1 THF-H2O (23 mL).  Potassium 
























equiv.), and Cs2CO3 (2.18 g, 6.70 mmol, 3 equiv.) were added, and the resulting mixture was 
stirred at 90 oC for 20 h.  After cooling to room temperature, the reaction mixture was diluted 
with EtOAc (30 mL) and washed with water (3 x 15 mL), brine (20 mL), dried over anhydrous 
Na2SO4, filtered, and evaporated to dryness under reduced pressure.  The crude product was 
chromatographed on a silica gel column using CH2Cl2 followed by 2% MeOH in CH2Cl2.  
Product 46 (1.08 g, 74% yield) was obtained as a white solid.  1H NMR (500 MHz, CDCl3): δ 
8.28 (s, 1H, Ar-H), 6.96 (dd, J = 11.1, 17.2 Hz, 1H, =CH), 6.48 (d, J = 17.2 Hz, 1H, =CHtrans), 
5.98 (d, J = 6.2 Hz, 1H, H-1’), 5.70 (d, J = 11.1 Hz, 1H, =CHcis), 5.44 (s, 2H, NH2), 5.30 (t, J = 
5.3 Hz, 1H, H-2’), 4.53–4.48 (m, 1H, H-3’), 4.07–4.04 (m, 2H, H-5’, H-5”), 3.77–3.73 (m, 1H, 
H-4’), 0.96, 0.86, and 0.74 (3s, 27H, t-Bu), 0.15 (2s, 6H, SiMe), 0.05, 0.01, –0.09, and –0.41 (4s, 
12H, SiMe). 
General procedure for the N-arylation of 8-ethenyl-2’,3’,5’-tris-O-(tert-butyldimethylsilyl) 
adenosine (46) 
 
With aryl iodides 
In a clean, dry, 8 mL vial equipped with a stirring bar were placed Pd(OAc)2 (2.6 mg, 1.2 
µmol), and Xantphos (6.8 mg, 1.2 µmol) in dry PhMe (0.8 mL), and the mixture was stirred for 2 
min.  Then 46 (50 mg, 0.08 mmol), Cs2CO3 (38.4 mg, 0.12 mmol) and the aryl iodide (1.3 
equiv.) were added to the mixture.  The reaction mixture was flushed with nitrogen gas, sealed 


























were monitored by TLC and upon consumption of the starting material, the reaction mixtures 
were diluted with EtOAc (20 mL) and washed with water (3 x 10 mL), brine (10 mL), dried over 
anhydrous Na2SO4, filtered, and evaporated to dryness under reduced pressure.  The crude 
reaction products were purified by column chromatography and then by preparative TLC using 
appropriate solvents (see the individual compound headings below).  
With aryl bromides 
In a clean, dry, 8 mL vial equipped with a stirring bar were placed Pd(OAc)2 (3.5 mg, 1.6 
µmol) and Xantphos (9.1 mg, 1.6 µmol) in dry PhMe (0.8 mL) and the mixture was stirred for 2 
min.  Then 46 (50 mg, 0.08 mmol), Cs2CO3 (38.4 mg, 0.12 mmol) and the aryl bromide (1.3 
equiv.) were added to the mixture.  The reaction mixture was flushed with nitrogen gas, sealed 
with a Teflon-lined cap, and placed in a sand bath that was maintained at 100 oC.  Reactions 
were monitored by TLC and upon consumption of the starting material, the reaction mixtures 
were diluted with EtOAc (20 mL) and washed with water (3 x 10 mL), brine (10 mL), dried over 
anhydrous Na2SO4, filtered, and evaporated to dryness under reduced pressure.  The crude 
reaction products were purified by column chromatography and then by preparative TLC using 
appropriate solvents (see the individual reactions below).  
N-Arylation of 8-ethenyl-2’,3’,5’-tris-O-(tert-butyldimethylsilyl)adenosine (46) with PhI 
The reaction was carried out with Pd(OAc)2 (2.6 mg, 1.2 µmol, 0.15 equiv.), Xantphos (6.8 mg, 
1.2 µmol, 0.15 equiv.), 46 (50 mg, 0.08 mmol, 1 equiv.), Cs2CO3 (38.4 mg, 0.12 mmol, 1.5 
equiv.), and PhI (12.0 µL, 0.10 mmol, 1.3 equiv.) in dry PhMe (0.8 mL), at 100 oC for 12 h.  
Purification of the crude material by chromatography on a silica gel column (200–300 mesh) 
with 5–10% EtOAc in hexanes gave compounds 66a and 59a as a mixture.  Subsequent elution 
! 134!
with 30% EtOAc in hexanes gave compound 48a (1.8 mg, 3% yield) as an off-white solid.  
Purification of the mixture of 66a and 59a by preparative TLC (1 mm, 20 x 20 cm SiO2 plate 
eluted with 5% EtOAc in hexanes) gave compound 66a (4.3 mg, 7% yield) as a light brown, 
viscous liquid and compound 59a (39.7 mg, 71% yield) as a brown, viscous liquid. 
2’,3’,5’-Tris-O-(tert-butyldimethylsilyl)-N6-phenyl-8-ethenyladenosine (59a)65 
 Rf (SiO2/10% EtOAc in hexanes) = 0.35.  1H NMR (500 MHz, CDCl3): 
δ 8.45 (s, 1H, Ar-H), 7.83 (d, J = 7.8 Hz, 2H, Ar-H), 7.66 (br s, 1H, 
NH), 7.39 (t, J = 7.8 Hz, 2H, Ar-H), 7.10 (t, J = 7.3 Hz, 1H, Ar-H), 
7.00 (dd, J = 11.1, 17.1 Hz, 1H, =CH), 6.52 (d, J = 17.1 Hz, 1H, 
=CHtrans), 6.02 (d, J = 6.3 Hz, 1H, H-1’), 5.74 (d, J = 11.2 Hz, 1H, =CHcis), 5.32 (t, J = 5.3 Hz, 
1H, H-2’), 4.50 (dd, J = 1.8, 4.2 Hz, 1H, H-3’), 4.12–4.05 (m, 2H, H-4’, H-5’), 3.79–3.74 (m, 1H, 
H-5’’), 0.97, 0.87, and 0.74 (3s, 27H, t-Bu), 0.16, 0.15, 0.06, 0.02, –0.09, and –0.41 (6s, 18H, 
SiMe). 
2’,3’,5’-Tris-O-(tert-butyldimethylsilyl)-8-[(E)-2-phenylethenyl]adenosine (48a)65 
1H NMR (500 MHz, CDCl3): δ 8.26 (s, 1H, Ar-H), 7.83 (d, J = 15.9 Hz, 
1H, =CHtrans), 7.59 (d, J = 7.3 Hz, 2H, Ar-H), 7.59 (t, J = 7.3 Hz, 2H, 
Ar-H), 7.36 (t, J = 7.3 Hz, 1H, Ar-H), 7.16 (d, J = 15.9 Hz, 1H, 
=CHtrans), 6.00 (d, J = 5.3 Hz, 1H, H-1’), 5.55 (br s, 2H, NH2), 5.51 (t, J 
= 4.9 Hz, 1H, H-2’), 4.60 (t, J = 3.6 Hz, 1H, H-3’), 4.12–4.04 (m, 2H, H-4’, H-5’), 3.76 (dd, J = 
4.0, 10.6 Hz, 1H, H-5’’), 0.98, 0.83, and 0.77 (3s, 27H, t-Bu), 0.18, 0.17, 0.02, –0.04, –0.06, and 





















 Rf (SiO2/10% EtOAc in hexanes) = 0.51.  1H NMR (500 MHz, CDCl3): 
δ 8.45 (s, 1H, Ar-H), 7.88 (d, J = 16.4 Hz, 1H, =CHtrans), 7.85 (d, J = 
8.2 Hz, 2H, Ar-H), 7.72 (br s, 1H, NH), 7.61 (d, J = 7.4 Hz, 2H, Ar-H), 
7.45–7.36 (m, 5H, Ar-H), 7.19 (d, J = 15.9 Hz, 1H, =CHtrans), 7.11 (t, J 
= 7.3 Hz, 1H, Ar-H), 6.03 (d, J = 5.4 Hz, 1H, H-1’), 5.57 (t, J = 4.8 Hz, 
1H, H-2’), 4.61 (t, J = 3.5 Hz, 1H, H-3’), 4.15–4.08 (m, 2H, H-4’, H-5’), 3.78 (dd, J = 3.7, 10.3 
Hz, 1H, H-5’’), 0.99, 0.84, and 0.78 (3s, 27H, t-Bu), 0.19, 0.18, 0.03, –0.02, –0.05, and –0.33 (6s, 
18H, SiMe).  13C NMR (125 MHz, CDCl3): δ 152.1, 151.8, 150.5 (2s), 139.1, 138.7, 136.0, 
129.6, 129.3, 129.1, 127.7, 123.5, 121.0, 120.3, 113.6, 88.7, 85.6, 72.7, 72.5, 62.7, 26.2, 26.1, 
26.0, 18.5, 18.4, 18.1, –4.2, –4.3, –4.9, –5.2, –5.3.  HRMS (ESI/TOF) m/z calculated for 
C42H66N5O4Si3 [M + H]+: 788.4417, found 788.4411. 
N-Arylation of 8-ethenyl-2’,3’,5’-tris-O-(tert-butyldimethylsilyl)adenosine (46) with PhBr 
The reaction was carried out with Pd(OAc)2 (3.5 mg, 1.6 µmol, 0.2 equiv.), Xantphos (9.1 mg, 
1.6 µmol, 0.2 equiv.), 46 (50 mg, 0.08 mmol, 1 equiv.), Cs2CO3 (38.4 mg, 0.12 mmol, 1.5 
equiv.), and PhBr (11.0 µL, 0.10 mmol, 1.3 equiv.) in dry PhMe (0.8 mL), at 100 oC for 12 h.  
Purification of the crude material by chromatography on a silica gel column (200–300 mesh) 
with 5–10% EtOAc in hexanes gave compound 66a (3.8 mg, 6% yield) as a light brown, viscous 
liquid and compound 59a (41.3 mg, 74% yield) as a brown, viscous liquid.  












The reaction was carried out with Pd(OAc)2 (2.6 mg, 1.2 µmol, 0.15 equiv.), Xantphos (6.8 mg, 
1.2 µmol, 0.15 equiv.), 46 (50 mg, 0.08 mmol, 1 equiv.), Cs2CO3 (38.4 mg, 0.12 mmol, 1.5 
equiv.), and 4-iodotoluene (22.3 mg, 0.10 mmol, 1.3 equiv.) in dry PhMe (0.8 mL), at 100 oC for 
12 h.  Purification of the crude material by chromatography on a silica gel column (200–300 
mesh) with 5–15% EtOAc in hexanes gave compounds 66b and 59b as a mixture.  Subsequent 
elution with 30% EtOAc in hexanes gave compound 48b (4.1 mg, 7% yield) as a pale-yellow 
solid.  Purification of the mixture of 66b and 59b by preparative TLC (1 mm, 20 x 20 cm SiO2 
plate eluted with 10% EtOAc in hexanes) gave compound 66b (3.1 mg, 5% yield) as a yellow 
solid and compound 59b (39.8 mg, 70% yield) as a yellow solid. 
2’,3’,5’-Tris-O-(tert-butyldimethylsilyl)-N6-(4-tolyl)-8-ethenyladenosine (59b)  
Rf (SiO2/20% EtOAc in hexanes) = 0.36.  1H NMR (500 MHz, CDCl3): 
δ 8.43 (s, 1H, Ar-H), 7.68 (d, J = 8.2 Hz, 2H, Ar-H), 7.58 (br s, 1H, 
NH), 7.19 (d, J = 8.0 Hz, 2H, Ar-H), 7.00 (dd, J = 11.1, 17.0 Hz, 1H, 
Ar-H, =CH), 6.52 (d, J = 17.1 Hz, 1H, =CHtrans), 6.01 (d, J = 6.1 Hz, 
1H, H-1’), 5.73 (d, J = 11.0 Hz, 1H, =CHcis), 5.34 (t, J = 5.0 Hz, 1H, H-
2’), 4.53–4.48 (m, 1H, H-3’), 4.12-4.07 (m, 2H, H-5’, H-5’’), 3.77 (app q, Japp ~ 6.9 Hz, 1H, H-
4’), 2.34 (s, 3H, Me), 0.97, 0.87, and 0.75 (3s, 27H, t-Bu), 0.16 (2s, 6H, SiMe), 0.06, 0.02, –0.08, 
and –0.40 (4s, 12H, SiMe).  HRMS (ESI/TOF) m/z calculated for C37H64N5O4Si3 [M + H]+: 
726.4261, found 726.4249. 
2’,3’,5’-Tris-O-(tert-butyldimethylsilyl)-8-[(E)-2-(4-tolyl)ethenyl]adenosine (48b)65 
1H NMR (500 MHz, CDCl3): δ 8.26 (s, 1H, Ar-H), 7.80 (d, J = 15.8 Hz, 1H, =CHtrans), 7.48 (d, J 












J = 5.4 Hz, 1H, H-1’), 5.55 (br s, 2H, NH2), 5.51 (t, J = 4.9 Hz, 1H, H-
2’), 4.60 (t, J = 3.6 Hz, 1H, H-3’), 4.12–4.05 (m, 2H, H-4’, H-5’’), 
3.76 (dd, J = 3.9, 10.5 Hz, 1H, H-5’’), 2.39 (s, 3H, Me), 0.98, 0.83, 




Rf (SiO2/10% EtOAc in hexanes) = 0.28.  1H NMR (500 MHz, 
CDCl3): δ 8.41 (s, 1H, Ar-H), 7.85 (d, J = 15.6 Hz, 1H, =CHtrans), 7.70 
(d, J = 8.1 Hz, 2H, Ar-H), 7.56 (br s, 1H, NH), 7.50 (d, J = 7.7 Hz, 2H, 
Ar-H), 7.23 (d, J = 7.7 Hz, 2H, Ar-H), 7.20 (d, J = 8.0 Hz, 2H, Ar-H), 
7.13 (d, J = 15.8 Hz, 1H, =CHtrans), 6.01 (d, J = 5.3 Hz, 1H, H-1’), 
5.56 (t, J = 4.3 Hz, 1H, H-2’), 4.61 (t, J = 3.3 Hz, 1H, H-3’), 4.14–4.07 (m, 2H, H-5’, H-5”), 
3.80–3.74 (m, 1H, H-4’), 2.40 (s, 3H, Me), 2.35 (s, 3H, Me), 0.98, 0.84, and 0.77 (3s, 27H, t-Bu), 
0.18 (2s, 6H, SiMe), 0.27, –0.02, –0.06, and –0.34 (4s, 12H, SiMe).  HRMS (ESI/TOF) m/z 
calculated for C44H69N5O4Si3Na [M + Na]+: 838.4550, found 838.4542. 
N-Arylation of 8-ethenyl-2’,3’,5’-tris-O-(tert-butyldimethylsilyl)adenosine (46) with 4-
bromotoluene 
The reaction was carried out with Pd(OAc)2 (3.5 mg, 1.6 µmol, 0.2 equiv.), Xantphos (9.1 mg, 
1.6 µmol, 0.2 equiv.), 46 (50 mg, 0.08 mmol, 1 equiv.), Cs2CO3 (38.4 mg, 0.12 mmol, 1.5 
equiv.), and PhBr (13.0 µL, 0.10 mmol, 1.3 equiv.) in dry PhMe (0.8 mL), at 100 oC for 12 h.  























pale-yellow solid.  Purification of the crude material by chromatography on a silica gel column 
(200–300 mesh) with 5–10% EtOAc in hexanes gave compounds 66b and 59b as a mixture.  
Subsequent elution with 30% EtOAc in hexanes gave compound 48b (1.1 mg, 2% yield) as a 
white solid.  Purification of the mixture of 66b and 59b by preparative TLC (1 mm, 20 x 20 cm 
SiO2 plate eluted with 10% EtOAc in hexanes) gave compound 66b (1.3 mg, 2% yield) as a 
yellow solid and compound 59b (39.5 mg, 69% yield) as a yellow solid.  
N-Arylation of 8-ethenyl-2’,3’,5’-tris-O-(tert-butyldimethylsilyl)adenosine (46) with 4-
iodoacetophenone 
The reaction was carried out with Pd(OAc)2 (2.6 mg, 1.2 µmol, 0.15 equiv.), Xantphos (6.8 mg, 
1.2 µmol, 0.15 equiv.), 46 (50 mg, 0.08 mmol, 1 equiv.), Cs2CO3 (38.4 mg, 0.12 mmol, 1.5 
equiv.), and 4-iodoacetophenone (25.1 mg, 0.10 mmol, 1.3 equiv.) in dry PhMe (0.8 mL), at 100 
oC for 12 h.  Purification of the crude material by chromatography on a silica gel column (200–
300 mesh) with 30% EtOAc in hexanes gave compound 59c with minor impurities.  Subsequent 
elution with 50% EtOAc in hexanes gave compound 48c (3.1 mg, 5% yield) as a pale-yellow 
solid.  Purification of the impure 59c using preparative TLC (1 mm, 20 x 20 cm SiO2 plate eluted 
with 30% EtOAc in hexanes) gave compound 59c (46.2 mg, 78% yield) as a yellow solid. 
2’,3’,5’-Tris-O-(tert-butyldimethylsilyl)-N6-(4-acetylphenyl)-8-ethenyladenosine (59c)  
 Rf (SiO2/20% EtOAc in hexanes) = 0.27.  1H NMR (500 MHz, CDCl3): 
δ 8.52 (s, 1H, Ar-H), 8.01 (d, J = 8.9 Hz, 2H, Ar-H), 7.99 (d, J = 8.9 Hz, 
2H, Ar-H), 7.91 (br s, 1H, NH), 7.02 (dd, J = 11.0, 17.1 Hz, 1H, =CH), 
6.55 (d, J = 17.1 Hz, 1H, =CHtrans), 6.03 (d, J = 6.3 Hz, 1H, H-1’), 5.77 












4.4 Hz, 1H, H-3’), 4.12–4.04 (m, 2H, H-4’, H-5’), 3.77 (dd, J = 3.5, 10.7 Hz, 1H, H-5’’), 2.60 (s, 
3H, –COCH3), 0.97, 0.87, and 0.74 (3s, 27H, t-Bu), 0.17, 0.16, 0.06, 0.03, –0.09, and –0.42 (6s, 
18H, SiMe).  13C NMR (125 MHz, CDCl3): δ 197.0, 152.1, 151.2, 151.0, 150.5, 143.7, 131.9, 
130.1, 124.9, 123.9, 120.9, 118.9, 88.0, 86.2, 73.1, 72.4, 62.8, 26.6, 26.1 (2s), 25.8, 18.6, 18.3, 
18.0, –4.2, –4.4, –5.1, –5.2, –5.3.  HRMS (ESI/TOF) m/z calculated for C38H63N5O4Si3Na [M + 
Na]+: 776.4029, found 776.4031. 
2’,3’,5’-Tris-O-(tert-butyldimethylsilyl)-8-[(E)-2-(4-acetylphenyl)ethenyl]adenosine (48c)65 
1H NMR (500 MHz, CDCl3): δ 8.28 (s, 1H, Ar-H), 8.00 (d, J = 8.3 Hz, 
2H, Ar-H), 7.86 (d, J = 15.9 Hz, 1H, =CHtrans), 7.66 (d, J = 8.2 Hz, 2H, 
Ar-H), 7.26 (d, J = 15.9 Hz, 1H, =CHtrans), 5.99 (d, J = 5.4 Hz, 1H, H-
1’), 5.54 (t, J = 4.8 Hz, 1H, H-2’), 5.49 (br s, 2H, NH2), 4.60 (t, J = 3.7 
Hz, 1H, H-3’), 4.12 (dt, 1H, J = 3.5, 6.8 Hz, H-4’), 4.07 (dd, J = 7.0, 10.7 Hz, 1H, H-5’’), 3.76 
(dd, J = 4.2, 10.8 Hz, 1H, H-5’’), 2.63 (s, 3H, –COCH3), 0.98, 0.82, and 0.77 (3s, 27H, t-Bu), 
0.18, 0.17, 0.02, –0.04, –0.05, and –0.33 (6s, 18H, SiMe). 
N-Arylation of 8-ethenyl-2’,3’,5’-tris-O-(tert-butyldimethylsilyl)adenosine (46) with 4-
bromoacetophenone 
The reaction was carried out with Pd(OAc)2 (3.5 mg, 1.6 µmol, 0.2 equiv.), Xantphos (9.1 mg, 
1.6 µmol, 0.2 equiv.), 46 (50 mg, 0.08 mmol, 1 equiv.), Cs2CO3 (38.4 mg, 0.12 mmol, 1.5 
equiv.), and 4-bromoacetophenone (20.3 mg, 0.10 mmol, 1.3 equiv.) in dry PhMe (0.8 mL), at 
100 oC for 12 h.  Purification of the crude material by chromatography on a silica gel column 












Further purification of impure 59c using preparative TLC (1 mm, 20 x 20 cm SiO2 plate eluted 
with 30% EtOAc in hexanes) gave compound 59c (46.9 mg, 79% yield) as a yellow solid.  
N-Arylation of 8-ethenyl-2’,3’,5’-tris-O-(tert-butyldimethylsilyl)adenosine (46) with 2-
iodotoluene 
The reaction was carried out with Pd(OAc)2 (2.6 mg, 1.2 µmol, 0.15 equiv.), Xantphos (6.8 mg, 
1.2 µmol, 0.15 equiv.), 46 (50 mg, 0.08 mmol, 1 equiv.), Cs2CO3 (38.4 mg, 0.12 mmol, 1.5 
equiv.), and 2-iodotoluene (13.0 µL, 0.10 mmol, 1.3 equiv.) in dry PhMe (0.8 mL), at 100 oC for 
12 h.  Purification of the crude material by chromatography on a silica gel column (200–300 
mesh) with 7–15% EtOAc in hexanes gave compounds 66d and 59d as a mixture.  Subsequent 
elution with 30% EtOAc in hexanes gave compound 48d (4.2 mg, 7% yield) as a white solid.  
Purification of the mixture of 66a and 59a by preparative TLC (1 mm, 20 x 20 cm SiO2 plate 
eluted with 10% EtOAc in hexanes) gave compound 66d (2.7 mg, 4% yield) as a yellow, viscous 
liquid and compound 59d (40.8 mg, 71% yield) as a yellow, viscous liquid. 
2’,3’,5’-Tris-O-(tert-butyldimethylsilyl)-N6-(2-tolyl)-8-ethenyladenosine (59d)  
 Rf (SiO2/10% EtOAc in hexanes) = 014.  1H NMR (500 MHz, CDCl3): 
δ 8.38 (s, 1H, Ar-H), 7.98 (d, J = 7.9 Hz, 1H, Ar-H), 7.50 (s, 1H, NH), 
7.29–7.26 (m, 2H, Ar-H), 7.12 (d, J = 7.4 Hz, 1H, Ar-H), 7.00 (dd, J = 
11.1, 17.1 Hz, 1H, Ar-H, =CH), 6.53 (dd, J = 1.3, 17.1 Hz, 1H, Ar-H, 
=CHtrans), 6.01 (d, J = 6.1 Hz, 1H, H-1’), 5.73 (dd, J = 1.3, 11.1 Hz, 1H, 
Ar-H, =CHcis), 5.34 (t, J = 5.3 Hz, 1H, H-2’), 4.54–4.50 (m, 1H, H-3’), 4.12–4.04 (m, 2H, H-4’, 
H-5’), 3.76–3.75 (m, 1H, H-5’’), 2.38 (s, 3H, Me), 0.97, 0.86, and 0.75 (3s, 27H, t-Bu), 0.16, 












150.6, 149.8, 136.6, 130.9, 129.2, 126.9, 125.2, 124.4, 123.9, 120.6, 120.3, 88.1, 86.0, 73.0, 72.4, 
62.7, 26.2, 26.1, 25.9, 18.6, 18.4, 18.3, 18.0, –4.2, –4.3, –4.4, –5.1, –5.2, –5.3.  HRMS 
(ESI/TOF) m/z calculated for C37H64N5O4Si3 [M + H]+: 726.4261, found 726.4240. 
2’,3’,5’-Tris-O-(tert-butyldimethylsilyl)-8-[(E)-2-(2-tolyl)ethenyl]adenosine (48d)65 
1H NMR (500 MHz, CDCl3): δ 8.27 (s, 1H, Ar-H), 8.08 (d, J = 15.8 Hz, 
1H, =CHtrans), 7.62 (d, J = 7.6 Hz, 1H, Ar-H), 7.28–7.24 (m, 2H, Ar-H), 
7.24–7.21 (m, 1H, Ar-H), 7.06 (d, J = 15.7 Hz, 1H, =CHtrans), 5.98 (d, J 
= 5.4 Hz, 1H, H-1’), 5.58 (br s, 2H, NH2), 5.52 (t, J = 4.8 Hz, 1H, H-2’), 
4.59 (t, J = 3.5 Hz, 1H, H-3’), 4.11–4.04 (m, 2H, H-4’, H-5’), 3.75 (dd, J = 4.0, 10.4 Hz, 1H, H-
5’’), 2.49 (s, 3H, Me), 0.97, 0.82, and 0.77 (3s, 27H, t-Bu), 0.17, 0.16, 0.01, –0.04, –0.06, and –
0.34 (6s, 18H, SiMe). 
2’,3’,5’-Tris-O-(tert-butyldimethylsilyl)-N6-(2-tolyl)-8-[(E)-2-(2-tolyl)ethenyl]adenosine 
(66d) 
Rf (SiO2/10% EtOAc in hexanes) = 0.18.  1H NMR (500 MHz, CDCl3): 
δ 8.37 (s, 1H, Ar-H), 8.12 (d, J = 15.7 Hz, 1H, =CHtrans), 7.98 (d, J = 
7.9 Hz, 1H, Ar-H), 7.66–7.62 (m, 1H, Ar-H), 7.47 (s, 1H, NH), 7.31–
7.22 (m, 5H, Ar-H), 7.15–7.06 (m, 2H, Ar-H, =CHtrans), 6.01 (d, J = 5.4 
Hz, 1H, H-1’), 5.58 (t, J = 4.8 Hz, 1H, H-2’), 4.61 (t, J = 3.6 Hz, 1H, H-
3’), 4.14–4.05 (m, 2H, H-4’, H-5’), 3.76 (dd, J = 3.6, 10.3 Hz, 1H, H-5’’), 2.51 (s, 3H, Me), 2.40 
(s, 3H, Me), 0.97, 0.82, and 0.78 (3s, 27H, t-Bu), 0.18, 0.17, and 0.01 (3s, 9H, SiMe), –0.04 (s, 
6H, SiMe), –0.31 (s, 6H, SiMe).  13C NMR (125 MHz, CDCl3): δ 152.5, 155.3, 150.6, 150.5, 























88.8, 85.5, 72.6, 72.5, 62.6, 26.2, 26.1, 25.9, 20.2, 18.5, 18.4, 18.1, –4.2, –4.3, –4.4, –4.9, –5.2, –
5.3.  HRMS (ESI/TOF) m/z calculated for C44H70N5O4Si3 [M + H]+: 816.4730, found 816.4718. 
N-Arylation of 8-ethenyl-2’,3’,5’-tris-O-(tert-butyldimethylsilyl)adenosine (46) with 1-
iodonaphthalene 
The reaction wascarried out with Pd(OAc)2 (2.6 mg, 1.2 µmol, 0.15 equiv.), Xantphos (6.8 mg, 
1.2 µmol, 0.15 equiv.), 46 (50 mg, 0.08 mmol, 1 equiv.), Cs2CO3 (38.4 mg, 0.12 mmol, 1.5 
equiv.), and 1-iodonaphthalene (15.0 µL, 0.10 mmol, 1.3 equiv.) in dry PhMe (0.8 mL), at 100 
oC for 12 h.  Purification of the crude material by chromatography on a silica gel column (200–
300 mesh) with 7–15% EtOAc in hexanes gave compounds 66e and 59e as a mixture.  
Subsequent elution with 30% EtOAc in hexanes gave compound 48e (2.5 mg, 4% yield) as a 
white solid.  Purification of the mixture of 66e and 59e by preparative TLC (1 mm, 20 x 20 cm 
SiO2 plate eluted with 10% EtOAc in hexanes) gave compound 66e (2.1 mg, 3% yield) as a 
yellow solid and compound 59e (40.6 mg, 68% yield) as a pale-yellow solid. 
2’,3’,5’-Tris-O-(tert-butyldimethylsilyl)-N6-(naphthalene-1-yl)-8-ethenyladenosine (59e)  
 Rf (SiO2/5% EtOAc in hexanes) = 0.14.  1H NMR (500 MHz, CDCl3): 
δ 8.39 (s, 1H, Ar-H), 8.16 (d, J = 7.4 Hz, 1H, Ar-H), 8.09–8.08 (m, 1H, 
Ar-H), 7.93–7.88 (m, 2H, Ar-H, NH), 7.74 (d, J = 8.2 Hz, 1H, Ar-H), 
7.57–7.51 (m, 3H, Ar-H), 7.03 (dd, J = 11.1, 17.1 Hz, 1H, =CH), 6.58 
(d, J = 17.1 Hz, 1H, =CHtrans), 6.03 (d, J = 6.1 Hz, 1H, H-1’), 5.77 (d, J 
= 11.1 Hz, 1H, =CHcis), 5.38 (t, J = 5.2 Hz, 1H, H-2’), 4.53 (dd, J = 2.2, 4.3 Hz, 1H, H-3’), 4.14–
4.06 (m, 2H, H-4’, H-5’), 3.80–3.74 (m, 1H, H-5’’), 0.97, 0.87, and 0.77 (3s, 27H, t-Bu), 0.17, 











150.8, 150.1, 134.6, 133.5, 128.9, 128.2, 126.4, 126.3, 126.0, 125.7, 124.5, 124.0, 121.7, 120.9 
(2s), 88.2, 86.0, 73.0, 72.4, 62.7, 26.2, 26.1, 25.9, 18.6, 18.4, 18.1, –4.2, –4.3, –4.4, –5.0, –5.2, –
5.3.  HRMS (ESI/TOF) m/z calculated for C40H64N5O4Si3 [M + H]+: 762.4261, found 762.4260.   
2’,3’,5’-Tris-O-(tert-butyldimethylsilyl)-8-[(E)-2-(naphthalene-1-yl)ethenyl]adenosine 
(48e)65 
1H NMR (500 MHz, CDCl3): δ 8.65 (d, J = 15.7 Hz, 1H, =CHtrans), 
8.30–8.28 (m, 2H, Ar-H), 7.89 (d, J = 7.9 Hz, 2H, Ar-H), 7.81 (d, J = 
7.2 Hz, 1H, Ar-H), 7.61–7.51 (m, 3H, Ar-H), 7.24 (d, J = 15.9 Hz, 1H, 
=CHtrans), 6.03 (d, J = 5.4 Hz, 1H, H-1’), 5.55–5.50 (m, 3H, NH2, H-2’), 
4.61 (t, J = 3.7 Hz, 1H, H-3’), 4.12–4.05 (m, 2H, H-4’, H-5’), 3.76 (dd, J = 4.0, 10.7 Hz, 1H, H-
5’’), 0.96, 0.82, and 0.77 (3s, 27H, t-Bu), 0.17, 0.16, 0.01, –0.05, and –0.31 (5s, 18H, SiMe). 
2’,3’,5’-Tris-O-(tert-butyldimethylsilyl)-N6-(naphthalene-1-yl)-8-[(E)-2-(napht-halene-1-yl) 
ethenyl]adenosine (66e) 
 Rf (SiO2/10% EtOAc in hexanes) = 0.18.  1H NMR (500 MHz, CDCl3): 
δ 8.75 (d, J = 15.6 Hz, 1H, =CHtrans), 8.40 (s, 1H, Ar-H), 8.35 (d, J = 
8.4 Hz, 1H, Ar-H), 8.19 (d, J = 7.5 Hz, 1H, Ar-H), 8.16 (dd, J = 0.7, 8.1 
Hz, 1H, Ar-H), 8.00 (br s, 1H, NH), 7.94–7.89 (m, 3H, Ar-H), 7.86 (d, 
J = 7.1 Hz, 1H, Ar-H), 7.76 (d, J = 8.1 Hz, 1H, Ar-H), 7.64–7.51 (m, 
6H, Ar-H), 7.30 (d, J = 15.6 Hz, 1H, =CHtrans), 6.01 (d, J = 5.2 Hz, 1H, H-1’), 5.62 (t, J = 4.8 Hz, 
1H, H-2’), 4.65 (t, J = 3.8 Hz, 1H, H-3’), 4.16–4.09 (m, 2H, H-4’, H-5’), 3.78 (dd, J = 3.9, 10.6 
Hz, 1H, H-5’’), 0.97, 0.83, and 0.81 (3s, 27H, t-Bu), 0.19, 0.18, 0.02, –0.01, –0.03, and –0.26 (6s, 




















133.7, 133.6, 131.7, 129.9, 128.9, 128.4, 126.9, 126.4 (2s), 126.3, 126.1, 125.9, 125.7, 124.6, 
124.0, 121.8, 121.3, 121.1, 116.4, 88.9, 85.6, 72.8, 72.5, 62.6, 26.2, 26.0 (2s), 18.5, 18.4, 18.1, –
4.2, –4.3, –4.4, –4.8, –5.2, –5.3.  HRMS (ESI/TOF) m/z calculated for C50H70N5O4Si3 [M + H]+: 
888.4730, found 888.4737. 
General procedure for the one-pot sequential diarylation of 8-ethenyl-3’,5’-bis-O-(tert-butyl 
dimethylsilyl)-2’-deoxyadenosine (45)  
 
Into a clean, dry, 8 mL vial equipped with a stirring bar were placed Pd(OAc)2 (2.2 mg, 1.0 
µmol), and DPEPhos (5.3 mg, 1.0 µmol) in dry PhMe (1 mL), and the mixture was stirred for 2 
min.  Then 45 (50 mg, 0.10 mmol), Cs2CO3 (48.4 mg, 0.15 mmol), and aryl iodide (1.3 equiv.) 
were added to the mixture.  The reaction mixture was flushed with nitrogen gas, sealed with a 
Teflon-lined cap, and placed in a sand bath that was maintained at 100 oC.  Reactions were 
monitored by TLC and upon consumption of the starting material, Pd(OAc)2 (2.2 mg, 1.0 µmol), 
Xantphos (5.7 mg, 1.0 µmol), Cs2CO3 (48.4 mg, 0.15 mmol), and aryl iodide (1.3 equiv.) were 
added to the mixture and stirred at 100 oC.  Upon completion, the reaction mixtures were diluted 
with EtOAc (20 mL) and washed with water (3 x 10 mL), brine (10 mL), dried over anhydrous 
Na2SO4, filtered, and evaporated to dryness under reduced pressure.  The crude reaction products 
were purified by column chromatography and then by preparative TLC using appropriate 



































In step 1, The reaction was carried out with Pd(OAc)2 (2.2 mg, 1.0 
µmol, 0.1 equiv.), DPEPhos (5.3 mg, 1.0 µmol, 0.1 equiv.), 45 (50 mg, 
0.10 mmol, 1 equiv.), Cs2CO3 (48.4 mg, 0.15 mmol, 1.5 equiv.), and 
PhI (15.0 µL, 0.13 mmol, 1.3 equiv.) in dry PhMe (1 mL), at 100 oC for 
18 h.  After completion of step 1, Pd(OAc)2 (2.2 mg, 1.0 µmol, 0.1 
equiv.), Xantphos (5.7 mg, 1.0 µmol, 0.1 equiv.), Cs2CO3 (48.4 mg, 0.15 mmol, 1.5 equiv.), and 
4-iodoacetophenone (31.7 mg, 0.13 mmol, 1.3 equiv.) were added to the vial containing the 
reaction mixture and stirred at 100 oC for 12 h.  Purification of the crude material by 
chromatography on a silica gel column (200–300 mesh) with 20% EtOAc in hexanes gave the 
compound 64f along with some impurities.  Further purification using preparative TLC (1 mm, 
20 x 20 cm SiO2 plate eluted with 20% EtOAc in hexanes) gave compound 64f (26.3 mg, 38% 
yield) as a light-brown solid.  Rf (SiO2/20% EtOAc in hexanes) = 0.34.  1H NMR (500 MHz, 
CDCl3): δ 8.51 (s, 1H, Ar-H), 8.01 (d, J = 9.0 Hz, 2H, Ar-H), 8.00 (d, J = 9.0 Hz, 2H, Ar-H), 
7.94 (br s, 1H, NH), 7.90 (d, J = 15.8 Hz, 1H, =CHtrans), 7.63 (d, J = 7.5 Hz, 2H, Ar-H), 7.43 (t, J 
= 7.3 Hz, 2H, Ar-H), 7.38 (t, J = 7.2 Hz, 1H, Ar-H), 7.27 (d, J = 15.8 Hz, 1H, =CHtrans), 6.46 (t, 
J = 6.5 Hz, 1H, H-1’), 4.87 (app q, Japp ~ 4.7 Hz, 1H, H-3’), 4.00 (app q, Japp = 4.8 Hz, 1H, H-4’), 
3.89 (dd, J = 6.0, 10.8 Hz, 1H, H-5’), 3.73 (dd, J = 4.6, 10.9 Hz, 1H, H-5’’), 3.66 (dt, J = 6.5, 
13.1 Hz, 1H, H-2’), 2.60 (s, 3H, CH3), 2.31 (ddd, J = 4.4, 6.7, 13.1 Hz, 1H, H-2’’), 0.95 and 0.81 
(2s, 18H, t-Bu), 0.16 (s, 6H, SiMe), 0.00 and –0.06 (2s, 6H, SiMe).  13C NMR (125 MHz, 











118.9 (2s), 114.0, 87.8, 84.4, 75.5, 63.0, 37.9, 29.9, 26.1 (2s), 18.6, 18.3, –4.4, –4.5, –5.2, –5.3.  
HRMS (ESI/TOF) m/z calculated for C38H54N5O4Si2 [M + H]+: 700.3709, found 700.3724. 
3’,5’-Bis-O-(tert-butyldimethylsilyl)-N6-phenyl-8-[(E)-2-(4-tolyl)-ethenyl]-2’-deoxyadenosi-
ne (64g) 
In step 1, The reaction was carried out with Pd(OAc)2 (2.2 mg, 1.0 
µmol, 0.1 equiv.), DPEPhos (5.3 mg, 1.0 µmol, 0.1 equiv.), 45 (50 mg, 
0.10 mmol, 1 equiv.), Cs2CO3 (48.4 mg, 0.15 mmol, 1.5 equiv.), and 
4-iodotoluene (28.1 mg, 0.13 mmol, 1.3 equiv.) in dry PhMe (1 mL), 
at 100 oC for 18 h.  After completion of step 1, Pd(OAc)2 (2.2 mg, 1.0 
µmol, 0.1 equiv.), Xantphos (5.7 mg, 1.0 µmol, 0.1 equiv.), Cs2CO3 (48.4 mg, 0.15 mmol, 1.5 
equiv.), and PhI (15.0 µL, 0.13 mmol, 1.3 equiv.) were added to the vial containing the reaction 
mixture and stirred at 100 oC for 12 h.  Purification of the crude material by chromatography on 
a silica gel column (200–300 mesh) with 5–10% EtOAc in hexanes gave compound 64g along 
with some impurities.  Further purification using preparative TLC (1 mm, 20 x 20 cm SiO2 plate 
eluted with 5% EtOAc in hexanes) gave compound 64g (28.1 mg, 42% yield) as a pale-yellow 
solid.  Rf (SiO2/10% EtOAc in hexanes) = 0.43.  1H NMR (500 MHz, CDCl3): δ 8.44 (s, 1H, Ar-
H), 7.85 (d, J = 15.9 Hz, 1H, =CHtrans), 7.84 (d, J = 8.1 Hz, 2H, Ar-H), 7.69 (br s, 1H, NH), 7.52 
(d, J = 8.0 Hz, 2H, Ar-H), 7.39 (t, J = 7.8 Hz, 2H, Ar-H), 7.25–7.17 (m, 3H, Ar-H, =CHtrans), 
7.10 (t, J = 7.4 Hz, 1H, Ar-H), 6.45 (t, J = 6.6 Hz, 1H, H-1’), 4.85 (dt, J = 4.0, 5.2 Hz, 1H, H-3’), 
4.00 (app q, Japp ~ 4.7 Hz, 1H, H-4’), 3.91 (dd, J = 6.3, 10.8 Hz, 1H, H-5’), 3.73 (dd, J = 4.7, 
10.8 Hz, 1H, H-5’’), 3.67 (dt, J = 6.5, 13.1 Hz, 1H, H-2’), 2.40 (s, 3H, Me), 2.28 (ddd, J = 4.2, 
6.7, 13.1 Hz, 1H, H-2’’), 0.95 and 0.83 (2s, 18H, t-Bu), 0.17, 0.16, 0.00, and –0.04 (4s, 12H, 











129.8, 129.2, 127.7, 123.4, 120.9, 120.3, 113.1, 87.8, 84.3, 72.7, 63.1, 37.9, 26.1 (2s), 21.7, 18.6, 
18.3, –4.4, –4.5, –5.2, –5.3.  HRMS (ESI/TOF) m/z calculated for C37H54N5O3Si2 [M + H]+: 
672.3760, found 672.3734. 
N-Arylation of p-aminostyrene 
 
In a clean, dry, 16 mL vial equipped with a stirring bar were placed Pd(OAc)2 (18.9 mg, 0.084 
mmol, 0.2 equiv.), and Xantphos (48.6 mg, 0.084 mmol, 0.2 equiv.) in dry PhMe (4.3 mL) and 
the mixture was stirred for 2 min.  Then p-aminostyrene (65 mg, 0.55 mmol, 1 equiv.), Cs2CO3 
(205 mg, 0.63 mmol, 1.5 equiv.), and PhI (47.0 µL, 0.42 mmol, 1.3 equiv.) were added to the 
mixture.  The reaction mixture was flushed with nitrogen gas, sealed with a Teflon-lined cap, and 
stirred at 100 oC for 6 h.  Upon consumption of the starting material, the reaction mixtures were 
diluted with EtOAc (20 mL) and washed with water (3 x 10 mL), brine (10 mL), dried over 
anhydrous Na2SO4, filtered, and evaporated to dryness under reduced pressure.  Purification of 
the crude material by chromatography on a silica gel column (200–300 mesh) with 1–5% EtOAc 
in hexanes gave compound 67 (50.8 mg, 62% yield) as a light-brown solid and compound 68 
(6.8 mg, 17% yield) as an off-white solid.  1H NMR of 6774 (500 MHz, CDCl3): δ 7.32 (d, J = 
8.5 Hz, 2H, Ar-H), 7.27 (d, J = 7.7 Hz, 2H, Ar-H), 7.08 (d, J = 7.8 Hz, 2H, Ar-H), 7.02 (d, J = 
8.5 Hz, 2H, Ar-H), 6.94 (t, J = 7.2 Hz, 1H, Ar-H), 6.66 (dd, J = 17.6, 10.8 Hz, 1H, =CH), 5.75 
(br s, 1H, NH), 5.61 (d, J = 17.6 Hz, 1H, =CHtrans), 5.11 (d, J = 10.9 Hz, 1H, =CHcis).  1H NMR 
of 6875 (500 MHz, CDCl3): δ 7.52 (d, J = 7.7 Hz, 2H, Ar-H), 7.45 (d, J = 8.3 Hz, 2H, Ar-H), 7.37 














J = 7.9 Hz, 2H, Ar-H), 7.11–7.06 (m, 3H, Ar-H, =CH), 6.99 (m, 2H, Ar-H, =CH), 5.81 (br s, 1H, 
NH).  HRMS (ESI/TOF) m/z calculated for C20H18N [M + H]+: 272.1434, found 272.1415.  
Heck-arylation of p-aminostyrene 
 
In a clean, dry, 16 mL vial equipped with a stirring bar were placed Pd(OAc)2 (18.9 mg, 0.084 
mmol, 0.2 equiv.), and DPEPhos (45.3 mg, 0.084 mmol, 0.2 equiv.) in dry PhMe (4.3 mL) and 
the mixture was stirred for 2 min.  Then p-aminostyrene (65 mg, 0.55 mmol, 1 equiv.), Cs2CO3 
(205 mg, 0.63 mmol, 1.5 equiv.), and PhI (47.0 µL, 0.42 mmol, 1.3 equiv.) were added to the 
mixture.  The reaction mixture was flushed with nitrogen gas, sealed with a Teflon-lined cap, and 
stirred at 100 oC for 24 h.  Upon consumption of the starting material, the reaction mixtures were 
diluted with EtOAc (20 mL) and washed with water (3 x 10 mL), brine (10 mL), dried over 
anhydrous Na2SO4, filtered, and evaporated to dryness under reduced pressure.  Purification of 
the crude material by chromatography on a silica gel column (200–300 mesh) with 5% EtOAc in 
hexanes gave compound 68 (0.8 mg, 1% yield) as an off-white solid.  Subsequent elution with 
20% EtOAc in hexanes gave compound 69 (72.2 mg, 88% yield) as a brown solid.  1H NMR of 
6976 (500 MHz, CDCl3): δ 7.47 (d, J = 7.6 Hz, 2H, Ar-H), 7.36–7.30 (m, 4H, Ar-H), 7.21 (t, J = 
7.3 Hz, 1H, Ar-H), 7.02 (d, J = 16.3 Hz, 1H, =CHtrans), 6.92 (d, J = 16.3 Hz, 1H, =CHtrans), 6.6d 
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STEREOSELECTIVE SYNTHESIS OF (±)-10β-AMINO-7β,8α,9β-
TRIHYDROXY-7,8,9,10-TETRAHYDROBENZO[a]PYRENE AND 
THE SYNTHESIS OF 2’-DEOXYADENOSINE AND 2’-
DEOXYGUANOSINE ADDUCTS 
[3.1] INTRODUCTION  
In 1775, Percivall Pott, a British surgeon observed the prevalence of scrotal cancer among 
chimney sweeps and reasoned that it was due to their exposure to soot particles.1  This 
phenomenon was again observed 100 years later, among many people working in paraffin 
industry.2,3  Eventually, the causation of scrotal cancer and ulceration of skin were officially 
attributed to pitch, tar, bitumen, mineral oil and paraffin.4  These observations led to the 
identification of carcinogenic substance present in all the above mentioned materials.  Hence, as 
an initial step towards finding the carcinogenic substance, several attempts were made to 
reproduce the same cancerous outcome in laboratory animals.  After a string of failed attempts, 
Yamagiwa and Ichikawa successfully developed a system, where repetitive application of coal 
tar to the skin of rabbits led to invasive skin tumors.2,5  Further investigation by Passey et al., 
showed that the active substance responsible for cancer can be extracted from soot with ether.6  
In a separate study, Bloch and Dreifuss identified a high boiling, nitrogen and sulfur-free 
complex hydrocarbon as the active carcinogenic substance from coal tar.7  This observation was 
further supported by Kennaway’s investigation, where he observed that the pyrolysis products of 
acetylene or isoprene at 700–920 oC under a hydrogen atmosphere were carcinogenic.8  Later 
studies on products obtained by reaction of tetralin with AlCl3 at 30–40 oC also showed 
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carcinogenic activity.9  These observations led to the conclusion that the active substance in all 
the carcinogenic materials is a polycyclic aromatic hydrocarbon (PAH).    
 
Figure 1. Some carcinogenic polycylic aromatic hydrocarbons (PAHs)     
Later, Mayneord obtained crucial information during his investigation on the fluorescence of 
carcinogenic substances.  He observed that the carcinogenic substances showed distinct bands at 
400, 418 and 440 nm in their fluorescence spectrum.  Although benz[a]anthracene (B[a]A, 
Figure 1) showed a fluorescence spectrum similar to that of the carcinogenic substances, none of 
the other compounds available at that period of time showed similar fluorescence.  Eventually, 
after the initial reports on the synthesis of dibenz[a,h]anthracene (DB[a,h]A, Figure 1) and 
dibenz[a,j]anthracene (DB[a,j]A, Figure 1) by Clar in 1930,10 Kennaway and Hieger conducted 
studies on these two compounds for their carcinogenic activity.  They observed that DB[a,h]A 
and DB[a,j]A not only showed strong carcinogenic activity but also showed fluorescence bands 
similar to that of carcinogenic tars.11,12  The next breakthrough was made by Hieger et al. by the 
isolation about 7 g of active carcinogenic crystalline material, from two tons of coal tar utilizing 
extensive separation techniques.13,14  The material thus obtained showed carcinogenic activity 












material yielded perylene and two unknown isomeric compounds.  After several evaluations, the 
major isomer with high carcinogenic activity was identified as benzo[a]pyrene (B[a]P, Figure 1) 
and the minor isomer with no carcinogenic activity was identified as benzo[e]pyrene (B[e]P, 
Figure 1).  Based on these studies, it was confirmed that B[a]P is the active species responsible 
for carcinogenicity of coal tar and the distinct fluorescence bands.5   
Apart from coal tar, B[a]P and other PAHs can be the source of any “carcinogenic materials” 
as they can be practically formed by thermal decomposition of any organic compound.  For 
example, 1 g of glucose, tobacco and paraffin wax decomposes at 700 oC under a nitrogen 
atmosphere, to yield 886 ng, 752 ng, and 66.6 µg, respectively, of B[a]P apart from other 
PAHs.15  Small portions of PAHs in the environment are produced due to natural events such as 
forest fires and volcanic activities, while human activities are the major contributing factors.  
Industries, which operate processes like coke production, aluminum smelting, iron and steel 
sintering, foundry operations, petrochemical processing, petroleum catalytic cracking, coal 
gasification, shale oil and asphalt production contribute in a major to the production of PAHs in 
the environment.2  Combustion for residential heating, power and heat generation, incineration, 
open fires, and combustion of gasoline or diesel fuels in motor vehicles also releases PAHs into 
environment.  Due to all these reasons, PAHs have become common pollutants in air, soil, water, 
and even in food.  A study by the Agency for Toxic Substances and Disease Registry in 1995 
showed that an average human consumes up to 0.207 µg, 0.027 µg, and 0.16–1.6 µg, of PAHs on 
a daily basis from air, water, and food.2  Apart from these common sources, tobacco smoke also 
plays a key role in the generation of PAHs in indoor air.  Cigarette smoke produces around 150 
different PAHs, among which many are carcinogenic.  About 10–50 ng of B[a]P is produced 
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from one cigarette alone.  Although modern cigarettes produce less than 10 ng of B[a]P, the 
production of other potential carcinogenic PAHs cannot be underestimated. 
After recognizing the carcinogenic activity of B[a]P and other PAHs, the focus then shifted 
to understanding the metabolism of PAHs.  Initial investigation by various research groups 
indicated that PAHs bind to proteins and DNA.2,16,17  PAHs have to be electrophilic in nature, in 
order to bind with the amino groups of the nucleobase in DNA.  However, PAHs are highly 
lipophilic and unreactive towards such reactions.  During that period of study, Boyland and Levi 
isolated different stereomers of 1,2-dihydroxy-1,2-dihydroanthracene from the urine of 
anthracene-fed rabbits and rats.18  This finding supported the hypothesis that PAHs undergo 
enzymatic transformations to electrophilic PAH derivatives that can easily bind to DNA.  Recent 
studies also support the theory that carcinogenesis occurs only from the metabolites of PAHs but 
not from the unmetabolized PAHs.2    Early studies on the metabolites showed that metabolism 
of anthracene and DB[a,h]A generated the corresponding arene oxides,18,19 which bound to 
DNA.20,21  Further investigation by Borgen et al. showed that the 7,8-dihydrodiol of B[a]P binds 
to DNA 10 times stronger than B[a]P itself.22  Later, Sims et al. observed that the 7,8-
dihydrodiol-9,10-epoxides of B[a]P are generated as the secondary metabolites from B[a]P.  
They also observed that the diol epoxide binds directly to the DNA and was relatively more 
carcinogenic and mutagenic than the arene oxides.23 
The metabolic activation of PAHs can take place in several steps and via different pathways.  
However, in order for a PAH to show carcinogenic activity, it has to possess certain structural 
features.  On the basis of observations made on the structural features of various carcinogenic 
and non-carcinogenic PAHs, it was initially hypothesized that PAHs that contain regions with 
notable olefinic character, termed as a K-region (shown in Figure 2), are carcinogenic.  However, 
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this hypothesis was dismissed as the K-region epoxides showed little carcinogenic activity 
compared to non K-region metabolites.2,5  Eventually, Jerina et al. proposed a new theory, where 
PAHs containing bay or fjord regions are more likely to be carcinogenic.24,25  A bay region is 
defined as the concave shape that arises due to the angular arrangement of benzo rings, whereas 
the fjord region is described as the narrow U-shaped region arised by fusing benzo ring to bay 
region PAH (Figure 2).  According to this hypothesis, PAHs undergo epoxidation adjacent to bay 
or fjord regions and the ensuing diol epoxide metabolites22 react with the amino moieties of 
nucleobases in DNA.  
 
Figure 2. PAHs containing K, bay and fjord regions 
Consistent with the proposal of Borgen et al., Jerina et al. developed the diol epoxide theory 
(explained later).  Apart from the diol epoxides formed from bay and fjord-region containing 
PAHs, several other metabolites can damage DNA.  The three commonly considered pathways 
that lead to all metabolites are discussed in detail below.  
1. One-Electron Oxidation Pathway 
In the one-electron oxidation pathway proposed by Cavalieri et al., the PAH undergoes 
















of electron usually takes place at the site of 
highest electron density.  For example, position 6 
of B[a]P and the benzylic position of 6-methyl 
B[a]P are more likely oxidized than other 
positions of B[a]P and 6-methyl B[a]P (as shown 
in Figure 3).  
After the removal of an electron from the PAH, the radical cation thus generated reacts with 
the DNA, specifically at the N7, N3 or C8 positions of the nucleobases.  The resulting DNA 
adducts possess a weakened glycosidic bond, and are susceptible to easy depurination.2  This 
results in the formation of apurinic sites, which may induce mutations leading to tumor 
formation.  A representative one electron oxidation reaction of B[a]P and leading to a DNA 
adduct by reaction at the N7 position of guanine in DNA, is shown in Scheme 1. 




Figure 3. Sites for one-electron oxidation 
of B[a]P and 6-Methyl B[a]P  
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2. Formation of Ortho-Quinones and Reactive Oxygen Species Pathway 
In this pathway, the initial activation of a PAH involves a non-K-region mono-oxygenation 
by cytochrome P450 (CYP450), followed by hydrolysis of the formed arene oxide with 
microsomal epoxide hydrolase (mEH).2  This results in the formation of non-K-region trans 
dihydrodiols that are further oxidized to ortho-quinones by dihydrodiol dehydrogenase.  
Dihydrodiol dehydrogenase belongs to the nicotinamide adenine dinucleotide phosphate-
dependent (NADPH-dependent) aldo-keto reductase (AKR) family and is most commonly found 
in rat liver as AKR1C9 and in human liver as AKR1C1–1C4.2  The enzymatic oxidation of non-
K-region dihydrodiols by NADPH-dependent aldo-keto reductase proceeds by initial generation 
of a ketol derivative that immediately tautomerises to a catechol (Scheme 2).28-30  Autoxidation 
of the catechol in the presence of superoxide anion radical generates unstable semiquinone anion 
radical along with hydrogen peroxide, via a single-electron-transfer mechanism.28-30  Further 
oxidation of semiquinone anion radical leads to the formation of ortho-quinone along with 
superoxide anion radical.28-30  Although the PAH ortho-quinones are good Michael acceptors, 




they are not very reactive for covalent modification of DNA.  The PAH ortho-quinones once 
generated can again undergo reduction to give semiquinone anion radical and catechol.   
The ortho-quinones cause DNA damage by forming stable and depurinating adducts with 
exocyclic amino groups of the DNA.30  However, the redox cycle involving catechol and ortho-
quinone generates reactive oxygen species such as superoxide anion radical and hydrogen 
peroxide, which are known to cause major DNA damage.29  The levels of the reactive oxygen 
species do not depend upon the amount of ortho-quinone produced, as the ortho-quinone redox 
cycle generates the reactive oxygen species continuously.  After their generation, the super oxide 
radical anion and H2O2 generate hydroxyl radical (HO!) either by reaction with each other or by 
Scheme 3. DNA damage caused by reactive oxygen species  
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decomposing in presence of transition metal atoms such as Cu(I), Cu(II), Fe (II) or Fe (III).2  The 
hydroxyl radical oxidizes guanine residues of DNA to 8-hydroxy-2’-deoxyguanosine (8-OH-dG 
DNA).  The 8-OH-dG DNA tautomerizes to the corresponding amido form (Scheme 3).  This 
leads to base mispairing with deoxyadenosine (dA) during DNA replication.  In vitro studies 
showed that these lesions cause deoxyguanosine (dG) to deoxythymidine (dT) transversions, 
making them mutagenic.29 
3. Diol Epoxide Pathway 
The diol epoxide pathway is considered to be the predominant pathway through which 
tumorigenesis and carcinogenesis are mostly likely to occur.  In this pathway, PAHs initially 
undergo monoxygenation, catalyzed by CYP450 enzymes such as CYP450 1A1, CYP450 1B1 
(expressed in the extrahepatic tissue), and CYP450 1A2, CYP450 3A4 (expressed in the liver).2  
This oxidation process is highly stereoselective and produce an enantiomeric pair of arene oxides.  
For example, monoxygenation of B[a]P by CYP450 produces the (7R, 8S)-oxide isomer 
predominantly and a minor amount of (7S, 8R)-oxide is also formed (Scheme 4).  These oxides 
undergo hydrolysis mediated by mEH (expressed highly in the liver and to a lesser extent in 
other organs) to give trans dihydrodiols.31-33 These trans dihydrodiols can produce reactive 
oxygen species and ortho quinone derivatives, as discussed above, or they can undergo 
detoxification either by glucorinic acid conjugation and/or sulfation.34,35  Concurrently, the trans 
dihydrodiols undergo secondary epoxidation with CYP450 enzymes to give diol epoxides.36,37  
Hence, the two enantiomeric dihydrodiols produce two enantiomeric pairs of diastereomers via a 
face-selective epoxidation.  The diol epoxides with epoxide ring cis to the benzylic hydroxyl 
group are labeled as series 1 diol epoxides (DE1 or syn), where as epoxide ring trans to the 
benzylic hydroxyl group are labeled as series 2 diol epoxides (DE2 or trans).  In the secondary 
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oxidation of the (–)-trans-B[a]P-(7R, 8R)-dihydrodiol, (+)-trans-B[a]P-DE2 is formed 
predominantly and in the case of (+)-trans-B[a]P-(7S,8S)-dihydrodiol, (+)-cis-B[a]P-DE1 is the 
preferentially produced isomer.38,39  In the overall three-step process, (+)-trans-B[a]P-DE2 is 
produced in higher quantities as compared to other three diol epoxides.  
Scheme 4. Metabolism of B[a]P via diol epoxide pathway 
  
Out of all the four diol epoxides of B[a]P, series 2 diol epoxides are highly tumorigenic, 
whereas the series 1 diol epoxides lack tumorigenicity.2  Among the 4 diol epoxides, (+)-trans-
B[a]P-DE2 exhibited the highest mutagenicity in mammalian cells and highest carcinogenic 





































are DNA alkylating agents.2,5  However, the extent of covalent binding to DNA by these diol 
epoxides is low.42  On the other hand, B[c]Ph is a weak carcinogen, but its diol epoxides 
covalently bind to DNA at significantly higher levels.43  Hence, the carcinogenic activity of a 
PAH is likely not dependent upon the ability of its diol epoxides to alkylate DNA.44  It was 
observed that the B[a]P diol epoxides alkylate predominantly the N2-amino group of 2’-
deoxyguanosine residues in the minor groove of DNA.42,45  By comparison, with the diol 
epoxides of B[c]Ph and DB[a,l]P, alkylation takes place predominantly at the N6-amino group of 
2’-deoxyadenosine residues in the major groove of the DNA.46,47  Extensive adduct-forming 
studies of various PAH diol epoxides with DNA indicate that the diol epoxides of planar PAHs 
are prone to producing a higher proportion of guanine adducts as compared to adenine adducts, 
whereas an opposite trend is observed with the non planar PAHs.44  
Scheme 5. DNA alkylation pathway by a diol epoxide 
 
DNA alkylation by the diol epoxides takes place in multiple steps.  After their metabolic 
formation, diol epoxides initially undergo DNA intercalation.  Then, the epoxide ring is 
protonated.  This facilitates epoxide ring-opening and formation of a stable, benzylic carbocation 
(Scheme 5).48,49  Nucleophilic capture of the benzylic carbocation by the exocyclic amino group 
of 2’-deoxyadenosine and 2’-deoxyguanine residues in DNA then leads to the formation of DNA 
































Because, the overall process takes place via an SN1-like mechanism, nucleophilic attack by 
DNA produces two DNA adducts each 2’-deoxyadenosine and 2’-deoxyguanine, with a single 
diol epoxide.  Hence, the 4 diol epoxides of any PAH produce 16 nucleoside adducts (Figure 
4).2,50    The formation of these adducts then leads to perturbation of the local DNA structures, 
which can eventually influence replication and/or repair mechanisms.  These events can then 
lead to mutations and then to tumorigenesis.42,51-57  Hence, it is important to have access to 
stereospecifically defined nucleoside and DNA adducts of diol epoxides in order to understand 
 
 Figure 4. Nucleoside adducts formed by DNA alkylation at the adenine and guanine residues 
by the four diol epoxides    
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how covalent interactions of PAH metabolites with DNA can lead to adverse or innocuous 
biological effects depending upon the diol epoxide stereochemistry. 
To date three approaches have been developed for the site-specific modification of DNA 
with stereochemically defined diol epoxide adducts, and these are discussed below. 
1. Direct Reaction of Diol Epoxides with DNA Oligomers  
This approach developed by Loechler et al.58 and Geacintov et al.59,60 involves direct reaction 
of a specific PAH diol epoxide with short oligonucleotides (Scheme 6).  However, the kind of 
adducts produced and the yields of the adducts completely depend up on the specific PAH diol 
epoxide used.  For example, in the case of B[a]P DE2, higher quantities of guanine adducts were 
Scheme 6.  An example of site-specific DNA modification by the direct reaction of a diol 
epoxide with a DNA oligomer 
     
!
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obtained compared to adenine adducts.61,62   Whereas, in the case of DB[a,l]P DE2, adenine 
adducts were obtained in excess compared to guanine adducts.63  Since the minor adducts may 
play an important role in events leading to mutagenesis and carcinogenesis, and obtaining minor 
adducts is difficult via this approach, it is not broadly applicable.  Another factor that limits this 
approach is the low yields of the adducts with many diol epoxides, due to competing hydrolysis 
of the diol epoxides.58-62  Besides, the presence of multiple exocyclic amino groups may lead to 
alkylation at multiple sites or result in multiple products, and cis and trans ring-opened products 
can result.  These pose separation and characterization problems. 
2. Post-Oligomerization Modification Approach 
In this approach, the DNA adducts were obtained by reaction of stereochemically defined 
PAH amino triols with DNA oligonucleotides containing a specifically placed electrophilic 
nucleoside (Scheme 7).64-66  The desired PAH amino triols are synthesized by diastereoselective 
chemical approaches and the reactive nucleoside in oligonucleotides typically contain either a 
halo or triflate group at the desired reaction site.  This approach is complementary to the direct 
Scheme 7. An example of the reaction of a PAH amino triol with a DNA oligomer containing 




reaction approach, as the PAH intermediate acts as a nucleophile and the DNA fragment acts as 
the electrophile.  As a consequence, this approach is more advantageous over the direct reaction 
approach.  However, there are some limitations to this approach such as low yields of the 
products and difficulties with DNA synthesis.64-67  
3. Total Synthesis Approach 
In this approach, nucleosides adducts are initially synthesized by reacting stereochemically 
defined PAH amino triols with electrophilic nucleosides (See similarity to the post-
oligomerization modification approach).  The PAH-adducted nucleosides so obtained are then 
utilized in the solid-phase DNA synthesis to prepare site-specifically modified DNA (Scheme 
8).68-74  Typically fluorinated purine nucleosides such as 6-fluoro-9-(2-deoxy-β-D-erythro-
pentafuranosyl)purine (6-FP) and 2-fluoro-2’-deoxyinosine (2-FdI) are used as the electrophilic 
nucleosides for preparing dA and dG adducts, respectively (Figure 5).68-75  However, the C-2-
triflate derivative of 2’-deoxyxanthosine (2-TdX) can also be applied for the synthesis of dG 
adducts (Figure 5).66  Even though this approach is labor intensive, it avoids the problems 
associated with direct reaction and post-oligomerization techniques.  This approach, in principle, 
allows access to all the nucleoside adducts and in turn, DNA adducts, and in substantial amounts.  
Hence this approach is more versatile than the other approaches. 
Scheme 8. Synthesis of nucleoside adduct from PAH amino triol and electrophilic nucleoside, 





Figure 5. Commonly used electrophilic nucleosides for the synthesis of nucleoside adducts 
In order to gain a greater understanding of the roles of specific B[a]P DE-DNA adducts in 
mutational events, the ensuing biological effects, and structure-activity relationships, the total 
synthesis approach seems to be a more reliable approach.  However, this requires the 
development of robust synthetic routes to various B[a]P metabolites and their nucleoside adducts.  
We68,76-79 and others73,74,80-86 have been extensively involved in synthetic studies leading to facile 
routes to PAH metabolites, stereochemically defined PAH-nucleoside adducts, and PAH-DNA 
adducts.  
Access to the B[a]P amino triols 1, 5 arising by a trans ring-opening of B[a]P series 1 and 2 
diol epoxides can be achieved fairly easily by either direct aminolysis68,77,80 or nucleophilic 
displacement with azide anion on B[a]P series 1 and 2 diol epoxides (Scheme 9).81,87,88  The 
azido triol derivatives 2 and 4 upon catalytic reduction produce amino triols 1 and 2, 
respectively.81,87,88  Typically, the free hydroxyl groups of the B[a]P azido triols 2 and 4 were 
benzoylated to give 3 and 7, prior to the catalytic hydrogenation (Scheme 9).  The resultant 
benzoyl-protected amino triols 4 and 8 were then reacted with fluorinated nulceosides (2-FdI or 
6-FdP) to give the nucleoside adducts.77,78,81,87,88  We78,79 and others89 recently  developed a new 
strategy for the synthesis of B[a]P-nucleoside adducts using palladium-catalyzed C–N bond-
forming reactions.  The N6-deoxyadenosine adducts were synthesized by the reaction of B[a]P 



























Scheme 9. Amino triol synthesis by the trans ring-opening displacement on B[a]P series 1 and 2 
DEs   
 
  On the other hand the N2-deoxyguanosine adducts were synthesized by the reaction of 


















1: X = NH2, R = H
2: X = N3, R = H
3: X = N3, R = COPh





5: X = NH2, R = H
6: X = N3, R = H
7: X = N3, R = COPh






Scheme 10. Synthesis of nucleoside adducts 11a,b and 13a,b by palladium-catalyzed C–N 
bond-forming reactions  
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palladium-catalyzed synthesis of the N6-deoxyadenosine adducts 11a,b and N2-deoxyguanosine 
adducts 13a,b are shown in Scheme 10.78  Typically, synthesis of 6-FdP and 2-FdI (commonly 
used for displacement reactions with PAH amines) requires several steps.  On the other hand, 
halo nucleoside derivatives 9 and 10, which do not undergo SNAr reactions with PAH amino 
triols effectively, are more easily accessible.  However, the Pd-catalyzed strategy allows the use 
of chloro and bromo nucleosides 9, 10, and 12 for the nucleoside adduct synthesis in relatively 
high yields, thus, providing a simple alternative route to the nucleoside-PAH adduct synthesis.  
Unlike the trans ring-opened B[a]P amino triol derivatives, the synthesis of cis ring-opened 
B[a]P amino triol derivatives is more  complex.  Due to the difficulties in their synthesis, the 
DNA adducts derived from cis ring-opening of B[a]P DEs, they are less studied as compared to 
DNA adducts derived from trans ring-opening of B[a]P DEs.  The first diastereoselective 
synthesis of a cis ring-opened B[a]P amino triol from (±)-B[a]P DE2 was reported by Meehan et 
al.90  In this, the trimethylsilyl ether derivative of (±)-B[a]P DE2 14 was reacted with 
trimethylsilyl azide (TMS-N3) and titanium tetraisopropxide (Ti(OiPr)4) in THF to give the 
corresponding B[a]P azido derivative (±)-15 (Scheme 11).  Desilylation followed by catalytic 
hydrogenation led to the formation of the cis ring-opened B[a]P amino triol ((±)-16).  However, 
the reasons for this stereochemical outcome are unknown.  This approach, however, when 
Scheme 11. Diastereoselective synthesis of cis ring-opened B[a]P amino triol ((±)-16) from 
B[a]P DE2  
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applied to trimethylsilyl ether derivative of (±)-B[a]P DE1 resulted in 1.5:1 ratio of cis/trans 
B[a]P azido triol derivatives.83        
An alternate approach for the synthesis of cis ring-opened B[a]P DE2-2’-deoxyadenosine 
adducts was developed by Jerina et al.83  This approach, which is based on Sharpless asymmetric 
aminohydroxylation (AA) protocol,91 involves the reaction of silyl protected 2’-deoxyadenosine 
17 with (±)-trans-7,8-dihydroxy-7,8-dihydro B[a]P (18) in presence tert-butyl hypochlorite, cat. 
(DHQD)2PHAL, and K2OsO2(OH)4 in n-propanol to give the desired diastereomeric pair of 
adducts 19a and 19b with 85% yield (Scheme 12).  Although this method circumvents the use of 
B[a]P amino triol derivatives, the dG adducts cannot be synthesized by this approach.83   
Scheme 12. Synthesis of cis ring-opened B[a]P DE2-2’-deoxyadenosine adducts by using 
asymmetric aminohydroxylation approach 
 
Jerina et al. reported another approach for the synthesis of cis ring-opened B[a]P-dG 
adducts.84-86  In this approach, direct ring-opening of B[a]P DE1 and B[a]P DE2 was conducted 
in trifluoroethanol (TFE) in the presence of disilyl O6-allyl protected 2’-deoxyguanosine 20 
(dGallyl), at room temperature (Scheme 13).  However, these reactions were not stereoselective 
and resulted in both cis and trans ring-opened B[a]P-dG adducts.  In the reaction with B[a]P 
DE2 two diastereomeric pairs of adducts 21a,b and 22a,b were obtained, whereas with B[a]P 
DE1 two diastereomeric pairs of adducts 23a,b and 24a,b were isolated.84-86  Notably, when 








































DE1 in TFE, only cis ring-opened B[a]P-dA adducts 19a,b and 25a,b respectively, were 
obtained (Scheme 13).  The major drawback of this approach is that TFE reacts at the C-10 
position of the B[a]P DE1 and DE2 and forms trans ring-opened B[a]P tetraol derivatives in 
Scheme 13. TFE mediated synthesis of cis ring-opened B[a]P-dG adducts 21a,b and 23a,b 
and cis ring-opened B[a]P-dA adducts 19a,b and 25a,b 
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significant amounts (~50% yield).  As a result of competing reaction with TFE and lack of 
stereoselectivity, the yields of the products in these reactions were very low.  Use of other 
fluorinated solvents such as hexafluoroisopropanol (HFIP) and perfluoro-t-butanol instead of 
TFE, improved the yields to some extent in the case of B[a]P-dG adducts.  However, no 
improvement was observed in the case of B[a]P-dA adducts.  The mixtures obtained in these 
reactions were separated by HPLC.  Because of all these complications, large scale synthesis of 
dG adducts by this approach is difficult.   
       This led Lakshman et al. to develop a novel diastereoselective approach for the synthesis of 
cis ring-opened B[a]P DE2 adducts of dG and dA.92  In this approach, the synthesis of cis ring-
opened B[a]P amino triol (±)-16 starts with 7,8-bis-benzyloxy-7,8-dihydro B[a]P derivative (±)-
27 (Scheme 14), which can be easily synthesized in three steps from 7,8,9,10-
tetrahdrobenzo[a]pyrene-7-ol (B[a]P-7-ol, 26).93  Diastereoselective dihydroxylation of 
dihydrodibenzoate B[a]P derivative (±)-27 with catalytic OsO4, NMO and PhB(OH)2 in CH2Cl2 
resulted in a single boronate ester B[a]P derivative (±)-28.  Oxidation of the boronate ester (±)-
Scheme 14. Diastereoselective synthetic approach to B[a]P amino triol  (±)-16 arising by 




28 with 50% H2O2 in EtOAc-acetone gave the tetraol dibenzoate (±)-29.92  Evaluation of the 
relative energies of formation for the boronate diastereomers  (±)-28 and the diol diastereomers 
(±)-29 showed that the cis α isomers of boronate diastereomers and diol diastereomers (±)-28 
and (±)-29 are more favored than their cis β counterparts.92  From the plausible transition state 
structures (shown in Figure 6), the addition of OsO4 is likely to occur from the bottom face of 
dihydrodibenoate (±)-27 resulting in the formation of boronate ester (±)-28 via transition state 1 
(TS1).  The top face addition of OsO4 to dihydrodibenoate (±)-27 via transition state 2 (TS2) is 
unlikely, since it contains eclipsing interactions.  These studies illustrate that torsion control on 
the OsO4 addition may be a key factor that influences the diastereoselectivity of the 
dihydroxylation reaction.  
 
Figure 6. Plausible transition states TS1 and TS2 for OsO4 addition to dihydrodibenoate B[a]P 
derivative (±)-27 
The tetraol B[a]P derivative (±)-29 was treated with 1-chorocarbonyl-1-methylethyl acetate 
(30) in MeCN to give the trans-chloro acetate intermediate (±)-31 (Scheme 14).  Nucleophilic 
displacement of chloro acetate derivative (±)-31 with NaN3 in DMF at 50 oC gave the desired cis 
azidotriol B[a]P derivative (±)-32 (Scheme 14).  Deacylation followed by catalytic reduction of 
the azidotriol (±)-32 gave the cis ring-opened B[a]P amino triol (±)-16.  The amino triol (±)-16 
facilitated the synthesis of dA and dG adducts from a common intermediate, and was also the 
first report on the synthesis of cis ring-opened dG adducts from B[a]P DE2.92   The synthetic 





















cis aminoalcohols were synthesized from cis diols.94,95  In that work, the cis diols 33 when 
treated with 1-chorocarbonyl-1-methylethyl acetate (30) in MeCN, gave the trans chloro acetates 
34 (Scheme 15).  Displacement of chloride with azide ion, followed by deacylation, and 
reduction of the azido group produced the desired cis aminoalcohols 36 with the amino group at 
the benzylic position.    
Scheme 15. Synthetic approach to cis aminoalcohols from cis diols 
 
Although, attempts towards synthesis of amino triols by cis ring-opening of B[a]P DE2 were 
successful, the same was not true for the synthesis of cis ring-opened B[a]P DE1 amino triols.  
As mentioned earlier, Jerina et al. synthesized cis ring-opened B[a]P DE1 amino triol, by 
utilizing a procedure developed by Jhingan and Meehan for cis ring-opening of B[a]P DE2 by 









































Ti(OiPr)4 and TMSN3 in THF at room temperature.  Subsequent desilylation with dil. HCl in 
MeOH resulted in the desired cis ring-opened B[a]P azido triol (±)-38 along with trans ring-
opened B[a]P azido triol (±)-6 in 1.5:1 ratio, in an overall yield of 89% (Scheme 16).   
The desired B[a]P azido triol (±)-38 was separated from the mixture by HPLC and was then 
reduced by catalytic hydrogenation to give the desired cis ring-opened B[a]P amino triol (±)-39 
(Scheme 17).  The B[a]P amino triol (±)-39 was then reacted with silyl protected 6-fluoro purine 
nucleoside 40 in the presence of 2,6-lutidine, hexamethyl disiloxane ((Me3Si)2O) in DMSO at 90 
oC.  This gave the diastereomeric pair of B[a]P DE1-dA adducts 25a and 25b respectively 
(Scheme 16).  The adducts 25a and 25b were separated and confirmed by various spectroscopic 
techniques.  Although, the strategy by Jerina et al. granted access to cis ring-opened B[a]P DE1-
dA adducts, the azido triol synthesis was not stereoselective and no attempts were made to 
synthesize B[a]P DE1-dG adducts arising via a cis ring-opening of B[a]P DE1.  Kroth et al. 
reported the synthesis of B[a]P DE1-dG adducts, however the process was not stereoselective.85  




This resulted in a mixture of adducts, in which two of them were cis ring-opened B[a]P DE1-dG 
adducts and the remaining two were trans ring-opened B[a]P DE1-dG adducts.  The adducts in 
the mixture was separated using HPLC.85  Hence, a highly diastereoselective synthetic route to 
B[a]P amino triol (±)-39 is still essential in order to synthesize substantial amounts of B[a]P 
DE1 adducts.          
In order to address the issue, we designed a new approach for the synthesis of B[a]P amino 
triol (±)-39.96  The synthesis in this approach starts with 7,8-dibenzyloxy-7,8-dihydro B[a]P 
derivative (±)-27, which is also a common precursor for the synthesis of cis ring-opened B[a]P 
amino triol (±)-16.  This can be synthesized from B[a]P-7-ol (26) in three steps.93  The B[a]P 
DE1 dibenzoate (±)-27 upon reaction with N-bromo succinimide (NBS) and NaOAc in THF-
H2O at room temperature for 18 h gave bromohydrin (±)-41 in a yield of 62% (Scheme 18).  
Epoxide (±)-42 was synthesized from reacting the bromohydrin (±)-41 with NaH in THF at 0 oC 
for 1.5 h.  The epoxide ring in the compound (±)-42 was opened by reacting it with dried LiCl, 
Ac2O, and a catalytic amount of DMAP in DMF at room temperature over 18 h.  The resultant 
mixture containing benzylic chlorohydrin derivative (±)-43 was then subjected to nucleophilic 
displacement with NaN3 in DMF at 50 oC for 18 h.  This resulted in the B[a]P azido triol 
derivative (±)-44 in 53% yield over two steps.  The stereochemistry of (±)-40 was confirmed by 
correlating the spatial interactions between H-9 and H-10 in its NOESY spectrum.  Deacylation 
of (±)-44 with NH3 saturated MeOH, at 50 oC over 24 h gave the B[a]P azido triol (±)-38 in 91% 
yield.  Reduction of azido triol by catalytic hydrogenation with Lindlar catalyst (Pd/CaCO3) in 
EtOH under an atmosphere of H2 at room temperature over 2.5 h gave the B[a]P amino triol (±)-
39 in a 96% yield. 
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Scheme 18. Stereoselective approach towards the synthesis of cis ring-opened B[a]P amino triol  
(±)-39 
  
Via this approach a diastereoselective synthesis of 10β-amino-7β,8α,9β-trihydroxy-7,8,9,10-
tetrahydrobenzo[a]pyrene (±)-39 is possible.  However, it requires certain improvements.  One 
such essential improvement is improving the yield for the transformation of (±)-42 to (±)-44.  
Although, a moderate 53% yield was obtained previously,96 a higher yielding transformation 
would be optimal for carrying out large-scale reactions.  The deacylation reaction of (±)-44 and 
the reduction reaction of (±)-38 were carried out on a relatively small scale (0.05 mmol of (±)-44 
and 0.087 mmol of (±)-38).   High-yielding, large-scale experiments have to be performed in 
order to show feasibility of this approach.  Hence, we intended focus on these two issues: i) 
improving the yield of the (±)-42 to (±)-44 conversion, and ii) carrying out deacylation and 
reduction reactions on larger scales.  Once the B[a]P amino triol (±)-39 was obtained, we 
intended to synthesize the 2 cis ring-opened B[a]P DE1-dA adducts 25a, b and  the 2 cis ring-
opened B[a]P DE1-dG adducts 46a, b (Scheme 19).  With the synthesis of dA and dG adducts, 
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Scheme 19. The dA and dG adducts to be synthesized by reacting amino triol  (±)-39 with 
fluorinated nucleosides 40 and 45  
 
Once the PAH-nucleoside adducts are acquired, PAH-DNA adducts becomes accessible.  
This allows studies on the structure and function of the PAH-DNA adducts.  Typically, the 
structures of modified DNAs were resolved by solution NMR studies.97  Several reports on the 
structure of cis and trans ring-opened B[a]P-nucleoside adducts in DNA duplexes were made 
possible by solution NMR studies.98-112  Since formation of B[a]P DE2-dG adduct is highly 
preferred, studies were mainly focused on these.98-102  In the case of deoxyguanosine adducts 
with 10S configuration, NMR studies showed that the PAH is oriented towards the 5’ end of the 
modified strand, not intercalated, and residing in the minor groove of the DNA.98,101,102  Whereas 
in the case of deoxyguanosine adducts with 10R configuration, the PAH may or may not 
intercalate but resides in the minor groove of the DNA, oriented towards the 3’ end of the 
modified strand.98,100  So far, no structural data on cis ring-opened B[a]P DE1-deoxyguanosine 
adducts were available.  However, unlike the case of deoxyguanosine adducts, solution structures 







































































10S configuration, NMR studies indicated that the PAH is oriented towards the 3’ end of the 
modified strand, intercalated, and located in the major groove of the DNA.104,105,108  Similar 
results were also observed in the case of adducts with 10R configuration, where the PAH is 
oriented towards the 3’ end of the modified strand, intercalated, and located in the major groove 
of the DNA.103,106,107,109-112   
Biochemical and biological experiments are employed to study the function of PAH-DNA 
adducts.  These experiments enable an understanding of the types of mutations produced, and 
effects on DNA replication and repair caused by specific DNA adducts.54,113-119  For instance, in 
one of the studies, it was observed that subtle differences in adduct conformation can greatly 
influence the UvrABC repair system and these also affect the excision repair process.115,119  
Studies on different DNA adducts showed that efficiency of UvrABC incision also depends upon 
the size of the aromatic system bound to the DNA.119  DNA bound with smaller aromatic groups 
such as C8-guanine adducts of 2-aminoflourene displayed the best incision efficiency in a bubble 
of three mismatched nucleotides.119  However, in the case of DNA attached to larger aromatic 
groups like in the case of cis ring-opened B[a]P DE2-guanine adduct, the best incision efficiency 
observed in a bubble of six mismatched nucleotides.119  Studies were also conducted on the 
activity of DNA polymerases (specifically Y family of DNA polymerases) with B[a]P diol 
epoxide adducts.120-124  It was observed that DNA polymerase ζ bypasses B[a]P DE-dG adducts 
in yeast cells.122  On the other hand, DNA polymerase κ successfully cleaves the undesired 
lesions and protects the mammalian cells against the mutagenic effects of B[a]P.121      
Hence from all the information discussed so far, it is evident that in order to have a better 
understanding on structure-activity relations of the B[a]P-DNA adducts, collaborative efforts 
that entails facile synthetic strategies, structural studies, biochemical and biological experiments 
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are necessary.  The synthesis of the stereochemically defined cis ring-opened B[a]P DE1-
nucleoside adducts 36a,b and 42a,b will help achieve one of these goals.   
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[3.2] RESULTS AND DISCUSSION 
In our efforts to improve the diastereoselective synthesis of 10β-amino-7β,8α,9β-trihydroxy-
7,8,9,10-tetrahydrobenzo[a]pyrene (±)-39 discussed in the introduction, we initially focused on 
improving the yield of B[a]P azido triol (±)-44.  We needed the B[a]P diol epoxide (±)-42 for 
this purpose and this was synthesized from 7,8-bis-benzyloxy-7,8-dihydro B[a]P (±)-27 in two 
steps as shown in Scheme 18.  The synthesis of (±)-27 was previously reported in three steps 
from B[a]P 7-ol (26).93 Hence, by following the reported procedure, we started the synthesis by a 
p-toluenesulfonic acid (p-TsOH) catalyzed dehydration of B[a]P 7-ol (26) in refluxing toluene 
over 0.5 h (Scheme 20).  This gave the B[a]P alkene 47 in a 90% yield.  Alkene 47 was then 
subjected to Prévost reaction using iodine and silver benzoate in dry toluene at reflux over 16 h.  
This resulted in the B[a]P dibenzoate (±)-48 in 88% yield (Scheme 20).  Oxidation of the 
dibenzoate derivative (±)-48 with DDQ in refluxing dry toluene over 17 h gave the 7,8-bis-
benzyloxy-7,8-dihydro B[a]P derivative (±)-27 in a 75% yield.  Reaction of compound (±)-27 
with N-bromosuccinimide (NBS) and sodium acetate in a THF-H2O mixture at room temperature 
over 16 h gave the B[a]P bromohydrin (±)-41 in a 75% yield (Scheme 20).  




























As shown in Scheme 18, the required B[a]P dibenzoyloxy epoxide (±)-42 can be synthesized 
by reaction of B[a]P bromohydrin (±)-41 with NaH in THF.  The epoxide (±)-42 from this 
reaction was obtained as a pink solid.  However, reports show that B[a]P diol epoxide 
derivatives are usually obtained as white solids or colorless crystals.125  This led us to believe 
that the pink color of (±)-42 is due to the presence of unknown impurities.  The impurities 
produced in this reaction could affect the yield in the next epoxide ring-opening reaction.  
Because, epoxide (±)-42 is reactive and sensitive to robust purification techniques, we decided to 
consider a different protocol to access epoxide (±)-42, involving mild conditions and easy 
purification.  In this regard, Jerina et al. have developed an efficient synthesis of (±)-42 from (±)-
41 under mild conditions.125  Following that protocol, epoxide (±)-42 was synthesized by 
reacting bromohydrin (±)-41 with dry Amberlite IRA-400 HO– form resin under subdued light 
for 3 days (Scheme 21).  The epoxide (±)-41 was obtained as a creamy-white solid in a 98% 
yield.  
Scheme 21. B[a]P epoxide (±)-41 synthesis by the reaction of B[a]P bromohydrin (±)-42 with 
Amberlite resin  
 
Ring opening of epoxide (±)-42 was carried out by reaction with dried LiCl, anhydrous Ac2O, 
and DMAP (catalytic amount), in DMF at room temperature  (Scheme 22).  After 18 h, the crude 
mixture containing product (±)-43 was worked-up to remove any byproducts and unreacted 
reagents.  The resultant crude material was dissolved in anhydrous DMF and subjected to 
nucleophilic displacement with NaN3 at 50 oC over 18 h.  This resulted in the B[a]P azido 















44 from 53% (as in Scheme 18) to 74% (as in Scheme 22) showed that the epoxide synthesized 
from (±)-41 using Amberlite IRA-400 resin (Scheme 21) was obtained in a pure form and was 
responsible for the high yield in this reaction.  Subsequent deacylation of (±)-44 with 7 N NH3 in 
MeOH at 50 oC over 6 h resulted the azido triol (±)-38 in a quantitative yield (Scheme 22).       
Scheme 22. Synthesis of B[a]P azido triol (±)-38  
 
Next, reduction of the azido triol (±)-38 using Lindlar catalyst, in EtOH under a H2 
atmosphere, gave the desired B[a]P amino triol (±)-39 in a 93% yield (Scheme 23).   To confirm 
the stereochemistry in amino triol (±)-39, the amino triol tetraacetate (±)-49 was synthesized 
directly from azido triol  (±)-38 in two steps (Scheme 23).  Initially, azido triol (±)-38 was 




























50 °C, 6 h
quant.
Scheme 23. Synthesis of B[a]P amino triol (±)-39 and B[a]P amino triol tetracetate (±)-49 
from B[a]P azido triol (±)-38 
    
!
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Ac2O, DMAP (catalytic amount), and pyridine, in N,N-dimethyl formamide (DMF) to give the 
peracetate (±)-49 in a 71% yield over two steps (Scheme 23).  
The structure and stereochemistry of the final product (±)-39 was assigned by comparative 
NMR analysis of various stereochemically defined B[a]P derivatives.  As a first step, the NMR 
of azido triol (±)-38 was compared to that of reported by Jerina et al (Table 1).83  The key 
chemical shifts H-7 (4.98 ppm), H-8 (3.68 ppm), H-9 (4.23 ppm), H-10 (5.44 ppm) and coupling 
constants J7,8 = 8.6, J8,9 = 8.5, J9,10 = 5.7 recorded in CD3OD at 500 MHz (entry 1, Table 1) 
correlate well with the reported chemical shifts H-7 (5.03 ppm), H-8 (3.79 ppm), H-9 (4.33 ppm), 
H-10 (5.52 ppm) and coupling constants J7,8 = 8.2, J8,9 = 8.2, J9,10 = 5.4 recorded in CDCl3-
CD3OD at 300 MHz by Jerina et al (entry 1, Table 1).83  On the other hand, the chemical shifts 
and coupling constants of (±)-38 were not in congruence with the chemical shifts H-7 (4.85 ppm), 
H-8 (4.13 ppm), H-9 (4.07 ppm), H-10 (5.78 ppm) and coupling constants J7,8 = 8.3, J8,9 = 10.7, 
J9,10 = 4.2 that were reported for the trans ring-opened B[a]P azido triol (±)-6 (entry 2, Table 
1).83  The coupling constant J7,8 ~ 8.2 in both cis and trans ring-opened B[a]P azido triols (±)-38 
and (±)-6 respectively (entries 1 and 2, Table 1), indicates a quasi diequatorial orientation of the 
hydroxyl groups.  Similar trend was also observed in the case of B[a]P amino triol (±)-39, where 
the coupling constant J7,8 = 7.4 also indicating a quasi diequatorial orientation of the hydroxyl 
groups (entry 4, Table 1).  However, upon acylation of compound (±)-39, compound (±)-49 
displayed a small coupling constant J7,8 = 4.5 (entry 5, Table 1), implying a quasi diaxial 
orientation of the substituents at the 7 and 8 positions.  A similar trend was also observed in 
other cis ring-opened peracylated derivatives derived from B[a]P DE2 (±)-32, (±)-52–(±)-54 
(entries 8–11, Table 1) with the coupling constant range J7,8 = 3.4–4.0.92  The differences in the 
orientation of substituents at 7 and 8 positions in unprotected and acyl protected B[a]P 
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derivatives can be rationalized as follows.  In the case of azido and amino triols, the quasi 
diequatorial orientation of the hydroxyl groups is preferred possibly due to internal hydrogen 
bonding, resulting in a quasi diaxial arrangement for protons H-7 and H-8 .  Upon peracylation 
of aminotriols, the substituents adopt a quasi diaxial arrangement possibly to avoid steric 
interactions between the substituents, loss of H-bonding, and dipole-dipole repulsions.  However, 
a large coupling constant J7,8 = 8.0 was observed in the case of cis ring-opened tetraol 
tetraacetate derivative (±)-50125 (entry 6, Table 1), which is an exception to the trend observed in 
other compounds. 
Table 1. Comparison of chemical shifts and coupling constants of tetrahydro ring protons in 
B[a]P derivatives 
Entry Compound H-7 H-8 H-9 H-10 
1 
 
d 4.98  t 3.68 dd 4.23 d 5.44  
(d 5.03)83 (t 3.79)83 (dd 4.33)83 (d 5.52)83 
500 MHz (CD3OD): J7,8 = 8.0; J8,9 = 8.0; J9,10 = 5.5   
[300 MHz (CDCl3-CD3OD): J7,8 = 8.0; J8,9 = 8.0; J9,10 = 5.5]83 
283 
 
d 4.85  dd 4.13 dd 4.07 d 5.78  
500 MHz (CDCl3-CD3OD): J7,8 = 8.3; J8,9 = 10.7; J9,10 = 4.2 
3 
 
d 7.14  t 5.84 dd 5.91 d 5.78  
500 MHz (CDCl3): J7,8 = 7.4; J8,9 = 5.9; J9,10 = 3.8 
4 
 
m 5.09–5.03  t 3.92 dd 4.19 m 5.09–5.03 
500 MHz (CD3OD): J7,8 = 7.4; J8,9 = 7.0; J9,10 = 4.4 
5 
 
d 6.61  t 5.63 dd 5.52 dd 6.34  






























d 6.64  t 6.02 dd 5.55 d 7.34  
500 MHz (CDCl3): J7,8 = 8.0; J8,9 = 11.5; J9,10 = 3.5 
792 
 
br m 5.34–5.32  br m 4.24 m 4.66–4.63 d 5.52  
500 MHz (acetone-d6): J7,8 = m; J8,9 = m; J9,10 = 4.9 
892 
 
d 7.08  dd 6.05 dd 6.22 d 6.00  
500 MHz (CDCl3): J7,8 = 4.0; J8,9 = 2.4; J9,10 = 5.0 
      
      
992 
 
d 6.64  dd 5.71 dd 5.90 d 5.74  
300 MHz (CDCl3): J7,8 = 3.6; J8,9 = 2.4; J9,10 = 5.4 
1092 
 
d 6.57 br m 5.64 dd 5.80 d 6.53  
500 MHz (acetone-d6): J7,8 = 3.4; J8,9 = 2.4; J9,10 = 5.0; J10,NH = 9.8 
1192 
 
d 6.67  t 5.68 dd 5.99 d 7.36  
500 MHz (CDCl3): J7,8 = 3.5; J8,9 = 2.5; J9,10 = 4.7 
 
 
Stereochemistry of B[a]P amino triol (±)-39 was further verified by evaluating the NOESY 
data of compound (±)-49 (Figure 7).  The NOESY data showed through-space interaction 
between H-9 and H-10.  A clear through-space interaction was also observed between H-9 and 
H-7, implying that H-7 and H-9 are located on the same face.  Similar interactions were also 
observed in the NOESY spectrum of B[a]P derivatives (±)-38  and (±)-44.96  Strong through-
































(±)-38, whereas only weak through-space interactions for H-7 and H-9 were observed in the case 
of azido triacyl derivative (±)-44. 
 
 
Figure 7. NOESY spectrum showing interactions between H-7 and H-9, as well as H-9 and H-10 
After verifying the supporting data for the stereochemistry of B[a]P amino triol (±)-39, we 
then focused on B[a]P-dA adduct synthesis.  Following our previous protocol on dA adduct 
synthesis,92 B[a]P amino triol (±)-39 was subjected to SNAr displacement reaction with 6-
fluoropurine nucleoside 40 in the presence hexamethyl disiloxane (HMDS) and 
diisopropylethylamine (DIPEA) in DMSO, at 80 oC for 5 h (Scheme 24).  This resulted in a 












adducts 25a and 25b by using preparative TLC.  However, these attempts were unsuccessful due 
to the polar nature of the adducts.  Hence, the free hydroxyl groups of adducts were acetylated in 
the hope that a solvent system could be found for the adduct separation on preparative TLC.  
Thus, adducts 25a and 25b were then treated with acetic anhydride and pyridine at room 
temperature for 14 h to give the acetylated B[a]P-dA adducts 55a and 55b.  The two adducts 55a 
and 55b could be carefully separated by chromatography on a preparative TLC plate (SiO2, 500 
µ, 20 x 20 cm), by eluting with 10% EtOAc in CH2Cl2.  This gave compounds 55a and 55b in a 
combined yield of 42% over two steps.  On the basis of the Circular Dichroism (CD) data of dA 
adducts 55a and 55b, the faster-eluting diastereomer was assigned as the 10S isomer (55a), as it 
displayed a positive band at 281 nm in its CD spectrum (Figure 8).  The slower-eluting 





its CD spectrum (Figure 8).  The CD spectra of the B[a]P-dA adducts 55a and 55b were 
consistent with the data reported by Jerina et al.83  
 
Figure 8. Normalized CD spectra (in MeOH) of (±)-B[a]P DE1-dA adducts 55a (red = 10S 
trans) and 55b (blue  = 10R cis) 
Following the successful synthesis of B[a]P-dA adducts, we moved to synthesis of the 
B[a]P-dG adducts by utilizing an addition-elimination reaction.  For this purpose, 2-fluoro-2’-
deoxyinosine derivative 45 was needed.  Typically, 45 was synthesized from a protected 2’-
deoxyguanosine derivative via its O6-benzyl derivative 59.71  The introduction of a benzyl group 
at the O-6 position of 2’-deoxyguanosine is usually carried out under Mitsunobu conditions.71  
However, these reaction conditions require high temperature, involve tedious purification 
process, and produce moderate yields.71  Hence, we decided to modify the strategy by using our 
previous report on a guanosine etherification protocol.126  The synthesis starts by reacting silyl-
protected 2’-deoxyguanosine derivative 56 with benzotriazol-1-
yloxy)tris(dimethylamino)phosphonium hexafluorophosphate (BOP) and 1,8-
diazabicyclo(5.4.0)undec-7-ene (DBU) in dry MeCN, at room temperature for 1 h (Scheme 25), 
following the reported procedure.126  This resulted in the formation of O6-benzotriazol-1-yl-2’-
deoxyguanosine derivative 57 in a 88% yield.  Then 57 was subjected to SNAr displacement 
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benzyl-2’-deoxyguanosine derivative 58 in a 92% yield.  Subsequent desilylation of 58 with KF 
in MeOH at 80 oC for 12 h resulted O6-benzyl-2’-deoxyguanosine 59 in a 95% yield (Scheme 
25).  2-Fluoro-2’-deoxyinosine derivative 47 was synthesized from 59 in three steps, with minor 
modifications to the reported procedure.71  Diazotization and fluorination of 59, with t-
butylnitrite (t-BuONO) and 60% HF in pyridine at –60 oC for 25 min gave the 2-fluoropurine 
nucleoside 60 in 85% yield.  Silyl protection of the free hydroxyl groups of 60 with TBDMSOTf 
and pyridine in DME at 0 oC over 45 min afforded the silyl derivative 61 in a 92% yield.  




Debenzylation of 61 under catalytic hydrogenation conditions i.e., 5% Pd/C, H2 (1 atm) in THF-
CH3OH mixture, at room temperature for 1 h, furnished the desired product 47 in a 96% yield.  
With 2-fluoro-2’-deoxyinosine derivative 45 in hand, we then pursued the B[a]P-dG adduct 
synthesis.  In this context, B[a]P amino triol (±)-39 was reacted with fluorinated nucleoside 45 
under the same conditions used for the synthesis of dA adducts 25a and 25b.  However, these 
attempts were unsuccessful and no product formation was observed.  We wondered whether the 
presence of any minor impurities in B[a]P amino triol (±)-39 could be preventing the reaction.  
Since, B[a]P amino triol (±)-39 is a sensitive substrate, we decided to synthesize the 
hydrochloride salt of amino triol, (±)-62, as it could be relatively easy to purify and can also be 
directly used for adduct synthesis.92  The amino triol salt (±)-62 was obtained in quantitative 
yield by treating B[a]P azido triol (±)-38 with Lindlar catalyst and 6 M HCl in EtOH under a 
hydrogen atmosphere, at room temperature over 2 h (Scheme 26).  Treatment of B[a]P amino 
triol (±)-39 with 6 M HCl in EtOH at room temperature for 2 h also afforded the amino triol 
hydrochloride salt (±)-62 in a quantitative yield.  Since the synthesis of amino triol hydrochloride 
Scheme 26. Synthesis of B[a]P amino triol hydrochloride salt (±)-62 from B[a]P azido triol 
(±)-38 and B[a]P amino triol (±)-39 
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salt (±)-62 involves acidic conditions, it is important to make sure no stereochemical changes 
occurred during the process.  Hence, we synthesized B[a]P amino triol tetraacetate (±)-49 by 
treating hydrochloride salt (±)-62 with Ac2O, pyridine and catalytic amount of DMAP in DMF at 
room temperature for 14 h (Scheme 26).  The 1H NMR data of (±)-49 was consistent with the 
same compound synthesized previously, shown in Scheme 23, indicating no stereochemical 
changes to  (±)-62. 
Next, we attempted the B[a]P-dG adduct synthesis, by coupling the amino triol 
hydrochloride salt (±)-62 with 2-fluoro-2’-deoxyinosine derivative 45 in the presence of 
(Me3Si)2O and DIPEA in DMSO at 80 oC for 6 h (Scheme 27).  This afforded the diastereomeric 
pair of B[a]P-dG adducts 46a and 46b.  The diastereomeric mixture 46a and 46b were then 
reacted with acetic anhydride and pyridine at room temperature for 12 h to give the desired 
acetylated B[a]P-dG adducts 63a and 63b.  The two adducts 63a and 63b were separated by 
chromatography on a preparative TLC plate (SiO2, 1 mm, 20 cm × 20 cm), by eluting with 
Scheme 27. B[a]P DE1-dG adduct synthesis via nucleophilic displacement by amino triol 
hydrochloride (±)-62 on 2-fluoro-2’-deoxyinosine derivative 45 
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1:19:80 MeOH-EtOAc-CH2Cl2.  Compounds 63a and 63b were obtained in a combined yield of 
22% over two steps.  On the basis of the CD data of the dG adducts 63a and 63b, the faster-
eluting diastereomer was assigned as the 10S isomer (63a), as it displayed a positive band at 
250.6 nm (Figure 9).  On the other hand, the slower-eluting diastereomer was assigned as the 
10R isomer (63b) as it displayed a negative band at 250.8 nm in its CD spectrum (Figure 9).  The 
CD spectra of the B[a]P-dG adducts 63a and 63b were consistent with the data reported by 
Jerina et al.85  
 
Figure 9. Normalized CD spectra (in MeOH) of (±)-B[a]P DE1-dG adducts 63a (red = 10S 
trans) and 63b (blue  = 10R cis) 
To further confirm the structure and stereochemistry of the adducts 55a (10S), 55b (10R), 
63a (10S), and 63b (10R) key coupling constants were compared to that of reported cis and trans 
ring-opened B[a]P DE1-nucleoside adducts (Table 2).  To our surprise, no correlation was 
observed with the reported coupling constant of the cis ring-opened B[a]P DE1-dA adducts and 
55a (J7,8 = 7.9 vs 6.2, J8,9 = 11.5 vs 6.9, entry 1, Table 2) and 55b (J7,8 = 8.0 vs 5.5, J8,9 = 11.5 vs 
6.5, entry 2, Table 2).  On the other hand, the coupling constants of 55a and 55b matched those 
of the trans ring-opened B[a]P DE1-dA adducts 64a and 64b (entries 1–4, Table 2).  Similarly, 
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coupling constant of the trans ring-opened B[a]P DE1-dA adducts 65a and 65b rather than cis 
ring-opened B[a]P DE1-dA adducts (entries 5–8, Table 2).   
Table 2. Comparison of coupling constants of the tetrahydro ring protons in B[a]P-nucleoside 
adductsa 
Entry Adduct J7,8 J8,9 J9,10 
 2’-deoxyadenosine adducts via cis ring-opening of B[a]P DE1 
1 
 
6.2b (3.4)c 6.9b (4.1)c 4.2b (2.3)c 
7.9b,d 11.5b,d 4.5b,d 
2 
 
5.5b (3.0)c 6.5b (3.7)c 4.4b (2.9)c 
8.0b,d 11.5b,d 4.5b,d 
 2’-deoxyadenosine adducts via trans ring-opening of B[a]P DE1 
3e 
 
6.0b (3.1)c 6.9b  (3.3)c 4.2b  (2.9)c 
4e 
 
5.8b (3.1)c 6.6b  (3.6)c 3.9b  (2.9)c 
 2’-deoxyguanosine adducts via cis ring-opening of B[a]P DE1 
5 
 
7.0f 7.2f 4.5f 
8.2b,g 11.8b,g 2.2b,g 
6 
 
6.3f 6.5f 3.6f 
8.2b,g 11.8b,g NAg 
 2’-deoxyguanosine adducts via trans ring-opening of B[a]P DE1 
7e 
 












































These observations suggest that the substituents at the C-9 and C-10 positions in the 
tetrahydro ring of dA and dG adducts 55a,b and 63a,b possess a trans stereochemistry rather 
than the desired cis orientation.  In comparing the 1H NMR data of the adducts 55a,b and 63a,b 
to the trans ring-opened B[a]P DE1-nucleoside adducts reported by Lakshman et al.,78 it is 
clearly evident that the adducts generated herein possess an all trans stereochemistry and the 
corrected structures of the adducts are shown in Figure 10.  
 
 
Figure 10. Corrected structures of the B[a]P DE1-nucleoside adducts 55a,b and 63a,b 
8e 
 
6.5f 6.5f 4.0f 
a Data obtained at 500 MHz under ambient conditions.  b Obtained in acetone-d6.  c Obtained in 
deacidified CDCl3.   d As reported by Jerina et al. (ref. 83).   e  As reported by Lakshman et al. 
























































Since the adduct synthesis involves SNAr and addition-elimination mechanisms, it is highly 
unlikely for change in chirality at the C-10 position to occur in the adduct-forming step.  Thus, 
any determination of chirality can occur only during the synthesis of azido triacyl derivative (±)-
44, since the process of installing the azido group at the C-10 position involves a double 
displacement reaction.  Hence, we re-evaluated the 1H NMR data of azido triol (±)-38, recorded 
in CD3OD and CDCl3-CD3OD at 500 MHz by comparing to the 1H NMR data of cis and trans 
ring-opened azido triols (±)-38 and  (±)-6 (Table 3).83  The chemical shift data for the H-7, H-8, 
H-9, and H-10 protons observed for azido triol (±)-38 synthesized herein, in CD3OD and CDCl3-
CD3OD were comparable to those reported (entries 1–3, Table 3) and was different from trans 
ring-opened azido triol (±)-6 (entries 2 and 4, Table 3).  However, comparing the coupling 
constants for the presently synthesized (±)-38 obtained in CDCl3-CD3OD to those of the cis or 
trans ring-opened azido triols reported (entries 2–4, Table 3) did not provide adequate 
confidence for unequivocal structure determination.  The data from entries 1–4 in Table 3 were 
not adequately clear-cut to indicate that the double displacement reaction on epoxide (±)-42 had 
successfully occurred.  Hence, we compared the data for the azido triol (±)-38 we synthesized to 
the trans ring-opened azido triol (±)-6 previously synthesized by Lakshman.127  In acetone-d6 at 
500 MHz, the chemical shift and coupling constant data were exactly comparable to those 
previously obtained at 300 MHz in the same solvent (entries 5 and 6, Table 3).  This indicates 
that the double-displacement reaction on epoxide  (±)-42, followed by deacylation of triacyl 
azidotriol (±)-44, resulted in the trans ring-opened B[a]P azido triol  (±)-6 rather than the desired 
cis isomer (±)-38.  The reasons behind the failure of proposed double displacement reaction and 
new avenues for the synthesis of cis ring-opened B[a]P amino triol are currently being 
investigated.    
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Table 3. Comparison of coupling constants of the tetrahydro ring protons in B[a]P-azidotriols 
(±)-38 and (±)-6 
Entry Compound H-7 H-8 H-9 H-10 
1 
 
d 4.98  t 3.68 dd 4.23 d 5.44  
CD3OD: J7,8 = 8.0; J8,9 = 8.0; J9,10 = 5.5 
2 
 
d 4.98  t 3.66 dd 4.22 d 5.30 
CDCl3-CD3OD: J7,8 = 8.5; J8,9 = 8.9; J9,10 = 6.3 
3b, c 
 
d 5.03  t 3.79 dd 4.33 d 5.52 
 CDCl3-CD3OD: J7,8 = 8.0; J8,9 = 8.0; J9,10 = 5.5  
4b 
 
d 4.85  dd 4.13 dd 4.07 d 5.78  
CDCl3-CD3OD: J7,8 = 8.3; J8,9 = 10.7; J9,10 = 4.2 
5 
 
d 5.04  t 3.79 dd 4.33 d 5.52 
 acetone-d6: J7,8 = 8.1; J8,9 = 7.9; J9,10 = 5.4  
6c, d 
 
d 5.03  t 3.78 dd 4.32 d 5.51 
acetone-d6: J7,8 = 8.3; J8,9 = 8.0; J9,10 = 5.5 
a Data obtained at 500 MHz under ambient conditions.  b As reported by Jerina et al. (ref. 83).   c 






































In conclusion, we prepared B[a]P epoxide (±)-42 from bromohydrin (±)-41 under mild 
conditions using hydroxide form resin (Amberlite IRA-400-OH) as previously reported.  
Epoxide (±)-42 was obtained in high yield and with high purity.  Using this epoxide in a double 
displacement reaction with LiCl, Ac2O, followed by NaN3, an improved the yield of B[a]P azido 
triacyl derivative (±)-44 was attained.  This modification along with minor changes in 
purification techniques improved the overall yield of (±)-10β-amino-7β,8α,9β-trihydroxy-
7,8,9,10-tetrahydrobenzo[a]pyrene.  The structure and stereochemistry of this amino triol was 
analyzed and by comparison of the NMR data with various B[a]P derivatives.  The amino triol 
was then used for the synthesis of dA adducts.  Moderate yields were obtained in this process 
and the diastereomeric pair of dA adducts 55a and 55b were separated using preparative TLC.  
The absolute configuration in the adducts were determined by the sign of the CD band at 281 nm 
and by comparing the CD data with the literature.  By utilizing a C-6 modification protocol for 
guanosine nucleosides via the amide activation by BOP, we developed a modified synthesis of 2-
fluoro-2’-deoxyinosine derivative 45.  This compound is necessary for the B[a]P-dG adduct 
synthesis.  However, the reaction of amino triol with 45 was unsuccessful.  Hence, the 
hydrochloride salt of the amino triol (±)-62 was prepared and was used in the dG adduct 
synthesis.  This reaction afforded the desired B[a]P-dG adducts 63a and 63b.  Adducts 63a and 
63b were separated using preparative TLC and the adducts were determined by comparing the 
CD data with the literature.  Surprisingly, the key coupling constant data of the adducts 55a,b 
and 63a,b did not correlate with the data of previously reported cis ring-opened B[a]P DE1-
nucleoside adducts and matched well with trans ring-opened B[a]P DE1-nucleoside adducts 
64a,b and 65a,b respectively.  This indicated that the double displacement reaction had failed 
! 204!
and the following steps yielded trans ring-opened B[a]P azido triol (±)-6 rather than cis ring-
opened isomer (±)-38.  Since, the trans ring-opened B[a]P azido triol was carried on for further 
steps, the nucleoside adducts prepared were not of the desired stereochemistry and, hence, 
structures of adducts were corrected.  Analysis of the double displacement reaction will be 
performed in the future to evaluate the failure of this reaction, because all indications were that 








[3.4] EXPERIMENTAL SECTION 
General Experimental Considerations. Thin layer chromatography was performed on 200 µm 
aluminum-foil-backed silica gel plates.  Column chromatography was performed using 200–300 
mesh silica gel.  Toluene was distilled over Na.  THF was distilled over LiAlH4 and then over Na.  
CH3CN and 1,2-dimethoxyethane (DME) were distilled from CaH2.  NaN3 was washed with 
acetone and dried under vacuum overnight before use.  Amberlite was stored in dry THF for a 
week under subdued light and the THF was replaced daily with freshly distilled THF.  The THF 
was filtered off before the Amberlite was used in the cyclization reaction.  All other reagents 
were used as received from commercial suppliers.  1H NMR spectra were obtained at 500 MHz 
and are referenced to the residual protonated solvent resonance.  13C NMR spectra were obtained 
at 125 MHz and are referenced to the solvent resonance.  Freshly deacidified CDCl3 was used as 
the solvent for acquiring NMR data of some samples (deacidification is done by percolating 
CDCl3 through a bed of basic alumina and NaHCO3 and discarding the first few drops).  
Chemical shifts (d) are reported in parts per million (ppm) and coupling constants (J) are in hertz 
(Hz).  Standard abbreviations are used to designate resonance multiplicities. 
9,10-Dihydrobenzo[a]pyrene (47)93  
 
In a clean, dry, 500 mL round bottom flask equipped with a stir bar was placed 7,8,9,10-
tetrahydrobenzo[a]pyrene-7-ol (7.0 g, 25.7 mmol, 1 equiv.) in dry toluene (266 mL).  Then p-
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mixture was heated at reflux for 0.5 h.  The mixture was cooled, evaporated to half of its volume, 
and filtered through a plug of cotton.  The filtrate was then washed with saturated aq. NaHCO3 (2 
x 100 mL) and brine (50 mL).  The organic layer was dried over anhydrous Na2SO4, filtered, and 
evaporated to dryness under reduced pressure.  Chromatography of the crude material on a silica 
gel column by sequential elution with hexanes, 5% CH2Cl2 in hexanes, and 10% CH2Cl2 in 
hexanes gave compound 47 (5.88 g, 90%) as a pale yellow solid.  1H NMR (500 MHz, CDCl3): δ 
8.28 (d, 1H, J = 9.3 Hz, Ar-H), 8.12 (d, 2H, J = 7.5 Hz, Ar-H), 8.07 (d, 1H, J = 9.3 Hz, Ar-H), 
7.99 (app s, 2H, Ar-H), 7.95 (t, 1H, J = 7.6 Hz, Ar-H), 7.87 (s, 1H, Ar-H), 6.87 (d, 1H, J = 9.5 
Hz, Ar-H), 6.27 (dt, 1H, J = 4.5, 9.3 Hz, Ar-H), 3.52 (t, 2H, J = 8.2 Hz, CH2), 2.62–2.56 (m, 2H, 
CH2).  
(±)-7β,8α-Dibenzoyloxy-7,8,9,10-tetrahydrobenzo[a]pyrene ((±)-48)93  
 
To a suspension of BzOAg (7.63 g, 33.30 mmol, 2.2 equiv.) in dry toluene (170 mL), was 
added iodine (4.23 g, 16.65 mmol, 1.1 equiv.) with dry toluene (30 mL).  The mixture was stirred 
for 0.5 h, at which point a yellow suspension had formed.  To this mixture compound 47 (3.85 g, 
15.13 mmol, 1 equiv.) was added with dry toluene (77 mL) and the mixture was stirred for 2.5 h 
at which point TLC showed consumption of compound 47.  The resulting mixture was then 
heated at reflux for 16 h, and filtered hot through Celite.  The filtrate was concentrated and 
suspended in acetone.  The suspension was sonicated and filtered. The solid was recovered and 








acetone and filtered.  This process was repeated several times until complete recovery of the 
product.  Compound (±)-48 (6.63 g, 88% yield) was obtained as a light-brown solid.  1H NMR 
(500 MHz, CDCl3): δ 8.33 (d, 1H, J = 9.3 Hz, Ar-H), 8.24–8.16 (m, 4H, Ar-H), 8.11 (d, 2H, J = 
7.7 Hz, Ar-H), 8.04–7.94 (m, 5H, Ar-H), 7.55 (t, 1H, J = 7.4 Hz, Ar-H), 7.49 (t, 1H, J = 7.4 Hz, 
Ar-H), 7.42 (t, 2H, J = 7.7 Hz, Ar-H), 7.35 (t, 2H, J = 7.7 Hz, Ar-H), 6.99 (d, 1H, J = 6.0 Hz, H-
7), 5.82–5.76 (m, 1H, H-8), 3.81–3.68 (m, 2H, H-9, H-9’), 2.74 (dq, 1H, J = 3.3, 10.0 Hz, H-10), 
2.54 (dq, 1H, J = 6.9, 13.9 Hz, H-10’). 
(±)-7β,8α-Dibenzoyloxy-7,8-dihydrobenzo[a]pyrene ((±)-27)93  
 
In a clean, dry, 500 mL round bottom flask equipped with a stir bar, DDQ (4.74 g, 20.88 
mmol, 1.3 equiv.) was stirred in dry toluene (100 mL) to give a dark reddish-brown solution.  
Then compound  (±)-48 (7.95 g, 16.02 mmol, 1 equiv.) was added to the mixture, with dry 
toluene (219 mL), and the resulting mixture was heated at reflux for 17 h.  The reaction mixture 
was filtered hot through Celite. Evaporation of the filtrate resulted in a greenish solid.  The solid 
was suspended in acetone, sonicated and filtered.  The solid was recovered and the filtrate was 
concentrated.  The solid obtained from the filtrate was sonicated again with acetone and filtered.  
This process was repeated several times until complete recovery of the product. Compound (±)-
27 (4.37 g, 75% yield) was obtained as a green solid.  1H NMR (500 MHz, CDCl3): δ 8.42 (d, 1H, 
J = 9.3 Hz, Ar-H), 8.22–8.15 (m, 4H, Ar-H), 8.13 (d, 2H, J = 7.6 Hz, Ar-H), 8.08 (d, 1H, J = 8.9 










H), 7.51 (t, 1H, J = 7.4 Hz, Ar-H), 7.44 (t, 2H, J = 7.8 Hz, Ar-H), 7.37 (t, 2H, J = 7.8 Hz, Ar-H), 
7.07 (d, 1H, J = 7.5 Hz, H-7), 6.47 (dd, 1H, J = 3.6, 10.1 Hz, H-9), 6.22 (ddd, 1H, J = 1.1, 3.6, 
7.4 Hz, H-8). 
 (±)-9α-Bromo-7β,8α-dibenzoyloxy-10β-hydroxy-7,8,9,10-tetrahydrobenzo[a] pyrene ((±)-
41)125  
  
To a pale yellow solution of dibenzoate (±)-27 (1.0 g, 2.022 mmol, 1 equiv.) in 250 mL of 
THF, NBS (464.8 mg, 2.63 mmol, 1.3 equiv.), NaOAc (497.6 mg, 6.066 mmol, 3 equiv.) and 
100 mL of deionized water were added.  The mixture was stirred, at room temperature, under 
subdued light for 16 h.  The reaction mixture was evaporated to a third of its volume and was 
extracted with CH2Cl2 (3 x 100 mL).   The organic layers were combined, washed with brine (50 
mL), dried over anhydrous Na2SO4, filtered, and evaporated to dryness under reduced pressure. 
The crude mixture was chromatographed on a silica gel column using 50% CH2Cl2 in hexanes as 
the eluent.  The resulting solid was washed with 1:1 hexanes-Et2O and 1:1 hexanes-CH2Cl2.  
Compound (±)-41 (896.9 mg, 75% yield) was obtained as a creamy, white solid.     
(±)-7β,8α-Dibenzoyloxy-9β,10β-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene ((±)-42)125  
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In a clean, dry, 500 mL round bottom flask equipped with a stir bar, was placed dry 
Amberlite IRA 400 (OH–) (36.0 g) in dry THF (250 mL).  To this, bromohydrin (±)-41 (1.0 g, 
1.69 mmol) was added and the mixture was stirred at room temperature under subdued light for 3 
days.  The mixture was filtered and the Amberlite was washed with dry THF.  The filtrate was 
concentrated under reduced pressure.  The resulting solid was suspended in dry Et2O, sonicated 
and filtered to give product (±)-42 (845.0 mg, 98% yield) as a white solid.  1H NMR (500 MHz, 
CDCl3): δ 8.62 (d, 1H, J = 9.3 Hz, Ar-H), 8.33 (s, 1H, Ar-H), 8.29–8.21 (m, 3H, Ar-H), 8.13 (br 
d, 3H, J = 8.6 Hz, Ar-H), 8.09–8.03 (m, 2H, Ar-H), 7.92 (br d, 2H, J = 7.8 Hz, Ar-H), 7.54 (t, 1H, 
J = 7.3 Hz, Ar-H), 7.50 (t, 1H, J = 7.4 Hz, Ar-H), 7.42 (t, 2H, J = 7.6 Hz, Ar-H), 7.34 (t, 2H, J = 
7.6 Hz, Ar-H), 6.96 (d, 1H, J = 3.9 Hz, H-7), 6.04–5.99 (m, 1H, H-9), 5.12 (d, 1H, J = 3.6 Hz, H-
10), 4.26–4.22 (m, 1H, H-8). 
(±)-9β-Acetoxy-10β-azido-7β,8α-dibenzoyloxy-7,8,9,10-tetrahydrobenzo[a]pyrene ((±)-44)96 
 
To a solution of the BaP diol epoxide (±)-42 (200 mg, 0.392 mmol, 1 equiv.) in dry DMF (4 
mL), prepared in a clean, dry, 8 mL reaction vial equipped with a stirring bar, DMAP (a few 
crystals) and Ac2O (741 µL, 7.834 mmol, 20 equiv.) were added under dry N2 gas, in a glove bag.  
In a separate 4 mL reaction vial, LiCl (249.0 mg, 5.88 mmol, 15 equiv.) was dried overnight at 
150 oC in an oven and then heated at 150 oC in a sand bath under vacuum for 2 h.  After cooling 
to room temperature under vacuum, the vial was transferred to the glove bag and the LiCl was 
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the mixture was stirred at room temperature for 18 h.  Four other reactions on the same scale 
were setup simultaneously.  After completion of the reactions as assessed by TLC, the reaction 
mixtures were combined, and diluted with EtOAc (60 mL).  The organic layer was washed with 
saturated aq. NaHCO3 (2 x 20 mL), 1:1 deionized water-brine (3 x 50 mL), and brine (10 mL).  
The organic layer was dried over anhydrous Na2SO4, filtered, and evaporated to dryness under 
reduced pressure.  To the concentrated and dried crude reaction mixture from step 1, dry DMF 
(20 mL) and NaN3 (1.27 g, 19.6 mmol) were added, the mixture was flushed with N2 gas, 
stoppered, and stirred at 50 oC for 18 h.  The reaction mixture was diluted with EtOAc (50 mL), 
washed with 1:1 deionized water-brine (3 x 30 mL), and brine (10 mL).  The aqueous layers 
were combined and back extracted with EtOAc (2 x 30 mL).  The organic layers were combined, 
washed with brine (10 mL), dried over anhydrous Na2SO4, filtered, and evaporated to dryness 
under reduced pressure.  The crude product was chromatographed on a silica gel column using 
CH2Cl2 as eluent.  The product obtained was then washed with cold EtOAc to give the 
compound (±)-44 (752.0 mg, 78% yield) as a pinkish-red solid.  1H NMR (500 MHz, CDCl3): δ 
8.42 (d, 1H, J = 9.3 Hz, Ar-H), 8.30 (d, 2H, J = 8.5 Hz, Ar-H), 8.26 (d, 1H, J = 7.6 Hz, Ar-H), 
8.17 (s, 1H, Ar-H), 8.16–8.11 (m, 3H, Ar-H), 8.09 (t, 1H, J = 7.6 Hz, Ar-H), 8.06–8.02 (m, 3H, 
Ar-H), 7.59 (t, 1H, J = 7.4 Hz, Ar-H), 7.54 (t, 1H, J = 7.3 Hz, Ar- H), 7.46 (t, 2H, J = 7.5 Hz, Ar-
H), 7.41 (t, 2H, J = 7.5 Hz, Ar-H), 7.14 (d, 1H, J = 7.4 Hz, H-7), 5.91 (dd, 1H, J = 4.1, 5.9 Hz, 
H-9), 5.84 (t, 1H, J = 6.7 Hz, H-8), 5.78 (d, 1H, J = 3.8 Hz, H-10), 2.03 (s, 3H, Me). 
(±)-10β-Azido-7β,8α,9β-trihydroxy-7,8,9,10-tetrahydrobenzo[a]pyrene ((±)-38)96  
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In a clean, dry, 15 mL pressure vial equipped with a stir bar were placed azido acetoxy 
dibenzoate (±)-44 (300 mg, 0.504 mmol, 1 equiv.) and 7 N NH3 in MeOH (10.5 mL).  The vial 
was tightly sealed, and the reaction mixture was stirred at 50 oC for 6 h, at which point the 
reaction mixture turned into a clear brownish-yellow solution.  The reaction mixture was diluted 
with EtOAc (60 mL) and washed with deionized water (2 x 15 mL).  The aqueous layers were 
combined and back extracted with EtOAc (2 x 20 mL).  The combined organic layer was washed 
with brine (15 mL), dried over anhydrous Na2SO4, filtered, and evaporated to dryness under 
reduced pressure.  The resulting yellow solid was washed with 1:1 Et2O-hexanes to give 
compound (±)-38 (173.7 mg, quantitative yield) as a light brown solid.  1H NMR (500 MHz, 
acetone-d6): δ 8.55 (s, 1H, Ar-H), 8.52 (d, 2H, J = 9.7 Hz, Ar-H), 8.35–8.28 (m, 3H, Ar-H), 8.18 
(s, 2H, Ar-H), 8.08 (t, 1H, J = 7.6 Hz, Ar-H), 5.52 (d, 1H, J = 5.4 Hz, H-10), 5.05 (d, 1H, J = 8.1 
Hz, H-7), 4.96 (br s, 2H, OH-7, OH-8), 4.90–4.79 (br, 1H, OH-9), 4.34 (dd, 1H, J = 5.7, 7.9 Hz, 
H-9), 3.80 (t, 1H, J = 8.2 Hz, H-8).  1H NMR (500 MHz, CD3OD): δ 8.49 (s, 1H, Ar-H), 8.46 (d, 
2H, J = 9.3 Hz, Ar-H), 8.27 (d, 1H, J = 7.8 Hz, Ar-H), 8.24 (d, 2H, J = 8.6 Hz, Ar-H), 8.14–8.10 
(m, 2H, Ar-H), 8.04 (t, 1H, J = 7.6 Hz, Ar-H), 5.44 (d, 1H, J = 5.6 Hz, H-10), 4.98 (d, 1H, J = 
8.7 Hz, H-7), 4.23 (dd, 1H, J = 5.7, 8.5 Hz, H-9), 3.68 (t, 1H, J = 8.6 Hz, H-8). 
(±)-10β-amino-7β,8α,9β-trihydroxy-7,8,9,10-tetrahydrobenzo[a]pyrene ((±)-38)96  
 
In a clean, dry, 100 mL two-neck round bottom flask, equipped with a stir bar, was placed 
















Lindlar catalyst (575 mg).  One neck of the flask was stoppered with a rubber septum and to the 
other neck, a balloon filled with H2 gas was attached via a gas inlet adapter with a Teflon 
stopcock.  The mixture was stirred and the entire unit was evacuated via a needle inserted 
through the rubber septum and connected to a vacuum line.  The flask was then filled with H2 
gas from the balloon, and this evacuation-refill process was repeated three times.  Finally, the 
reaction was allowed to proceed for 2 h at room temperature under the H2 gas-filled balloon.  
Then the reaction mixture was filtered through Celite and washed with EtOH (50 mL).  The solid 
material obtained by concentrating the filtrate under reduced pressure was suspended in Et2O, 
sonicated, and filtered to obtain compound (±)-39 (98.6 mg, 93% yield) as a light-brown solid.  
Rf (10% MeOH in CH2Cl2): 0.05.  1H NMR (500 MHz, CD3OD): δ 8.47 (d, 1H, J = 9.4 Hz, Ar-
H), 8.44 (s, 1H, Ar-H), 8.27–8.22 (m, 3H, Ar-H), 8.13–8.11 (m, 2H, Ar-H), 8.04 (t, 1H, J = 7.6 
Hz, Ar-H), 5.09–5.03 (m, 2H, H-7, H-10), 4.19 (dd, 1H, J = 4.4, 7.2 Hz, H-9), 3.92 (t, 1H, J = 
7.0 Hz, H-8).  13C NMR (125 MHz, CD3OD): δ 137.0, 132.8, 132.6, 132.0, 130.3, 129.6, 128.9, 
128.5, 127.3, 126.7, 126.5, 125.9 (2s), 125.8, 123.8, 75.6, 75.4, 73.5, 54.7.  HRMS (ESI/TOF) 
m/z calculated for C20H18NO3 [M + H]+: 320.1281, found 320.1282. 
Hydrochloride salt of (±)-10β-amino-7β,8α,9β-trihydroxy-7,8,9,10-tetrahydrobenzo[a]pyre-
ne ((±)-62)  
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In a clean, dry, 25 mL two-neck round bottom flask, equipped with a stir bar, was placed 
azidotriol (±)-38 (50.0 mg, 0.145 mmol, 1 equiv.) in EtOH (10.8 mL).  To the solution were 
added Lindlar catalyst (250 mg) and 6 M aq. HCl (48 µL, 0.290 mmol, 2 equiv.).  One neck of 
the flask was stoppered with a rubber septum and to the other neck a balloon filled with H2 gas 
was attached via a gas inlet adapter with a Teflon stopcock.  The mixture was stirred and the 
entire unit was evacuated via a needle inserted through the rubber septum and connected to a 
vacuum line.  The flask was then filled with H2 gas from the balloon, and this evacuation-refill 
process was repeated three times.  Finally, the reaction was allowed to proceed for 2 h at room 
temperature under the H2 gas-filled balloon.  Then the reaction mixture was filtered through 
Celite, washed with EtOH (20 mL), and the filtrate was concentrated under reduced pressure.  
The resulting solid material was suspended in Et2O, sonicated and filtered.  The product was then 
washed with EtOAc, followed by 1:1 Et2O-MeOH to obtain compound (±)-62 (46.2 mg, 
quantitative yield) as a light-brown solid.  Rf (SiO2/MeOH) = 0.10.  1H NMR (500 MHz, 
CD3OD): δ 8.49 (s, 1H, Ar-H), 8.40–8.29 (m, 4H, Ar-H), 8.22–8.14 (m, 2H, Ar-H), 8.11 (t, 1H, J 
= 7.6 Hz, Ar-H), 5.52 (d, 1H, J = 4.0 Hz, H-10), 5.08 (d, 1H, J = 5.2 Hz, H-7), 4.47 (dd, 1H, J = 
4.0, 6.3 Hz, H-9), 4.17 (t, 1H, J = 5.8 Hz, H-8).  13C NMR (125 MHz, CD3OD): δ 137.5, 133.7, 
132.6, 131.9, 130.5, 130.4, 129.7, 128.3, 127.7, 127.2, 127.1, 126.8, 125.9, 125.6, 123.2, 122.8, 
74.1, 73.1, 72.6, 53.4.  HRMS (ESI/TOF) m/z calculated for C20H19ClNO3 [M + H]+: 356.1048, 
found 356.1048. 
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In a clean, dry, 8 mL reaction vial equipped with a stir bar, was placed BaP amino triol (±)-
39 (40.0 mg, 0.125 mmol, 1 equiv.) in EtOH (1 mL).  To the stirring solution 6 M aq. HCl (42 
µL, 0.250 mmol, 2 equiv.) was added. The vial was sealed, the mixture was stirred at room 
temperature for 2 h.  The mixture was evaporated under reduced pressure.  The resulting brown 
solid was suspended in Et2O, sonicated, and filtered.  The product was washed with EtOAc, 
followed by 1:1 Et2O-MeOH to obtain compound (±)-62 (44.5 mg, quantitative yield) as a light-
brown solid.   
(±)-10β-Acetylamino-7β,8α,9β-trisacetoxy-7,8,9,10-tetrahydrobenzo[a]pyrene ((±)-49)96  
From (±)-10β-azido-7β,8α,9β-trihydroxy-7,8,9,10-tetrahydrobenzo[a]pyrene ((±)-38)96 
 
In a clean, dry, 25 mL two-neck round bottom flask, equipped with a stir bar, was placed 
azidotriol (±)-32 (30.0 mg, 0.0869 mmol, 1 equiv.) in EtOH (6.5 mL).  To the mixture Lindlar 
catalyst (150 mg) was added.  One neck of the flask was stoppered with a rubber septum and to 
the other neck a balloon filled with H2 gas was attached via a gas inlet adapter with a Teflon 
stopcock.  The mixture was stirred and the entire unit was evacuated via a needle inserted 
through the rubber septum and connected to a vacuum line.  The flask was then filled with H2 
gas from the balloon, and this evacuation-refill process was repeated three times.  Finally, the 
reaction was allowed to proceed for 2 h at room temperature under the H2 gas-filled balloon.  
Then the reaction mixture was filtered through Celite and washed with EtOH (20 mL).  The pale-
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for 2 h.  The resulting crude material was dissolved in dry DMF (1 mL), Ac2O (164 µL, 1.737 
mmol, 20 equiv.), pyridine (140 µL, 1.737 mmol, 1 equiv.), and DMAP (a few crystals) were 
added. The reaction mixture was stirred at room temperature for 18 h.  The mixture was then 
diluted with EtOAc (30 mL) and washed with 1 N aq. HCl (10 mL), deionized water (10 mL), 
saturated aq. NaHCO3 (2 x 10 mL), deionized water (10 mL), and brine (10 mL).  The organic 
layer was dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure, to 
give an off-white solid.  This material was chromatographed on a silica gel column by sequential 
elution with 20% EtOAc in CH2Cl2 and 50% EtOAc in CH2Cl2 to give product (±)-45 (30.0 mg, 
71% yield) as an off-white solid.  1H NMR (500 MHz, CDCl3): δ 8.27–8.19 (m, 4H, Ar-H), 
8.11–8.00 (m, 4H, Ar-H), 6.61 (d, 1H, J = 4.5 Hz, H-7), 6.34 (dd, 1H, J = 3.2, 9.0 Hz, H-10), 
5.87 (d, 1H, J = 9.0 Hz, NH), 5.63 (t, 1H, J = 5.2 Hz, H-8), 5.52 (dd, 1H, J = 3.5, 5.5 Hz, H-9), 
2.21 (s, 3H, Me), 2.11 (s, 3H, Me), 2.06 (s, 3H, Me), 2.00 (s, 3H, NHCOMe). 
 From the salt of (±)-10β-amino-7β,8α,9β-trihydroxy-7,8,9,10-tetrahydrobenzo[a]pyrene ((±)-
62) 
 
To a solution of BaP aminotriol hydrochloride (±)-62 (40.0 mg, 0.112 mmol, 1 equiv.) in dry 
DMF (1 mL), Ac2O (212 µL, 2.25 mmol, 20 equiv.), pyridine (227 µL, 2.81 mmol, 25 equiv.), 
and DMAP (a few crystals) were added.  The reaction mixture was stirred at room temperature 
for 14 h. The reaction mixture was then diluted with EtOAc (30 mL) and washed with 1 N aq. 
HCl (2 x 10 mL), saturated aq. NaHCO3 (2 x 10 mL), deionized water (10 mL), and brine (10 
Ac2O, Py
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mL).  The organic layer was dried over anhydrous Na2SO4, filtered, and concentrated under 
reduced pressure to give an off-white solid.  This material was chromatographed on a silica gel 
column by sequential elution with 20% EtOAc in CH2Cl2 and 50% EtOAc in CH2Cl2 to give 




To a solution of fluoro nucleoside 40 (50.4 mg, 0.104 mmol, 1 equiv.) in DMSO (0.54 mL) 
were added BaP aminotriol (±)-39 (40.0 mg, 0.125 mmol, 1.2 equiv.), iPr2NEt (182 µL, 1.04 
mmol, 10 equiv.) and (Me3Si)2O (0.89 mL, 4.18 mmol, 40 equiv.).  The biphasic mixture was 
flushed with N2 gas, sealed, and vigorously stirred at 85 oC for 5 h.  The mixture was cooled to 
room temperature, diluted with EtOAc (30 mL), and washed with deionized water (15 mL).  The 
aqueous layer was extracted with EtOAc (2 x 20 mL).  The combined organic layer was dried 
over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The crude mixture 
was carefully chromatographed on a silica gel column using CH2Cl2 followed by 3% MeOH-
CH2Cl2.  To the resulting off-white product were added Ac2O (441 µL, 4.67 mmol, 45 equiv.), 
pyridine (441 µL, 5.46 mmol, 52.5 equiv.), and DMAP (a few crystals).  The mixture was stirred 
at room temperature, overnight.  The mixture was diluted with EtOAc (30 mL) and washed with 










































combined organic layer was dried over anhydrous Na2SO4, filtered, and concentrated under 
reduced pressure. The two diastereomeric products 55a and 55b were carefully separated by 
chromatography on a preparative TLC plate (SiO2, 500 µ, 20 x 20 cm), eluted with 10% EtOAc 
in CH2Cl2.  This separation yielded 9.7 mg of the less-polar adduct 55a as a pale-yellow solid, 
10.0 mg of the more-polar adduct 55b as an off-white solid and 20.0 mg of the mixture of 
diastereomers (combined yield of 42% over the two steps). 
The faster-eluting diastereomer was the 10S isomer (55a) as determined by the presence of a 
positive band at 281 nm in its CD spectrum.  Rf (5% EtOAc in CH2Cl2): 0.33.  1H NMR (500 
MHz, CDCl3): δ 8.63 (br s, 1H, Ar-H), 8.30 (d, J = 9.3 Hz, 1H, Ar-H), 8.22–8.15 (m, 3H, Ar-H), 
8.12–7.99 (m, 5H, Ar-H), 6.78–6.76 (br m, 1H, H-10), 6.67 (d, J = 3.4 Hz, 1H, H-7), 6.46 (t, J = 
6.2 Hz, 1H, H-1’), 6.19–6.17 (br m, 1H, –NH), 5.70 (t, J = 3.7 Hz, 1H, H-8), 5.64 (dd, J = 2.3, 
4.1 Hz, 1H, H-9), 4.60 (app q, Japp ~ 4.2 Hz, 1H, H-3’), 4.01 (app q, Japp ~ 3.4 Hz, 1H, H-4’), 
3.87 (dd, J = 3.9, 11.3 Hz, 1H, H-5’), 3.76 (dd, J = 2.6, 11.2 Hz, 1H, H-5’’), 2.65 (dt, J = 6.0, 
12.3 Hz, 1H, H-2’), 2.46 (dt, J = 2.6, 12.5 Hz, 1H, H-2’’), 2.18, 2.11, and 2.05 (3s, 9H, 
OCOCH3), 0.92 and 0.86 (2s, 18H, t-Bu), 0.11, 0.10, 0.05, and 0.03 (4s, 12H, SiMe).  13C NMR 
(125 MHz, CDCl3): δ 170.2, 169.8, 169.1, 163.4, 153.4, 153.0, 139.0, 132.1, 131.4, 131.0, 130.4, 
129.7, 129.2, 128.7, 127.3, 126.7, 126.3, 126.1, 126.0, 125.8, 125.5, 124.5, 123.3, 120.5, 88.0, 
84.7, 71.8, 69.2, 69.1, 68.5, 62.8, 41.6, 29.9, 26.1, 26.0, 21.4, 21.2, 21.1, 18.6, 18.2, –4.4, –4.6, –
5.2, –5.3.   HRMS (ESI/TOF) m/z calculated for C48H62N5O9Si2 [M + H]+: 908.4081, found 
908.4076. 
The slower-eluting diastereomer was the 10R isomer (55b) as determined by the presence of 
a negative band at 281 nm in its CD spectrum.  Rf (5% EtOAc in CH2Cl2): 0.16.  1H NMR (500 
MHz, CDCl3): δ 8.62 (br s, 1H, Ar-H), 8.32 (d, J = 9.3 Hz, 1H, Ar-H), 8.22–8.15 (m, 3H, Ar-H), 
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8.12–7.99 (m, 5H, Ar-H), 6.80–6.76 (br m, 1H, H-10), 6.67 (d, J = 2.9 Hz, 1H, H-7), 6.46 (t, J = 
6.0 Hz, 1H, H-1’), 6.21–6.13 (br m, 1H, –NH), 5.69 (t, J = 3.1 Hz, 1H, H-8), 5.67–5.63 (m, 1H, 
H-9), 4.62 (app q, Japp ~ 4.5 Hz, 1H, H-3’), 4.00 (app q, Japp ~ 3.4 Hz, 1H, H-4’), 3.89 (dd, J = 
4.1, 11.2 Hz, 1H, H-5’), 3.77 (dd, J = 2.8, 11.2 Hz, 1H, H-5’’), 2.64 (dt, J = 6.3, 12.9 Hz, 1H, H-
2’), 2.44 (dt, J = 5.8, 12.1 Hz, 1H, H-2’’), 2.18, 2.10, and, 2.04 (3s, 9H, OCOCH3), 0.91 and 0.87 
(2s, 18H, t-Bu), 0.10 (s, 6H, SiMe), 0.05 and 0.03 (2s, 6H, SiMe).  13C NMR (125 MHz, CDCl3): 
δ 170.2, 169.8, 169.1, 163.4, 153.4, 153.0, 139.1, 132.1, 131.4, 131.0, 130.4, 129.7, 129.2, 128.7, 
127.4, 126.7, 126.4, 126.0 (2c), 125.8, 125.5, 124.5, 123.3, 120.4, 88.0, 84.5, 71.9, 69.1 (2c), 
68.5, 62.8, 41.5, 29.9, 26.1, 26.0, 21.4, 21.2, 21.1, 18.6, 18.2, –4.4, –4.6, –5.2, –5.3.  HRMS 
(ESI/TOF) m/z calculated for C48H61N5O9Si2Na [M + Na]+: 930.3900, found 930.3904. 
O6-(Benzotriazol-1-yl)-3’,5’-di-O-(t-butyldimethylsilyl)-2’-deoxyguanosine (57)126  
 
To a suspension of 3’,5’-di-O-(t-butyldimethylsilyl)-2’-deoxyguanosine (56, 2.5 g, 5.04 
mmol, 1 equiv.) in dry CH3CN (20 mL), BOP (3.34 g, 7.56 mmol, 1.5 equiv.) and DBU (1.39 
mL, 10.09 mmol, 2 equiv.) were added.  The mixture was stirred at room temperature for 1 h.  
The mixture was then diluted with EtOAc (50 mL) and washed with deionized water (2 x 30 mL), 
and brine (10 mL).  The organic layer was dried over anhydrous Na2SO4, filtered, and 



















r.t., 1 h, 88%
56 57
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column by eluting with 10% EtOAc in hexanes, followed by 25% EtOAc in hexanes, to yield the 
product 57 (2.71 g, 88% yield) as a white solid.  1H NMR (500 MHz, CDCl3): δ 8.17–8.09 (m, 
2H, H-8, Ar-H), 7.58–7.42 (m, 3H, Ar-H), 6.35 (t, 1H, J = 6.3 Hz, H-1’), 4.74 (s, 2H, NH2), 4.61 
(dt, 1H, J = 3.2, 5.9 Hz, H-3’), 4.00 (app q, 1H, Japp ~ 3.2 Hz, H-4’), 3.85 (dd, 1H, J = 3.8, 11.3 
Hz, H-5’), 3.77 (dd, 1H, J = 2.9, 11.3 Hz, H-5’), 2.58 (dt, 1H, J = 6.3, 12.9 Hz, H-2’), 2.45–2.34 
(m, 1H, H-2’), 0.92 (s, 18H, t-Bu), 0.11 and 0.10 (2s, 12H, SiMe).   
O6-Benzyl-3’,5’-di-O-(t-butyldimethylsilyl)-2’-deoxyguanosine (58)128  
 
To a suspension of O6-(benzotriazol-1-yl)-2’-deoxyguanosine derivative 57 (742.0 mg, 1.212 
mmol, 1 equiv.) in DME (7.4 mL), BnOH (314.0 µL, 3.03 mmol, 2.5 equiv.) and Cs2CO3 (987.0 
mg, 3.030 mmol, 2.5 equiv.) were added, and the mixture was stirred at room temperature.  After 
24 h, the reaction was incomplete, hence, additional BnOH (157 µL, 1.515 mmol, 1.25 equiv.) 
and Cs2CO3 (494.0 mg, 1.515 mmol, 1.25 equiv.) were added to the mixture, and was stirred at 
room temperature for 12 h.  The mixture was then diluted with EtOAc (30 mL), washed with 
deionized water (2 x 20 mL), and brine (10 mL).  The organic layer was dried over anhydrous 
Na2SO4, filtered, and concentrated under reduced pressure.  The resulting material was purified 
over a long silica gel column by sequential elution initially with 5% EtOAc in hexanes, 10% 
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white solid.  1H NMR (500 MHz, CDCl3): δ 7.91 (s, 1H, H-8), 7.50 (d, 2H, J = 7.3 Hz, Ar-H), 
7.35 (t, 2H, J = 7.3 Hz, Ar-H), 7.30 (t, 1H, J = 7.4 Hz, Ar-H), 6.32 (t, 1H, J = 6.5 Hz, H-1’), 
5.60–5.52 (m, 2H, OCH2), 4.82 (s, 2H, NH2), 4.58 (dt, 1H, J = 3.1, 5.8 Hz, H-3’), 3.97 (app q, 
1H, Japp ~ 3.5 Hz, H-4’), 3.81 (dd, 1H, J = 4.3, 11.2 Hz, H-5’), 3.75 (dd, 1H, J = 3.2, 11.1 Hz, H-
5’), 2.57 (dt, 1H, J = 6.5, 13.1 Hz, H-2’), 2.34 (ddd, 1H, J = 3.7, 6.0, 13.0 Hz, H-2’), 0.91 and 
0.90 (2s, 18H, t-Bu), 0.10 (s, 6H, SiMe), 0.07 (s, 6H, SiMe). 
O6-Benzyl-2’-deoxyguanosine (59)  
 
To a solution of O6-benzyl-2’-deoxyguanosine derivative 58 (600 mg, 1.024 mmol, 1 equiv.) 
in MeOH (10.5 mL), KF (238.0 mg, 4.096 mmol, 4 equiv.) was added, and the mixture was 
stirred at 80 oC for 12 h. After completion of the reaction, the mixture was concentrated under 
reduced pressure, and purified over a short silica gel column by sequential elution with 2% 
MeOH in EtOAc and 5% MeOH in EtOAc, to yield product 59 (0.35 g, 95% yield) as a pale-
yellow solid.  1H NMR (500 MHz, CD3OD): δ 8.04 (s, 1H, H-8), 7.51 (d, 2H, J = 7.4 Hz, Ar-H), 
7.37 (t, 2H, J = 7.4 Hz, Ar-H), 7.31 (t, 1H, J = 7.2 Hz, Ar-H), 6.32 (dd, 1H, J = 6.2, 8.0 Hz, H-
1’), 5.55 (s, 2H, OCH2), 4.56 (dt, 1H, J = 2.5, 5.4 Hz, H-3’), 4.04 (app q, 1H, Japp ~ 2.8 Hz, H-4’), 
3.84 (dd, 1H, J = 3.0, 12.2 Hz, H-5’), 3.74 (dd, 1H, J = 3.4, 12.2 Hz, H-5’), 2.79 (ddd, 1H, J = 


























To a 60% HF in pyridine solution (13.47 mL) at –60 °C in a 25 mL polypropylene vial, was 
added O6-benzyl-2’-deoxyguanosine (59, 432.0 mg, 1.209 mmol) and the mixture was stirred 
until a clear solution was observed.  Then t-BuONO (971.0 µL, 8.160 mmol, 6.75 equiv.) 
precooled to –50 °C was slowly added to the reaction mixture and the mixture was stirred at –
60 °C for 25 min.  The dark-yellow reaction mixture was then poured into cold water (75 mL), 
and was extracted with CHCl3 (5 x 75 mL).  The organic layer was passed through a column of 
solid NaHCO3 and washed with saturated aq. NaHCO3 (2 x 20 mL), dried over a mixture of 
anhydrous Na2SO4 and solid NaHCO3, filtered, and concentrated under reduced pressure.  The 
resulting material was washed with 1:1 CH2Cl2-hexanes, to obtain product 60 (0.37 g, 85% 
yield) as a pale-yellow solid.  1H NMR (500 MHz, CDCl3): δ 8.04 (s, 1H, H-8), 7.51 (d, 2H, J = 
7.2 Hz, Ar-H), 7.41–7.29 (m, 3H, Ar-H), 6.32 (dd, 1H, J = 5.9, 8.3 Hz, H-1’), 5.63 (s, 2H, 
OCH2), 4.75 (dt, 1H, J = 2.4, 5.1 Hz, H-3’), 4.2 (app q, 1H, Japp ~ 2.0 Hz, H-4’), 3.94 (dd, 1H, J 
= 2.1, 12.7 Hz, H-5’), 3.78 (dd, 1H, J = 2.2, 12.7 Hz, H-5’), 2.86 (ddd, 1H, J = 5.3, 8.5, 13.6 Hz, 
H-2’), 2.36 (ddd, 1H, J = 1.9, 5.7, 13.4 Hz, H-2’). 














































DME, 0 °C, 
45 min, 92%
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To a solution of 60 (100.0 mg, 0.277 mmol, 1 equiv.) in dry DME (1.8 mL), pyridine (112.0 
µL, 1.387 mmol, 5 equiv.) was added and the stirring mixture was cooled down to 0 °C.  
TBDMSOTf (160.0 µL, 0.694 mmol, 2.5 equiv.) was added to the solution and the mixture was 
stirred at 0 °C for 45 min.  The resulting yellow solution was diluted with EtOAc (20 mL), 
washed with brine (2 x 10 mL), dried over anhydrous Na2SO4, filtered, and concentrated under 
reduced pressure.  The crude material was chromatographed on a silica gel column by sequential 
elution with hexanes and CH2Cl2 to yield product 61 (154.6 mg, 95% yield) as a pale-yellow oil.  
1H NMR (500 MHz, CDCl3): δ 8.23 (s, 1H, H-8), 7.54 (d, 2H, J = 7.6 Hz, Ar-H), 7.40–7.31 (m, 
3H, Ar-H), 6.39 (t, 1H, J = 6.3 Hz, H-1’), 5.69–5.60 (m, 2H, OCH2), 4.61–4.59 (m, 1H, H-3’), 
4.00 (app q, 1H, Japp ~ 3.4 Hz, H-4’), 3.88 (dd, 1H, J = 4.0, 11.3 Hz, H-5’), 3.77 (dd, 1H, J = 2.9, 
11.2 Hz, H-5’), 2.58 (dt, 1H, J = 6.4, 12.9 Hz, H-2’), 2.42 (ddd, 1H, J = 4.1, 6.0, 13.2 Hz, H-2’), 
0.91 and 0.90 (2s, 18H, t-Bu), 0.10 and 0.08 (2s, 12H, SiMe). 
3’,5’-Di-O-(t-butyldimethylsilyl)-2-fluoro-2’-deoxyinosine (45)71  
 
To a suspension of 5% Pd/C (30.0 mg) in 1:1 THF-MeOH (5.6 mL) in an 8 mL reaction vial, 
61 (135.0 mg, 0.279 mmol, 1 equiv.) was added.  The vial was placed into a two-necked round 
bottom flask.  To one neck was attached a hydrogen balloon via a gas inlet adapter with a Teflon 
stopcock and the other neck was stoppered with a rubber septum.  The flask was connected to a 
vacuum line via a needle inserted through the septum.  The flask was evacuated and filled with 




















 H2 (1 atm)
1:1 THF-CH3OH
r.t., 1 h, 96%
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reaction was allowed to proceed for 1 h at room temperature under a balloon filled with H2 gas.  
The mixture was filtered through Celite and the residue was washed with THF (50 mL).  The 
filtrate was concentrated under reduced pressure and dried under high vacuum to give the 
compound 45 (109.6 mg, 96%) as a white solid.  1H NMR (500 MHz, CD3OD): δ 8.16 (s, 1H, H-
8), 6.28 (t, 1H, J = 6.3 Hz, H-1’), 4.73 (app q, 1H, Japp ~ 4.6 Hz, H-3’), 3.96 (app q, 1H, Japp ~ 
3.8 Hz, H-4’), 3.88 (dd, 1H, J = 4.6, 11.3 Hz, H-5’), 3.78 (dd, 1H, J = 3.5, 11.2 Hz, H-5’), 2.77 
(dt, 1H, J = 6.3, 13.0 Hz, H-2’), 2.43 (ddd, 1H, J = 4.7, 6.4, 13.2 Hz, H-2’), 0.95 and 0.89 (2s, 




The aminotriol hydrochloride (±)-62 (30.0 mg, 0.0843 mmol, 1 equiv.) was suspended in 
DIPEA (147.0 µL, 0.843 mmol, 10 equiv.) and the mixture was stirred for 15 min.  After this dry 
DMSO (0.42 mL), (Me3Si)2O (723.0 µL, 3.384 mmol, 40 equiv.), and 2-fluoro-2’-deoxyinosine 
derivative 45 (63.0 mg, 0.126 mmol, 1.5 equiv.) were added. The biphasic mixture was flushed 
with N2 gas, capped, and vigorously stirred at 80 oC for 6 h.  The mixture was cooled to room 
1. (Me3Si)2O, DIPEA
    DMSO, 80 °C, 6 h











































temperature, diluted with EtOAc (30 mL) and washed with deionized water (2 x 15 mL), brine 
(15 mL), dried over anhydrous Na2SO4, filtered, and evaporated under reduced pressure.  To the 
crude material (81.3 mg), pyridine (954.0 µL, 11.80 mmol, 140 equiv.), DMAP (a few crystals), 
and Ac2O (956.0 µL, 10.12 mmol, 120 equiv.) were added and the mixture was stirred at room 
temperature for 12 h.  The reaction mixture was diluted with EtOAc (40 mL) and washed with 
deionized water (20 mL).  The aqueous layer was back extracted with EtOAc (2 x 30 mL).  The 
combined organic layers was dried over anhydrous Na2SO4, filtered, and concentrated under 
reduced pressure.  The crude material was chromatographed on a short silica gel column by 
sequential elution with 50% EtOAc in hexanes, EtOAc, and 1% MeOH in EtOAc to yield 
peracylated amino triol derivative (±)-49 (10.8 mg) as a dark-brown solid and the mixture of two 
diastereomers 63a and 63b (31.2 mg) also as a dark-brown solid.  The two diastereomers 63a 
and 63b were carefully separated by preparative TLC (SiO2, 1 mm, 20 cm × 20 cm) by elution 
with 1:19:80 MeOH-EtOAc-CH2Cl2 to yield 9.5 mg of the less-polar adduct 63a, and 7.9 mg of 
the more-polar adduct 63b (combined yield of 22% over the two steps and 30% based on the 
recovered (±)-49).   
The faster-eluting diastereomer was the 10S isomer (63a) as determined by the presence of a 
positive band at 250.6 nm in its CD spectrum.  Rf (5% MeOH in EtOAc): 0.44.  1H NMR (500 
MHz, DMSO-d6): δ 10.68 (br s, 1H, guanine ring NH), 8.36 (d, J = 7.5 Hz, 1H, Ar-H), 8.33–8.27 
(m, 2H, Ar-H), 8.26–8.20 (m, 4H, Ar-H), 8.12 (t, J = 7.6 Hz, 1H, Ar-H), 7.98 (s, 1H, Ar-H), 7.21 
(br d, J = 7.7 Hz, 1H, exocyclic NH), 6.68 (d, J = 7.0 Hz, 1H, H-7), 6.26 (t, J = 6.4 Hz, 1H, H-
1’), 6.20 (dd, J = 4.5, 7.6 Hz, 1H, H-10), 5.86 (dd, J = 4.5, 7.2 Hz, 1H, H-9), 5.44 (t, J = 7.2 Hz, 
1H, H-8), 4.50 (app q, Japp ~ 4.7 Hz, 1H, H-3’), 3.89 (app q, Japp ~ 4.2 Hz, 1H, H-4’), 3.79 (dd, J 
= 5.0, 11.2 Hz, 1H, H-5’), 3.74 (dd, J = 4.5, 11.2 Hz, 1H, H-5’’), 2.59–2.56 (m, 1H, H-2’), 2.32–
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2.28 (m, 4H, H-2’’, OCOCH3), 2.08, and 1.99 (2s, 6H, OCOCH3), 0.88 and 0.85 (2s, 18H, t-Bu), 
0.07 (s, 3H, SiMe), 0.05 (s, 6H, SiMe), 0.04 (s, 3H, SiMe).  13C NMR (125 MHz, DMSO-d6): δ 
170.3, 169.3 (2c), 156.7, 151.3, 149.9, 135.5, 131.3, 130.9, 130.7, 130.1, 128.8 (2c), 128.3, 127.2, 
126.9, 126.7, 126.1, 125.9, 124.0, 123.4, 122.9, 122.8, 117.2, 86.9, 82.4, 76.6, 71.7, 71.1, 70.1, 
69.8, 62.7, 50.8, 25.8, 25.7, 20.9, 20.6, 20.5, 18.0, 17.8, –4.7, –5.0, –5.4.  HRMS (ESI/TOF) m/z 
calculated for C48H62N5O10Si2 [M + H]+: 924.4030, found 924.4030. 
The slower-eluting diastereomer was the 10R isomer (63b) as determined by the presence of 
a negative band at 250.8 nm in its CD spectrum.  Rf (5% MeOH in EtOAc): 0.36.  1H NMR (500 
MHz, DMSO-d6): δ 10.60 (br s, 1H, guanine ring NH), 8.35 (d, J = 7.6 Hz, 1H, Ar-H), 8.33–8.28 
(m, 2H, Ar-H), 8.26–8.22 (m, 3H, Ar-H), 8.16–8.01 (m, 2H, Ar-H), 7.97 (s, 1H, Ar-H), 7.14 (br 
d, J = 8.0 Hz, 1H, exocyclic NH), 6.63 (d, J = 6.3 Hz, 1H, H-7), 6.24 (dd, J = 6.1, 7.7 Hz, 1H, H-
1’), 6.19 (dd, J = 3.6, 8.0 Hz, 1H, H-10), 5.81 (dd, J = 4.0, 6.5 Hz, 1H, H-9), 5.43 (t, J = 6.5 Hz, 
1H, H-8), 4.49 (dt, J = 2.5, 5.0 Hz, 1H, H-3’), 3.86–3.81 (m, 1H, H-4’), 3.75 (dd, J = 7.4, 10.5 
Hz, 1H, H-5’), 3.71 (dd, J = 4.5, 10.8 Hz, 1H, H-5’’), 3.08 (ddd, J = 5.6, 7.7, 13.1 Hz, 1H, H-2’), 
2.28 (ddd, J = 2.7, 5.4, 13.0 Hz, 1H, H-2’’), 2.25, 2.07, and 1.99 (3s, 9H, OCOCH3), 0.87, and 
0.64 (2s, 18H, t-Bu), 0.01, 0.08. –0.23, and –0.31 (4s, 12H, SiMe).  HRMS (ESI/TOF) m/z 





1. Pott, P.: Chirurgical observations relative to the cataract: The polypus of the nose, the 
cancer of the scrotum, the different kinds of ruptures, and the mortification of the toes 
and feet; T.J. Carnegy, L. Hawes, W. Clarke, and R. Collins: London, 1775. 
2. Luch, A.: The Carcinogenic Effects of Polycyclic Aromatic Hydrocarbons; Imperial 
College Press, 2005. 
3. Bell, J.: Paraffin epithelioma of the scrotum. Edinb. Med. J. 1876, 22, 135–137. 
4. Henry, S. A.: Occupational cutaneous cancer attributable to certain chemicals in industry. 
Br. Med. Bull. 1947, 4, 389–401. 
5. Dipple, A.: Polycyclic Aromatic Hydrocarbon Carcinogenesis. In Polycyclic 
Hydrocarbons and Carcinogenesis; American Chemical Society, 1985; Vol. 283; pp 1–
17. 
6. Passey, R. D.; Carter-Braine, J.: Experimental soot cancer. J. Pathol. Bacteriol. 1925, 28, 
133–44. 
7. Bloch, B.; Driefuss, W.: Ueber die experimentelle Erzeugung von Carcinomen mit 
Lymphdrusen- und Lungenmetastasen durch Teerbestandteile. Schweiz. Med. 
Wochenschr. 1921, 51, 1033–1037. 
8. Kennaway, E. L.: Experiments on cancer-producing substances. Br. Med. J. 1925, 2, 1-4. 
9. Schroeter, G.: Uber den Chemismus der Auf- und Abbaureaktionen mittels 
Aluminiumchlorids. Ber. Dtsch. Chem. Ges 1924, 57, 1990–2003. 
10. Clar, E.: Zur Kenntnis mehrkemiger aromatischer Kohlenwasserstoffe und ihrer 
Abkommlinge, I. Mitt.: Dibenzanfhracene und ihre Chinone. Ber. Dtsch. Chem. Ges. 
1929, 62, 350–359. 
11. Kennaway, E. L.; Hieger, I.: Carcinogenic substances and their fluorescence spectra. Br. 
Med. J. 1930, 1044–1046. 
12. Kennaway, E. L.: Further experiments on cancer-producing substances. Biochem. J. 1930, 
24, 497–504. 
13. Hieger, I.: The fluorescence spectram of 3,4-benzpyrene. Am. J. Cancer, 29, 705–714. 
14. Cook, J. W.; Hewett, C. L.; Hieger, I.: Theisolationofacancer-producing hydrocarbon 
from coal tar. Parts I, II, and III. . J. Chem. Soc 1933, 395–405. 
15. Grimmer, G.: In Environmental Carcinogens: Polycyclic Aromatic Hydrocarbons; 
Grimmer, G., Ed.; CRC Press: Boca Raton, FL, USA, 1983; pp 27–60. 
! 227!
16. Brookes, P.; Lawley, P. D.: Evidence for the Binding of Polynuclear Aromatic 
Hydrocarbons to the Nucleic Acids of Mouse Skin : Relation between Carcinogenic 
Power of Hydrocarbons and their Binding to Deoxyribonucleic Acid. Nature 1964, 202, 
781–784. 
17. Miller, E. C.: Studies on the Formation of Protein-bound Derivatives of 3,4-Benzpyrene 
in the Epidermal Fraction of Mouse Skin. Cancer Res. 1951, 11, 100–108. 
18. Boyland, E.; Levi, A. A.: Metabolism of polycyclic compounds: Production of 
dihydroxydihydroanthracene from anthracene. Biochem. J. 1935, 29, 2679–2683. 
19. Boyland, E.; Levi, A. A.; Mawson, E. H.; Roe, E.: Metabolism of poly-cyclic compounds. 
IV. Production of a dihydroxy-l,2,5,6-dibenzanthracene from 1,2,5,6-dibenzanthracene. 
Biochem. J. 1941, 35, 184–191. 
20. Booth, J.; Boyland, E.; Sato, T.; Sims, P.: Metabolism of polycyclic compounds. 17. The 
reaction of 1:2-dihydronaphthalene and 1:2-epoxy-1:2:3:4-tetrahydronaphthalene with 
glutathione catalysed by tissue preparations. Biochem. J. 1960, 77, 182–186. 
21. Boyland, E.; Sims, P.: Metabolism of polycyclic compounds. 16. The metabolism of 1:2-
dihydronaphthalene and 1:2-epoxy-1:2:3:4-tetrahydronaphthalene. Biochem. J. 1960, 77, 
175–181. 
22. Borgen, A.; Darvey, H.; Castagnoli, N.; Crocker, T. T.; Rasmussen, R. E.; Wang, I. Y.: 
Metabolic conversion of benzo[a]pyrene by Syrian hamster liver microsomes and binding 
of metabolites to deoxyribonucleic acid. J. Med. Chem. 1973, 16, 502–506. 
23. Sims, P.; Grover, P. L.; Swaisland, A.; Pal, K.; Hewer, A.: Metabolic activation of 
benzo(a)pyrene proceeds by a diol-epoxide. Nature 1974, 252, 326–328. 
24. Lehr, R. E.; Kumar, S.; Levin, W.; Wood, A. W.; Chang, R. L.; Conney, A. H.; Yagi, H.; 
Sayer, J. M.; Jerina, D. M.: The bay region theory of polycyclic aromatic hydrocarbon 
carcinogenesis. ACS Symp. Ser. 1985, 283, 63–84. 
25. Jerina, D. M.; Lehr, R. E.: The Bay-Region theory: a quantum mechanical approach to 
aromatic hydrocarbon-induced carcinogenicity. Pergamon, 1977; pp 709–720. 
26. Cavalieri, E. L.; Rogan, E. G.: One-Electron Oxidation in Aromatic Hydrocarbon 
Carcinogenesis. In Polycyclic Hydrocarbons and Carcinogenesis; American Chemical 
Society, 1985; Vol. 283; pp 289–305. 
27. Cremonesi, P.; Cavalieri, E. L.; Rogan, E. G.: One-electron oxidation of 6-substituted 
benzo[a]pyrenes by manganic acetate. A model for metabolic activation. J. Org. Chem. 
1989, 54, 3561–3570. 
28. Smithgall, T. E.; Harvey, R. G.; Penning, T. M.: Spectroscopic identification of ortho-
quinones as the products of polycyclic aromatic trans-dihydrodiol oxidation catalyzed by 
! 228!
dihydrodiol dehydrogenase. A potential route of proximate carcinogen metabolism. J. 
Biol. Chem. 1988, 263, 1814–1820. 
29. Penning, T. M.; Burczynski, M. E.; Hung, C.-F.; McCoull, K. D.; Palackal, N. T.; 
Tsuruda, L. S.: Dihydrodiol Dehydrogenases and Polycyclic Aromatic Hydrocarbon 
Activation:+ Generation of Reactive and Redox Active o-Quinones. Chem. Res. Toxicol. 
1999, 12, 1–18. 
30. Bolton, J. L.; Trush, M. A.; Penning, T. M.; Dryhurst, G.; Monks, T. J.: Role of Quinones 
in Toxicology. Chem. Res. Toxicol. 2000, 13, 135–160. 
31. Oesch, F.: Mammalian epoxide hydrases. Inducible enzymes catalyzing the inactivation 
of carcinogenic and cytotoxic metabolites derived from aromatic and olefinic compounds. 
Xenobiotica 1973, 3, 305–340. 
32. Conney, A. H.: Induction of microsomal enzymes by foreign chemicals and 
carcinogenesis by polycyclic aromatic hydrocarbons: G. H. A. Clowes Memorial Lecture. 
Cancer Res. 1982, 42, 4875–4917. 
33. Lacourciere, G. M.; Armstrong, R. N.: The catalytic mechanism of microsomal epoxide 
hydrolase involves an ester intermediate. J. Am. Chem. Soc. 1993, 115, 10466–10467. 
34. Armstrong, R. N.: Enzyme-catalyzed detoxication reactions: mechanisms and 
stereochemistry. CRC Crit. Rev. Biochem. 1987, 22, 39–88. 
35. Nemoto, N.: Glutathione, glucuronide, and sulfate transferase in polycyclic aromatic 
hydrocarbon metabolism. Academic, 1981; Vol. 3; pp 213–258. 
36. Phillips, D. H.; Grover, P. L.: Polycyclic hydrocarbon activation: Bay regions and beyond. 
Drug Metab. Rev. 1994, 26, 443–467. 
37. Guengerich, F. P.; Shimada, T.: Oxidation of toxic and carcinogenic chemicals by human 
cytochrome P-450 enzymes. Chem. Res. Toxicol. 1991, 4, 391–407. 
38. Thakker, D. R.; Yagi, H.; Akagi, H.; Koreeda, M.; Lu, A. Y. H.; Levin, W.; Wood, A. 
W.; Conney, A. H.; Jerina, D. M.: Metabolism of benzo[a]pyrene. VI. Stereoselective 
metabolism of benzo[a]pyrene and benzo[a]pyrene-7,8-dihydrodiol to diol epoxides. 
Chem.-Biol. Interact. 1977, 16, 281–300. 
39. Yang, S. K.: Stereoselectivity of cytochrome P-450 isozymes and epoxide hydrolase in 
the metabolism of polycyclic aromatic hydrocarbons. Biochem. Pharmacol. 1988, 37, 
61–70. 
40. Wood, A. W.; Chang, R. L.; Levin, W.; Yagi, H.; Thakker, D. R.; Jerina, D. M.; Conney, 
A. H.: Differences in mutagenicity of the optical enantiomers of the diastereomeric 
benzo[a]pyrene 7,8-diol-9,10-epoxides. Biochem. Biophys. Res. Commun. 1977, 77, 
1389–1396. 
! 229!
41. Jerina, D. M.; Sayer, J. M.; Agarwal, S. K.; Yagi, H.; Levin, W.; Wood, A. W.; Conney, 
A. H.; Pruess-Schwartz, D.; Baird, W. M.; Pigott, M. A.; Dipple, A.: Reactivity and 
Tumorigenicity of Bay-Region Diol Epoxides Derived from Polycyclic Aromatic 
Hydrocarbons. In Biological Reactive Intermediates III: Mechanisms of Action in Animal 
Models and Human Disease; Kocsis, J. J., Jollow, D. J., Witmer, C. M., Nelson, J. O., 
Snyder, R., Eds.; Springer US: Boston, MA, 1986; pp 11–30. 
42. Sayer, J. M.; Chadha, A.; Agarwal, S. K.; Yeh, H. J. C.; Yagi, H.; Jerina, D. M.: Covalent 
nucleoside adducts of benzo[a]pyrene 7,8-diol 9,10-epoxides: structural reinvestigation 
and characterization of a novel adenosine adduct on the ribose moiety. J. Org. Chem. 
1991, 56, 20–29. 
43. Agarwal, S. K.; Sayer, J. M.; Yeh, H. J. C.; Pannell, L. K.; Hilton, B. D.; Pigott, M. A.; 
Dipple, A.; Yagi, H.; Jerina, D. M.: Chemical characterization of DNA adducts derived 
from the configurationally isomeric benzo[c]phenanthrene-3,4-diol-1,2-epoxides. J. Am. 
Chem. Soc. 1987, 109, 2497–2504. 
44. Szeliga, J.; Dipple, A.: DNA Adduct Formation by Polycyclic Aromatic Hydrocarbon 
Dihydrodiol Epoxides. Chem. Res. Toxicol. 1998, 11, 1–11. 
45. Meehan, T.; Straub, K.: Double-stranded DNA stereoselectively binds benzo(a)pyrene 
diol epoxides. Nature 1979, 277, 410–412. 
46. Ralston, S. L.; Lau, H. H. S.; Seidel, A.; Luch, A.; Platt, K. L.; Baird, W. M.: The Potent 
Carcinogen Dibenzo[a,l]pyrene Is Metabolically Activated to Fjord-Region 11,12-Diol-
13,14-Epoxides in Human Mammary Carcinoma MCF-7 Cell Cultures. Cancer Res. 1994, 
54, 887–890. 
47. Ralston, S. L.; Seidel, A.; Luch, A.; Platt, K. L.; Baird, W. M.: Stereoselective activation 
of dibenzo[a,l]pyrene to (–)-anti(11R,12S,13S,14R)- and (+)-syn(11S,12R,13S,14R)-
11,12-diol 13,14-epoxides which bind extensively to deoxyadenosine residues of DNA in 
the human mammary carcinoma cell line MCF-7. Carcinogenesis 1995, 16, 2899–2907. 
48. Dipple, A.: Reactions of polycyclic aromatic hydrocarbons with DNA. In DNA Adducts: 
Identification and Biological Significance; Hemminki, K., Dipple, A., Shuker, D. E. G., 
Kadlubar, F. F., Segerback, D., Bartsch, H., Eds.; International Agency for Research on 
Cancer: Lyon, 1994; Vol. 125; pp 107–129. 
49. Shabad, L. M.: Circulation of carcinogenic polycyclic aromatic hydrocarbons in the 
human environment and cancer prevention. J. Natl. Cancer Inst. 1980, 64, 405–410. 
50. Penning, T. M.: Chemical Carcinogenesis; Humana Press, 2011. 
51. Wei, S. J. C.; Chang, R. L.; Hennig, E.; Cui, X. X.; Merkler, K. A.; Wong, C. Q.; Yagi, 
H.; Jerina, D. M.; Conney, A. H.: Mutagenic selectivity at the HPRT locus in V-79 cells: 
comparison of mutations caused by bay-region benzo[a]pyrene 7,8-diol-9,10-epoxide 
enantiomers with high and low carcinogenic activity. Carcinogenesis 1994, 15, 1729–
1735. 
! 230!
52. Jelinsky, S. A.; Liu, T.; Geacintov, N. E.; Loechler, E. L.: The Major, N2-Gua Adduct of 
the (+)-anti-Benzo[a]pyrene Diol Epoxide Is Capable of Inducing GA and GC, in 
Addition to GT, Mutations. Biochemistry 1995, 34, 13545–13553. 
53. Zou, Y.; Liu, T.-M.; Geacintov, N. E.; Van Houten, B.: Interaction of the UvrABC 
Nuclease System with a DNA Duplex Containing a Single Stereoisomer of dG-(+)- or 
dG-(-)-anti-BPDE. Biochemistry 1995, 34, 13582–13593. 
54. Shukla, R.; Jelinsky, S.; Liu, T.; Geacintov, N. E.; Loechler, E. L.: How Stereochemistry 
Affects Mutagenesis by N2-Deoxyguanosine Adducts of 7,8-Dihydroxy-9,10-epoxy-
7,8,9,10-tetrahydrobenzo[a]pyrene: Configuration of the Adduct Bond Is More Important 
Than Those of the Hydroxyl Groups. Biochemistry 1997, 36, 13263–13269. 
55. Hanrahan, C. J.; Bacolod, M. D.; Vyas, R. R.; Liu, T.; Geacintov, N. E.; Loechler, E. L.; 
Basu, A. K.: Sequence Specific Mutagenesis of the Major (+)-anti-Benzo[a]pyrene Diol 
Epoxide−DNA Adduct at a Mutational Hot Spot in Vitro and in Escherichia coli Cells. 
Chem. Res. Toxicol. 1997, 10, 369–377. 
56. Fernandes, A.; Liu, T.; Amin, S.; Geacintov, N. E.; Grollman, A. P.; Moriya, M.: 
Mutagenic Potential of Stereoisomeric Bay Region (+)- and (-)-cis-anti-Benzo[a]pyrene 
Diol Epoxide-N2-2'-deoxyguanosine Adducts in Escherichia coli and Simian Kidney 
Cells. Biochemistry 1998, 37, 10164–10172. 
57. Jerina, D. M.; Chadha, A.; Cheh, A. M.; Schurdak, M. E.; Wood, A. W.; Sayer, J. M.: 
Covalent Bonding of Bay-Region Diol Epoxides to Nucleic Acids. In Biological Reactive 
Intermediates IV: Molecular and Cellular Effects and Their Impact on Human Health; 
Witmer, C. M., Snyder, R. R., Jollow, D. J., Kalf, G. F., Kocsis, J. J., Sipes, I. G., Eds.; 
Springer New York: Boston, MA, 1991; pp 533–553. 
58. Benasutti, M.; Ezzedine, Z. D.; Loechler, E. L.: Construction of an Escherichia coli 
vector containing the major DNA adduct of activated benzo[a]pyrene at a defined site. 
Chem. Res. Toxicol. 1988, 1, 160–168. 
59. Cosman, M.; Ibanez, V.; Geacintov, N. E.; Harvey, R. G.: Preparation and isolation of 
adducts in high yield derived from the binding of two benzo[a]pyrene-7,8-dihydroxy-
9,10-oxide stereoisomers to the oligonucleotide d(ATATGTATA). Carcinogenesis 1990, 
11, 1667–1672. 
60. Mao, B.; Xu, J.; Li, B.; Margulis, L. A.; Smirnov, S.; Ya, N.-Q.; Courtney, S. H.; 
Geacintov, N. E.: Synthesis and characterization of covalent adducts derived from the 
binding of benzo[a]pyrenediol epoxide to a -GGG- sequence in a deoxyoligonucleotide. 
Carcinogenesis 1995, 16, 357–365. 
61. Reardon, D. B.; Bigger, C. A. H.; Strandberg, J.; Yagi, H.; Jerina, D. M.; Dipple, A.: 
Sequence selectivity in the reaction of optically active hydrocarbon dihydrodiol epoxides 
with rat H-ras DNA. Chem. Res. Toxicol. 1989, 2, 12–14. 
! 231!
62. Colapietro, A. M.; Goodell, A. L.; Smart, R. C.: Characterization of benzo[a]pyrene-
initiated mouse skin papillomas for Ha-ras mutations and protein kinase C levels. 
Carcinogenesis 1993, 14, 2289–2295. 
63. Chakravarti, D.; Mailander, P.; Franzen, J.; Higginbotham, S.; Cavalieri, E. L.; Rogan, E. 
G.: Detection of dibenzo[a,l]pyrene-induced H-ras codon 61 mutant genes in 
preneoplastic SENCAR mouse skin using a new PCR-RFLP method. Oncogene 1998, 16, 
3203–3210. 
64. Harris, C. M.; Zhou, L.; Strand, E. A.; Harris, T. M.: New strategy for the synthesis of 
oligodeoxynucleotides bearing adducts at exocyclic amino sites of purine nucleosides. J. 
Am. Chem. Soc. 1991, 113, 4328–4329. 
65. Kim, S. J.; Stone, M. P.; Harris, C. M.; Harris, T. M.: A postoligomerization synthesis of 
oligodeoxynucleotides containing polycyclic aromatic hydrocarbon adducts at the N6 
position of deoxyadenosine. J. Am. Chem. Soc. 1992, 114, 5480–5481. 
66. Cooper, M. D.; Hodge, R. P.; Tamura, P. J.; Wilkinson, A. S.; Harris, C. M.; Harris, T. 
M.: Synthesis of oligonucleotides containing bulky adducts at guanine N2 via the 
phosphoramidite of O2-triflate-O6-NPE 2'-deoxyxanthosine. Tetrahedron Lett. 2000, 41, 
3555–3558. 
67. Page, J. E.; Zajc, B.; Oh-hara, T.; Lakshman, M. K.; Sayer, J. M.; Jerina, D. M.; Dipple, 
A.: Sequence Context Profoundly Influences the Mutagenic Potency of Trans-Opened 
Benzo[a]pyrene 7,8-Diol 9,10-Epoxide-Purine Nucleoside Adducts in Site-Specific 
Mutation Studies. Biochemistry 1998, 37, 9127–9137. 
68. Lakshman, M. K.; Sayer, J. M.; Jerina, D. M.: Chemical synthesis of a bay-region 
polycyclic aromatic hydrocarbon tetrahydroepoxide-deoxyadenosine adduct and its site-
specific incorporation into a DNA oligomer. J. Am. Chem. Soc. 1991, 113, 6589–6594. 
69. Lakshman, M. K.; Sayer, J. M.; Jerina, D. M.: Synthesis and site-specific incorporation of 
a bay-region cis ring-opened tetrahydro epoxide-deoxyadenosine adduct into a DNA 
oligomer. J. Org. Chem. 1992, 57, 3438–3443. 
70. Lakshman, M. K.; Sayer, J. M.; Yagi, H.; Jerina, D. M.: Synthesis and duplex-forming 
properties of a nonanucleotide containing an N6-deoxyadenosine adduct of a bay-region 
diol epoxide. J. Org. Chem. 1992, 57, 4585–4590. 
71. Zajc, B.; Lakshman, M. K.; Sayer, J. M.; Jerina, D. M.: Epoxide and diol epoxide adducts 
of polycyclic aromatic hydrocarbons at the exocyclic amino group of deoxyguanosine. 
Tetrahedron Lett. 1992, 33, 3409–3412. 
72. Custer, L.; Zajc, B.; Sayer, J. M.; Cullinane, C.; Phillips, D. R.; Cheh, A. M.; Jerina, D. 
M.; Bohr, V. A.; Mazur, S. J.: Stereospecific Differences in Repair by Human Cell 
Extracts of Synthesized Oligonucleotides Containing trans-Opened 7,8,9,10-
Tetrahydrobenzo[a]pyrene 7,8-Diol 9,10-Epoxide N2-dG Adduct Stereoisomers Located 
within the Human K-ras Codon 12 Sequence. Biochemistry 1999, 38, 569–581. 
! 232!
73. Steinbrecher, T.; Becker, A.; Stezowski, J. J.; Oesch, F.; Seidel, A.: Synthesis of 
oligodeoxyribonucleotides containing diastereomeric dihydrodiol epoxide-N6-
deoxyadenosine adducts of polycyclic aromatic hydrocarbons. Tetrahedron Lett. 1993, 34, 
1773–1774. 
74. Lee, H.; Luna, E.; Hinz, M.; Stezowski, J. J.; Kiselyo, A. S.; Harvey, R. G.: Synthesis of 
Oligonucleotide Adducts of the Bay Region Diol Epoxide Metabolites of Carcinogenic 
Polycyclic Aromatic Hydrocarbons. J. Org. Chem. 1995, 60, 5604–5613. 
75. Robins, M. J.; Basom, G. L.: Nucleic acid-related compounds. 8. Direct conversion of 2'-
deoxyinosine to 9-(2-deoxy-β-D-erythro-pentofuranosyl)-6-chloropurine and selected 6-
substituted deoxynucleosides and their evaluation as substrates of adenosine deaminase. 
Can. J. Chem. 1973, 51, 3161–3169. 
76. Lakshman, M.; Lehr, R. E.: Synthesis of polycyclic aromatic hydrocarbon substituted 2'-
deoxyadenosine analogs. Tetrahedron Lett. 1990, 31, 1547–1550. 
77. Chaturvedi, S.; Lakshman, M. K.: Site-specific modification of the human N-ras proto-
oncogene with each diol epoxide metabolite of benzo[a]pyrene and thermal denaturation 
studies of the adducted duplexes. Carcinogenesis 1996, 17, 2747–2752. 
78. Champeil, E.; Pradhan, P.; Lakshman, M. K.: Palladium-Catalyzed Synthesis of 
Nucleoside Adducts from Bay- and Fjord-Region Diol Epoxides. J. Org. Chem. 2007, 72, 
5035–5045. 
79. Lakshman, M. K.; Gunda, P.: Palladium-Catalyzed Synthesis of Carcinogenic Polycyclic 
Aromatic Hydrocarbon Epoxide-Nucleoside Adducts:+ The First Amination of a Chloro 
Nucleoside1. Org. Lett. 2003, 5, 39–42. 
80. Kim, S. J.; Harris, C. M.; Jung, K. Y.; Koreeda, M.; Harris, T. M.: Nonbiomimetic route 
to deoxyadenosine adducts of carcinogenic polycyclic aromatic hydrocarbons. 
Tetrahedron Lett. 1991, 32, 6073–6076. 
81. Steinbrecher, T.; Wameling, C.; Oesch, F.; Seidel, A.: Chemistry of carcinogenic 
metabolites. 2. Activation of the C-2 position of purine via the trifluoromethanesulfonate 
group: synthesis of N2-alkylated deoxyguanosines. Angew. Chem. 1993, 105, 408–410 
(See also Angew. Chem., Int. Ed. Engl., 1999, 32, 404–406). 
82. Jhingan, A. K.; Meehan, T.: Regioselective and stereoselective synthesis of (±)-10β-
amino-7β,8α,9α-trihydroxy-7,8,9,10-tetrahydrobenzo[a]pyrene. J. Chem. Res., Synop. 
1991, 122–123. 
83. Pilcher, A. S.; Yagi, H.; Jerina, D. M.: A Novel Synthetic Method for Cis-Opened 
Benzo[a]pyrene 7,8-Diol 9,10-Epoxide Adducts at the Exocyclic N6-Amino Group of 
Deoxyadenosine. J. Am. Chem. Soc. 1998, 120, 3520–3521. 
! 233!
84. Ramesha, A. R.; Kroth, H.; Jerina, D. M.: Novel trifluoroethanol mediated synthesis of 
benzo[a]pyrene 7,8-diol 9,10-epoxide adducts at the N2-position of deoxyguanosine and 
the N6-position of deoxyadenosine. Tetrahedron Lett. 2001, 42, 1003–1005. 
85. Kroth, H.; Yagi, H.; Seidel, A.; Jerina, D. M.: New and Highly Efficient Synthesis of Cis- 
and Trans-Opened Benzo[a]pyrene 7,8-Diol 9,10-Epoxide Adducts at the Exocyclic N2-
Amino Group of Deoxyguanosine. J. Org. Chem. 2000, 65, 5558–5564. 
86. Ramesha, A. R.; Kroth, H.; Jerina, D. M.: Solvent-Free Synthesis of Benzo[a]pyrene 7,8-
Diol 9,10-Epoxide Adducts at the N2-Position of Deoxyguanosine. Org. Lett. 2001, 3, 
531–533. 
87. Lakshman, M.; Nadkarni, D. V.; Lehr, R. E.: Regioselective ring opening of polycyclic 
aromatic hydrocarbon epoxides by polymer-supported azide anion. J. Org. Chem. 1990, 
55, 4892–4897. 
88. Lakshman, M. K.; Chaturvedi, S.; Lehr, R. E.: Improved high-yield synthesis of 
polycyclic aromatic hydrocarbon amino tribenzoates, nucleophilic components for 
synthesis of diol epoxide-nucleoside adducts. Synth. Commun. 1994, 24, 2983–2988. 
89. Johnson, F.; Bonala, R.; Tawde, D.; Torres, M. C.; Iden, C. R.: Efficient Synthesis of the 
Benzo[a]pyrene Metabolic Adducts of 2'-Deoxyguanosine and 2'-Deoxyadenosine and 
Their Direct Incorporation into DNA. Chem. Res. Toxicol. 2002, 15, 1489–1494. 
90. Jhingan, A. K.; Meehan, T.: Regioselective and stereoselective synthesis of (±)-10β-
amino-7β,8α,9α-trihydroxy-7,8,9,10-tetrahydrobenzo[a]pyrene. J. Chem. Res. (S) 1991, 
122–123. 
91. Li, G.; Chang, H.-T.; Sharpless, K. B.: Catalytic asymmetric aminohydroxylation (AA) 
of olefins. Angew. Chem., Int. Ed. Engl. 1996, 35, 451–454. 
92. Lakshman, M. K.; Keeler, J. C.; Ngassa, F. N.; Hilmer, J. H.; Pradhan, P.; Zajc, B.; 
Thomasson, K. A.: Highly diastereoselective synthesis of nucleoside adducts from the 
carcinogenic benzo[a]pyrene diol epoxide and a computational analysis. J. Am. Chem. 
Soc. 2007, 129, 68–76. 
93. McCaustland, D. J.; Engel, J. F.: Metabolites of polycyclic aromatic hydrocarbons. II. 
Synthesis of 7,8-dihydrobenzo[a]pyrene-7,8-diol and 7,8-dihydrobenzo[a]pyrene-7,8-
epoxide. Tetrahedron Lett. 1975, 16, 2549–2552. 
94. Lakshman, M. K.; Zajc, B.: Regio- and stereocontrolled synthesis of aryl cis amino 
alcohols from cis glycols. Tetrahedron Lett. 1996, 37, 2529–2532. 
95. Lakshman, M. K.; Chaturvedi, S.; Zajc, B.; Gibson, D. T.; Resnick, S. M.: A general 
chemoenzymic synthesis of enantiopure cis β-amino alcohols from microbially derived 
cis-glycols. Synthesis 1998, 1352–1356. 
! 234!
96. Thomson, P. F.; City University of New York, C.: Palladium-catalyzed Aryl Aminations 
of Halo Nucleosides Platinum-catalyzed Synthesis of New Benzo[c]phenanthrene 
Derivatives and Synthesis of a Cis Ring-opened Amino Triol from Benzo[a]pyrene Series 
1 Diol Epoxide, 2012. 
97. Geacintov, N. E.; Cosman, M.; Hingerty, B. E.; Amin, S.; Broyde, S.; Patel, D. J.: NMR 
Solution Structures of Stereoisomeric Covalent Polycyclic Aromatic Carcinogen−DNA 
Adducts:+ Principles, Patterns, and Diversity. Chem. Res. Toxicol. 1997, 10, 111–146. 
98. Cosman, M.; de los Santos, C.; Fiala, R.; Hingerty, B. E.; Singh, S. B.; Ibanez, V.; 
Margulis, L. A.; Live, D.; Geacintov, N. E.; Broyde, S.: Solution conformation of the 
major adduct between the carcinogen (+)-anti-benzo[a]pyrene diol epoxide and DNA. 
Proc. Natl. Acad. Sci. U. S. A. 1992, 89, 1914–1918. 
99. De Los Santos, C.; Cosman, M.; Hingerty, B. E.; Ibanez, V.; Margulis, L. A.; Geacintov, 
N. E.; Broyde, S.; Patel, D. J.: Influence of benzo[a]pyrenediol epoxide chirality on 
solution conformations of DNA covalent adducts: the (-)-trans-anti-[BP]G·C adduct 
structure and comparison with the (+)-trans-anti[BP]G·C enantiomer. Biochemistry 1992, 
31, 5245–5252. 
100. Cosman, M.; de los Santos, C.; Fiala, R.; Hingerty, B. E.; Ibanez, V.; Luna, E.; Harvey, 
R.; Geacintov, N. E.; Broyde, S.; Patel, D. J.: Solution conformation of the (+)-cis-anti-
[BP]dG adduct in a DNA duplex: Intercalation of the covalently attached 
benzo[a]pyrenyl ring into the helix and displacement of the modified deoxyguanosine. 
Biochemistry 1993, 32, 4145–4155. 
101. Cosman, M.; Hingerty, B. E.; Luneva, N.; Amin, S.; Geacintov, N. E.; Broyde, S.; Patel, 
D. J.: Solution Conformation of the (-)-cis-anti-Benzo[a]pyrenyl-dG Adduct Opposite dC 
in a DNA Duplex: Intercalation of the Covalently Attached BP Ring into the Helix with 
Base Displacement of the Modified Deoxyguanosine into the Major Groove. 
Biochemistry 1996, 35, 9850–9863. 
102. Fountain, M. A.; Krugh, T. R.: Structural Characterization of a (+)-trans-anti-
Benzo[a]pyrene-DNA Adduct using NMR, Restrained Energy Minimization, and 
Molecular Dynamics. Biochemistry 1995, 34, 3152–3161. 
103. Schurter, E. J.; Yeh, H. J. C.; Sayer, J. M.; Lakshman, M. K.; Yagi, H.; Jerina, D. M.; 
Gorenstein, D. G.: NMR Solution Structure of a Nonanucleotide Duplex with a dG 
Mismatch Opposite a 10R Adduct Derived from Trans Addition of a Deoxyadenosine 
N6-Amino Group to (-)-(7S,8R,9R,10S)-7,8-Dihydroxy-9,10-epoxy-7,8,9,10-
tetrahydrobenzo[a]pyrene. Biochemistry 1995, 34, 1364–1375. 
104. Yeh, H. J. C.; Sayer, J. M.; Liu, X.; Altieri, A. S.; Byrd, R. A.; Lakshman, M. K.; Yagi, 
H.; Schurter, E. J.; Gorenstein, D. G.; Jerina, D. M.: NMR Solution Structure of a 
Nonanucleotide Duplex with a dG Mismatch Opposite a 10S Adduct Derived from Trans 
Addition of a Deoxyadenosine N6-Amino Group to (+)-(7R,8S,9S,10R)-7,8-Dihydroxy-
9,10-epoxy- 7,8,9,10-tetrahydrobenzo[a]pyrene: An Unusual syn Glycosidic Torsion 
Angle at the Modified dA. Biochemistry 1995, 34, 13570–13581. 
! 235!
105. Schwartz, J. L.; Rice, J. S.; Luxon, B. A.; Sayer, J. M.; Xie, G.; Yeh, H. J. C.; Liu, X.; 
Jerina, D. M.; Gorenstein, D. G.: Solution Structure of the Minor Conformer of a DNA 
Duplex Containing a dG Mismatch Opposite a Benzo[a]pyrenediol Epoxide/dA Adduct: 
Glycosidic Rotation from Syn to Anti at the Modified Deoxyadenosine. Biochemistry 
1997, 36, 11069–11076. 
106. Schurter, E. J.; Sayer, J. M.; Oh-hara, T.; Yeh, H. J. E.; Yagi, H.; Luxon, B. A.; Jerina, D. 
M.; Gorenstein, D. G.: NMR solution structure of an undecanucleotide duplex with a 
complementary thymidine base opposite a 10R adduct derived from trans addition of a 
deoxyadenosine N6-amino group to (-)-(7R,8S,9R,10S)-7,8-dihydroxy-9,10-epoxy-
7,8,9,10-tetrahydrobenzo[a]pyrene. Biochemistry 1995, 34, 9009–9020. 
107. Mao, B.; Gu, Z.; Gorin, A.; Chen, J.; Hingerty, B. E.; Amin, S.; Broyde, S.; Geacintov, N. 
E.; Patel, D. J.: Solution Structure of the (+)-cis-anti-Benzo[a]pyrene-dA ([BP]dA) 
Adduct Opposite dT in a DNA Duplex. Biochemistry 1999, 38, 10831–10842. 
108. Pradhan, P.; Tirumala, S.; Liu, X.; Sayer, J. M.; Jerina, D. M.; Yeh, H. J. C.: Solution 
Structure of a Trans-Opened (10S)-dA Adduct of (+)-(7S,8R,9S,10R)-7,8-Dihydroxy-
9,10-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene in a Fully Complementary DNA Duplex: 
Evidence for a Major Syn Conformation. Biochemistry 2001, 40, 5870–5881. 
109. Volk, D. E.; Thiviyanathan, V.; Rice, J. S.; Luxon, B. A.; Shah, J. H.; Yagi, H.; Sayer, J. 
M.; Yeh, H. J. C.; Jerina, D. M.; Gorenstein, D. G.: Solution Structure of a Cis-Opened 
(10R)-N6-Deoxyadenosine Adduct of (9S,10R)-9,10-Epoxy-7,8,9,10-
tetrahydrobenzo[a]pyrene in a DNA Duplex. Biochemistry 2003, 42, 1410–1420. 
110. Zegar, I. S.; Kim, S. J.; Johansen, T. N.; Harris, C. M.; Harris, T. M.; Stone, M. P.: 
Adduction of the Human N-ras Codon 61 Sequence with (-)-(7S,8R,9R,10S)-7,8-
Dihydroxy-9,10-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene: Structural Refinement of the 
Intercalated SRSR(61,2) (-)-(7S,8R,9S,10R)-N6-[10-(7,8,9,10-
Tetrahydrobenzo[a]pyrenyl)]-2'-deoxyadenosyl Adduct from 1H NMR. Biochemistry 
1996, 35, 6212–6224. 
111. Zegar, I. S.; Chary, P.; Jabil, R. J.; Tamura, P. J.; Johansen, T. N.; Lloyd, R. S.; Harris, C. 
M.; Harris, T. M.; Stone, M. P.: Multiple Conformations of an Intercalated (-)-
(7S,8R,9S,10R)-N6-[10-(7,8,9,10-Tetrahydrobenzo[a]pyrenyl)]-2'-deoxyadenosyl 
Adduct in the N-ras Codon 61 Sequence. Biochemistry 1998, 37, 16516–16528. 
112. Volk, D. E.; Rice, J. S.; Luxon, B. A.; Yeh, H. J. C.; Liang, C.; Xie, G.; Sayer, J. M.; 
Jerina, D. M.; Gorenstein, D. G.: NMR Evidence for Syn-Anti Interconversion of a Trans 
Opened (10R)-dA Adduct of Benzo[a]pyrene (7S,8R)-Diol (9R,10S)-Epoxide in a DNA 
Duplex. Biochemistry 2000, 39, 14040–14053. 
113. Christner, D. F.; Lakshman, M. K.; Sayer, J. M.; Jerina, D. M.; Dipple, A.: Primer 
Extension by Various Polymerases Using Oligonucleotide Templates Containing 
Stereoisomeric Benzo[a]pyrene-Deoxyadenosine Adducts. Biochemistry 1994, 33, 
14297–14305. 
! 236!
114. Zou, Y.; Luo, C.; Geacintov, N. E.: Hierarchy of DNA Damage Recognition in 
Escherichia coli Nucleotide Excision Repair. Biochemistry 2001, 40, 2923–2931. 
115. Hoare, S.; Zou, Y.; Purohit, V.; Krishnasamy, R.; Skorvaga, M.; van Houten, B.; 
Geacintov, N. E.; Basu, A. K.: Differential Incision of Bulky Carcinogen-DNA Adducts 
by the UvrABC Nuclease: Comparison of Incision Rates and the Interactions of Uvr 
Subunits with Lesions of Different Structures. Biochemistry 2000, 39, 12252–12261. 
116. Roth, R. B.; Amin, S.; Geacintov, N. E.; Scicchitano, D. A.: Bacteriophage T7 RNA 
polymerase transcription elongation is inhibited by site-specific, stereospecific 
benzo[c]phenanthrene diol epoxide DNA lesions. Biochemistry 2001, 40, 5200-5207. 
117. Zhuang, P.; Kolbanovskiy, A.; Amin, S.; Geacintov, N. E.: Base sequence dependence of 
in vitro translesional DNA replication past a bulky lesion catalyzed by the exo- klenow 
fragment of Pol I. Biochemistry 2001, 40, 6660–6669. 
118. Kramata, P.; Zajc, B.; Sayer, J. M.; Jerina, D. M.; Wei, C. S. J.: A single site-specific 
trans-opened 7,8,9,10-tetrahydrobenzo[a]pyrene 7,8-diol 9,10-epoxide N2-
deoxyguanosine adduct induces mutations at multiple sites in DNA. J. Biol. Chem. 2003, 
278, 14940–14948. 
119. Zou, Y.; Shell, S. M.; Utzat, C. D.; Luo, C.; Yang, Z.; Geacintov, N. E.; Basu, A. K.: 
Effects of DNA Adduct Structure and Sequence Context on Strand Opening of Repair 
Intermediates and Incision by UvrABC Nuclease. Biochemistry 2003, 42, 12654–12661. 
120. Chiapperino, D.; Kroth, H.; Kramarczuk, I. H.; Sayer, J. M.; Masutani, C.; Hanaoka, F.; 
Jerina, D. M.; Cheh, A. M.: Preferential misincorporation of purine nucleotides by human 
DNA polymerase η opposite benzo[α]pyrene 7,8-diol 9,10-epoxide deoxyguanosine 
adducts. J. Biol. Chem. 2002, 277, 11765–11771. 
121. Ogi, T.; Shinkai, Y.; Tanaka, K.; Ohmori, H.: Polκ protects mammalian cells against the 
lethal and mutagenic effects of benzo[a]pyrene. Proc. Natl. Acad. Sci. U. S. A. 2002, 99, 
15548–15553. 
122. Simhadri, S.; Kramata, P.; Zajc, B.; Sayer, J. M.; Jerina, D. M.; Hinkle, D. C.; Wei, C. S. 
J.: Benzo[a]pyrene diol epoxide-deoxyguanosine adducts are accurately bypassed by 
yeast DNA polymerase zeta in vitro. Mutat. Res. 2002, 508, 137–145. 
123. Suzuki, N.; Ohashi, E.; Kolbanovskiy, A.; Geacintov, N. E.; Grollman, A. P.; Ohmori, 
H.; Shibutani, S.: Translesion Synthesis by Human DNA Polymerase κ on a DNA 
Template Containing a Single Stereoisomer of dG-(+)- or dG-(-)-anti-N2-BPDE (7,8-
Dihydroxy-anti-9,10-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene). Biochemistry 2002, 41, 
6100–6106. 
124. Xie, Z.; Braithwaite, E.; Guo, D.; Zhao, B.; Geacintov, N. E.; Wang, Z.: Mutagenesis of 
Benzo[a]pyrene Diol Epoxide in Yeast: Requirement for DNA Polymerase ζ and 
Involvement of DNA Polymerase η. Biochemistry 2003, 42, 11253–11262. 
! 237!
125. Yagi, H.; Thakker, D. R.; Hernandez, O.; Koreeda, M.; Jerina, D. M.: Synthesis and 
reactions of the highly mutagenic 7,8-diol 9,10-epoxides of the carcinogen 
benzo[a]pyrene. J. Am. Chem. Soc. 1977, 99, 1604–1611. 
126. Lakshman, M. K.; Frank, J.: A simple method for C-6 modification of guanine 
nucleosides. Org. Biomol. Chem. 2009, 7, 2933–2940. 
127. Mahesh, K. L.: Unpublished work. 
128. Lakshman, M. K.; Ngassa, F. N.; Keeler, J. C.; Dinh, Y. Q. V.; Hilmer, J. H.; Russon, L. 
M.: Facile Synthesis of O6-Alkyl-, O6-Aryl-, and Diaminopurine Nucleosides from 2'-












SYNTHESIS OF HIPPADINE 
[4.1] INTRODUCTION 
Amaryllidaceae alkaloids represent a vast and important group of natural products and plants 
belonging to this family have been used in medicine for years.1  These alkaloids are classified 
into nine main subgroups based on their structural features.  Lycorine alkaloids, a main subgroup 
of the amaryllidaceae alkaloid family, consist of a pyrrolophenanthridine skeleton, and possess 
interesting pharmacological properties.  As examples, hippadine (1) inhibits fertility in male rats 
reversibly,2 kalbretorine (3) has shown antitumor activity,2 and anhydrolycorinium chloride (5) is 
active against P-338 murine leukemic cell line,3 ungeremine (4) shows antitumor as well as 
antileukemic properties.4  Oxoassoanine (6) is the synthetic precursor to pratosine (2), 
anhydrolycorinone (7) is the synthetic precursor for hippadine (1), and anhydrolycorinium 
chloride (5), respectively (Figure 1).  Because of the biological properties and common structural 
features exhibited by these compounds, we wanted to develop a modular approach towards the 
synthesis of hippadine (1) via anhydrolycorinone (7). 
 
Figure 1. Some important molecules belonging to the lycorine alkaloid family 
To date, different research groups have developed various strategies for the synthesis of 
hippadine (1) and anhydrolycorinone (7).  Some of these strategies include oxazoline mediated 














1, Hippadine (R1 = -CH2-, R2 = H)
2, Pratosine (R1 = -CH3, R2 = H)
3, Kalbretorine (R1 = -CH2-, R2 = OH)
4, Ungeremine (R1 = OH)
5, Anhydrolycorinium chloride 
(R1 = H)
6, Oxoassoanine (R1 = CH3)
7, Anhydrolycorinone (R1 = -CH2-)
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cyclization,11 metal-mediated coupling reaction,12-15 and C–H functionalization16-18 as one of 
their key steps. More detailed descriptions of some of the important strategies are discussed 
below. 
[4.1.1] Oxazoline-Mediated Synthesis5 
Meyers et al. developed a synthetic route where a Grignard reagent of 7-bromo indoline 
derivative 8 was reacted with oxazoline derivative 9 to give the biaryl compound 10 (Scheme 1).  
In this reaction, the oxazoline group of 9 serves both as a protecting group for the carboxylic acid 
and directs the Grignard reagent to couple at the ortho position to oxazoline ring of compound 9.  
Biaryl compound 10 was then subjected to hydrolysis and reduction, leading to lactamization and 
anhydrolycorinone (7).  Subsequent oxidation of 7 with DDQ resulted in the formation of 
hippadine (1) in an overall yield of 32.7% over 4 steps (Scheme 1). 
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[4.1.2] Via Intramolecular Diels-Alder Reaction 
Castedo et al. have developed a method to construct the pyrrolophenanthridine ring system 
by an intramolecular Diels-Alder reaction of appropriately substituted pyrones with alkynes.7  
On the basis of this strategy, they synthesized anhydrolycorinone (7) from the pyrone derivative 
14 (Scheme 2).6  Reaction of the homophthalic anhydride derivative 11 with pent-4-yn-1-amine 
gave the corresponding imide 12, which upon heating with malonyl derivative 13, resulted in the 
formation of 14.  Heating a solution of 14 in nitrobenzene at 210 °C, promoted the 
intramolecular cycloaddition reaction, with the loss of CO2 via retro Diels-Alder reaction, gave 
15.  Subsequent hydrolysis followed by decarboxylation of 15 resulted in the formation of 
anhydrolycorinone (7), in an overall yield of 31.9% over four steps.  
Scheme 2. Synthesis of anhydrolycorinone (7) via intramolecular an cycloaddition reaction of 
alkynyl pyrone derivative 14   
 
A similar strategy was developed by Padwa et al.,8 where they initially synthesized 
substituted indolines and tetrahydroquinolines from the intramolecular cycloaddition reaction of 
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The key compound, amido furan derivative 18 was synthesized in two steps.  The amidation of 
6-iodopiperonylic acid with the amino oxazole derivative 16, gave the amide 17.  The resultant 
amide 17 along with trimethylsilylacetylene, under Sonogoshira cross-coupling conditions, 
underwent a subsequent intramolecular cycloaddition reaction to give the desired amido furan 
derivative 18.  Heating 18 at 320 °C in 1,2,4-trichlorobenzene caused the intramolecular 
cycloaddition reaction to give anhydrolycorinone (7), in an overall yield of 11.3 % over four 
steps (Scheme 3).8   
Scheme 3. Synthesis of anhydrolycorinone (7) via an intramolecular cycloaddition reaction of 
amido furan derivative 18   
 
Boger et al. synthesized hippadine (1) in 7 steps with an overall yield of 21%, by using a 
sequential intramolecular azadiene cycloaddition reaction (Scheme 4).9  The synthesis starts with 
the displacement of one of the thiomethyl groups of tetrazine 19 with but-3-yne-1-amine 
hydrochloride to give the key intermediate 20.  Protection of the free amine in 20 with 
(Boc)2O/DMAP, and intramolecular inverse-electron-demand Diels-Alder reaction gave the 
diazine 21.  An amidation reaction with piperonylic acid derivative 23, was carried out after the 
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subsequent aromatization reaction was achieved by heating the amide 24 at 265 °C, which gave 
25.  From 25, hippadine (1) was prepared by reduction of the thiomethyl group with Raney Ni, 
followed oxidation with DDQ.  
Scheme 4. Sequential intramolecular cycloaddition reaction of tetrazine 19 leading to the 
synthesis of hippadine (1) 
 
[4.1.3] Through Radical Cyclization 
The first attempt to synthesize pyrrolophenanthridine based compounds via radical 
cyclization of 1-o-iodobenzoylindole was made by Carruthers et al. but instead they obtained 
1,2-fused aryl indole as the major product.19  Later, Tsuge et al. successfully synthesized 
hippadine (1) under the radical cyclization conditions from the benzoyl indole derivative 26,10 
which was prepared from 7-bromoindole and piperonylchloride (Scheme 5).  Even though this 
method complements previous attempts, the regioisomeric product 27 was also formed along 
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Scheme 5. Intramolecular radical cyclization of 26 leading to hippadine (1) and regioisomer 27  
!
[4.1.4] Via Iron-Mediated Oxidative Cyclization 
Knölker et al. have developed a unique strategy for the synthesis of hippadine (1) by using 
iron-mediated oxidative-cyclization as the key step (Scheme 6).20  In this strategy, ester 30 was 
prepared by treating lithium ester enolate 29 with cyclohexadienyl iron salt 28.  Ester 30 was 
then reduced to aldehyde 31 with DIBAL.  Reductive amination of 31 with amine 32 resulted in 
the formation of alkylamine substituted iron complex 33.  Complex 33 upon oxidative 
cyclization with Cp2FePF6/Na2CO3 yielded the tetrahydroindolo complex 34.  Demetalation of 
34 led to tetrahydroindole 35, which upon treatment with stoichiometric Pd(PPh3)4 underwent a 
Heck-type cyclization reaction, concurrent aromatization of the cyclohexadiene ring, and 
oxidation at the benzylic position, to give anhydrolycorinone (7).  Hippadine (1) was synthesized 
by the oxidation of 7 with DDQ, in an overall yield of 7.8% over 7 steps. 































[4.1.5] Via Copper-Mediated Alkyne Cyclization 
Recently, an interesting method was developed by Hiroya et al. for the synthesis of indoles 
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Scheme 7. Copper-mediated intramolecular cyclization of 36 en route to hippadine (1) 
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methodology, they have developed an approach for the synthesis of hippadine (1) (Scheme 7).  
Biaryl alkyne derivative 36,11 upon refluxing with a stoichiometric amount of Cu(OAc)2, 
underwent cyclization to give the indole derivative 37, which upon deprotection followed by 
formylation led to the formamide 39.  Under Bischler-Napieralski reaction conditions,21 
compound 39 gave hippadine (1), in an overall yield of 6.2% over four steps.     
[4.1.6] Using Palladium-Mediated Coupling Reactions 
It has been reported in the literature that during the synthesis of aryltrialkyl stannanes, often 
homocoupled products were obtained as undesired compounds when aryl iodides or bromides 
were treated with hexamethyl- or hexabutylditin and a Pd(0) source.22-24  On the basis of these 
results, Grigg et al. investigated the use of Pd(0)/R3Sn-SnR3 combination for the intramolecular 
coupling of aryl halides, and have successfully developed a route to the synthesis of hippadine 
(1).12  In their strategy, anhydrolycorinone (7) was prepared by the intramolecular coupling of 
the appropriately substituted diiodide derivative 40.  Then compound 7 was oxidized with DDQ 
to give hippadine (1), in an overall yield of 54% over two steps (Scheme 8).   
Scheme 8. Palladium-mediated intramolecular cyclization approach to hippadine (1) 
 
Sneickus et al. attempted the synthesis of hippadine (1), utilizing the Suzuki cross-coupling 
chemistry.13  One of the Suzuki coupling partners 41 was synthesized by the thallium-mediated 
























41, and after a subsequent lactamization gave anhydrolycorinone (7).  Oxidation of 7, with DDQ 
gave hippadine (1) in an overall yield of 34.2% over five steps (Scheme 9). 
Scheme 9. Hippadine (1) synthesis via Suzuki cross-coupling  
 
Having observed that the Suzuki coupling conditions developed by Snieckus et al. resulted in 
low yields (41 + 42, Scheme 9), Tønder et al. extensively studied on this particular coupling 
reaction by modifying and interchanging the coupling partners.14  They also tested the other 
cross-coupling reactions such as the Kumada, the Negishi and the Stille reactions, but they were 
unsuccessful in preparing the requisite metalated coupling partners.  However, they developed a 
one-pot synthesis of hippadine (1), by borylation of 7-bromoindole followed by cross-coupling 
with 6-iodopiperonyl ester 44 and subsequent lactamization (Scheme 10). 
Scheme 10. One-pot synthesis of hippadine (1) from 7-bromoindole 
  
Kerr et al. developed a strategy that involves a palladium-mediated amidation as a key 
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46 was prepared by a palladium-mediated amidation of carbonate 45 with piperonylamide, and a 
subsequent intramolecular cyclization reaction.  Amide 46 upon oxidative-cyclization with 
PIFA/BF3!Et2O gave anhydrolycorinone (7), which upon oxidation with DDQ resulted in the 
formation of hippadine (1), in an overall yield of 56.4% over three steps (Scheme 11).   
Scheme 11. Synthesis of hippadine (1) via a palladium-mediated amidation reaction 
 
[4.1.7] By C–H Functionalization 
Knowing the importance of 7-substituted indoles and the difficulties involved in their 
synthesis, Snieckus et al. studied the synthesis of 7-substituted indoles by C–H 
functionalization.16  They were able to successfully install various electrophiles at position C-7 
of 1-(N,N-diethylcarbomyl)-2-trimethylsilyl indole under strongly basic conditions, with the 
amide group acting as a metalation director, and the trimethylsilyl group acts as a blocking agent 
at the C-2 position.  On the basis of these results they have synthesized 7-borylated indole 
derivative 48 by lithiation followed by borylation of 1-(N,N-diethylcarbomyl)-2-trimethylsilyl 
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49 under Suzuki conditions, to give biaryl compound 50 as well as hippadine (1) in 9:1 ratio, 
respectively.  The biaryl compound 50 was cyclized with either NaOH or LiOH to give 
hippadine (1). 
Scheme 12. Lithium mediated C–H functionalization reaction leading to 1 
 
Hartwig et al. further explored the synthesis of 7-borylated indoles, by an using iridium-
catalyzed C–H functionalization, precluding the necessity of blocking groups at the C-2 of the 
indole.17  On the basis of this methodology, they have developed a one-pot synthesis of 
hippadine (1, Scheme 13).  Initially, the nitrogen atom of the indole was silylated using Et3N, 
Me2SiHCl.  The silyl group attached to the nitrogen directs the iridium catalyst to selectively 
activate C–H bond at the C-7 of the indole, forming the plausible intermediate 52.  This 
intermediate undergoes borylation to give the 7-borylated indole derivative. Once the borylated 
species is formed, it was subjected to Suzuki cross-coupling conditions with the bromo ester 51.  
Under these conditions, the silyl group on the nitrogen of the indole underwent desilylation, and 
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Scheme 13. One-pot synthesis of 1 by C–H functionalization of indole 
 
Garden et al. developed a method for C–H functionalization at the C-7 position of indole but 
by a completely different approach.18  In this approach, benzyl isatin 54 was synthesized from 
isatin and benzyl chloride derivative 53 (Scheme 14).  The keto group of benzyl isatin 54, was 
then converted to its corresponding spiro-dioxolane 55.  Palladium catalyzed C–H 
functionalization at the C-7 position of isatin part of spiro-dioxolane 55 gave the cyclized 
product 56.  Once the cyclized product 56 was obtained, it was hydrolyzed to isatin derivative 57, 
which upon carbonyl reduction followed by oxidation with MnO2-SiO2 gave hippadine (1). 
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Many of the strategies developed so far for the synthesis of hippadine (1), require multiple 
steps, harsh reaction conditions, specialized starting materials that are not easily accessible, and 
use of stoichiometric amounts of expensive catalysts.  Hence we decided to evaluate a relatively 





[4.2] RESULTS AND DISCUSSION 
Recently, Lakshman et al. developed a simple method for the synthesis of amides from 
various carboxylic acids and amines by using the inexpensive combination of PPh3 and I2 or 
polymer-supported PPh3 and I2 (Scheme 15).25  Reactions of wide variety of aromatic, alkyl, and 
hetero-aromatic carboxylic acids with aromatic, alkyl (1o, 2o) amines were tested under the 
conditions developed, and these gave fruitful results.  In those cases where the yields were 
moderate, an additional equivalent of phosphine 
and I2 or the base led to improve yields. 
The scope, generality, involvement of cheap 
reagents such as PPh3, I2, as well as the ease of 
purification made this an attractive route to 
hippadine (1), which possess an amide 
functionality.  According to our strategy, 
illustrated in Scheme 16, hippadine (1) can be 
easily obtained by the oxidation2,13 of 
anhydrolycorinone (7), which can be obtained by 
Scheme 16. Retrosynthetic analysis for 
the synthesis of hippadine (1)  
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the oxidative-cyclization of amide 46.  By employing the PPh3/I2 amidation reaction conditions 
to piperonylic acid and indoline, the amide 46 can be easily attained.   
On the basis of our strategy discussed above, we initially started the synthesis of N-
(piperonoyl)indoline (46), by reaction of piperonylic acid and indoline using 1 molar equivalent 
each of PPh3 and I2, and 1.5 molar equivalents of iPr2NEt in CH2Cl2 as solvent (Scheme 17).  
Under these conditions, amide 46 was obtained in 70% yield.  When the reaction was performed 
under similar conditions except that PPh3 was replaced by Pol-PPh3, amide 46 was obtained in a 
comparable 74% yield (Scheme 17).  
Scheme 17. Synthesis of N-(piperonoyl)indoline (46) using PPh3/I2 and Pol–PPh3/I2 
 
In the course of examining the spectral data of product 46, we observed some unusual 
features.  Even though the 1H NMR data of our product matched that reported,15 it is quite 
surprising that in CDCl3, compound 46 showed only six aromatic resonances instead of seven 
aromatic resonances (Panel A, Figure 2).  To be certain that no other side reactions occurred on 
one of the aromatic rings during the course of the reaction, we sought additional data.  Hence, the 
1H NMR spectrum of compound 46 was recorded in C6D6.  Here we observed an additional 
broad signal at 8.1 ppm (Panel B, Figure 2), which increased in intensity upon heating the 1H 
NMR sample.  Finally, a clearly discernible resonance was observed when the spectrum was 
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in C6D6, further confirmed that the new downfielded resonance that appeared in the spectrum 
indeed belonged to the amide 46.  Also, a long-range coupling of a benzylic CH2 with an 
aromatic proton of the indoline ring was observed (Figure 3). 
 
Figure 2. NMR studies on amide 46. Panel A: 1H NMR spectrum of compound 46 in CDCl3 at 
25 °C. Panel B: 1H NMR spectrum of compound 46 in C6D6 at 25 °C. Panel C: 1H NMR 
spectrum of compound 46 in C6D6 at 70 °C.   
 
! 255!
Figure 3. COSY spectrum of 46 in C6D6 at 70 °C showing a correlation between the aromatic 
proton and the new resonance and a long range coupling between the benzylic CH2 and an 
aromatic proton.  
Oxidative cyclization of amide 46 with PIFA and BF3!Et2O in CH2Cl2 at –25 °C, resulted 
anhydrolycorinone (7) in 23% yield (Scheme 18).  This result is much lower than what is 
reported in literature (83% reported yield).15  However, the 23% yield was consistently 
reproducible in our hands.  One possible reason for the low yield could be the subambient 
temperature of the reaction.  At low temperature there could be restricted rotation around the 
amide linkage.  Thus if in the rotamers the two aryl rings do not come in proximity for the 
reaction to occur, this could produce a low yield.  This argument is supported by the fact that, the 
1H NMR spectrum of an amide similar to 46 (N-(3,4-dimethoxybenzoyl)indoline) in CDCl3 at 
room temperature, showed four distinct methoxy resonances at δ = 3.31, 3.30, 3.28, and 3.27 
ppm.  These slowly merged into two signals upon heating the sample.  This amide under the 
same oxidation conditions did not cyclize.25  These results clearly support the possibility of 
rotamers in the case of N-(piperonoyl)indoline (46) at sub-ambient temperature, and thus the low 
yielding reaction.  Oxidation of anhydrolycorinone (7) with DDQ, proceeded uneventfully to 
yield hippadine (1) in 78% yield (Scheme 18). 
Scheme 18. Synthesis of hippadine (1) from anhydrolycorinone (7) by oxidative cyclization of 46 
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We have developed a straightforward approach for the synthesis of hippadine (1) via 
anhydrolycorinone (7) using a PPh3/I2 mediated amidation reaction as a key step.  Both PPh3/I2 
and Pol-PPh3/I2 combinations gave comparable amidation yields, when piperonylic acid and 
indoline were reacted, to give N-(piperonoyl)indoline 46.  The amide obtained via this amidation 
conditions was confirmed as the desired amide 46, with its 1H NMR and COSY data.  Amide 46 
was cyclized by PIFA and BF3!Et2O to give anhydrolycorinone (7), which was finally oxidized 










[4.4] EXPERIMENTAL SECTION 
General Experimental Considerations. Thin-layer chromatography was performed on 200 µm 
aluminum-back silica gel plates and column chromatographic purifications were performed on 
200–300 mesh silica gel. CH2Cl2 and iPr2NEt were distilled from CaH2, and THF was distilled 
from LiAlH4 and redistilled from Na prior to use. All other reagents were obtained from 
commercial sources and were used without further purification. Pol–PPh3 (PS-
triphenylphosphine, 2.28 mmol/g) was obtained from Biotage. 1H NMR spectra were recorded at 
500 MHz and are referenced to the residual protonated solvent. Chemical shifts (δ) are reported 
in parts per million (ppm) and coupling constants (J) are in hertz (Hz). 
N-(Piperonoyl)indoline (46)15 
 
Using Pol–PPh3: To a stirring solution of I2 (253.8 mg, 1.0 mmol) in dry CH2Cl2 (5 mL) at 0 °C 
was added Pol–PPh3 (438.0 mg, 1.0 mmol). The reaction mixture was flushed with nitrogen gas 
and allowed to stir at 0 °C for 5 min. At this temperature, piperonylic acid (166.1 mg, 1.0 mmol) 
was added, followed by the dropwise addition of iPr2NEt (260.0 µL, 1.5 mmol) and indoline 
(112 µL, 1.0 mmol). The reaction mixture was slowly brought to room temperature and allowed 
to stir for 2 h. The mixture was filtered and evaporated to dryness. Chromatographic purification 
on a silica gel column (30% EtOAc in hexanes) afforded 199.2 mg (74% yield) of N-

















Using PPh3: To a stirring solution of I2 (253.8 mg, 1.0 mmol) in dry CH2Cl2 (5 mL) at 0 °C was 
added PPh3 (438.0 mg, 1.0 mmol). The reaction mixture was flushed with nitrogen gas and 
allowed to stir at 0 °C for 5 min. At this temperature, piperonylic acid (166.1 mg, 1.0 mmol) was 
added, followed by the dropwise addition of iPr2NEt (260.0 µL, 1.5 mmol) and indoline (112 µL, 
1.0 mmol). The reaction mixture was slowly brought to room temperature and allowed to stir for 
2 h. The reaction mixture was diluted with water and extracted with CH2Cl2. The organic layer 
was dried with anhydrous Na2SO4 and evaporated under reduced pressure. Chromatographic 
purification on a silica gel column (30% EtOAc in hexanes) afforded 188.4 mg (70% yield) of N-
(piperonoyl)indoline as a colorless solid. Rf (SiO2/40% EtOAc in hexanes) = 0.60. 1H NMR (500 
MHz, CDCl3, ambient temperature): δ 7.21 (d, 1H, Ar-H, J = 7.4 Hz), 7.18–7.09 (br s, 1H, Ar-H), 
7.09 (dd, 1H, Ar-H, J = 1.3, 8.0 Hz), 7.05 (s, 1H, Ar-H), 7.01 (t, 1H, Ar-H, J = 7.4 Hz), 6.85 (d, 
1H, Ar-H, J = 8.0 Hz), 6.03 (s, 2H, OCH2), 4.10 (t, 2H, NCH2, J = 7.9 Hz), 3.11 (t, 2H, 
indolinyl-CH2, J = 7.9 Hz). 1H NMR (500 MHz, C6D6, 70 °C): δ 7.96 (br s, 1H, Ar-H), 7.01 (t, 
1H, Ar-H, J = 8.0 Hz), 6.98 (s, 1H, Ar-H), 6.91 (d, 2H, Ar-H, J = 7.8 Hz), 6.84 (t, 1H, Ar-H, J = 
7.3 Hz), 6.53 (d, 1H, Ar-H, J = 7.8 Hz), 5.31 (s, 2H, OCH2), 3.54 (t, 2H, NCH2, J = 8.0 Hz), 2.47 
(t, 2H, indolinyl-CH2, J = 8.0 Hz). 
Anhydrolycorinone (7)2,26 
 
In a clean and dry 50 mL round-bottom flask equipped with a stir bar, phenyl iodonium 












25 °C, 1.5 h
23%
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min at –25 °C under an argon balloon.  To this stirring reaction mixture, BF3!Et2O (228 µL, 1.8 
mmol) was added dropwise followed by the addition of a solution of N-(piperonoyl)indoline 
(200 mg, 0.748 mmol) in dry CH2Cl2 (6 mL) maintaining the temperature at –25 °C. This 
reaction mixture was stirred at the same temperature for 1.5 h at which point TLC showed the 
consumption of the starting material. The mixture was then neutralized with saturated aq 
NaHCO3 (25 mL) and washed with deionized water (3 x 20 mL). The aqueous layer was back 
extracted with EtOAc (3 x 15 mL). The organic layers were combined, washed with brine (20 
mL), dried over anhydrous Na2SO4, and carefully evaporated. Purification of the crude material 
on a short silica gel column using 50% EtOAc in hexanes yielded 45.6 mg (23% yield) of 
anhydrolycorinone (7) as a dark-brown solid.  Rf (SiO2/100% EtOAc) = 0.32.  1H NMR (500 
MHz, CDCl3): δ 7.93 (s, 1H), 7.76 (d, 1H, J = 7.7 Hz), 7.56 (s, 1H), 7.30 (dd, 1H, J = 0.9, 7.2 
Hz), 7.20 (t, 1H, J = 7.6 Hz), 6.13 (s, 2H), 4.47-4.50 (m, 2H), 3.44 (t, 2H, J = 8.2 Hz). 
Hippadine (1)2 
 
In a clean, dry 100 mL round-bottom flask equipped with a stir bar, anhydrolycorinone (7) (40 
mg, 0.15 mmol) dissolved in dry benzene (50 ml). DDQ (136.2 mg, 0.60 mmol) was added and 
the mixture was refluxed for 18 h, and then benzene was evaporated.  The resulting crude solid 
was dissolved in EtOAc (15 mL) and washed with saturated aq NaHCO3 (3 x 15 mL), deionized 
water (10 mL), and then brine (10 mL). The organic layer was dried over Na2SO4 and evaporated. 
Purification of the crude material over a short silica gel plug using 20% EtOAc in hexanes gave 















1H, J = 3.6 Hz), 7.99 (s, 1H), 7.93 (d, 1H, J = 7.7 Hz), 7.76 (d, 1H, J = 7.7 Hz), 7.67 (s, 1H), 
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SYNTHESIS OF DEUTERATED 1,2,3-TRIAZOLES 
[5.1] INTRODUCTION 
Among the heterocyclic compounds, 1,2,3-triazoles are of great importance because of their 
applications in various fields.  They are found to be active against HIV,1 Cantagalo,2 SARS, and 
orthopox viruses.3  1,2,3-Triazole derivatives are also used as insecticides,4 fungicides,5 plant 
growth regulators,6,7 optical brighteners,8 corrosion inhibitors,9 and photo stabilizers.10  The 
Huisgen 1,3-dipolar cycloaddition of azides and alkynes is one of the most atom-economical 
synthesis of 1,2,3-triazoles.11,12  However, under the thermal conditions two isomers, 1,4- and 
1,5-disubstituted 1,2,3-triazoles are often observed, as this process lacks regioselectivity 
(Scheme 1). 
Scheme 1. 1,2,3-Triazole synthesis by Huisgen azide–alkyne ligation 
 
Independent research by Sharpless and coworkers13 and Meldal and coworkers14 led to the 
discovery of a copper-catalyzed azide–alkyne cycloaddition (CuAAC) reaction, and 1,4-
disubstituted 1,2,3-triazoles became more accessible.  These reactions are mild and highly 
regioselective (Scheme 2).  The CuAAC reactions are catalyzed by Cu(I) salts in presence of 
protic solvents.  Some of the Cu(I) sources typically used in the CuAAC reactions are CuI14 and 
a combination of CuSO4/Na ascorbate.13  




















Sharpless et al. first proposed the mechanism for the CuAAC reaction13 (Figure 1), where  
the Cu(I) catalyst initially reacts with the alkyne to form a copper (I) acetylide 1A.  This species 
1A, coordinates to the azide to form intermediate 1B, which then cyclizes to give a six-
membered metallocycle 1C.  This intermediate rearranges to give the cuprated triazole 1D. Upon 
abstraction of a proton from the solvent, the cuprated triazole 1D is converted to the 1,4-
disubstituted 1,2,3-triazole (1) and the Cu(I) catalyst.  There are assumptions that once copper (I) 
acetylide 1A reacts with the azide, it directly forms the cuprated triazole intermediate 1D in a 
concerted pathway.  However, the DFT calculations showed that a step-wise mechanistic 
pathway is favored over the concerted pathway by about 12-15 kcal.13 
 








































A number of important features were recognized during recent mechanistic investigations of 
CuAAC reaction.15-18  It was found that CuAAC reactions are second order in Cu(I) under 
catalytic conditions.  One of the two possible explanations is that the azide and alkyne are 
activated by different metal centers like in the intermediate 1E (Figure 2a).16  The second 
explanation was on the basis of the observation that the electron density of C-1 in the 
intermediate 1C (Figure 1) is localized.  Hence it was postulated that the second copper atom 
may provide extra stability to the intermediates and the transition state to the path of 1I, by 
coordinating with either the triple bond of the alkyne (1F, 1G) or the C-1 carbon of the 
intermediates 1H and 1I (Figure 2b).15 
 
Figure 2. (a) Azide-alkyne interaction by a dinuclear metal complex. (b) Mechanistic outline of 
the intermediates with σ- and π-coordinated metal centers to the alkyne leading to 1I. 
Although the involvement of Cu-acetylides in CuAAC reaction is highly anticipated, the 
involvement of π-coordinating copper with the alkyne is questionable.16-18  However, recent 
studies by Cantillo et al. proved the intermediacy of the Cu-acetylides formed from the terminal 
alkynes.18  They observed that the copper-catalyzed reaction of benzyl azide with (ethynyl-
D)benzene in t-BuOH/H2O gave only the C-5 protio triazole 3a, rather than the C-5 deuterated 
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3b would be the product. Since 3a is exclusively formed under these conditions, it is clearly 
evident that Cu-acetylides are formed and may be responsible for the CuAAC reaction.   
Scheme 3. Regioselective synthesis of 1,4-disubstituted 1,2,3-triazoles by CuAAC 
 
In order to prove the intermediacy of a π-complex between copper with the alkyne in 
CuAAC reactions, Fokin et al. conducted experiments with benzyl azide and a stoichiometric 
amount of Cu-acetylide 4 in the presence and absence of Cu(PPh3)4NO3 catalyst (Scheme 4).  
These reactions were monitored by real-time heat-flow reaction calorimetry and showed that the 
catalyzed reaction was complete within 20 min to form the copper triazolide 5.  On the other 
hand, the uncatalyzed reaction showed no conversion to the copper triazolide 5.  Similar results 
were observed when other azides and soluble copper catalysts were used.  These results clearly 
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Scheme 4. Experiments conducted to study the role of copper π-complex and isotopic 
enrichment of copper triazolide 5 
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the role of two copper atoms, another experiment was conducted with benzyl azide and copper 
acetylide 4 (63Cu-69% and 65Cu-31%) with isotopically pure copper-63 catalyst 
(63Cu(MeCN)4PF6)  in THF at room temperature (Scheme 4).  This reaction was monitored by 
time-of-flight mass spectrometry (TOF-MS) and showed the formation of copper triazolide 5.  
Surprisingly, the triazolide 5 was 50% isotopically enriched (63Cu-85% and 65Cu-15%).  The 
isotopic enrichment of copper triazolide 5 could have taken place via the copper acetylide 4 
and/or via triazolide intermediate 5 and/or within an intermediate during cycloaddition reaction.  
However, when copper acetylide 4 and triazolide 5 were individually reacted with isotopically 
pure catalyst 63Cu(MeCN)4PF6 neither showed any isotopic enrichment.  This clearly indicated 
that the enrichment event took place during the cycloaddition reaction.   
On the basis of all the observations discussed above, Fokin et al. proposed a plausible 
mechanism for the CuAAC reaction (Figure 3).  In this mechanism, the alkyne initially forms a 
copper π-complex 1J, which then undergoes deprotonation to form π-coordinated copper 
acetylide species 1K with another copper atom.  Then the azide coordinates to the π-bound 
copper atom to form intermediate 1L.  Next, the β-carbon atom of the alkyne attacks at the N-3 
atom of the azide to give the intermediate 1M.  The ligand exchange is more likely to take place 
within intermediate 1M, since from the previous discussion, it is known that ligand exchange did 
not occur from the copper acetylide 4 and the triazolide 5 to the 63Cu catalyst.  Intermediate 1M, 
containing two chemically equivalent copper atoms, also accounts for the isotopic enrichment 
observed in the case of triazolide 5.  Intermediate 1M then results in the formation of cuprated 
triazole 1N via the mononuclear metallacycle stabilized by the second copper atom (as shown in 
Figure 2b).  By abstracting a proton from solvent, cuprated triazole 1N is converted to the 1,4-
disubstituted 1,2,3-triazole (1) and the Cu(I) catalyst.  
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Figure 3. Proposed mechanistic model for the CuAAC reaction showing the involvement of two 
copper atoms in the mechanism 
As discussed earlier, C-5 deuterated triazoles from terminal deuterated alkynes is highly 
improbable to form, under aqueous conditions (Scheme 3).  However, aqueous conditions are 
essential as they have been shown to increase the rate of CuAAC reactions.17  Thus, it was quite 
surprising that very few transformations were reported that lead to the deuterated triazoles and 
none involving CuAAC. Some of the previously reported methodologies are shown in Scheme 5.  
Recently, Micouin et al. reported a methodology for the synthesis of C-5 deuterated triazoles 
(Scheme 5, eq. 1).19  In this transformation, ethynylbenzene is aluminated by treating it with 
AlMe3 and MeN(SiMe3)2 to give dimethylphenylalkynylaluminum 6.  Then compound 6 was 
reacted with benzyl azide in the presence of CuI and N,N,N′,N′′,N′′-
pentamethyldiethylenetriamine (PMDTA) to give aluminated triazole intermediate 7, which upon 
exposure to DCl/D2O resulted in the formation of C-5 deuterated triazole 8.  Hu et al. reported 
another transformation for the synthesis of C-5 deuterated triazoles by AcOD promoted copper 
catalysis (Scheme 5, eq. 2).20  Dinuclear copper acetylide 9 was initially prepared from a Cu(I) 








































with benzyl azide to give the C-5 deuterated triazole 8. However, unlike other processes, this 
process is stoichiometric in Cu-acetylide and does not lead to 8 from the corresponding cuprated 
triazole in the absence of AcOD.  
Scheme 5. Previously reported syntheses of deuterated triazoles  
 
One of the oldest strategies utilized for the synthesis of C-5 deuterated triazole synthesis was 
developed by Ohta et al., where the triazole 10 is initially lithiated at the C-5 position by 
treatment with n-BuLi in THF (Scheme 5, eq. 3).21  Quenching this lithiated triazole 11 with D2O 
gave the C-5 deuterated triazole 12.  A complementary method was reported by Krasiński et al. 
for the synthesis of C-4 deuterated triazole from magnesium acetylide (Scheme 5, eq. 4).22 
Ethynylbenzene was reacted with 1 M solution of EtMgBr in THF at –40 °C, to give magnesium 
acetylide 13, which upon treatment with phenyl azide gave the corresponding magnesiated 
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triazole 14.  Triazole 14 upon reaction with DCl/D2O gave the C-4 deuterated triazole 15. 
Dideuterated triazole 16 was also reported by the reaction of CaC2 with an azide in the presence 
of CuI, Et3N and D2O, at 55 °C (Scheme 5, eq. 5).23  Sharpless et al. reported that C-5 
deuteration of triazoles by CuAAC reaction, but the details are unavailable.17 
The role of deuterated molecules in studying reaction mechanisms, biosynthetic pathways, 
and mass spectrometry is well known.  Also, deuterium substituted drug candidates, called as 
“heavy drugs,” have shown potential advantages over their unsubstituted analogues.  The 
effectiveness of a drug may decrease due to its metabolism in the body by the cleavage of C-H 
bonds. This sometimes may lead to side effects.  Hence, by switching those weak C–H bonds 
with the relatively stronger C–D bonds can slow down this unwanted metabolic activation.24-28 
Examples of deuterated analogues of some of the drug candidates are shown in Figure 4.  
The deuterated analogues of several drugs have shown superiority over their protio analogues 
by circumventing the undesired metabolic activation and longer retention in the biological 
system.  For example, the deuterated analogue of the HIV protease inhibitor atazanavir, CTP-518 
(Figure 4), has proven to show slower hepatic metabolism.24  It also eliminated the necessity of 
“anti-HIV boosters”, which are very expensive.27  In the undeuterated version of CTP-347 
(paroxetine), the methylene dioxy group generates a carbene during the metabolism which 
irreversibly inactivates hepatic CYP2D6.24  This process inhibits the uptake of other drugs co-
administered with it.24-26 CTP-347 successfully circumvents the formation of carbene and 
thereby prevents the inactivation of CYP2D6.  Other deuterated analogues of commercial drugs 
C-20081 (deuterated analogue of the antibiotic, linezolid), SD-254 (deuterated analogue of the 
antidepressant, venlafaxine), and tamoxifen-d5 (dueterated analogue of tamoxifen, used to treat 
breast cancer), exhibited superior activity over their fully protio analogues.24-29  
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Figure 4. Some deuterated pharmaceutical agents. 
On the basis of all these considerations of isotopic labeling, as well as the medicinal 
importance of 1,2,3-triazoles, we decided to develop a simple and mild synthesis of C-5 




























































[5.2] RESULTS AND DISCUSSION 
Our hypothesis for the one-pot triazole-forming deuteration strategy mainly relies on the 
following mechanistic considerations of CuAAC reaction.  The acidity of alkynyl proton is 
increased by the π-coordination of Cu(I) to the terminal alkyne.  This facilitates the formation of 
Cu-acetylides in aqueous media.17  Since the azide coordination to the Cu center occurs after the 
formation of Cu-acetylide, terminal alkynes can be directly utilized.  However, our hypothesis 
mainly relies on the cuprated triazole intermediate 1D, (Figure 1) formation step.  In a typical 
CuAAC reaction, 1D is protonated from a proton source, to give 1,4-disubstituted C-5 protio 
triazole.13  Hence, by deuteration of 1D, from a cheap deuterium source like D2O, 1,4-
disubstituted C-5 deuterated triazole can be obtained. 
Typical solvent system used in CuAAC reactions is a mixture of t-BuOH and H2O.13 Hence, 
the mixture of t-BuOD and D2O can be used for our methodology, but that would be cost 
prohibitive.  Recently, Lakshman et al. observed the competing azide reduction in their CuAAC 
reactions of 6-azidopurine nucleosides.30  This is not a typical case in CuAAC reactions, and 
they have overcome it by using biphasic reaction medium i.e., 1:1 CH2Cl2 and H2O. This guided 
us to use the biphasic solvent system with D2O as one of the phases.  This should allow the C-5 
cuprated triazole 1D formed in the CuAAC reaction, to get deuterated from D2O.    
On the basis of the aforementioned considerations, the initial optimization conditions for the 
formation of 1,4-disubstituted, C-5 deuterated triazoles were tested (Table 1).  CuSO4!5H2O was 
dried and desiccated prior to the reaction, to reduce the risk of competing protonation of cuprated 
triazole intermediate.  The extent of %D incorporation increased with the usage of rigorously 
dried CuSO4 and 99.8% D2O (entry 2).  However, the reaction was incomplete and 8% of phenyl 
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azide (14) was recovered. By increasing the catalyst loading, a complete reaction was achieved 
with 75% yield and 96% D incorporation (entry 3).  In this case %D incorporation was assessed 
in two ways. 96% D incorporation was observed when CH2Cl2 was used as internal NMR 
standard, where as 94% D incorporation was observed when residual H-5 resonance was 
compared with the other resonances of 16a.  Additional attempts were made to enhance the %D 
incorporation by performing a reaction under the same conditions as in entry 3, except that Na 
ascorbate was evaporated from D2O under vacuum.  However, this did not improve the %D 
incorporation (entry 4).  To reduce the proton source, a reaction was carried out with 1 
equivalent of alkyne, but this resulted in an incomplete reaction (entry 5).  In order to evaluate 
whether a water miscible solvent would ameliorate the reaction, a 1:1 mixture of CH3CN/D2O 
was used as the solvent system.  To our surprise, only 5% of the product was observed after 24 h 
(entry 6).  In order to confirm this result, another reaction was carried out with 1:1 CH3CN/H2O, 
again 5% product was observed even after 5 d (entry 7).  Prior investigations on CuAAC reaction 
reported the primacy of CH2Cl2/H2O over CH3CN/H2O, DMSO/H2O, EtOH/H2O, t-BuOH/H2O 
and other solvent combinations.31  Other Cu(I) source, CuCl was also evaluated, but it did not 
turn out to be advantageous over CuSO4!5H2O (entry 8).  
Table 1. Optimization for Cu(I) catalyzed synthesis of C-5 deuterated 1,2,3-triazolesa 
 
Entry Solvent, Catalytic System, Reation Time Product: Resultsb,c 
1d,e 1:1 CH2Cl2/D2O, 5 mol% CuSO4, 10 mol% Na ascorbate, 12 h 
16a: 60% yield, 80% D 
incorporation, reaction was 
incompletef 
2g,h 1:1 CH2Cl2/D2O, 7 mol% CuSO4, 15 mol% Na ascorbate, 12 h 
16a: 65% yield, 95% D 









14                        15                                         16a, R = D, δ = 8.19 ppm
                                                                         16b, R = H, δ = 8.16 ppm
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incompletei 
3g,h 1:1 CH2Cl2/D2O, 10 mol% CuSO4, 20 mol% Na ascorbate, 12 h 
16a: 75% yield, 96% D 
incorporation 
4g,h 1:1 CH2Cl2/D2O, 10 mol% CuSO4, 20 mol% Na ascorbate (dried from D2O), 12 h 
16a: 74% yield, 96% D 
incorporation 
5g,h,j 1:1 CH2Cl2/D2O, 10 mol% CuSO4, 20 mol% Na ascorbate (dried from D2O), 12 h 
16a: reaction was incomplete (ca. 
80% azide consumed) 
6g,h 1:1 CH3CN/D2O, 10 mol% CuSO4, 20 mol% Na ascorbate (dried from D2O), 24 h 
16a: reaction was incomplete (< 
5% azide consumed)k 
7 1:1 CH3CN /H2O, 10 mol% CuSO4, 20 mol% Na ascorbate, 5 d 
16b: reaction was incomplete (< 
5% azide consumed)k 
8 1:1 CH2Cl2/H2O, 20 mol% CuCl, 24 h 16b: reaction was incompletel 
a Reactions were conducted at room temperature with 0.2 M azide and 2 mol equiv of alkyne in 
anhydrous CH2Cl2 or in CH3CN.  b Yield of isolated and purified product.  c %D incorporation 
was assessed from the residual H-5 resonance in the 1H NMR.  Deuterium resonances are 
referenced to the 2H resonance of CDCl3 (δ = 7.24 ppm).  d D2O contained 98% D (not a freshly 
opened sample).  e CuSO4•5H2O was heated with a heat gun until the color changed from blue to 
grey.  f Phenyl azide (10%) was recovered.  g D2O contained 99.8% D.  h CuSO4•5H2O was 
heated at 120 ˚C, under vacuum, until the color changed from blue to grey.  i Phenyl azide (8%) 
was recovered.  j 1 mol equiv of alkyne was used.  k Assessed by 1H NMR.  l Assessed by TLC. 
 
Once the initial optimization conditions were evaluated, we next focused on assessing the 
generality of C-5 deuteration strategy.  A wide spectrum of various azides and alkynes were 
tested, and good to excellent yields were obtained with high %D incorporation (Table 2).  2H 
NMR chemical shifts of C-5 deuterium of all the triazole are shown in parenthesis.  Compounds 
17-23 are structurally similar to resveratrol triazole analogues that have shown potent cytotoxic 
and antiproliferative activity higher than resveratrol.  Complex nucleoside triazoles 25 and 26 
were also synthesized with high yields and excellent %D incorporation.  The yield of the AZT 
based triazole 25 is comparable to the microwave assisted CuAAC of AZT.32  These AZT based 
protio triazoles, have proven to be excellent Ureaplasma parvum thymidine kinase inhibitors.32  
The C-6 azidopurine nucleoside, which is the precursor of 26 was known to show significant 
azide-tetrazole equilibrium, and readily reduced under CuAAC conditions.30  However, we did 
not encounter any issues under our CuAAC conditions. Pyridine-based triazole derivative 24, a 
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deuterated analogue of a highly active nicotinic acetylcholine receptor modulator 29, was also 
synthesized in good yield.  
Table 2. Scope of the one-pot triazole-forming deuteration strategya-e 
 
a Reactions were conducted at room temperature with 0.2 M azide and 2 mol equiv of 
alkyne.  b Yields are of isolated and purified products.  c %D incorporation was assessed 
from the residual H-5 resonance in the 1H NMR.  Deuterium resonances are referenced 
to the 2H resonance of CDCl3 (δ = 7.24 ppm).  d Syntheses of 15 to 23 were performed 
with 10 mol% CuSO4, 20 mol% Na ascorbate (0.048 M solutions of CuSO4 and 0.096 
M Na ascorbate were prepared in 99.8% D2O and used).  e Synthesis of 24 was 
performed with 5 mol% CuSO4, 10 mol% Na ascorbate (0.048 M solutions of CuSO4 











































17: 72%, (rxn time 24 h)
94% D (δ = 8.22 ppm)
20: 91%, (rxn time 12 h)
97% D (δ = 8.16 ppm)
25: 96%, (rxn time 7 h)
96% D (δ = 7.65 ppm)
21: 85%, (rxn time 48 h)
96% D (δ = 8.20 ppm)
23: 71%, (rxn time 24 h)
98% D (δ = 7.97 ppm)
22: 72%, (rxn time 48 h)





24: 70%, (rxn time 48 h)
94% D (δ = 8.38 ppm)
18: 87%, (rxn time 24 h)
96% D (δ = 8.10 ppm)
19: 70%, (rxn time 24 h)





10 mol % CuSO4












26: 88%, (rxn time 4 h)
95% D (δ = 9.35 ppm)
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Compound 29 was also synthesized under the same CuAAC reaction conditions except that 
D2O was replaced with H2O (Scheme 6). 29 was obtained in 70% yield, while the literature 
reported yield was 54%.33  
Scheme 6. Synthesis of 29 under CuAAC reaction conditions 
   
These results clearly display the efficiency and generality of this methodology.  This made us 
curious to build poly- and fully deuterated molecules by using our deuteration strategy, where 




20 mol% Na ascorbate
 CH2Cl2/H2O





29 (δ = 8.33 ppm)
NC
27 28
Scheme 7. Synthesis of poly- and fully deuterated triazoles 
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three compounds (31, 34 and 35) were synthesized (Scheme 7).  Compound 31 was synthesized 
from phenyl azide-D5 (30) and 4-ethynyltoluene (15), where as compound 34 was synthesized 
from ethynylbenzene-D5 (32) and TBDMS-protected AZT 33.  Fully deuterated 1,2,3-triazole 35 
was synthesized from phenyl azide-D5 (30) and ethynylbenzene-D5 (32).  The %D incorporation 
of the triazolyl deuterium in compounds 31 and 33 was assessed from the residual H-5 resonance 
in the 1H NMR spectra, where as in the case of 35, it was assessed by using CH2Cl2 as an internal 
standard.  
We next focused on evaluating the extent of protonation versus deuteration, when both 
processes compete in the CuAAC reaction.  Since the O–D bond is more stronger than O–H 
bond, deuteration should be less favorable than protonation.34  In order to assess that, we have 
conducted two parallel experiments with phenyl azide (14) and 4-ethynyltoluene (15).  The co-
solvent in one reaction was D2O (99.8%), and in the other reaction was equimolar H2O/ D2O 
(99.8%) (Scheme 8).  The amount of 16b formed in the reaction with D2O (99.8%) basing on the 
1H NMR, using CH2Cl2 as internal standard, was calculated to be 4%. Where as in the case of the 
other reaction it was 73% (77% observed–4% observed in the control experiment).  The yields 
from the reactions with D2O and H2O/ D2O are 74% and 76% respectively. The ratio of 16b/16a 




in the reaction with H2O/ D2O is 2.7.  The higher percentage of 16b as compared to 16a could be 
due to the rapid protonation of cuprated triazole.  This could be one of the major reasons for the 












In summary, a simple and mild method has been developed for the regioselective C-5 
deuteration of 1,2,3-triazoles by the CuAAC reaction, using dehydrated CuSO4 and Na ascorbate.  
For these reactions, the biphasic CH2Cl2/D2O system was clearly superior to CH3CN/D2O system.  
Under these conditions, no reduction of the azide in the azido purine nucleosides occurs.  Poly- 
and fully deuterated 1,2,3-triazoles were also synthesized by using this methodology.  On the 
basis of our strategy, multiply labeled compounds can be synthesized by combining deuteration 
strategy with the incorporation of other isotopes such as 13C and 15N.  This one-pot deuteration 
strategy is likely to be of importance to medicinal chemistry applications, as it avoids the 














[5.4] EXPERIMENTAL SECTION 
General Experimental Considerations.  Thin layer chromatography was performed on 
aluminum foil-backed TLC plates of 200 µm thickness and column chromatographic 
purifications were performed on 200–300 mesh silica gel.  CH2Cl2 and MeCN were distilled over 
CaH2, Et2O was distilled over LiAlH4 and then over Na.  All other reagents were obtained from 
commercial sources and were used without further purification.  Glassware used for reactions 
was dried at 150 °C in an oven and cooled in a desiccator.  Melting points reported are of 
chromatographically purified materials and are uncorrected.  1H NMR spectra were recorded at 
500 MHz and are referenced to the residual solvent resonance.  13C NMR spectra were recorded 
at 125 MHz in CDCl3 and are referenced to the solvent resonance.  2H NMR spectra were 
recorded at 77 MHz using CDCl3 as an internal standard.  For this, first the 1H NMR spectrum of 
CDCl3 was recorded at 500 MHz and the residual protonated solvent resonance was set to δ 7.26 
ppm.  Next, the 2H NMR of the same sample was recorded at 77 MHz, and this showed a 
resonance at δ 7.24 ppm.  From this analysis, CDCl3 was referenced to δ 7.24 ppm for all 2H 
NMR experiments.  19F NMR spectra was recorded at 282 MHz using CFCl3 as internal standard.  
Chemical shifts (δ) are reported in parts per million (ppm) and coupling constants (J) are in hertz 
(Hz).  HRMS analyses were performed using a TOF analyzer, the ionization methods are 
provided in the compound characterization. 
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Step 1.  Synthesis of 3-((triisopropylsilyl)ethynyl)pyridine (36) 
Following a literature procedure,35 in a clean, dry three-neck round-bottom flask equipped with a 
stirring bar, 3-bromopyridine (122 µL, 1.26 mmol) was dissolved in (iso-Pr)2NH (5 mL).  TIPS-
acetylene (336 µL, 1.512 mmol), (Ph3P)2PdCl2 (44.0 mg, 0.063 mmol), and CuI (12.0 mg, 0.063 
mmol) were added and the reaction mixture was heated with stirring under a reflux condenser at 
100 oC for 1 h, in a nitrogen atmosphere.  The reaction mixture was then diluted with EtOAc (20 
mL) and filtered through Celite.  The filtrate was washed with deionized H2O (3 x 20 mL), of 
brine (15 mL).  The organic layer was separated, dried over anhydrous Na2SO4, and concentrated 
under reduced pressure.  Purification of the crude material, by passing it through a short silica gel 
plug with the initial elution using hexanes followed by 5% EtOAc in hexanes, gave 294 mg 
(90% yield) of TIPS-protected ethynylpyridine (36) as a pale-yellow, viscous liquid.  Rf 
(SiO2/10% EtOAc in hexanes) = 0.40.  1H NMR (500 MHz, CDCl3): δ 8.69 (s, 1H, H-2), 7.51 (d, 
1H, H-6, J = 4.1 Hz), 7.73 (dt, 1H, H-4, J = 1.9, 7.8 Hz), 7.22 (dd, 1H, H-5, J = 4.9, 7.8 Hz), 
1.13 (s, 21H, Si(iso-Pr)3).  13C NMR (125 MHz, CDCl3): δ 153.0, 148.8, 139.0, 123.0, 120.9, 
103.8, 95.1, 18.7, 11.6.  HRMS (ESI) calculated for C16H26NSi [M + H]+ 260.1829, found 
260.1835. 
Step 2.  Synthesis of 3-ethynylpyridine (28)36 
Following a literature procedure,37 in a clean, dry round-bottom flask equipped with a stirring bar, 
TIPS-protected ethynylpyridine (36, 286 mg, 1.102 mmol) was dissolved in dry MeOH (15 mL).  
Powdered KOH (433 mg, 7.72 mmol) was added and the reaction mixture was stirred at 45 oC 
for 24 h.  To the reaction mixture was added a saturated aqueous NH4Cl solution, and the 
mixture was extracted with Et2O (3 x 15 mL). The organic layer was separated, washed with 
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brine (10 mL), dried over anhydrous Na2SO4, and carefully evaporated.  The reaction mixture 
was carefully evaporated.  Purification of the crude material on a short silica gel column using 
10% Et2O in hexanes yielded 51.0 mg (45% yield) of 3-ethynylpyridine (28) as a white solid.  Rf 
(SiO2/20% Et2O in hexanes) = 0.39.  1H NMR (500 MHz, CDCl3): δ 8.73 (s, 1H, H-2), 8.57 (d, 
1H, H-6, J = 4.6 Hz), 7.77 (d, 1H, H-4, J = 7.8 Hz), 7.37 (t, 1H, H-5, J = 6.4 Hz), 3.22 (s, 1H, 
≡CCH). 
Synthesis of Ethynylbenzene-D5 (29) 
 
Step 1.  Synthesis of triisopropyl(phenylethynyl)silane-D5 (37) 
Following a literature procedure,35 in a clean, dry 3-neck round-bottom flask equipped with a 
stirring bar, bromobenzene-D5 (500 mg, 3.085 mmol) was dissolved in (iso-Pr)2NH (12.5 mL).  
TIPS-acetylene (823 µL, 3.702 mmol), (Ph3P)2PdCl2 (108.3 mg, 0.154 mmol), and CuI (29.4 mg, 
0.154 mmol) were added and the reaction mixture was heated with stirring at 100 oC in a 
nitrogen atmosphere, under a reflux condenser for 1.5 h.  The reaction mixture was then diluted 
with EtOAc (20 mL) and filtered through Celite.  The filtrate was washed with deionized H2O (3 
x 20 mL), of brine (15 mL).  The organic layer was separated, dried over anhydrous Na2SO4, and 
concentrated under reduced pressure.  Purification of the crude material, by passing it through a 
short silica gel plug using hexanes as the eluting solvent gave 500 mg (61% yield) of TIPS-
protected ethynylbenzene-D5 (37) as a colorless viscous liquid.  Rf (hexanes/SiO2) = 0.70.  1H 
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J = 24.8 Hz), 128.0 (t, J = 24.0 Hz), 127.8 (t, J = 24.5 Hz), 123.6, 107.3, 90.6, 18.9, 11.6.  2H 
NMR (77 MHz, CHCl3): δ 7.51, 7.33, 7.20.  HRMS (ESI) calculated for C17H22D5Si [M + H]+ 
264.2190, found 264.2111. 
Step 2. Synthesis of ethynylbenzene-D5 (29)38 
By modifying a literature procedure,39 in a clean, dry 25 mL round-bottom flask equipped with a 
stirring bar, TIPS-protected ethynylbenzene-D5 (35, 700 mg, 2.656 mmol) was dissolved in dry 
Et2O (11 mL) with stirring.  A 1 M solution of n-Bu4N+F– in THF (3.2 mL, 3.2 mmol) was added 
and the mixture was stirred for 5 min.  The mixture was concentrated under a stream of nitrogen 
gas and loaded onto a short silica gel column.  Elution with hexanes, followed by careful rotary 
evaporation of the fractions containing the product using a water bath at ≤ 65 oC, gave 171 mg 
(61% yield) of ethynylbenzene-D5 (29) as a pale-yellow liquid.  Rf (SiO2/hexanes) = 0.42.  1H 
NMR (500 MHz, CDCl3): δ 3.08 (s, 1H, ≡CCH).  2H NMR (77 MHz, CHCl3): δ 7.52, 7.38, 7.35. 
Synthesis of azides 
Unless mentioned otherwise, all azides were synthesized from the corresponding boronic 
acids.40 6-Azido-9-[2,3,5-tri-O-(tert-butyldimethylsilyl)-β-D-ribofuranosyl]purine (38) was 
previously synthesized in the lab.30 
General procedure for the synthesis of azides (14, 39-41) 
 
Following the literature procedure,40 in a clean 10 mL round-bottom flask equipped with a 








2.4 mmol) and CuSO4•5H2O (50 mg, 0.2 mmol) were added to the reaction mixture, and the 
mixture was stirred in an open flask at room temperature until the starting material was 
consumed.  The solvent was evaporated under reduced pressure and EtOAc (10 mL) was added.  
The mixture was extracted with H2O (10 mL) and the aqueous layer was back extracted with 
EtOAc (3 x 10 mL).  The combined organic layers were dried over Na2SO4 and concentrated 
under reduced pressure. The crude material was purified by chromatography on a silica gel 
column.  See compound headings below for details.    
Phenyl azide (14)40 
1H NMR (500 MHz, CDCl3): δ 7.38-7.34 (m, 2H), 7.15 (t, 1H, J = 7.4 Hz), 7.04 (d, 2H, 
J = 7.6 Hz).   
1-Azido-4-methoxybenzene (39)40 
1H NMR (500 MHz, CDCl3): δ 6.96 (d, 2H, J = 8.9 Hz), 6.90 (d, 2H, Ar-H, J = 
8.9 Hz), 3.80 (s, 4H, OMe). 
1-azidonaphthalene (40)40 
1H NMR (500 MHz, CDCl3): δ 8.13 (d, 1H, J = 7.7 Hz), 7.79 (d, 1H, J = 7.4 Hz), 7.66 
(d, 1H, J = 8.3 Hz), 7.57-7.52 (m, 1H), 7.47 (t, 1H, J = 7.8 Hz), 7.29 (d, 1H, J = 7.6 Hz). 
4-(Tert-butyl)phenyl azide (41)41 
Chromatography using hexanes yielded 311.5 mg (89% yield) of 39 as an orange-
red liquid.  Rf (SiO2/hexanes) = 0.60.  1H NMR (500 MHz, CDCl3): δ 7.38 (d, 2H, 
Ar-H, J = 8.6 Hz), 6.98 (d, 2H, Ar-H, J = 8.6 Hz), 1.32 (s, 9H, tert-Bu).  4-(Tert-butyl)phenyl 









Following a literature procedure,43 in a clean, dry round-bottom flask equipped with a stirring bar, 
3-aminobenzonitrile (200 mg, 1.69 mmol) was dissolved in dry MeCN (4 mL) and cooled to 0 oC.  
To the stirring solution tert-butyl nitrite (300 µL, 2.54 mmol) was added dropwise followed by 
dropwise addition of Me3SiN3 (270 µL, 2.03 mmol).  The mixture was warmed to room 
temperature and stirred for 2 h.  This reaction mixture was diluted with EtOAc (15 mL) and 
washed with deionized H2O (3 x 15 mL), and brine (10 mL). The organic layer was separated, 
dried over anhydrous Na2SO4, and concentrated under reduced pressure. Chromatography of the 
crude material on a silica gel column using 5% EtOAc in hexanes yielded 190 mg (78% yield) of 
the title compound as a brown solid. Rf (SiO2/10% EtOAc in hexanes) = 0.30. 1H NMR (500 
MHz, CDCl3): δ 7.49-7.42 (m, 2H), 7.29-7.26 (m, 2H). m-Azidobenzonitrile (27) has previously 
been synthesized by diazotization of m-cyanoaniline.42 
Phenyl azide-D5 (30)44 
 
Following a literature procedure,45 in a clean, dry 2-neck round-bottom flask equipped with a 
stirring bar, bromobenzene-D5 (400 mg, 2.468 mmol) was dissolved in 7:3 EtOH/H2O (4.8 mL). 
N,N’-Dimethylethylenediamine (40 µL, 0.37 mmol), NaN3 (321 mg, 4.936 mmol), Na ascorbate 

























100 °C, reflux, 2 h
! 288!
with stirring at 100 oC, in an argon atmosphere, under a reflux condenser for 2 h. The mixture 
was cooled to room temperature and diluted with Et2O (20 mL) and deionized H2O (10 mL). The 
aqueous layer was separated and extracted with Et2O (3 x 20 mL). The organic layers were 
combined and washed with brine (10 mL), dried over anhydrous Na2SO4 and concentrated under 
reduced pressure.  Chromatography of the crude material on a short silica gel column using 
hexanes yielded 261 mg (85% yield) of 30 as a yellow liquid. Rf (SiO2/hexanes) = 0.50. 13C 
NMR (125 MHz, CDCl3): δ 139.8, 129.2 (t, J = 24.2 Hz), 124.3 (t, J = 24.2 Hz), 118.6 (t, J = 
24.2 Hz). 2H NMR (77 MHz, CHCl3): δ 7.29, 7.08, 6.98. Phenyl azide-D5 (28) has previously 
been synthesized by diazotization of aniline-D5.44 
3’-azido-3’-deoxy-5’-O-(tert-butyldimethylsilyl)thymidine (33)46  
 
Following the literature procedure,46 in a clean, dry, RB flask equipped with a stirring bar were 
placed AZT (400 mg, 1.496 mmol) and dissolved in 8 mL of Dry DMF. Then TBDMSCl (338 
mg, 2.245 mmol) and imidazole (305 mg, 4.49 mmol) were added to the stirring mixture, the 
flask was flushed with nitrogen gas and stoppered. After being stirred at room temperature for 
overnight, the reaction mixture was diluted with water (50 mL) and then washed with ethyl 
acetate (3 x 50 mL). The collected organic layers were washed with brine, dried over anhydrous 
Na2SO4, filtered and concentrated under reduced pressure. Chromatography of the crude material 
on a short silica gel column using 40% EtOAc in hexanes yielded 502 mg (88% yield) of the 33 



















1H, H-1’, J = 6.5 Hz), 4.24 (dt, 1H, H-3’, J = 3.7, 7.3 Hz), 3.98-3.93 (m, 2H, H-4’, H-5’), 3.80 
(dd, 1H, H-5’, J = 2.2, 11.4 Hz), 2.43 (ddd, 1H, H-2’, J = 4.1, 6.1, 13.6 Hz), 2.22 (dt, 1H, H-2’, J 
= 7.0, 13.8 Hz), 1.92 (s, 3H, CH3), 0.93 (s, 9H, tert-Bu), 0.13 (s, 6H, SiCH3).   
General procedure for the synthesis of deuterated triazoles (16-26, 31, 34 and 35) 
 
In a clean, dry, 10 mL round-bottom flask equipped with a stirring bar, was placed the 
appropriate azide (0.335 mmol) in 1.6 mL of dry CH2Cl2.  To this stirred solution the appropriate 
alkyne (0.67 mmol) was added.  In a separate vial CuSO4•5H2O (8.4 mg, 0.0335 mmol, 10 
mol %) was heated at 120 oC under vacuum until the color changed from blue to grey.  Using 
this desiccated CuSO4 a 0.048 M solution was prepared in a glove bag by the addition of D2O 
(99.8% D, 0.7 mL), and this solution was transferred to the reaction mixture.  To the reaction 
mixture a 0.098 M solution of Na ascorbate (13.3 mg in 0.7 mL of 99.8% D2O, 20 mol %) was 
added.  The reaction mixture was sealed and stirred under nitrogen gas at room temperature until 
TLC showed consumption of azide.  Then the organic layer of the reaction mixture was 
separated and the aqueous layer was back extracted with EtOAc (3 x 5 mL).  The combined 
organic layers were washed with brine (5 mL), dried over anhydrous Na2SO4, and concentrated 
under reduced pressure.  The crude material was purified by chromatography on a silica gel 
column.  See compound headings below for details. 
5-Deutero-1-phenyl-4-(p-tolyl)-1H-1,2,3-triazole (16a)47 
Chromatography using hexanes followed by 20% EtOAc in hexanes gave an off-white solid.  Rf 












10 mol % CuSO4
20 mol % Na Ascorbate
! 290!
7.55 (t, 2H, Ar-H, J = 7.4 Hz), 7.46 (t, 1H, Ar-H, J = 7.3 Hz), 7.28 (d, 2H, 
Ar-H, J = 7.4 Hz), 2.41 (s, 3H, CH3).  13C NMR (125 MHz, CDCl3): δ 
148.7, 138.5, 137.5, 129.9, 129.8, 128.8, 127.8, 126.1, 120.7, 117.2 (t, J = 30.4 Hz), 21.4.  2H 
NMR (77 MHz, CHCl3): δ 8.19.  HRMS (ESI) calculated for C15H13DN3 [M + H]+ 237.1245, 
found 237.1248. 
Assessment of %D incorporation using an external standard.  CH2Cl2 (16 µL, 0.25 mmol) was 
added to the solution of the product (16a, 11.8 mg) in CDCl3 (0.5 mL).  The 1H NMR of this 
solution was acquired and the resonances were integrated.  The signal at δ 5.30 ppm (CH2Cl2) 
was set to 10 whereby the signal at δ 8.16 ppm (residual triazolyl C5-H) integrated to 0.04. Thus, 
the %D incorporation in the reaction was estimated to be 4%. 
5-Deutero-1,4-diphenyl-1H-1,2,3-triazole (17) 
Chromatography using hexanes followed by 20% EtOAc in hexanes gave a 
white solid.  Rf (SiO2/25% EtOAc in hexanes) = 0.34.  1H NMR (500 MHz, 
CDCl3): δ 7.92 (d, 2H, Ar-H, J = 8.1 Hz), 7.80 (d, 2H, Ar-H, J = 7.8 Hz), 7.55 (t, 2H, Ar-H, J = 
7.8 Hz), 7.48-7.45 (m, 3H, Ar-H), 7.37 (t, 1H, Ar-H, J = 7.4 Hz).  13C NMR (125 MHz, CDCl3): 
δ 148.6, 137.4, 130.6, 130.0, 129.1, 128.9, 128.6, 126.2, 120.8, 117.6 (s, J = 28.1 Hz).  2H NMR 
(77 MHz, CHCl3): δ 8.22.  HRMS (ESI) calculated for C14H11DN3 [M + H]+ 223.1089, found 
223.1086. 
5-Deutero-1-(4-methoxyphenyl)-4-(p-tolyl)-1H-1,2,3-triazole (18) 
Chromatography using hexanes followed by 20% EtOAc in hexanes 
gave a white solid.  Rf (SiO2/25% EtOAc in hexanes) = 0.26.  1H 











(d, 2H, Ar-H, J = 7.6 Hz), 7.02 (d, 2H, Ar-H, J = 8.6 Hz), 3.87 (s, 3H, OCH3), 2.40 (s, 3H, CH3).  
13C NMR (125 MHz, CDCl3): δ 159.9, 148.3, 138.4, 130.7, 129.7, 127.7, 125.9, 122.3, 117.5 (t, 
J = 28.9 Hz), 114.9, 55.8, 21.5.  2H NMR (77 MHz, CHCl3): δ 8.10.  HRMS (ESI) calculated for 
C16H15DN3O [M + H]+ 267.1351, found 267.1356. 
5-Deutero-4-(4-fluorophenyl)-1-(4-methoxyphenyl)-1H-1,2,3-triazole (19) 
 Chromatography using hexanes followed by 20% EtOAc in hexanes 
gave an off-white solid,. Rf (SiO2/25% EtOAc in hexanes) = 0.22. 1H 
NMR (500 MHz, CDCl3): δ 7.89-7.86 (m, 2H, Ar-H), 7.67 (d, 2H, Ar-H, J = 8.9 Hz), 7.14 (t, 2H, 
Ar-H, J = 8.6 Hz), 7.04 (d, 2H, Ar-H, J = 8.9 Hz), 3.88 (s, 3H, OCH3).  13C NMR (125 MHz, 
CDCl3): δ 164.1, 162.1, 160.3, 147.5, 130.8, 127.8 (d, J = 8.1 Hz), 127.0 (d, J = 3.2 Hz), 122.4, 
117.6 (t, J = 28.9 Hz), 116.1 (d, J = 21.8 Hz), 115.1, 55.9.  2H NMR (77 MHz, CHCl3): δ 8.09.  
19F NMR (282 MHz, CDCl3): δ –113.8 (relative to CFCl3).  HRMS (ESI) calculated for 
C15H12DFN3O [M + H]+ 271.1100, found 271.1105. 
5-Deutero-1-(4-methoxyphenyl)-4-phenyl-1H-1,2,3-triazole (20) 
Chromatography using hexanes followed by 20% EtOAc in hexanes 
gave a white solid.  Rf (SiO2/25% EtOAc in hexanes) = 0.23.  1H NMR 
(500 MHz, CDCl3): δ 7.90 (d, 2H, Ar-H, J = 7.8 Hz), 7.69 (d, 2H, Ar-H, J = 8.9 Hz), 7.46 (t, 2H, 
Ar-H, J = 7.6 Hz), 7.37 (t, 1H, Ar-H, J = 7.4 Hz), 7.04 (d, 2H, Ar-H, J = 8.9 Hz), 3.88 (s, 3H, 
OCH3).  13C NMR (125 MHz, CDCl3): δ 160.2, 148.4, 130.9, 130.8, 129.1, 128.5, 126.1, 122.4, 
117.8 (t, J = 28.3 Hz), 115.1, 55.9.  2H NMR (77 MHz, CHCl3): δ 8.16.  HRMS (ESI) calculated 









Chromatography using hexanes followed by 20% EtOAc in hexanes gave 
an off-white solid.  Rf (SiO2/25% EtOAc in hexanes) = 0.46.  1H NMR 
(500 MHz, CDCl3): δ 7.92 (d, 2H, Ar-H, J = 8.1 Hz), 7.70 (d, 2H, Ar-H, J = 8.5 Hz), 7.53 (d, 2H, 
Ar-H, J = 8.5 Hz), 7.44 (t, 2H, Ar-H, J = 7.6 Hz), 7.35 (dt, 1H, Ar-H, J = 1.0, 7.4 Hz), 1.38 (s, 
9H, tert-Bu).  13C NMR (125 MHz, CDCl3): δ 152.3, 148.3, 134.8, 130.5, 129.1, 128.5, 126.8, 
126.0, 120.4, 117.8 (t, J = 28.9 Hz), 35.0, 31.5.  2H NMR (77 MHz, CHCl3): δ 8.20.  HRMS 
(ESI) calculated for C18H19DN3 [M + H]+ 279.1715, found 279.1709. 
5-Deutero-1-(naphthalen-1-yl)-4-phenyl-1H-1,2,3-triazole (22) 
Chromatography using hexanes followed by 20% EtOAc in hexanes gave a 
brown solid.  Rf (SiO2/25% EtOAc in hexanes) = 0.34.  1H NMR (500 MHz, 
CDCl3): δ 8.00-7.92 (m, 4H, Ar-H), 7.69 (d, 1H, Ar-H, J = 8.3 Hz), 7.59-7.49 (m, 4H, Ar-H), 
7.46 (t, 2H, Ar-H, J = 7.7 Hz), 7.04 (dt, 1H, Ar-H, J = 1.0, 7.4 Hz).  13C NMR (125 MHz, 
CDCl3): δ 147.9, 134.5, 134.0, 130.6, 130.5, 129.1, 128.9, 128.6, 128.5, 128.1, 127.3, 126.1, 
125.2, 123.7, 122.6, 122.2 (t, J = 28.6 Hz).  2H NMR (77 MHz, CHCl3): δ 8.17.  HRMS (ESI) 
calculated for C18H13DN3 [M + H]+ 273.1245, found 273.1247. 
5-Deutero-1-(4-methoxyphenyl)-4-(N-phthalimidomethyl)-1H-1,2,3-triazole (23) 
Chromatography using hexanes followed by 40% EtOAc in hexanes 
gave an off-white solid.  Rf (SiO2/50% EtOAc in hexanes) = 0.40.  
1H NMR (500 MHz, CDCl3): δ 7.85 (dd, 2H, Ar-H, J = 3.1, 5.3 Hz), 
7.72 (dd, 2H, Ar-H, J = 3.1, 5.3 Hz), 7.57 (d, 2H, Ar-H, J = 8.9 Hz), 6.97 (d, 2H, Ar-H, J = 8.9 














134.3, 132.2, 130.5, 123.6, 122.4, 121.1 (t, J = 28.8 Hz), 114.8, 55.8, 33.2.  2H NMR (77 MHz, 
CHCl3): δ 7.97.  HRMS (ESI) calculated for C18H14DN4O3 [M + H]+ 336.1201, found 336.1204. 
5-Deutero-1-(3-cyanophenyl)-4-(pyridin-3-yl)-1H-1,2,3-triazole (24) 
Chromatography using 10% EtOAc in hexanes followed by EtOAc gave 
an off-white solid.  Rf (SiO2/EtOAc) = 0.34.  1H NMR (500 MHz, CDCl3): 
δ 9.17 (br s, 1H, Ar-H), 8.73 (br s, 1H, Ar-H), 8.31 (d, 1H, Ar-H, J = 7.9 Hz), 8.15 (t, 1H, Ar-H, 
J = 1.6 Hz), 8.11 (ddd, 1H, Ar-H, J = 1.1, 2.2, 8.1 Hz), 7.79 (dt, 1H, Ar-H, J = 1.3, 7.7 Hz), 7.74 
(t, 1H, Ar-H, J = 7.9 Hz), 7.47 (br s, 1H, Ar-H). 13C NMR (125 MHz, CD3OD, 55 ˚C): δ 150.2, 
147.8, 146.8, 139.1, 135.2, 133.7, 132.5, 128.4, 126.1, 125.7, 125.1, 121.2 (t, J = 29.6 Hz), 118.7, 
115.4.  2H NMR (77 MHz, CHCl3): δ 8.38.  HRMS (ESI) calculated for C14H9DN5 [M + H]+ 
249.0993, found 249.0997. 
5’-O-(Tert-butyldimethylsilyl)-3’-deoxy-3’-(5-deutero-4-(4-methylphenyl)-1H-1,2,3-triazol-
1-yl)thymidine (25) 
For this reaction 0.131 mmol of azide, 0.262 mmol of alkyne, 10 mol % of 
anhydrous CuSO4 in 273 µL of D2O, 20 mol % of Na ascorbate in 273 µl of 
D2O, and 0.65 mL of dry CH2Cl2 were used.  Chromatography using 
hexanes followed by 45% EtOAc in hexanes gave a white solid.  Rf 
(SiO2/75% EtOAc in hexanes) = 0.48.  1H NMR (500 MHz, CDCl3): δ 9.41 
(br s, 1H, NH), 7.70 (d, 2H, Ar-H, J = 7.9 Hz), 7.49 (s, 1H, Ar-H), 7.22 (d, 2H, Ar-H, J = 7.9 
Hz), 6.44 (t, 1H, H-1’, J = 6.5 Hz), 5.33 (app dt, 1H, H-3’, Japp = 4.6, 9.1 Hz), 4.49-4.47 (m, 1H, 
H-4’), 4.02 (dd, 1H, H-5’, J = 2.4, 11.6 Hz), 3.88 (dd, 1H, J = 2.4, 11.6 Hz), 3.00 (app dt, 1H, H-


















3H, CH3), 0.93 (s, 9H, tert-Bu), 0.13 and 0.12 (2s, 6H, SiCH3).  13C NMR (125 MHz, CDCl3): δ 
163.8, 150.5, 148.6, 138.5, 135.5, 129.8, 127.7, 125.9, 118.5 (t, J = 28.7 Hz), 111.3, 85.8, 85.0, 
62.9, 59.8, 38.8, 26.1, 21.4, 18.6, 12.7, –5.1, –5.2.  2H NMR (77 MHz, CHCl3): δ 7.85.  HRMS 
(ESI) calculated for C25H35DN5O4Si [M + H]+ 499.2594, found 499.2600. 
6-[5-Deutero-4-(4-methylphenyl)-1,2,3-triazol-1-yl]-9-[2,3,5-tri-O-(tert-butyldimethylsilyl)-
β-D-ribofuranosyl]purine (26) 
For this reaction 0.198 mmol of azide, 0.395 mmol of alkyne, 5 mol% of 
anhydrous CuSO4 in 0.2 mL of D2O, 10 mol % of Na ascorbate in 0.2 ml 
of D2O, and 0.95 mL of CH2Cl2 were used.   Chromatography using 
hexanes followed by 15% EtOAc in hexanes gave a pale-yellow, viscous 
liquid.  Rf (SiO2/20% EtOAc in hexanes) = 0.28.  1H NMR (500 MHz, 
CDCl3): δ 8.97 (s, 1H, Ar-H, J = 7.8 Hz), 8.65 (s, 1H, Ar-H), 7.91 (d, 1H, Ar-H, J = 8.0 Hz), 
7.29 (d, 2H, Ar-H, J = 8.0 Hz), 6.24 (d, 1H, H-1’, J = 5.1 Hz), 4.68 (t, 1H, H-2’, J = 4.7 Hz), 
4.35 (t, 1H, H-3’, J = 3.9 Hz), 4.20 (app q, 1H, H-4’, Japp = 3.0 Hz), 4.06 (dd, 1H, H-5’, J = 3.5, 
11.4 Hz), 3.85 (dd, 1H, H-5’, J = 2.4, 11.4 Hz), 2.41 (s, 3H, CH3), 0.99, 0.96, and 0.81 (3s, 27H, 
tert-Bu), 0.19, 0.18, 0.13, 0.12, –0.02, and –0.21 (6s, 18H, Si-CH3).  13C NMR (125 MHz, 
CDCl3): δ 154.5, 152.5, 148.5, 145.2, 145.0, 138.8, 129.8, 127.5, 126.4, 123.5, 119.5 (t, J = 26 
Hz), 88.9, 86.1, 76.5, 72.3, 62.8, 26.4, 26.1, 25.9, 21.5, 18.8, 18.3, 18.1, –4.1, –4.3, –4.4, –4.6, –
4.7, –5.1.  2H NMR (77 MHz, CHCl3): δ 9.35.  HRMS (ESI) calculated for C37H60DN7O4Si3Na 
[M + Na]+ 775.4048, found 775.4046. 
5-Deutero-1-phenyl-D5-4-(4-methylphenyl)-1H-1,2,3-triazole (31) 













(SiO2/50% EtOAc in hexanes/) = 0.60.  1H NMR (500 MHz, CDCl3): 
δ 7.83 (d, 2H, Ar-H, J = 7.8 Hz), 7.29 (d, 2H, Ar-H, J = 7.8 Hz), 2.42 
(s, 3H, -CH3).  13C NMR (125 MHz, CDCl3): δ 148.6, 138.5, 137.2, 129.8, 129.5 (t, J = 25.0 Hz), 
128.4 (t, J = 25.0 Hz), 127.6, 126, 120.3 (t, J = 24.9 Hz), 117.2 (t, J = 29.4 Hz), 21.5.  2H NMR 
(77 MHz, CHCl3): δ 8.19, 7.82, 7.58, 7.49.  HRMS (ESI) calculated for C15H8D6N3 [M + H]+ 
242.1559, found 242.1553.  
5’-O-(Tert-butyldimethylsilyl)-3’-deoxy-3’-(5-deutero-4-(phenyl-D5)-1H-1,2,3-triazol-1-
yl)thymidine (34) 
For this reaction 0.131 mmol of azide, 0.262 mmol of alkyne, 10 mol % of 
anhydrous CuSO4 in 0.273 mL of D2O, 20 mol % of Na ascorbate in 0.273 
ml of D2O, and 0.65 mL of dry CH2Cl2 were used in this reaction.  
Chromatography using hexanes followed by 50% EtOAc in hexanes gave a 
white solid.  Rf (SiO2/50% EtOAc in hexanes) = 0.21.  1H NMR (500 MHz, 
CDCl3): δ 9.20 (br s, 1H, NH), 7.50 (s, 1H, Ar-H), 6.45 (t, 1H, H-1’, J = 6.5 Hz), 5.34 (dt, 1H, 
H-3’, J = 4.6, 8.8 Hz), 4.49-4.51 (m, 1H, H-4’), 4.03 (dd, 1H, H-5’, J = 2.1, 11.5 Hz), 3.88 (dd, 
1H, H-5’, J = 1.8, 11.5 Hz), 3.01 (ddd, 1H, H-2’, J = 5.2, 6.3, 14.0 Hz), 2.64 (ddd, 1H, H-2’, J = 
6.5, 8.1, 14.3 Hz), 1.95 (s, 3H, CH3), 0.94 (s, 9H, tert-Bu), 0.14 and 0.13 (2s, 6H, SiCH3).  13C 
NMR (125 MHz, CDCl3): δ 163.8, 150.5, 148.4, 135.5, 130.1, 128.6 (t, J = 23.8 Hz), 128.1 (t, J 
= 23.0 Hz), 125.6 (t, J = 24.1 Hz), 118.7 (t, J = 28.8 Hz), 111.4, 85.6, 85.0, 62.8, 59.8, 38.9, 29.9, 
26.1, 18.6, 12.8, –5.1, –5.2.  2H NMR (77 MHz, CHCl3): δ 7.87, 7.45.  HRMS (ESI) calculated 



























 Chromatography using hexanes followed by 20% EtOAc in hexanes 
gave an off-white solid.  Rf (SiO2/50% EtOAc in hexanes) = 0.60.  13C 
NMR (125 MHz, CDCl3): δ 148.5, 137.2, 130.3, 129.5 (t, J = 24.3 Hz), 128.6 (t, J = 23.3 Hz), 
128.5(t, J = 23.1 Hz), 128.1 (t, J = 21.8 Hz), 125.7 (t, J = 24.2 Hz), 120.3 (t, J = 25.2 Hz), 117.6 
(t, J = 26.9 Hz).  2H NMR (77 MHz, CHCl3): δ 8.23, 7.94, 7.83, 7.58, 7.49.  HRMS (ESI) 
calculated for C14HD11N3 [M + H]+ 233.1716, found 233.1717. 
Assessment of %D in 33.  CH2Cl2 (16 µL, 0.25 mmol) was added to the solution of 33 (11.7 mg, 
0.05 mmol) in CDCl3 (0.5 mL).  The 1H NMR of this solution was acquired and the resonances 
were integrated.  The signal at δ 5.30 ppm (CH2Cl2) was set to 10 whereby the signal at δ 8.19 
ppm (residual triazolyl C5-H) integrated to 0.06.  Thus, the %D incorporation in the reaction was 
estimated to be 94%. 
1-(3-Cyanophenyl)-4-(pyridin-3-yl)-1H-1,2,3-triazole (29)33 
 
In a clean, extremely dry, 10 mL round-bottom flask equipped with a stirring bar, m-
azidobenzonitrile (25, 57 mg, 0.335 mmol) was dissolved in CH2Cl2 (1.6 mL).  3-
Ethynylpyridine (26, 69 mg, 0.67 mmol) was added to the flask, followed by CuSO4•5H2O (8.4 
mg, 0.0335 mmol), Na ascorbate (13.3 mg, 0.067 mmol), and H2O (1.4 mL).  The mixture was 
stirred at room temperature for 48 h and then diluted with CH2Cl2 (5 mL).  The aqueous layer 
was separated and back extracted with CH2Cl2 (3 x 5 mL).  The combined organic layers were 
washed with brine (5 mL), dried over anhydrous Na2SO4, and concentrated under reduced 
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with 10% EtOAc in hexanes followed by EtOAc, yielded 58 mg (70% yield) of 29 as an off-
white solid.  Rf (SiO2/EtOAc) = 0.34.  1H NMR (500 MHz, CDCl3): δ 9.13 (br s, 1H, Ar-H), 8.68 
(br s, 1H, Ar-H), 8.33 (s, 1H, Ar-H), 8.31 (d, 1H, Ar-H, J = 7.7 Hz), 8.15 (t, 1H, Ar-H, J = 1.5 
Hz), 8.11 (ddd, 1H, Ar-H, J = 1.1, 2.1, 8.1 Hz), 7.79 (dt, 1H, Ar-H, J = 1.2, 7.8 Hz), 7.73 (t, 1H, 
Ar-H, J = 7.9 Hz), 7.47 (br s, 1H, Ar-H).  13C NMR (125 MHz, CD3OD, 55 ˚C): δ 150.2, 147.8, 
146.8, 139.1, 135.2, 133.7, 132.5, 128.4, 126.1, 125.7, 125.1, 121.4, 118.7, 115.4. 
Competitive Experiment using H2O and D2O 
 
In a clean, extremely dry, 10 mL round-bottom flask equipped with a stirring bar, was placed the 
phenyl azide (14, 40.0 mg, 0.335 mmol) in dry CH2Cl2 (1.6 mL).  To this stirring solution p-
ethynyl toluene (15, 85 µL, 0.67 mmol) was added.  In a separate vial CuSO4•5H2O (8.4 mg, 
0.0335 mmol, 10 mol %) was heated at 120 oC under vacuum until the color changed from blue 
to grey.  Using this dehydrated CuSO4, a 0.048 M solution was prepared in a glove bag by the 
addition of D2O (99.8% D, 0.7 mL) and this solution was transferred to the reaction mixture.  To 
the reaction mixture a 0.098 M solution of Na ascorbate (13.3 mg in 0.7 mL of 99.8% H2O, 20 
mol %) was then added.  The reaction mixture was sealed and stirred under nitrogen gas at room 
temperature until TLC showed consumption of azide.  Then the organic layer of the reaction 
mixture was separated and the aqueous layer was back extracted with EtOAc (3 x 5 mL).  The 
organic layers were combined and washed with brine (5 mL), dried over anhydrous Na2SO4, and 
concentrated under reduced pressure.  The crude material was purified by chromatography on a 

















contained 15.6 mg (19.7 %) of 16a and 44.4 mg (56.3 %) of 16b.  Rf (25% EtOAc in 
hexanes/SiO2) = 0.34. 
Assessment of the amounts of 14a and 14b in the product mixture.  CH2Cl2 (16 µL, 0.25 mmol) 
was added to the solution of the product mixture (11.8 mg) in CDCl3 (0.5 mL).  The 1H NMR of 
this solution was acquired and the resonances were integrated.  The signal at δ 5.30 ppm 
(CH2Cl2) was set to 10 whereby the signal at δ 8.16 ppm (residual triazolyl C5-H) integrated to 
0.77.  On the basis of these values the amount of 16b was estimated at 9.058 mg (77%) and that 
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